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Abstract
There have been many reports linking the overexpression of the lung resistance-related 
protein (LRP) with cross-resistance to chemotherapeutic drugs. However, no conclusive 
evidence existed to link LRP with a direct role in multidrug resistance (LRP). The OAW42SR 
is a cell line derived from a serous adenocarcinoma of the ovaries, and displays an increase in 
resistance to cytotoxic drugs concomitant with a moderate increase in LRP expression. Anti- 
LRP ribozyme and antisense expression plasmids were employed in this study in order to 
inhibit LRP expression in the OAW42SR cell line and examine any resulting effect on the 
drug resistance of the cells. Antisense oligonucleotides were also used to decrease LRP 
expression in the OAW42SR cell line in order to provide a clearer picture of whether LRP is 
involved in MDR.
A large number of clones were isolated after transfection of the OAW42SR cell line with anti- 
LRP ribozyme and antisense expression plasmids. These clones displayed varying levels of 
LRP at both the mRNA and protein level. Cells transfected with only a control vector also 
displayed decreases in LRP expression, highlighting the extent of clonal variation within the 
OAW42SR population. The anti-LRP ribozyme construct appeared to significantly reduce 
LRP expression at both the mRNA and protein level. The anti-LRP antisense RNA construct 
failed to reduce LRP mRNA expression levels, but dramatically reduced LRP at the protein 
level. This demonstrated that antisense RNA acts mainly through steric inhibition of mRNA 
processing rather than cleavage of the target RNA, as with ribozymes. Resistance to 
anthracyclines and Vinca alkaloids was reduced in many of the clones. However, the levels of 
LRP expression could not be correlated with the reduction in resistance to the tested drugs. 
The levels of expression of the MDR facilitators, multidrug resistance gene 1 (mdr-1) and 
multidrug resistance-associated protein (MRP), within the clones was largely invariant, and 
could not be directly correlated with the observed reductions in drug resistance. The drug 
resistance profiles of the OAW42SR clones were, however, strikingly similar to that of 
typical mdr-1 overexpressing cell lines. It cannot be ruled out, therefore, that variation in P- 
glycoprotein activity, due to post-translational modifications, may be the sole mechanism of 
drug resistance in these clones. Antisense oligonucleotides targeted to LRP, reduced 
expression at both the mRNA and protein level in the OAW42SR cells, but failed to induce a 
reduction in resistance to adriamycin. This thesis provides the first direct evidence that LRP is 
not involved in multidrug resistance, at last within the OAW42SR cell line.
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1. INTRODUCTION
1.1 INTRODUCTION TO MULTIDRUG RESISTANCE (MDR).
The occurrence of cellular drug resistance remains a major problem in the 
chemotherapeutic treatment of cancer. For most metastatic cancers, the currently 
available anti-cancer drugs are merely used to prolong life and/or alleviate symptoms, 
rather than to cure the patient. Although many cancers, including breast and ovarian 
cancers, non-Hodgkin’s lymphoma, adult acute leukaemia, and numerous childhood 
cancers initially respond well to chemotherapy, very often the tumors become resistant 
to cytotoxic drugs during or shortly after therapy (Nooter and Stoter, 1996). Other 
cancers, such as non-small cell lung cancer and cancers of the colon, stomach, kidney 
and pancreas, are inherently resistant to anti-cancer drugs even before the start of 
treatment.
A large variety of drug resistance mechanisms have been characterised, using in vitro 
cell lines made resistant against the different classes of anti-cancer agents. Alterations 
in target proteins, carrier mediated drug uptake, drug metabolism, cellular repair 
mechanisms and cellular drug efflux can mediate drug resistance in vitro. Most drug 
resistant cell lines have been obtained by step-wise increased exposure to a specific 
anti-cancer drug. This results in the cell line being resistant to the drug used for 
selection and drugs with similar chemical structure to the biologically active moiety, as 
expected. However, during selection of the cells for resistance to these so-called 
“naturally occurring” anti-cancer drugs, such as anthracyclines, Vinca alkaloids, 
epidophyllotoxins, actinomycin D and colchicine, the cells can develop cross-resistance 
to other apparently structurally and functionally unrelated natural compounds (Nielsen 
and Skovsgaard, 1992; Clynes, 1993; Hill 1993). This phenomenon is referred to as 
multidrug or multiple-drug resistance (MDR). These MDR-related naturally occurring 
drugs are derived from plants and micro-organisms, but are structurally dissimilar and 
have different intracellular targets. They are all, however, rather large (between 300- 
900 kD molecular weight), amphipatic, and enter the cell by passive diffusion, as they 
are soluble in lipids at physiological pH (Nooter and Stoter, 1996).
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1.1.1 Multiple drug resistance 1 (mdr-1) gene and P-glycoprotein (Pgp)
The molecular basis for the phenomenon of broad-spectrum resistance to anti-cancer 
drugs, has been the subject of intensive research. Of the various mechanisms by which 
cancer cells evade the cytotoxic action of the anti-neoplastic drugs, the best 
characterised form of drug resistance has been ascribed to the expression of the 
multiple drug resistance 1 (mdr-1) gene and its protein product phospho- or P- 
glycoprotein (Pgp) (Clynes, 1993; Kiehntopf et al., 1994; Nooter and Stoter, 1996; 
Srivastava et al., 1996). Pgp is a plasma membrane efflux pump with ATPase activity 
and a molecular weight of 170 kDa. It is composed of two similar halves, each 
containing six putative transmembrane domains and one nucleotide-binding site 
consensus sequence (Srivastava et al., 1996). This unique structural characteristic of 
Pgp has been conserved in a large number of membrane associated transporters from 
bacteria to higher eukaryotes, forming a novel superfamily of proteins called the ATP 
binding cassettes (ABC) transporters (Higgins, 1992). Pgp acts to promote the efflux 
of a variety of drugs with resultant reduction in intracellular drug concentration 
(Clynes, 1993; Srivastava et a l, 1996). The physiological function of Pgp is not, 
however, completely understood. Detoxification of naturally occurring compounds and 
excretion of endogenous metabolites, e.g. steroid hormones, are possibilities 
(Gottesmann and Pastan, 1993), while there is evidence that it is an essential 
component of a volume-regulated chloride channel (Valverde et al., 1992).
Due to the negative effects on chemotherapy of Pgp overexpression, and its prevalence 
(with some estimates that Pgp is increased in as much as 50% of all human tumours at 
some stage of treatment with natural drugs (Gottesmann, 1988)), there has been much 
interest and effort in reversing MDR. In the laboratory, the methods to reverse MDR 
caused by Pgp membrane transport system have focused mainly on two approaches: i) 
development of reversing agents that are recognised by Pgp but are less toxic and, in 
large concentrations block the efflux of chemotherapeutic drugs; and ii) development 
of analogs of chemotherapeutic agents which express a lower affinity for Pgp binding 
site, hence, less potential for resistance mediated by drug efflux (Srivastav et al., 
1996). To date, several classes of reversing agents have been studied including 
calcium-channel blockers (e.g. verapamil), immunosuppressants (e.g. cyclosporin A),
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steroids (e.g. progesterone), steroid antagonists (e.g. tamoxifen), cardiac 
antiarrythmics (e.g. amiodarone and quinidine) and others (e.g. amphotericin, Tween 
80, reserpine) (Srivastava et al., 1996). Even cells with very high levels of P- 
glycoprotein can have active drug efflux blocked with the simultaneous addition of a 
P-glycoprotein antagonist. However, a lack of specificity or toxic side effects of these 
compounds has resulted in a limited clinical application for many of these chemo- 
modulators. Therefore, there is considerable need to find alternative ways of 
circumventing mdr-1 mediated drug resistance. To this end, the molecular biology 
tools of antisense and ribozymes, which can specifically target and disrupt the DNA or 
RNA of a gene, have been employed to great effect. These tools and their application 
to reversal of MDR are dealt with in detail later (see Sections 1.3 to 1.5).
1.1.2 M ultidrug resistance-associated protein (MRP)
After the initial surge of interest and research into Pgp, it soon became evident that 
overexpression of mdr-1 was not the sole MDR mechanism, and that alternative 
mechanisms of multidrug resistance must exist. Some malignancies, such as lung 
cancer, frequently displayed either acquired or intrinsic multidrug resistance without 
elevated levels of mdr-1 (Lai et al., 1989). A number of multidrug resistant tumour cell 
lines, such as the human small cell lung cancer cell line H69AR, have also been 
described which do not overexpress mdr-1 (Mirski et al., 1987; Reeve et al., 1990; 
Taylor et al., 1991). H69AR cells display a cross-resistance profile very similar to cells 
which overexpress the mdr-1 gene, but express no more mdr-1 than parental NCI-H69 
(H69) cells (Mirski et al., 1987; Cole et al., 1991). Additionally, multidrug resistance 
in these cells is poorly reversed by chemosensitisers that are effective in cells 
overexpressing mdr-1 (Cole et al., 1989).
In a search for proteins responsible for the multidrug resistance of H69AR cells, 
cDNAs corresponding to an mRNA that is highly expressed in the resistant cells but 
not in drug-sensitive parental or revertant cells, were cloned, isolated and sequenced 
(Cole et al., 1992). The mRNA coded for a protein of 1531 amino acids and was 
named the multidrug resistance-associated protein (MRP). The predicted primary 
sequence and secondary structure of MRP indicate that it is also a member of the
4
ATP-binding cassette superfarnily of membrane transport proteins (Higgins, 1992), 
although it only shares 15% amino acid homology with Pgp (Lautier et a l, 1996). 
Increased concentrations of MRP mRNA have been detected in multidrug-resistant cell 
lines derived from a wide variety of tissues (Cole et a l, 1991; Krishnamachary and 
Center, 1993; Slovak et a l, 1993). Several of these cell lines were shown to contain 
multiple copies of the MRP gene as a result of amplification and translocation of a 
region of chromosome 16 spanning the MRP gene at band pl3.1 (Slovak et a l,  1993). 
In H69AR cells, the MRP gene is amplified 40-50 fold.
In order to prove that the MRP gene itself could confer resistance, and that the gene 
was not simply co-amplified with some other gene that does, HeLa cells were 
transfected with MRP expression vectors (Grant et a l, 1994). The transfectants were 
found to display an increase in resistance to doxorubicin that is proportional to the 
levels of a 190 kDa integral membrane protein recognised by anti-MRP antibodies. 
However, the drug cross-resistance profiles of cells that overexpress MRP or Pgp are 
similar but not identical. For example, taxol is an efficient substrate for Pgp, but not for 
MRP (Zaman et a l,  1994). There also appear to be fundamental differences in the 
mechanisms by which the two proteins transport chemotherapeutic drugs. Pgp- 
enriched membrane vesicles have been shown to directly transport several 
chemotherapeutic drugs, whereas vincristine transport by MRP-enriched membrane 
vesicles is demonstrable only in the presence of reduced glutathione (Lautier et a l, 
1996). Several potential physiologic substrates of MRP have been identified, such as 
leukotriene C4 and 17P-estradiol-17-(P-D-glucuronide) (Loe et a l, 1996). In contrast, 
these conjugated organic anions are transported poorly, if at all, by P-glycoprotein. In 
addition, agents that reverse Pgp-associated resistance are usually much less effective 
in MRP-associated resistance (Lautier et a l, 1996). Due to lack of suitable 
circumvention agents, MRP represents an ideal target for antisense or ribozyme- 
mediated suppression for the reversal of MDR. Attempts to decrease MRP expression 
using these methods are dealt with later (see Section 1.3 to 1.5)
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1.1.3 Alternative mechanisms of MDR
Alteration of Topoisomerase II (Topo II) activity is a frequent atypical mechanism of 
multidrug resistance (Eijdjems, 1985; Cole et al., 1991). Topo II is a ubiquitous 
nuclear enzyme that is essential for many aspects of DNA function, including 
replication, recombination and transcription. This enzyme is the target of many 
clinically important antineoplastic drugs such as anthracyclines, ellipticines, amsacrines 
and epipodophyllotoxins (Zijlstra et al., 1990). These drugs stabilise the cleavable 
complex formed between topo II and DNA, resulting in increased DNA excision, 
detectable as DNA single-strand or double-strand breaks, and DNA-protein cross-links 
(Mattern and Volm, 1995). Drug induced cell destruction is proportional to the level 
of topo II, the more the enzyme the greater the toxicity. Therefore, a reduction in topo 
II could be a major mechanism of resistance to many antineoplastic drugs. 
Characteristically, there is cross-resistance to the full range of drugs that interact with 
the enzyme, including those mentioned above, but not the Vinca alkaloids (Nooter and 
Stoter, 1996). Although atypical MDR is potentially of clinical importance, the 
question whether the phenomenon contributes to clinical drug resistance cannot yet be 
answered, because only very limited data are currently available on the expression of 
topoisomerase II in human tumour specimens (Gekeler et al., 1992; McKenna et al., 
1993; Kaufmann et al., 1994; Van der Zee et al., 1994; Nooter and Stoter, 1996).
Another form of drug resistance that can affect several classes of drugs is associated 
with increased cellular levels of glutathione (GSH) and/or glutathione S-transferase 
(GST) (Kramer et al., 1988; Puchalski and Fahl 1990; Godwin et al., 1992), Although 
it is firmly established by transfection experiments that increased levels of GST cause 
resistance to some alkylating agents, it has been more difficult to prove that GSH and 
GST are directly involved in other forms of resistance, e.g. resistance to cisplatin and 
anthracyclines (Kramerv et al., 1988; Puchalski and Fahl, 1990; Godwin et a l, 1992). 
It has been shown that this type of resistance may be complex, because it involves two 
steps; i) formation of GSH S-conjugate and ii) removal of toxic conjugate from the cell 
by a GSH S-conjugate export carrier (GS-X pump) (Ishikawa, 1992). Conjugation of 
cisplatin and GSH can occur non-enzymatically under physiological conditions, but 
export from the cell requires the GS-X pump. The GS-X pump is also known as the
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multispecific organic anion transporter (MOAT) or the leukotriene C4 (LTC4) 
transporter, and is present in many mammalian cells such as hepatocytes, erythrocytes, 
cardiac cells, leukaemic cells, mast cells, and lung cells (Muller et al., 1994). The GS- 
X pump has a relatively broad substrate specificity. It transports substrates containing 
a hydrophobic section and at least two negative charges (lshikawa, 1992). Transport 
can be inhibited by orthovanadate and by competing anionic organic substrates, but not 
by many of the basic or neutral amphiphillic compounds that act as substrates for Pgp 
(Gottesmann and Pastan, 1993).
Cyclic-AMP (cAMP)-dependent protein kinase (PKA) and protein kinase C (PKC) are 
recent additions to the list of MDR facilitators. The number of studies involving PKA 
is limited, but it has been shown that phosphorylation of mouse Pgp is enhanced by 
cAMP and that Pgp is phosphorylated by the catalytic subunit of PKA (Mellado and 
Horwitz, 1987). PKA may also phosphorylate human Pgp (Chambers el al., 1994). 
mdr-1 expression can be modulated by PKA type I (PKA-I), opening up the possibility 
of modulating MDR by selectively down regulating the activity of PKA-dependent 
transcription factors which up-regulate MDR expression (Rohlff et al., 1993). High 
levels of PKA-I occur in primary breast carcinomas and patients exhibiting this 
phenotype show decreased survival (Miller et al., 1993). Cells containing a mutated RI 
cAMP-binding subunit of PKA-I do not have an active PKA and exhibit down- 
regulation of mdr-1 expression and increased sensitivity to MDR related drugs (Chin et 
al., 1992). It has been shown that analogs of cAMP down-regulate PKA-dependent 
MDR-associated transcription factors, and that a selective inhibitor of PKA decreased 
mdr-1 gene transcription and the activity of the mdr-1 promoter (Srivastava et al.,
1996). These results indicate that PKA-I plays an imortant role in drug resistance and 
site selective cAMP analogs are novel modulators of multidrug resistance.
PKC, an enzyme that is activated by diacylglycerol resulting from the receptor- 
mediated hydrolysis of inositol phospholipids, relays information of a variety of 
extracellular signals across the cell membrane to regulate many intracellular processes 
(Nishizuka, 1988). There is evidence to support the idea that the MDR phenotype is 
associated with changes in PKC activity and its isozyme content (to date, 11 PKC 
isozymes have been identified(Nishizuka, 1995)). This conclusion was based on: i)
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Drug resistant lines have higher levels of PKC, calcium and a PKC activator than their 
parental lines (Tsuruo et a l,  1984; O’Brian et a l, 1989). MDR cell lines also contain 
more PKC in the membrane fraction than parental cell lines suggesting intrinsic 
activation of PKC (Aquino et al., 1988); ii) Inhibitors of PKC such as H7, 
staurosporine, calphostin C, calcium channel blockers, phenothiazines, antiarrythmics, 
antiestrogens and synthetic peptide inhibitors can partially reverse MDR and inhibit 
Pgp phosphorylation (Srivastava et al., 1996); iii) PKC activators (including phorbol 
esters, OAG and deoxycholate) can induce the MDR phenotype in non-MDR cells and 
enhance the phenotype of cells already expressing MDR (Srivastava et a l, 1996); iv) 
PKC has been shown to phosphorylate Pgp on similar sites both in vitro and in vivo 
(Chambers et a l,  1990). Inhibition of PKC in MDR tumor cells is associated with 
decreased Pgp phosphorylation and enhanced intracellular drug retention (Bates et a l, 
1993); v) Over expression of PKCa in cells expressing Pgp can enhance the MDR 
phenotype of those cells and the overexpression of PKCP1 can induce MDR by a Pgp 
independent manner (Fan et al., 1992). All these studies define a specific role for 
PKCa in modulating the MDR phenotype.
Metallothioneins (MT) are intracellular proteins of low molecular weight (6-7 kDa) 
that are present in a wide variety of eukaryotes (Mattern and Volm, 1995). The 
synthesis of MT by tumour cells has been proposed as a possible mechanism for the 
intracellular inactivation of metal-containing chemotherapeutic agents such as cisplatin. 
MT content and MT mRNA levels correlate well with the sensitivity of small cell lung 
carcinoma cell lines to cisplatin (Kasahara et al., 1991). A transfected cell line that 
overexpresses MT proved not only resistant to cisplatin but also to chlorambucil, 
melphalan and doxorubicin (Kelley et a l,  1988). However, cells of various origins 
selected for cisplatin resistance often, but not always, show increased MT expression, 
suggesting that increased MT expression alone may not be the sole mediator of 
cisplatin resistance. There are other mechanisms of MDR, on which only limited work 
has been carried o u t, 06-alkylguanine-DNA alkyltransferase, thymidylate synthase and 
certain cell cycle related proteins (Muller and Volm, 1995).
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From the above review of currently known MDR mechanisms, it can be seen that the 
MDR phenomenon is a complicated and widespread problem in the treatment of 
almost every class of tumour. The methods of circumvention are, so far, of quite 
limited, which leaves the way open for the use of specific genetic techniques which 
may prove to be the most effective means available for tackling this hindrance to 
effective chemotherapy.
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1.2 LUNG RESISTANCE-RELATED PROTEIN (LRP)
1.2.1 Discovery and Characterisation of LRP
While investigating alternative mechanisms of MDR, Scheper et al. (1993), selected 
the Pgp negative MDR cell line 2R120 by stepwise doxorubicin exposure (to 120 nM) 
of SW1573 non-small cell lung carcinoma cell line. The SW1573/2R120 MDR cell line 
was characterised by energy-dependent reduction of drug accumulation and exhibited 
cross-resistance to vincristine, gramicidin D and etoposide. No mdr-1 gene 
overexpression or Pgp was detectable. In contrast, SW1573/2R160 subline, obtained 
by exposure of 2R50 cells to slightly higher doxorubicin concentration (160 nM) 
displayed strong mdr-1 overexpression. BALB/c mice were immunized with 2R120 
cells and a monoclonal antibody (LRP-56) was selected for strong immunoreactivity 
with 2R120 cells compared to parental SW1573 cells (Scheper et al, 1993). The LRP- 
56 monoclonal antibody (MAb) displayed a characteristic cytoplasmic punctate 
staining pattern in the 2R120 cells, which has subsequently been found in all other 
LRP-56-positive MDR cell lines tested (Izquierdo et al., 1995, Izquierdo et al., 1996a, 
1996b, Scheffer et al., 1995). Immunoprecipitation studies showed that the LRP-56 
antibody specifically reacted with a protein of approximately 1 lOkDa. This protein was 
given the name Lung Resistance-related Protein (LRP) (Scheper et al., 1993). It was 
found to be overexpressed in various Pgp-negative MDR cell Unes, including a 
fibrosarcoma, small cell lung cancer and myeloma cell lines (Scheper et al., 1993).
The cDNA coding for the LRP gene product was isolated by screening a cDNA library 
generated from a MDR human fibrosarcoma cell line with mouse MOP8 cells and the 
LRP-56 antibody (Scheffer et al., 1995). The LRP sequence was found to display a 
single open reading frame of 2688 basepairs coding for an 896-amino-acid protein with 
a calculated Mr of 100 kDa. From the sequence, several potential phosphorylation 
motifs for protein kinase C, casein kinase II and tyrosine-protein kinase, as well as a 
phosphopantetheine attachment site and an amidation site were identified (Scheffer et 
a l, 1995). It did not appear, however, that transmembrane fragments or the ATP 
binding ‘active transport’ signature that is characteristic for the transmembrane 
transporter proteins Pgp and MRP were present. The LRP gene was localised, using
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fluorescence in situ hybridisation, to the short arm of chromosome 16, within the 
16pl 1.2-16p 13.1 chromosomal region, close to the MRP gene site (Scheffer et al., 
1995, Slovak et al., 1995). However, it appeared that MRP and LRP were rarely co- 
amplified and are not normally located within the same amplicon (Slovak et al., 1995). 
Interestingly, the protein kinase C-|3 gene, involved in MDR by activating the mdr-1 
gene, and possibly the LRP gene also, has been mapped to this same region (Komarov 
et al., 1997). Comparison of the elucidated LRP sequence with known gene sequences 
on databases revealed that LRP showed strong homology with the major vault protein 
(MVP) from Dictyostelium discodeum and Rattus norvégiens (Kickhoefer et al., 1994, 
Scheffer et al., 1995, Vasu et al., 1995). Alignment of the protein sequences of human 
LRP and rat MVP showed that 87.7% of the amino acids are identical, indicating that 
LRP is the human MVP (Scheffer et al., 1995).
1.2.2 LRP and Vaults
In 1986, a hitherto unknown cell organelle was described and given the name “vault”, 
chosen to describe the morphology of the particles consisting of multiple arches 
reminiscent of those from cathedral vaults (Kedersha and Rome, 1986). They were first 
discovered (by negative staining and transmission electron microscopy) as contaminant 
particles of clathrin-coated vesicle preparations derived from rat liver (Kedersha and 
Rome, 1986, Rome et al., 1991). They are ribonucleoprotein particles which are 
composed of a major vault protein of 104 kDa, which accounts for over 70% of the 
mass of the particle, three minor proteins of 210, 192 and 54 kDa, and a small RNA 
molecule. The vault components are assembled in a barrel-like structure with a 
molecular mass of around 13 MDa, approximately three times the size of a ribosome, 
and as such compose the largest ribonucleoprotein complex reported to date 
(Izquierdo et al., 1998). The vaults have two-fold symmetry and each half can be 
opened into a flower-like structure which contains eight petals surrounding a central 
ring (Kedersha et al., 1991). It is thought that these dynamic structural variations are 
likely to play a role in vault function (Izquierdo et al., 1998).
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Vaults have been isolated from a wide variety of species including lower eukaryotes, 
amphibians, avians and mammals (Kedersha et al., 1990; Rome et al., 1991). The 
amino acid composition of the MVP is highly conserved through evolution, with the 
identity between the mammalian MVPs being approximately 90% (Scheffer et al,
1995). The potential phosphorylation sites are evolutionarily conserved in all MVPs 
(Scheffer et al., 1995). Also antibodies raised against rat vaults recognise the MVP in 
all eukaryotic species tested. This data supports the notion that vault function is 
essential to eukaryotic cells (Kedersha et al., 1990; Kedersha et a l, 1991). The
majority of vaults are present in the cytoplasm and most cells contain thousands of 
vaults (Izquierdo et al., 1998). A small fraction of vaults are localised to the nuclear 
membrane and the nuclear pore complex (NPC) (Chugani, et al., 1993; Rome et a l, 
1991). Structural similarities support the hypothesis that vaults constitute the central 
plugs of the NPC (Izquierdo et a l, 1998). However, as yet, the precise fonction of 
vaults is unknown. The location of vaults at the NPC along with the data suggesting 
that vaults are the transporter units of the MPC raises the possibility that vaults mediate 
the bidirectional transport of a variety of substrates between the nucleus and the 
cytoplasm (Chugani, et al., 1993; Rome et al, 1991). There is also evidence to 
suggest that vaults are involved in vesicular transport processes (Herrmann, et al, 
1996; Kedersha and Rome, 1986), cell motility (Rome et a l, 1991), cell growth (Vasu 
et al., 1995) and play a central role in cell homeostasis (Herrmann et al., 1996; Rome 
et al., 1991).
1.2.3 LRP and drug resistance
Overexpression of LRP has been found in a large number of drug-selected MDR cell 
lines of various histogenic origins and selected by different drugs (Moran et a l, 1997; 
Scheper et a l, 1993; Verovski et a l, 1996). This indicates that diverse cancer cells 
react by up-regulating the expression of the LRP gene after exposure to anti-cancer 
agents. Overexpression is seen in both highly resistant MDR cell lines and at the early 
steps of resistance selection (Moran et al., 1997; Verovski et al, 1996; Wyler et al.,
1997). LRP is also expressed in cell lines not selected with drugs, which may be more 
clinically relevant. LRP was found to be expressed at various levels in 78% of 61 
human cancer cell lines of different histogenic origins used at the National Cancer
12
Institute (NCI; USA) for screening of new anticancer drugs, highlighting the 
widespread nature of LRP-associated mechanisms of resistance in human malignancies 
(Izquierdo et a l, 1996b).
In drug-selected MDR cell lines, expression of LRP and Pgp appears to be mutually 
exclusive (Moran et a l, 1997; Scheper et al., 1993). Up-regulation of LRP at low 
levels of resistance and a switching to up-regulation of Pgp at high levels of resistance 
has been frequently observed (Moran et al., 1997; Scheper et al., 1993, Versantvoort 
et al., 1995). However, concomitant expression of LRP and Pgp has been seen in some 
unselected MDR cell lines (Moran et al., 1997; Izquierdo et a l, 1996b). In contrast to 
Pgp, most LRP overexpressing cell lines display increased levels of MRP as well 
(Flens et a l,  1994; Scheper et a l,  1993). The concomitant expression of several drug 
resistance mechanisms may be necessary to cause the phenotype of drug resistance 
observed in LRP and MRP positive drug-selected MDR cell lines. Although MRP gene 
amplification has been shown to be the cause of overexpression and resistance in a 
number of cells lines (Slovak et a l, 1995), amplification of the LRP gene has not been 
widely reported. As mentioned earlier, despite the chromosomal proximity of MRP and 
LRP, they are very rarely co-amplified, and indeed, to date there is only one reported 
finding of LRP gene amplification (Laurencot et a l,  1997). Interestingly, tumor 
necrosis factor-a has been shown to reduce LRP gene expression at both mRNA and 
protein level in colon carcinoma cell lines, similar to its effect on the mdr-1 gene (Stein 
et a l,  1997). However, it had the opposite effect on MRP expression. Additional data 
indicates that the genes coding for Pgp, MRP and LRP are differentially regulated by 
12-O-tetradecanolphorbol-13-acetate and cytotoxic drugs (Komarov et a l, 1997). In 
drug unselected cancer cell lines and clinical tumor specimens, expression of only one 
of these three proteins is not uncommon (Izquierdo et a l,  1995, 1996b).
The range of drugs which have been used to select LRP overexpressing drug resistant 
cell lines is broad, including doxorubicin, mitoxantrone, etoposide, vincristine, 
cytarabine, methotrexate and cisplatin (Scheper et a l, 1993; Ikeda et al., 1997; 
Komarov et a l, 1997; Moran et al., 1997; Parker et al., 1997; Wyler et a l, 1997). 
Thus, the overexpression of LRP is not only associated with classical MDR drugs, but
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also with drugs not included in the classical MDR phenotype. Most MDR cell lines 
with LRP overexpression have been selected with doxorubicin, but display a cross­
resistance to etoposide, vincristine and other MDR-related drugs (Scheper et a l, 1993; 
Moran et a l, 1997). This broad spectrum of drug resistance associated with LRP 
overexpression is also seen in drug-unselected cell lines. From a panel of 61 human 
cancer cell lines from the NCI, LRP was found to show the greatest individual value as 
a marker of in vitro resistance to both classical-MDR related drugs (i.e. doxorubicin, 
vincristine) and also non-classical MDR drugs (i.e. cisplatin, carboplatin and 
melphalan) (Izquierdo et a l, 1996b). Interestingly, LRP mRNA expression was a 
somewhat better indicator of drug sensitivity than LRP protein expression (Laurencot 
et a l, 1997). Although LRP overexpression and increased drug resistant generally go 
hand in hand, it is not always the case. In an ovarian carcinoma cell line (OAW42-S), 
an increase in LRP expression in later passages of the cells did not result in an increase 
in drug resistance, which points towards a possible non-functional form of LRP 
(Moran et a l, 1997). It has also been shown that the up-regulation of LRP gene 
expression is accompanied by up to a 15-fold increase in the synthesis of whole vault 
particles (Kickhoefer et a l, 1997). It appears that the formation of vaults is limited by 
the expression of the major vault protein LRP, or possibly the other minor vault 
proteins, but not by the synthesis of vault RNA which is in excess to LRP (Izquierdo el 
a l, 1998). The fact that the cancer cells response to cytotoxic anticancer agents is the 
formation of such large complex particles as vaults, lends support for their role in drug 
resistance.
1.2.4 LRP expression in Tissues/Tumours and clinical value as prognostic 
indictor
Proteins related to in vitro drug resistance have been found expressed in various 
normal human tissues, where they are proposed to play a protective role against toxic 
compounds. LRP has been shown to be widely distributed in human normal tissues and 
tumours (Izquierdo et a l, 1996a; Sugawara et al, 1997). High expression levels were 
seen in tissues chronically exposed to xenobiotics (i.e. epithelia of the bronchus, 
digestive tract, and keratinocytes), in metabolically active tissues (i.e. adrenal cortex),
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and in macrophages, with varying levels found in other organs (Izquierdo et a l, 
1996a). This distribution pattern resembles that of Pgp and MRP, suggesting a 
common role in the defence against xenobiotics (van der Valk et a l, 1990; Flens et al.,
1996). In support of this theory, it has been observed that in normal lung tissue, LRP 
expression is higher in those who had smoked more than 10 pack years (1 cigarette 
pack per day/10 years) compared with those who had never smoked.
In order to investigate whether the expression of LRP in clinical specimens is 
predictive of response to chemotherapy, a number of studies have been undertaken on 
various tumor types. The monoclonal antibody LRP-56 has been used extensively, for 
immunocytochemical, flow cytometry and immunohistochemical studies (Izquierdo et 
al., 1998). More recently the LMR-5, rat monoclonal antibody, which can also detect 
LRP, has also been used in these studies (Flens et al., 1997). In a series of ten 
melanoma cell lines, MDR-1, MRP and LRP gene expression (as measured at the 
mRNA level by RT-PCR) was detected in 2, 4 and 10 cell lines respectively 
(Schadendorf et al., 1995). The same group studied 21 primary and 37 metastatic 
malignant melanoma specimens using immunohistochemistry, and found the expression 
of Pgp, MRP and LRP to be 2, 43 and 62% respectively (Schadendorf et al., 1995). 
The number of metastatic melanomas that expressed high levels of LRP was 
significantly greater among those that had previously been exposed to chemotherapy. 
These results pointed to a role for LRP, and also MRP, in malignant melanoma drug 
resistance.
In two separate studies, non-small cell lung cancer (NSCLC) cell lines were found to 
express LRP at a rate of between 80 to 86%, while a more sensitive subtype, small cell 
lung carcinoma (SCLC) showed no expression of LRP (Dingemans et a l, 1996; 
Izquierdo et al., 1996a). However, further studies are required to elucidate the 
prognostic significance of LRP in lung cancer. The expression of LRP in multiple 
myeloma has been reported to be between 13 and 48%, according to two separate 
studies (Izquierdo et al., 1998). No difference in LRP expression was found between 
myelomas with or without prior chemotherapy. The expression levels of LRP in 
neuroblastoma, a relatively chemosensitive tumor type, was found to be low in 
untreated patients (16%), similar to other chemosensitive tumour types (Ramani and
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Dewchand, 1995; Izquierdo et al., 1996a). However, after treatment, the expression 
rate rose to between 78 to 82% (Ramani and Dewchand, 1995). This data suggests an 
association between exposure to anticancer agents and induction of expression of LRP.
The molecular basis of drug resistance in childhood acute lymphoblastic leukaemia 
(ALL) is largely unknown (Pieters et al., 1997). In one study of 30 patients with 
relapsed childhood ALL, the expression of LRP, but not Pgp, was significantly 
associated with an increased in vitro resistance of fresh leukaemic cells to daunorubicin 
(Klumper et al., 1995). More recently, the expression of LRP was found to be 
significantly higher in relapsed versus initial samples and correlated weakly with in 
vitro resistance to daunorubicin and etoposide (Veerman et al., 1997). These 
preliminary studies, suggest that expression of LRP may result in low intracellular 
concentrations of daunorubicin and point to LRP as a relevant resistance protein in 
childhood ALL.
In adult acute leukemia (AML), only 1 out of 6 leukaemia cell lines from the NCI 
panel expressed LRP (Izquierdo et al., 1996b). However, the studies performed to 
date show that the expression of LRP is consistently associated with poor response to 
induction chemotherapy, as well as with shorter progression-free and overall survival 
(List et al., 1996; Izquierdo et al., 1998). Hart et al. (1995), showed that LRP mRNA 
expression, but not MDR-1 or MRP, was significantly increased in patients failing to 
respond to intensive chemotherapy compared with those achieving complete response, 
while List et al., (1996), showed that the prognostic value of LRP was superior to that 
of Pgp. These data show that expression of LRP is a poor prognostic factor in AML 
and point to LRP as a clinically relevant drug resistance gene in AML. A study of 57 
women with ovarian cancer indicated that LRP positive tumors had a significantly 
inferior response to platinum and alkylating agent based chemotherapy (Izquierdo et 
al., 1995). Furthermore, the expression of LRP was significantly associated with a 
shorter interval until tumor progression and shorter overall survival. This clinical data 
correlated with in vitro studies on the 61 cell lines of the NCI panel, which showed an 
association between LRP expression and intrinsic resistance to cisplatin (Izquierdo et 
al., 1996b).
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The results of the studies mentioned above, while limited in number, seem to support a 
strong role for LRP as a useful prognostic indicator in the clinic. It is interesting that 
LRP was found to be a much stronger prognostic indicator in these particular studies 
than the original MDR marker Pgp, and also MRP. This tends to indicate a direct role 
for vaults in drug resistance to both classical and non-classical MDR drugs. 
Alternatively, it may be that LRP is simply co-expressed with other resistance 
mechanisms.
1.2.5 Postulated mechanism of LRP-related drug resistance
From the observations carried out into drug re-distribution in MDR cancer cell lines 
and leukaemic blast cells and from data on structure and cellular localisation of vaults, 
a plausible hypothesis regarding the functional role of vaults in drug resistance has 
been put forward (Izquierdo el al., 1996c, Izquierdo el al., 1998). It has been shown 
that LRP overexpressing MDR cancer cells, in a similar fashion to most MDR cells, 
distribute daunorubicin into the perinuclear region and subsequently redistribute drug 
away from the nucleus into a punctate cytoplasmic pattern, whereas parental cells 
localise daunorubicin in a diffuse nuclear and cytoplasmic pattern (Schuurhuis et a l, 
1989; Dietel et a l, 1990). Micheili et a l, (1997) reported that leukaemic blast cells 
which only expressed LRP, but not Pgp or MRP, showed an impaired intracellular 
accumulation of daunorubicin and suggested that vaults could be implicated in this 
phenomenon. Vaults are good candidates to be the perinuclear and cytoplasmic 
structures mediating daunorubicin re-distribution within MDR cells and leukaemic 
blast cells. Vaults are located at the nuclear pore complex (NPC), and could be, in fact, 
the transporter units (Chugani et al., 1993). With this information, Scheper et al. 
hypothesised that vaults can mediate drug resistance by regulating both the 
nucleocytoplasmic transport of drugs and their cytoplasmic redistribution within 
vesicles, keeping cytotoxic agents away from their cellular targets (Izquierdo et a l, 
1996c). Transfection of the LRP gene alone has failed to confer MDR, an expected 
finding considering that the complete vault particle will be required for functional
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activity (Scheffer el al., 1995). It is therefore apparent that the optimal method for 
assessing LRPs role in MDR is to perform knock out assays, where LRP expression is 
eliminated or decreased and examine the resulting effect on drug resistance. Anti-LRP 
ribozymes and antisense molecules allow such experiments to be carried out in a 
similar fashion to those investigating the role of Pgp and MRP.
18
1.3 RIBOZYMES
The word “ribozyme” is derived from the words ribonucleic acid (RNA) and enzyme. 
and it denotes an RNA molecule with catalytic properties (Kashani-Sabet and Scanlon, 
1995; Ohkawa et a l, 1995). The first ribozyme was described by Cech and colleagues, 
which was the 413-nucleotide Group I intervening sequence in the pre-rRNA of 
Tetrahymena Termophila (Cech et al, 1981). The intervening RNA sequence 
catalyzes its own excision, called self-splicing. The first truly catalytic ribozyme that 
could cleave other molecules with multiple turnover, was reported by Altman and 
collaborators (Guerrier-Takada et a l, 1983). It was the 400-nucleotide RNA 
component of bacterial RNase P. To date, a number of naturally occurring ribozymes 
have been identified and can be classified into 6 groups :
1) Ribozymes derived from self-splicing tetrahymena group I introns (Cech et. al,. 
1981; Kruger et a l, 1982);
2) RNA components of RNase P (Guerrier-Takada et a l, 1983);
3) Hammerhead ribozymes (Uhlenbech, 1987)
4) Hairpin ribozymes (Buzayan et a l, 1986);
5) Genomic and anti-genomic RNase of hepatitis 8 virus (Perotta and Been, 1992);
6) RNA transcripts of mitochondrial DNA plasmid of Neurospora (Symons, 1994).
1.3.1 Hammerhead ribozymes
Among these catalytic RNAs, the hammerhead ribozyme is the smallest (Kashani-Sabet 
and Scanlon, 1995; Ohkawa et a l, 1995). The name “hammerhead” derives from the 
predicted shape of the ribozymes secondary structure. Naturally occurring 
hammerhead ribozymes were found within RNA viruses and they act in cis during viral 
replication by the rolling circle mechanism (Symons, 1992; Bratty et a l, 1993). 
Through genetic engineering, the hammerhead was manipulated to enable it to cleave 
its target in trans and act in a truly catalytic manner (Uhlenbeck, 1987). Using in vitro 
mutagenesis studies of the plus strand of satellite RNA of tobacco ringspot virus
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(sTobRVO), the consensus sequences required to maintain catalytic cleavage by the 
ribozyme were defined (Haseloff and Gerlach, 1987). It is this information that allows 
for the design of ribozymes to target any gene of interest once the sequence is known.
In terms of secondary structure, the trans-acting hammerhead ribozyme developed by 
Haseloff and Gerlach, is composed of the catalytic core (or hammerhead domain) 
region and three hybridising helices or stems (Figure 1.3.1): stems I and III hybridise 
to the flanking sequences of the cleavage site and act as an antisense, and the stem 
loop II is usually composed of eight complementary ribonucleotides in the loop 
structure (Kashani-Sabet and Scanlon, 1995; Ohkawa et al., 1995). In terms of the 
substrate, the mutational analysis revealed the requirement of XUN sequences, with X 
being any nucleotide and N being A, C or U (Haseloff and Gerlach, 1988; Ruffner et 
al., 1990). Gerlach and co-workers have expanded the substrate sequences cleaved by 
the hammerhead ribozyme (Perriman et al., 1992). In general, targets containing GUC, 
GUA, GUU, CUC and UUC sequences are well cleaved and targets containing, GUG, 
AUC, XAC, and XCC sequences are either not cleaved or cleaved with a substantially 
reduced rate. It is the likelihood of finding an appropriate target within a given gene 
sequence that makes hammerhead ribozymes such a potentially useful tool.
The basic reaction scheme of a ribozyme cleaving its target is as follows (Ohkawa et 
al., 1995): First the substrate (together with Mg2+ ions) binds to the ribozyme via the 
formation of base pairs with stems I and III. Then, a specific phosphodiester bond in 
the bound substrate is cleaved by the action of the Mg2+ ions (the ribozyme functions 
as a metalloenzyme as it requires the presence of magnesium). This cleavage generates 
products with 2’, 3’-cyclic phosphate and 5’-hydroxyl groups. Finally the cleaved 
fragments dissociate from the ribozyme and the liberated ribozyme is now available for 
a new series of catalytic events. With respect to the ribozyme itself, several 
requirements must be met for the development of an effective catalytic RNA. Several 
groups have probed the actual requirements within the catalytic core, which are almost 
exclusively composed of RNA (Perreault et al., 1990, 1991; Yang et al., 1992). An all 
DNA ribozyme was shown to be devoid of catalytic activity (Perreault et al., 1990). 
Further studies using DNA at specific sites established that the minimum
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Figure 1.3.1 Diagram of TVa/w-acting hammerhead ribozyme
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ribonucleotide requirement is that at bases highlighted in Figure 1.3 (Perreault et a l, 
1990, 1991; Yang etal., 1992).
Several investigators have examined the effects of changes in the flanking sequences of 
the ribozyme on catalytic activity (Fedor and Uhlenbeck, 1990; Herschlag, 1991; 
Bertrand et al., 1994). Fedor and Uhlenbeck (1990) demonstrated that ribozymes 
differing in the number as well as in the sequence of RNA helices I and III differed 
drastically in cleavage kinetics. Herschlag (1991) observed that while increasing the 
recognition sequence increased ribozyme specificity, the dissociation step between 
ribozyme and substrate was too slow to increase overall cleavage. Recent studies have 
suggested that 12 bases may represent the optimal length of flanking sequence 
(Bertrand et a l, 1994). In addition, substrate sequences flanking the cleavage site rich 
in A or U were favoured over GC rich sequences to enhance discrimination 
(Herschlag, 1991). In particular, U-rich sequences are preferred in the substrate and A- 
rich sequences in the ribozyme. A further study identified that stem II in the 
hammerhead ribozyme, may not be essential to the cleavage reaction, as stems with 
two base pairs rather than four retained catalytic activity, while however, further 
elimination’s were not tolerated (Tuschl and Eckstein, 1993).
1.3.2 Hairpin ribzoymes
The hairpin ribozyme is derived from the minus strand of sTobRV RNA, and site- 
specifically cleaves RNA in trans (Hampel and Tritz, 1989; Feldstein et al., 1989). The 
original hairpin ribozyme consisted of 50 bases and cleaves corresponding 14 base 
RNA substrates, in the presence of Mg2+. The proposed secondary structure from 
which this ribozyme derives its name, was devised by mutational analysis, computer 
modelling and phylogenetic studies (Hampel et al., 1990). This consists of four helical 
regions separated by two internal loop sequences. The substrate binds to the ribozyme 
through two helices (helix 1 and 2). Cleavage occurs to the 5’ side of a guanosine 
within the internal loop (loop A) of the substrate separating helices 1 and 2. A second 
internal loop (loop B) separates the two helices (helix 3 and helix 4) of the ribozyme. 
As with the hammerhead ribozyme, studies have been carried out to determine the 
nucleotide sequences essential for catalytic activity. Within loop A, there are four
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essential bases and one in the substrate (Berzal-Herranz et al., 1993). Within loop B, 
nine of 11 bases are essential sequences, while only one base within the four helices is 
important for catalytic activity. It therefore appears that both loop A and loop B play 
an important role in catalysis.
1.3.3 Ribozyme delivery
For the ribozyme to be effective in a cellular environment, it needs to be delivered to 
the intracellular milieu. Researchers have used either exogenous delivery (using naked 
ribozymes complexed with cationic liposomes) or vector-based systems to promote 
endogenous ribozyme expression. In the case of exogenous delivery, the susceptibility 
of RNA oligonucleotides (including ribozymes) to ribonuclease attack intracellularly or 
in the serum, required the search for modifications to enhance ribozyme stability while 
maintaining cleavage capability. To this end, a number of chemical modifications of the 
nucleotides have been made. These include the incorporation of 2’-fluoro, 2’-amino, 
2’-0-allyl and 2’-0-methyl nucleotides into hammerhead ribozymes (Pieken et a l, 
1991; Paolella et a l,  1992). A second class of modifications involves the substitution 
of phosphorothioate molecules in the phosphate moiety. One study examined the 
combination of 2’-pyrimidine modifications as well as four terminal phosphorothioate 
linkages and demonstrated that the resultant ribozyme had a cleavage efficiency similar 
to that of the unmodified ribozyme.
A third and most successful approach, yielding ribozyme stability without sacrificing 
cleavage activity, concerns the introduction of deoxynucleotides outside of the 
catalytic core. Rossi and co-workers showed that chimeric DNA/RNA ribozymes, with 
DNA in helices I and III had a 6-fold greater catalytic activity than an analogous all- 
RNA ribozyme (Taylor et al., 1992). This difference could be attributable to the 
differences in dissociation of the DNA-RNA complex versus that of the RNA-RNA 
complex. One group combined the use of DNA in helices I and III of the ribozyme 
with phosphorothioate linkages in stems I, II and III and demonstrated a 7-fold higher 
cleavage activity, as well as resistance to degradation in human serum (Shimayama et 
al., 1993).
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In contrast to exogenous delivery, many studies utilise the cellular machinery to 
express the ribozyme. Here, the ribozyme gene is cloned into an available vector ( 
expression plasmid or retroviral vector) and delivered to the cells by transfection of the 
plasmid or by retroviral infection. Other delivery systems, such as cationic liposomes, 
adenoviruses and adeno-associated viruses (AAV), are being studied in order to 
optimize ribozyme activity (Kashani-Sabet and Scanlon, 1995). The choice of delivery 
system can depend heavily on the disease type. Adenoviruses, due to their tissue 
tropism, could be suitable for the therapy of respiratory diseases, such as lung cancer 
and cystic fibrosis. AAV systems, however, may be useful for ribozyme delivery, as 
their small genome size would accommodate ribozyme genes, but not necessarily 
larger ones. In addition, as AAV may infect nonreplicating cells, this system could be 
used to transduce bone marrow cells (Kashani-Sabet and Scanlon 1995).
Another critical element in ensuring optimal ribozyme activity is the choice of 
promoter. The first reported intracellular expression of a ribozyme (anti-CAT) used the 
SV40 early promoter, with the ribozyme embedded in the 3’ untranslated region of the 
firefly luciferase gene (Cameron and Jennings, 1989). Other viral promoters tested so 
far include the herpes simplex virus thymidine kinase (HSV-tk) promoter, the HIV and 
Rous sarcoma virus (RSV) long terminal repeats (LTRs), and the cytomegalovirus 
(CMV) promoter. The use of cellular promoters is also common, such as the P-actin 
promoter or by incorporating the ribozyme in to tRNA genes to take advantage of 
RNA polymerase Ill-mediated transcription (Kashani-Sabet and Scanlon 1995). 
Tighter control over ribozyme expression is achievable with inducible promoters such 
as the mouse mammary tumor virus (MMTV) dexamethasone-inducible promoter and 
the bacteriophage T7 promoter induced by isopropyl-P-D-thiogalactoside.
Once the ribozyme has been successfully introduced intracellularly, demonstration of 
ribozyme activity is required. Expression of the ribozyme itself can be detected by 
reverse-transcriptase-polymerase chain reaction (RT-PCR) or Northern blot analysis. 
Proof of efficacy of the ribozyme is reliant on a demonstration of inhibition of the 
target gene expression (at RNA and/or protein level) and any downstream phenotypic 
effects such as decreased tumor growth, viral replication or drug resistance. Since, the
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ribozyme has the potential to act as antisense, it is desirable to demonstrate that the 
ribozyme retains the ability to cleave. Saxena and Ackerman, (1990), demonstrated 
that a ribozyme cleaved its target when both elements were injected into oocytes. 
Others have shown that cellular extracts of ribozyme expressing cells cleave target 
RNA in vitro (Chang et a l, 1990; Scanlon et a l, 1991; Kashani-Sabet et a l,  1992), 
suggesting that the ribozyme expressed intracellularly retains the ability to cleave its 
target. However, detection of the cleavage products has been elusive in many studies, 
due, most likely, to the rapid degradation of short RNAs. Some studies have detected 
such products by PCR analysis (Sarver et al., 1990; Kashani-Sabet et al., 1992; Cantor 
et al., 1993). More recently, detection of the cleaved fragment of mdr-1 RNA was 
reported by Northern analysis in human ovarian carcinoma cells (Scanlon et a l, 1994). 
But of all the ribozyme studies carried out to date, these remain the few cases where 
cleavage products have been readily detectable.
1.3.4 Ribozyme in the study of MDR
Several groups have demonstrated ribozyme-mediated modulation of MDR in human 
cancer cells (for review see Byrne et a l, in press). Scanlon and co-workers report the 
reversal of the MDR phenotype in human ovarian carcinoma cells using either a mdr-1 
ribozyme or a fo s  ribozyme (Scanlon et al., 1994). Using an anti-mdr-1 ribozyme 
designed to cleave the CUC sequence of codon 880 (a target site between 2 ATP 
binding sites which may play a role in the Pgp pump), resistance in a human ovarian 
carcinoma cell line (16.6 fold resistant to actinomycin D and over-expressing mdr-1) 
was completely reversed to the sensitive level. Mdr-1 expression was reduced and 
actinomycin D intracellular transport level was increased. The anti-fos ribozyme 
(which targets the GUC sequence of codon 309) reversed actinomycin D resistance 
more quickly than did the mdr-1 ribozyme. This may suggest that c-fos may modulate 
the expression of genes other than mdr-1 which also contribute to the MDR 
phenotype. In this cell line the anti-fos ribozyme down-regulated not only c-fos but 
also the expression of mdr-1 and topoisomerase I (the mdr-1 promoter has an AP-1 
binding site (Teeter et al., 1991)).
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The mdr-1 ribozyme has been shown to be effective in a number of other MDR cell 
types. Holm and co-workers report the reversal of daunorubicin resistance in resistant 
(1600 fold) human pancreatic carcinoma cells (Holm et al., 1994). The ribozyme- 
containing cells were only 5.3-fold more resistant to daunorubicin than the parent 
sensitive cells. In two lung cell lines the ribozyme has a similar effect; mdr-1 ribozyme 
transfectants of two MDR lung cell lines (DLKP-A and SKMES-1ADR) were found 
to be more sensitive to adriamycin, vincristine and VP-16 (Daly et al., 1996). The anti- 
mdr-1 ribozyme does not result in complete reversal of resistance to the level of the 
sensitive parent. Possibly the level of mdr-1 mRNA remaining in the mdr-1 ribozyme 
transfectants is capable of mediating drug resistance and/or other mechanism of 
resistance may be present in these lines.
Kobayashi and colleagues have designed ribozymes directed at other areas of the mdr- 
1 mRNA transcript (Kobayashi et al., 1994). They designed two hammer-head 
ribozymes; one targeted at codon 179 and the other at codon 196. In cell free studies 
the ribozyme targeted at the 196 codon proved most effective. This ribozyme was then 
used in transfections to target mdr-1 mRNA in an acute leukemia cell line. The 
ribozyme down-regulated mdr-1 mRNA as well as Pgp expression. Vincristine 
resistance was decreased from 700- to 20-fold. Once again complete reversal of drug 
resistance did not occur. This leukemic cell line was highly drug resistant and as such 
possibly not enough ribozyme was expressed to down-regulate the over-expressed 
mdr-1 mRNA or the resistance mechanism in these cells could be multi-factorial.
Bertram and co-workers have studied the ribozyme-mediated reversal of drug 
resistance in a human colorectal carcinoma (LoVo/Dx) cell line resistant to 
doxorubicin (LoVo/Dx1^) (using a ribozyme directed against mdr-1 mRNA) (Bertram 
et al., 1995). These authors designed two ribozymes against mdr-1, ribozyme 1 
(targeting the CUC sequence at position 2429) and ribozyme 2 (targeting the GUC 
sequence at position 2440). In vitro these ribozymes reduced the mdr-1 mRNA from 
the LoVo/Dxr  cells by up to 80%. Modified ribozymes (containing fluoro and allyl 
substituted bases to increase stability against ribonucleocytic attack) reduced chemo- 
resistance of these cells by up to 50%. Using three mdr-1 ribozymes (ribozyme 1 
targeting position 2429, ribozyme 2 targeting position 2440 and ribozyme 3 targeting
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2408) in in vitro assays, Palfner and co-workers (1995) assayed conditions such as 
ribozyme-to-target ratio, pH, MgCk concentration and incubation time on cleavage 
efficiency (Palfner el al., 1995). Their most efficient ribozyme cleaved 91% of an in 
vitro transcribed mdr-1 mRNA transcript.
Ribozyme studies can also be used in functional assays of multi-drug resistance. 
Eijdems and co-workers report the down-regulation of mdr-1 mRN A using an mdr-1 
ribozyme targeted at codon 196 (Kobayashi et al., 1994; Eijdems et al., 1995) in a 
human non-small cell lung cancer cell line SW-1573 selected in a low concentration of 
doxorubicin. In a clone having reduced mdr-1 mRNA level there was no detectable 
change in sensitivity to drug which suggests that mdr-1 does not contribute to drug- 
resistance in these cells. These authors have concluded that resistance in this cell line is 
associated with the presence of an altered form of MRP.
Increased expression of c-fos is often found associated with drug-resistance and 
several of these drugs (e.g. cisplatin) are not substrates for mdr-1 or MRP (Hollander 
and Fornace, 1989; Scanlon et al., 1994). fo s  is believed to mediate its effects through 
transcriptional activation, after interaction with the Jun protein, to form the AP-1 
complex. This complex affects proliferation, apoptosis and drug resistance through 
transcriptional activation of genes via AP-1 elements in their regulatory regions. The 
A2780 ovarian carcinoma cell line resistant to cisplatin has been shown to exhibit c-fos 
overexpression as well as the over-expression of c-myc, H-ras, thymidylate synthesis, 
DNA polymerase B and Topoisomerase I (Scanlon et al., 1990, 1991; Kashani-Sabet 
et al., 1990). This may suggest that c-fos is involved in cisplatin resistance by directing 
expression of enzymes carrying out DNA synthesis and repair processes. Tumour 
tissue from a patient with colon carcinoma failing cisplatin/5-fluorouracil treatment 
revealed a similar pattern of gene expression to the resistant A2780 subclone (Kashani- 
Sabet et al., 1990). These data suggest that the c-fos gene regulates downstream 
enzymes associated with DNA synthesis and repair and may play a central role in 
cisplatin resistance.
It has already been discussed how anti-fos ribozymes are effective in lowering 
resistance in classic MDR cell lines, /os-ribozymes have also been shown to be
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effective in altering resistance in non-classic MDR e.g. resistance to cisplatin. Cisplatin 
is one of the most widely used anti-cancer agents and its multifactorial mechanisms of 
resistance pose serious clinical problems in cancer chemotherapy (Ishida et al., 1995). 
Studies in cisplatin-resistant cell lines support the importance of the c-fos oncogene in 
maintaining the drug-resistant phenotype (Scanlon et al., 1989). A hammer-head 
ribozyme against the c-fos gene has been investigated in a cisplatin resistant line 
(Scanlon et al., 1991; Funato et al., 1992). The cisplatin resistant human ovarian 
carcinoma A2780 subclone (A2780DDP, 10-fold resistant to cisplatin) was transfected 
with an anti-fos ribozyme and was rendered sensitive to the antineoplastic effects of 
cisplatin (as well as camptothecin, 5-fluorouracil and azidothymidine to which 
A2780DDP cells are cross-resistant). The ribozyme transfectant was found to have 
down-regulation of c-fos gene expression as well as down-regulation of c-fos 
responsive genes such as DNA polymerase B, Topoisomerase I and metallothionein 
IIA. Down-regulation of c-fos may reverse drug-resistance by several mechanisms 
involving DNA synthesis as well as Pgp.
Funato and co-workers (1997) prepared a hammer-head ribozyme to selectively cleave 
fos mRNA. The ribozyme was transfected into implanted human colon cancer cells 
SW480DDP and SW620DDP (which over-express the fos gene and are resistant to 
cisplatin treatment) and it reduced the expression of the fos gene in vivo and also 
reversed cell sensitivity to cisplatin.
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1.4 THE USE OF ANTISENSE RNA TO INHIBIT GENE EXPRESSION
The use of antisense RNA to inhibit gene function within cells is very similar to the use 
of ribozymes. The main difference is that the antisense sequences don’t have any 
catalytic activity. However, in general, plasmid derived-antisense RNA tends to be 
much longer than ribozyme sequences. Whole or partial cDNA fragments are usually 
cloned into a plasmid in a reverse (antisense) orientation, giving rise to antisense RNA 
sequences, usually 0.6 to 2 kb in size. The very size of many of these antisense RNA 
molecules can have significant effect on the potency of these molecules. For instance, 
annealing rates must be considered, as they have been shown to be related to the extent 
of inhibition (Rittner et al., 1993). In addition, secondary structure formation (such as 
stem-loops, internal loops, bulges) can play an important role the accessibility of the 
RNA and its stability. However, the antisense RNA sequence used in this thesis 
comprises of only 14 bases, and differs from the LRP-ribozyme construct only in its 
lack of catalytic domain.
It is also important to understand that antisense RNA differs from the more common 
antisense DNA oligonucleotides in its mode of action. Antisense RNA molecules bind 
to the target mRNA, forming RNA-RNA duplexes. These duplexes are not susceptible 
to attack by RNase H, which is the main method of action for most DNA based 
antisense oligonucleotides (Branch, 1996). They act mainly through steric hindrance of 
the ribosomal machinery along the mRNA molecule, preventing the formation of 
proteins. However, there are a number of cellular enzymes that can interfere with RNA 
duplexes, as these duplexes play a role in cell functioning. The RNA duplexes 1) guide 
ribosomal maturation; 2) serve as substrates for RNase III, an enzyme that cleaves 
ribosomal RNA precursors and dsRNA; 3) activate enzymes of the interferon- 
associated antiviral pathway; and 4) serve as substrates for a deaminase (Branch, 
1996). As a result of these interactions, antisense RNA may not reduce the expression 
of target RNA to the same levels as a ribozyme or antisense oligonucleotides directed 
at the same target, but may be just as effective at decreasing expression of the protein 
product.
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Antisense RNAs have been used widely in the study of oncogene function. Targets 
have included DNA polymerase B (Horton et a l,  1995), phosphoprotein p i8 (Jeha el 
a l,  1996), cyclin D1 (Zhou et al., 1995), K-ras (Zhang et al., 1993), glial fibrillary 
acidic protein (GFAP) (Rutka et a l, 1994), vascular endothelial growth factor (VEGF) 
(Saleh et a l,  1996), epidermal growth factor receptor (EGF-R) (Giovanni et al., 
1996), insulin-like growth factor I (IGF-I) (Trojan et a l, 1992), insulin-like growth 
factor I receptor (IGF-IR) (Resnicoff et a l,  1994), c-myb (Raschella et a l,  1992), p53 
(Velasco et al., 1995), fibroblast growth factor 2 (FGF-2) (Maret et a l,  1995), and 
transforming growth factor a  (TGF-a) (Laird et al., 1994).
There has only been one report of the use of antisense RNA for the downregulation of 
mdr-1 expression. Hanchett and colleagues used a 963 bp fragment of the mdr-1 
cDNA cloned into an expression vector, which used a P-actin promoter, in a reverse 
orientation (Hanchett et a l, 1994). They transfected this construct into MDR variants 
of a human nasopharyngeal epidermoid carcinoma cell line (KB 3-1) and analysed the 
cells for a reduction in drug resistance, mdr-1 mRNA and Pgp expression. However, 
out of 10 isolated clones that expressed the antisense construct, only one actually 
exhibited a decrease in drug resistance. Studies using rhodamine-123, a fluorescent 
substrate for Pgp, revealed that dye retention in individual cells was highly variable 
within this antisense-expressing clone. Sub-populations were established from this 
original clone, based on rhodamine-123 retention. Despite the fact that all the 
subclones expressed similar amounts of the antisense, the levels of mdr-1 raRNA 
varied dramatically. Nuclear run-on analysis indicated that the mdr-1 gene was 
transcribed at the same rate in all populations, which suggested that the reduction in 
mdr-1 mRNA was mediated post-transcriptionally. Cells with the greatest reduction in 
mdr-1 mRNA accumulated distinct antisense RNA transcripts in the nuclear RNA 
fraction, suggesting that antisense effectiveness in this system was associated with a 
nuclear event or process.
These results reveal that antisense RNA activity is not necessarily distributed evenly 
within a clonal population. The results also highlight potential problems with the 
transfection of antisense RNA. Out of 16 that were initially transfected, only 10
I
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actually expressed the antisense RNA. Of these 10, only one exhibited a decrease in 
mdr-1 mRNA levels (50%) and Pgp (50%) as measured by Northern and western blot 
respectively. Some studies have suggested that a large excess of antisense RNA is 
necessary to drive hybrid RNA duplex formation and establish an antisense effect 
(Yokoyama and Imamoto, 1987; Krystal et a l,  1990). There have also been 
descriptions of anti sense effects in situations where a large excess of antisense RNA 
has not been detected (Nishikura and Murray, 1987; Kasid et a l, 1989). Hanchett and 
co-workers stated that there was an 80-fold excess of antisense to mdr-1 mRNA in 
their original clone (Hanchett et a l,  1994). However, in another study with the same 
cell line, Wang and Dolnick have shown that an antisense RNA excess of 200-fold was 
insufficient to achieve an anti sense effect targeting di-hydrofolate reductase mRNA 
(Wang and Dolnick, 1993).
Why antisense RNA works well in some systems but is ineffective in others is an 
important, but as yet largely unanswered. Different mRNA targets can be expected to 
have unique characteristics with respect to structure, stability, processing, and post- 
transcriptional control, which may affect the susceptibility of a particular mRNA to 
antisense RNA. The results of Hanchett et a l, (1994), illustrate a dynamic aspect of 
antisense action at the cellular level, and demonstrate the extent of variability in 
effectiveness that can be observed with antisense RNA.
The anti-LRP antisense RNA expression plasmid used in this thesis targets exactly the 
same region in the LRP sequence, bases 1147 to 1160 as the LRP ribozyme. This 
allows direct comparison of the efficacy of the antisense RNA and ribozyme, as both 
should have equal accessibility to the target site. It would be expected that the 
ribozyme would be more efficient, as it has the added benefit of catalytic cleavage in 
addition to its basic antisense effect.
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1.5 USE OF ANTISENSE OLIGODEOXYNUCLEOTIDES TO STUDY DRUG 
RESISTANCE
1.5.1 Antisense Technology
The notion of using specific oligonucleotides for the modulation of gene expression 
surfaced two decades ago when Zamenick and Stephenson inhibited the replication of 
the Rous Sarcoma virus (Zamenick and Stephenson 1978). They added a synthetic 
piece of DNA to the medium of chick fibroblasts in tissue culture to block the 
circularisation step by hybridising specifically with the 3’ end of the viral RNA in a 
competitive way. It inhibited the formation of new virus, and also prevented the 
transformation of chick fibroblasts into sarcoma cells.
The term ‘antisense’ ascribed to a nucleic acid sequence, refers to the fact that it forms 
complementary base pairs to a part or all of a genetic coding sequence which is termed 
the ‘sense’ strand. Thus once all or part of the sequence of a target gene is known, an 
antisense molecule can be designed which specifically binds to this gene alone. In 
addition to this hydrogen bonding, the affinity of the antisense molecules to their 
targets is affected by base-stacking in the double helix of the oligonucleotides and also 
the ionic strength of the system (Crooke and Bennett, 1996). Affinity between the 
antisense oligonucleotide and target polynucleotide increases as the length of the 
antisense molecule increases, due to the increased hydrogen bonding between bases 
and stacked pairs (Crooke and Bennett, 1996). Theoretically, at least, this allows for 
the design of drugs to attack any unwanted or mutated form of a gene, and leave the 
normal copy of the gene untouched, even if the two forms differ by only a single base 
pair or nucleotide (Crooke and Bennett, 1996, Milligan et al., 199A, Giles el al.,
1995).
Antisense molecules can consist of relatively short synthetic oligonucleotides 
introduced into cellular systems by various means (Stein el al., 1993, Brysch and 
Schilingensiepen, 1994, Helene, 1994, Scanlon et a l, 1995, Zon, 1995, Crooke and 
Bennett, 1996, Wagner and Flanagan, 1997). This form is currently the most widely 
used and entails the use of DNA and RNA based oligonucleotides or combinations of 
both. Alternatively, antisense molecules can consist of a whole gene, or a specific
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fragment of a gene, cloned into an expression vector in a reverse orientation and 
transfected into a cell, where it is expressed as antisense RNA either endogenously or 
upon stimulation (Scanlon et a l, 1995, Branch, 1996, Tolume et a l, 1996, Zhang, 
1996, Sczakiel, 1997).
1.5.2 Mechanisms of antisense action
The mechanisms by which interactions of antisense oligonucleotides with nucleic acids 
may induce biological effects are quite complex. The most basic mode of action of 
antisense is an occupancy-only one (Crooke and Bennett, 1996). The antisense acts as 
a classic competitive antagonist by binding to specific sequences, inhibiting the 
interaction of the RNA or DNA with proteins, other nucleic acids or factors required 
for the essential steps in the intermediary metabolism of the RNA or its utilisation by 
the cell. Another mechanism is the inhibition of excision of introns or ‘splicing’, which 
is a key step in the intermediary metabolism of most mRNA molecules (Crooke and 
Bennett, 1996, Sharma and Narayanan, 1995, Neckers et a l, 1992). The mechanism 
for which the majority of oligonucleotides have been designed to date is to cause 
translational arrest by binding to the translation initiation codon or alternatively to bind 
to areas in the coding region to attempt steric hindrance of ribosome progression along 
the mRNA (Brysch and Schilingensiepen, 1994, Crooke and Bennett, 1996, Ohkawa et 
ah, 1996, Bouffard et ah, 1996, Probst and Skutella, 1996). Although the ribosomal 
machinery is quite powerful and tends to sweep away most obstacles in its path, 
targeting the AUG initiation codon where the ribosomes first begin translation has 
been shown to be a very effective target (Vasanthakumar and Ahmed, 1989, 
Jaroszewski et ah, 1990, Rivoltini et ah, 1990, Clynes et ah, 1992, Corrias et ah, 
1992, Efferth et ah, 1993, Thierry et ah, 1993, Quattrone et ah, 1994 (b), Bertram et 
al, 1995, Nakashima et a l, 1995, Alahari et ah, 1996, Cucco and Calabretta, 1996 , 
Liu et ah, 1996, Sola and Colombani, 1996, Stewart et ah, 1996, Hirtake et a l, 1991, 
Li etal., 1991)
One of the most important mechanisms of action of DNA based-antisense targeted to 
RNA is the activation of ribonuclease H (RNase H) (Brysch and Schlingensiepen,
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1994, Crooke and Bennett, 1996, Helene, 1994, Bouffard et al., 1996, Ohkawa et a l, 
1996, Sharma and Nayaran, 1995, Wagner and Flanagan, 1997, Giles et a l, 1995, 
Branch, 1996). RNase H is an ubiquitous enzyme that selectively cleaves the RNA 
component of RNA-DNA duplexes. Other mechanisms of inhibition of translation 
include interference with secondary structures, such as stem loops, (Vickers et al, 
1991, Ecker et a l, 1992, Thierry et al., 1993, Crooke and Bennett, 1996, Liu et al., 
1996, Tolume et al., 1996), inhibition of 5’ capping (Baker, 1993, Alahari et al., 1996, 
Stewart et al., 1996, Crooke and Bennett, 1996) and interference with 3’ 
polyadenylation (Chiang et al., 1991, Alahari et al., 1996, Stewart et a l,  1996). 
Oligonucleotides conjugated to alkylating and photoactivable alkylating species have 
been synthesised. These can then inhibit the target DNA by covalently modifying them, 
rendering them non-functional (Webb and Mateucci, 1986, Crooke and Bennett,
1996). Activation of mRNA breakdown is not universal, however; Probst & Skatella 
(1996) found elevation of specific mRNAs by antisense, but not by sense treatments.
1.5.3 Antisense modifications
Numerous chemical modifications have been made to the oligonucleotide backbones 
and sugar bases to render them more nuclease resistant and give them greater affinity 
to their targets. The earliest modifications involved substituting the non-bridging 
oxygen atoms in the internucleotide bonds (see Figure 1.5.3) with either a methyl or a 
sulphur group to give methylphosphonate and phosphorothioate oligodeoxynucleotides 
respectively (Marcus-Sekura et al., 1987, Matsukura et al., 1987). This made the 
oligonucleotides more resistant to nuclease degradation, which was a problem for 
natural phosphodiester oligonucleotides (Wickstrom, 1986), thus extending the half- 
life of the oligonucleotides and improving their efficacy. In the methylphosphonate 
substitution, the negative charge of the oligonucleotide is eliminated, and they exhibit 
low toxicity and high stability, while, however, being unable to elicit the action of 
RNase H (Wickstrom et al., 1992). Phosphorothioates keep the negative charge and 
retain the ability to activate RNase H (Gao et al., 1992). As a result, phosphorothioate 
oligos remain the most widely used base analogue, and are currently being tested in a
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Figure 1.5.3 Basic diagram of phosphodiester oligonucleotide structure
number of clinical trials (Roth and Cristiano, 1997, Wagner and Flanagan, 1997).
Second generation oligonucleotides include: substituting pyrimidines at the C-5 
position with 5-methyl, 5-bromo and 5-propynyluracil (Lonnberg and Vuorio, 1996) 
replacement of the sugar and phosphate residues with alkyl amide or carbamate 
linkage (Crooke and Bennett, 1996, Stirchak et al, 1989); 2’-0-propyl, 2’- 
methoxyethoxy, 2’-0-methyl, 2 ’-0-allyl and 2’-fluoro ribose modifications (Monia et 
al, 1993, Wagner, 1995, Crooke and Bennett, 1996); covalent linkage of functional 
groups, such as cholesterol, to alter physical properties, provide ligands or provide 
resistance (Krieg el al, 1993, Manoharan et al., 1995, Crooke and Bennett, 1996); 
replacement of the central phosphorus with a methylene group creating a formacetal 
linkage (Milligan et al., 1994). All of these modifications display either enhanced 
affinity or resistance or both, but many of them do not elicit RNase H activity.
i s
As a result, many researchers are looking towards the use of chimeric oligonucleotides, 
which combine segments of RNase H activating oligonucleotide, flanked by sequences 
which enhance nuclease resistance and target affinity (Giles and Tidd, 1992, Monia et 
al., 1993, Giles et al., 1993, Kandamilla et al., 1991).
A very important consideration when designing antisense experiments is the possibility 
of the oligonucleotide causing sequence specific and non-sequence specific side effects 
of a non-antisense nature. This can be due to the down-regulation of non-targeted 
genes and the binding to cellular proteins and nucleic acids, thereby inhibiting their 
function. These effects can lead to misinterpretation of results that might otherwise be 
ascribed to an expected antisense effect. Although these unforeseen side effects are 
sometimes even beneficial, leading to new potential therapies, they should be 
distinguished from a true antisense effect. The only way to efficiently design new and 
improved antisense therapies is through a proper understanding of the antisense 
mechanisms. Most of the work examining non-specific side effects has been performed 
on phosphorothioate oligonucleotides, as these are the most commonly used 
oligonucleotide analogue and are the only form currently in use in clinical trials.
The ubiquitous enzyme RNase H can cause unspecific side effects. It can cleave DNA- 
RNA duplexes which are as short as 4 bp in vitro and lObp in vivo (Donis Keller, 
1979; Wolf et al., 1992). As a result, it is probably not possible to obtain cleavage of 
an intended RNA target without causing at least partial degradation of many 
nontargeted RNAs. It is therefore prudent to screen potential antisense 
oligonucleotides against gene databases to identify and select those expected to knock 
out the fewest essential genes. A fact often ignored, is that charged oligonucleotides, 
such as phosphorothioates are actually polyanions (Stein, 1994). Polyanions, such as 
the naturally occurring glycosaminoglycans heparin and heparan, play extremely 
important physiological roles (Stein, 1995). Therefore, the introduction of PS 
oligonucleotides can interfere with normal cellular functioning, thereby mimicking an 
antisense effect. G-quartets are well known as causing sequence-specific non-antisense 
effects (Higgins et al., 1993; Maltese et al., 1995; Stein, 1995) as are CG dinucleotides 
(K riegeia/., 1995).
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It is therefore clear that there is a requirement, when designing antisense experiments, 
for strict and rigorous control measures, to allow the clear and unambiguous 
demonstration of an antisense effect. There are now a number of generally accepted 
guidelines for the design and evaluation of antisense experiments (Stein, 1994; 
Wagner, 1994; Branch, 1996).
1. There should be a clear demonstration of a decrease in the levels of the target 
protein. Showing a decrease in the mRNA levels of a target gene is not a prerequisite, 
as it requires that the oligonucleotide in question being able to activate RNase H, and 
implies that blockade of the ribosomal readthrough is irrelevant. If, however, the 
measurement of target protein levels is omitted for whatever reason, additional 
controls should be included that demonstrate a lack of effect on cell lines that do not 
have the target sequence.
2. The choice of target sequence must be made carefully. Many investigators have 
chosen to target the translation initiation site of an mRNA on the assumption that this 
region is important and accessible. However, most regions are now though to be 
accessible (Dean et al. 1994), with the relative efficacy of different sites depending on 
secondary structures and the chemistry of the oligo modification (Fenster et al. 1994). 
To avoid biasing the outcome of an experiment by the choice of target sequence 
selection, it is important to show that the same effect is produced by more than one 
antisense sequence.
3. The choice of control sequences is a critical element in the design of any antisense 
experiment. There are four types of control oligos that should be considered.
(a) Sense control: This type maintains structural features (e.g. palindromes, stem 
loops, class), but does not maintain composition. G-quartet effects will not be picked
(b) Scrambled control: This type of control does not maintain structural features, but 
does maintain composition. However, this type will also not highlight G-quartet 
effects.
(c) Mismatched control: This type of control, with only one or two mismatches in the 
central section of the oligo, demonstrates target hybridisation selectivity, and can 
maintain composition if two mismatches are made. Depending on where the 
mismatches are made, it may or may not be able to maintain structural features.
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(d) Mismatched target control (i.e. using cells with a mutant or deleted gene): This 
control may demonstrate a lack of non-sequence specificity, but the control cells may 
thus be significantly different from the target cells with regard to other critical 
parameters, such as oligo internalization and compartmentalization.
Ideally, the control should differ from the antisense sequence no more than is necessary 
to prevent specific hybridisation. There is no scientifically correct number of controls 
to employ in a certain experiment. The more control oligos that are used, however, the 
more likely that the observed end point has resulted from a true antisense mechanism.
1.5.4 Use of Antisense Oligonucleotides to Inhibit MDR-1 Expression
Over the last number of years, there have been several studies that have looked at the 
effect of using antisense oligonucleotides to down-regulate expression of the mdr-1 
gene (See Table 1.5.4. For review see Byrne et al., in press). These will be discussed 
in some detail, since they illustrate well some of the different approaches and 
achievements, as well as the limitations and problems which may be expected when 
applying antisense technology to investigate drug resistance. The first such study came 
in, 1989, carried out by Vasanthakumar and Ahmed (1989). They used a 15 base pair 
(bp) methylphosphonate oligonucleotide, targeted to a region containing the initiation 
codon of mouse mdr-1 (see Table 1.5.4), on a human erythroleukemic cell line 
K562/III which had been selected for Daunorubicin resistance (119-fold compared to 
parent K562/S). This cell line was cross-resistant to vincristine, doxorubicin and 
etoposide. It also exhibited mdr-1 amplification and increased expression of its 
transcripts (30-fold increase). The oligo was used at a 30(iM concentration and was 
added free in the cell culture medium (which contained 10% heat-inactivated serum). 
After 72 hour incubation time at this concentration PGP expression was totally 
eliminated in the K562/III cell line. A complementary sense oligo targeted to the same 
region had no effect on PGP levels. Both the antisense and sense oligos were shown to 
have no apparent biological effect on the parental sensitive cell line K562/S. The IC50
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values of Daunorubicin in the K562/1II cell line fell from 119-fold greater than the 
parent to 85-fold. There was no change in the IC50 values of Daunorubicin in the 
antisense treated parent cell line, while the sense oligos had no effect on either cell line. 
These results indicated the potential of using antisense against mdr-1 to cause a down- 
regulationin PGP expression and a concomitant decrease in drug-resistance. However, 
the antisense sequence chosen was compatible with the mouse mdr-1 sequence and not 
human mdr-1. There were in fact three base-pair mismatches as regards the human 
sequence, and this should be taken into account when considering the results.
Jaroszewski et al. (1990), designed five different phosphorothioate oligos which were 
used to down regulate mdr-1 in the human breast cancer cell line MCF-7 ADR, which 
was 192-fold more resistant to adriamycin than its parent cell line MCF7. One was 
targeted to the initiation codon region, one just 3’ to the initiation codon, and three 
spread out within the coding region (Table 1.5.4). They demonstrated the uptake and 
distribution of the phosphorothioate oligos in MCF-7 cells by using 35S-labelling, 
showing that only 2% of the oligos were taken up from the media and, of that, 64% 
remained in the cytoplasm. Of the five oligos tested the most effective was the one 
targeted at nucleotide +18 to +32 in relation to the first base in the mRNA sequence 
(taken as +1). It caused a 4-fold increase in Adriamycin toxicity. However they did not 
present evidence of decreases in the mdr-1 levels or give actual IC50 values. They also 
speculated on the reasons behind the variation in effect of the five oligos. They 
postulated that this was due to differences in the mdr-1 mRNA secondary structure at 
the different sites targeted, as the mRNA is extensively folded, 62% being paired.
Rivoltini et al. (1990) used a 12 bp phosphodiester oligo targeted to bases -6 to +6 of 
mdr-1 mRNA (Table 1.5.4). Human colorectal adenocarcinoma cells LoVo/Dx, which 
are resistant to Doxorubicin and show increased PGP expression, were cultured for 3 
days in the presence of the oligos, resulting in a reduction of PGP to a level equal to or 
lower than that of the sensitive parent cell line L0V0/H. The ID50 of the LoVo/Dx cells
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Table 1.5.4 Types and target sites of antisense directed against mdr-1 mRNA
Target site* Oligo Type Cells used Reference
-457 to -474 Phosphorothioate(PS) LoVo/Dx,S 180Dx,KBCh85 Bertram et al.
-20 to -1 PS oligo CEM 60VCR Li et al.
-20 to -1 2’-0-methyl modified CEM 60VCR Li et al.
-20 to +1 Phosphodiester LoVo/Dx Corrias et al.
-14 to +4 PS oligo NIH3T3 Alahari et al. **
-9 to +6 PO with PS 3’ & 5’ends Kidney Primary cultures Efferth et al.
-9 to +6 PS oligo MCF-7/ADR Jaroszewski et al.
-9 to +6 PS oligo K562/VCRino Sola et al.
-9 to +6 PS oligo LoVo/Dx, S180Dx,KbCh85 Bertram et al.
-9 to +6 Methylphosphonate K562/III Vasanthakumar et al.
-9 to +9 PO oligo LoVo/Dx Quattrone et al.
-6 to +6 PO oligo LoVo/Dx Rivoltini e t al.
-6 to +9 PO with PS 3’ & 5’ends SKVLB Thierry e t al.
-6 to +10 PS oligo K562/ADM Liu et al.
-1 to +24 PS oligo P388/Adr Nakashima et al.
+1 to +18 PS oligo HL-60/Vinc Cucco & Calbretta.
+1 to +18 PO oligo CHrC5 Clynes et al.
+1 TO + 20 PS oligo P3 88/Doxorrubicin Hirtake et al.
+1 to +20 PO oligo LoVo/Dx Corrias et al.
+12 to +36 PS oligo CEM 60VCR Li et al.
+18 to +32 PS oligo MCF-7/ADR Jaroszewski et al.
+21 to +40 PO oligo LoVo/Dx Corrias et al.
+156 to +1118 cDNA KB 8-5 Hanchctte/ al.
+336 to +354 PS oligo MCF-7/ADR Jaroszewski et al.
+336 to +359 PS oligo MCF-7/ADR Jaroszewski et al.
+991 to +1007 PS oligo K562/ADM Liu et al.
+993 to +1008 PO with PS 3’ & 5’ends SKVLB Thierry et al.
+1152 to+1176 PS oligo MCF-7/ADR Jaroszewski et al.
+2420 to +2434 PS oligo LoVo/Dx, S180DX>KbCh85 Bertram et al.
+2990 to +3007 PS oligo LoVo/Dx, S180Dx,KbCh85 Bertram et al.
+4026 to +4045 PO oligo LoVo/Dx Corrias et al.
* The first base in the coding sequence (i.e. the A in the ATG initiation codon) is given a position of 
+1
** Alahari et al. tested almost 40 different antisense sequences to various regions of the mdr-1 
transcript with different backbones and modifications. Only the most effective antisense sequence is 
given above.
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was reduced 100-fold when cultured in the presence of the antisense oligo, giving a 
similar effect to that obtained from the MDR modulator, verapamil.
Clynes el al. (1992) found that antisense, but not sense, oligodeoxynucleotides 
corresponding to the first 18 bases of the human mdr-1 sequence caused an increase in 
adriamycin sensitivity in the human lung squamous cell PGP over expressing MDR line 
DLKP-A, and also, perhaps surprisingly in view of some sequence difference between 
the species, in the hamster MDR line CHrC5.
Corrias and Tonini (1992) targeted five 20bp phosphodiester oligonucleotides (Table
1.5.4) to the human mdr-1 gene in the LoVo/Dx doxorubicin resistant cell line. They 
analysed stability and cellular uptake of the oligos. One of the oligos, targeted 
immediately 5’ to the initiation codon, stood out from the others in terms of 
effectiveness, causing 60% of the cells to lose their resistance to doxorubicin, 
preventing them from forming colonies in the presence of the drug. They determined 
the half-life of the mRNA of mdr-1 to be approximately 4 h, and demonstrated that 
alteration of the mRNA occurred after treatment with the antisense. However, no 
actual IC50 data was given after the antisense treatment. They suggested that the other 
antisense oligonucleotides were ineffective due to these sequences being highly 
conserved among pgp and many other proteins.
In, 1993, Efferth and Volm used 2x15 bp oligonucleotide targeted to bases -9 to +6 of 
the mdr-1 mRNA sequence (Table 1.5.4), taking in the AUG initiation codon and a 
Shine-Dalgarno like sequence (AGGUGG), which recognises the ribosome binding 
site (Efferth and Volm, 1993). One was a simple phosphodiester oligonucleotide, the 
other with 3 phosphorothioate bases at the 3’ end. The corresponding sense sequence 
was used as a control. The oligos were incubated with primary cultures of kidney 
tumor and normal kidney from 3 different patients, for 3 days at concentrations of 1, 5 
and 10|iM. They found that the 10 |J,M concentration of antisense significantly 
decreased PGP levels in cells which expressed high levels of PGP initially, while there 
was only a slight decrease observed for the patient with low-PGP expressing cells. The 
latter patients cells also showed no inhibition of growth when the antisense was
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combined with vincristine or doxorubicin in a 7-day growth assay. The cells for the 
patients with high PGP expression were inhibited by up to 70% by the combination of 
antisense and drug. The inhibitory effect was more pronounced for the 3’ 
phosphorothioate capped oligo. This gave an early illustration of the increased efficacy 
of using nuclease-resistant phosphorothioate oligos when targeting mdr-1 mRNA.
Thierry et al., (1993), used an unique approach to delivering the two 15 bp antisense 
and one 15bp sense oligonucleotides they designed against mdr-1 (Table 1.5.4). They 
delivered the oligos to the human ovarian carcinoma cells SKOY3 and the multidrug 
resistance variant SKVLB, either free to the cells or by Minimal Volume Entrapment 
(MVE). Small unilamellar vesicles were made from a mixture of different lipids, which 
were dried by evaporation, rehydrated with phosphate-buffered saline (PBS) 
containing 10 (ig/ml of the oligonucleotide, vortexed vigorously and then sonicated, 
giving a final concentration of between 60 and 70 |ig oligo/ml lipid. 5|_iM final 
concentration of the oligos, which had two phosphorothioate bases at each end of a 
phosphodiester backbone, was used. The two antisense oligos were directed towards 
the AUG initiator codon-containing region (ASin) and a loop forming site located at 
bases +993 to +1008 from the first AUG codon (ASlp). Using a 5 fiM concentration 
of the ASlp oligo added free to the cell culture media, they caused a 40% reduction in 
PGP expression, as measured by flow cytometry and doxorubicin resistance. However, 
using MVE to deliver the oligos, they demonstrated a nearly complete inhibition of 
PGP expression and a four-fold decrease in doxorubicin resistance. The lack of 
complete reversal o f doxorubicin resistance accompanying the complete inhibition of 
PGP indicated that there were other mechanisms of resistance involved in these cells. 
Adding free ASin oligo caused very little effect on PGP levels or resistance, as did the 
freely added corresponding sense oligo. ASin added by the MVE method, however, 
gave a two-fold decrease in PGP levels and a four-fold decrease in the doxorubicin 
resistance. This down-regulation of the mdr-1 gene was shown to be sequence non­
specific, due to the fact that the corresponding sense oligo delivered by MVE also 
demonstrated a significant, if not as large, decrease in PGP expression and resistance 
to doxorubicin. This sequence non-specific effect was dependent on the sequence used, 
though, as the sense to the loop-forming region had no effect whether free or
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liposomally encapsulated. Thierry et al. postulated that bases at the 5’ end of mdr-1 
coding region might be pairing intramolecularly and the sense oligo to this region 
might be forming a triple helix structure, thereby inhibiting mRNA processing. They 
proposed loop-forming regions as a more effective site for antisense targeting, and 
they backed this claim up by citing that another loop-targeting antisense (bases +568 to 
+583) was equally as effective as the one above, but they did not present data to 
support this. The results, therefore, demonstrated the importance of the choice of 
target site and also the benefits of encapsulating the oligonucleotides in liposomes. It 
was shown, during their work, that oligos were effectively protected from 
environmental degradation when encapsulated by MVE, showing no degradation after 
incubation for a week in 10% serum containing medium, while the free oligonucleotide 
was mostly degraded after 30 min.
In, 1994, Quattrone et a l demonstrated the use of a mixture of antisense oligos for 
down-regulating mdr-1 mRNA in the 75-fold doxorubicin resistant subline (LoVo/Dx) 
of the human adenocarcinoma cell line LoVo (Quattrone et al., 1994 (b)). They 
designed three contiguous 18 bp phosphodiester oligos to attack the region from -9 to 
+45 from the first AUG codon (Table 1.5.4), which had previously been shown to be 
effective (Uhlmann and Peyman, 1992). They used an equimolar mixture of the three at 
a final concentration of 10 |_iM in conjunction with 5 |J.g/ml of the liposomal 
transfection reagent DOTAP. They incubated the cells in the presence of the antisense 
mixture for 15 days, changing the media and adding fresh oligos every 72 h. At the end 
of the culture, the cells were exposed to an IC50 value of doxorubicin (relative to the 
resistant and sensitive lines respectively) while maintaining the presence of the oligos. 
They used the three oligos together in a mixture because of a postulated synergistic 
inhibitory effect of contiguously targeted oligos (Maher and Dolnick, 1998). They 
demonstrated that the DOTAP used for delivery of the oligos increased their cellular 
uptake 25-fold and afforded protection from cytoplasmic nuclease cleavage. The 15 
day incubation was employed due to the relatively long half-life of PGP (72 h), and the 
fact that previous studies had only used 3 or 4 day studies, which were not deemed 
sufficiently long. The combination of 10(iM oligos with 5|ig/ml of DOTAP was shown 
to a moderate inhibitory effect on cell growth, 26% and 38% for a scrambled control
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oligo and the antisense oligos respectively. The decrease in cell growth when the 
doxorubicin was added was double the expected additive effect of growth inhibition of 
the antisense oligos/DOTAP mixture and the doxorubicin separately for the antisense 
treatment. The inhibitory effect was simply an additive for the combination of the sense 
oligo/DOTAP and the drug. After 5 days of the incubation, the mdr-1 mRNA levels 
were shown to be significantly decreased by the antisense mixture, with no effect 
observed on untreated or sense treated cells. After the full 15 day incubation, the 
mRNA levels had decreased down to the level of the drug-sensitive parent line. As 
regards PGP expression, there was no observed change after 5 days treatment with the 
antisense oligos, while at 15 days, there was a reduction in PGP levels in comparison 
to the untreated and sense-treated cells, but not to the level of the drug-sensitive 
parent. They showed, however, that there was a good correlation between the mdr-1 
mRNA/PGP levels and resistance to doxorubicin induced cytotoxicity, and postulated 
that the greater cytotoxic effect of the antisense/DOTAP mixture compared to the 
sense/DOTAP mixture, without the addition of drug, indicated that a marked and 
prolonged decrease in mdr-1 gene expression could be intrinsically toxic for cells. This 
is a relevant consideration for possible future in vivo administration of mdr-1 targeted 
antisense.
Hanchett and his colleagues tried a different approach by using antisense RNA 
transcribed from an expression vector (Hanchett el al., 1994). They used a 963bp 
fragment from the mdr-1 cDNA (bases +156 to +1118) cloned into an expression 
vector pHpAPr-3-neo (Table 1.5.4), driven by the P-actin promoter, in both the 
normal and reverse orientation, to give the sense and antisense molecules. They 
transfected the mdr variant, KB 8-5 (4-fold resistant to colchicine), of the human 
nasopharyngeal epidermoid carcinoma cell line with HeLa markers, KB 3-1, with the 
antisense containing plasmid, as well as the sense containing vector and the vector with 
no insert as controls. They isolated 16 clones from each transfection. Of the 16 
selected from the antisense transfection, only 10 actually expressed the antisense RNA, 
and of these only 1 exhibited a decrease in mdr-1 mRNA levels (50%) and PGP levels 
(50%) as detected by Northern Blot/ RNase protection assay and Western Blots 
respectively. This clone also displayed a corresponding decrease in colchicine
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resistance (50%) but was still almost 3-fold more resistant than the sensitive parent KB 
3-1. Despite the large amount of effort involved in producing one successfully 
transfected clone, this work showed the potential of using antisense RNA as an 
alternative to DNA-based oligonucleotides. However, despite the fact that all cells in 
this population were isolated from one clone, the authors pointed out that there was a 
high degree of heterogeneity, with highly varying levels of PGP expression, as 
demonstrated by Rhodamine 123 retention assays. Even subclones of the initial clone 
retained this heterogeneous phenotype, showing that it was an inherited trait of this 
clone. The authors went as far as performing Restriction-Fragment-Length- 
Polymorphism assays to prove that all phenotypically distinct subpopulations 
descended from the same transfected clones. This level of heterogeneity in transfected 
cells could be a possible deterrent to the future use of antisense RNA.
Bertram et a l, (1995), attempted reversal of the MDR phenotype in two PGP 
overexpressing variant human cell lines (LoVo/DxR and KBChR8-5) and one murine 
resistant cell line (S180DxR). They used antisense designed to four different regions in 
the mdr-1 mRNA the 5’ promoter region, S-ODN1, the ATG initiation region (bases - 
9 to +6), S-ODN2, and two within the coding region (bases +2420 to +2434 and 
+2990 to +3007), S-ODN3 and S-ODN4 (Table 1.5.4). They were all phosphodiester 
oligonucleotides with a G-C content of between 40 and 60%. They were used at a 
concentration of either 0.2, 2 or 5|xM, with 2(iM being the most efficient. Only a single 
dose of the antisense was applied and incubated with the cells for 12 h before the 
addition of 10% fetal-calf serum (FCS). Cells were then further incubated for a total of 
72h before various assays were carried out. A 2pM concentration of S-ODN2 and 3 
applied to LoVo/Dx^ cells caused a decrease in [3H]thymidine incorporation of 10 and 
50% respectively, with corresponding sense oligos exerting no effect. Western blots 
using the mdr-1 MAb C-219 showed that S-ODN2 and 4 were unable to reduce PGP 
expression in LoVo/Dx11 compared to untreated cells, while S-ODN 3 reduced the PGP 
down to the level of the sensitive cells. S-ODN1 showed a less pronounced effect than 
S-ODN3, but still caused around a 75% reduction. Analysis of the time scale of the 
reduction showed that after 24h the levels of PGP remained unchanged, after 48h a 
reduction was apparent, while after 72 h the levels of PGP were down to the those in
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the sensitive parent cells. S-0DN3 was found to be most effective in the LoVo/Dx* 
cell line with a 62% reduction in the ED50 in the presence of doxorubicin, with the S- 
ODN1 only giving a reduction of 20%. In KBChR8-5 cells, S-ODN3 was once again 
more effective, decreasing the ID 50 by 30%, with S-ODN1 having no effect. In the 
murine sarcoma cell line S180DX11, however, S-ODN3 was ineffective, while S-ODN1 
reduced the ID50 in the presence of doxorubicin by 60%. The differences in 
effectiveness of the same oligonucleotides in different cell lines highlighted the 
importance of the accessibility of the target region for the antisense, which could be 
altered between various species and cells due to slight variations in sequence and in the 
processing of the mRNA Tests comparing the effectiveness of the S-ODN3 antisense 
on LoVo/Dxr cells as compared to the classic chemomodulators verapamil and 
tamoxifen on PGP function, demonstrated that in this cell line at least, the antisense 
molecule was at least equally effective in decreasing the K)50 values.
Nakashima et al. (1995) tested a 25bp phosphodiester targeted to the AUG initiation 
codon and loop forming region (Table 1.5.4) on mouse leukaemia adriamycin sensitive 
(P388/S) and resistant (P388/ADR) cells. The resistant cells were 100-fold and 300- 
fold more resistant than the sensitive cells to Vincristine and adriamycin respectively. 
Concentrations of oligo below 30(iM were used, due to toxicity of higher 
concentrations. They showed, by flow cytometry, that after 72h the level of PGP in 
the P388/ADR cells was slightly, but significantly, reduced as compared to untreated 
P388/ADR cells, while the sense oligo was ineffective. 15|iM of the antisense oligo 
caused 2-fold more vinblastine accumulation in P388/ADR cells than the sense oligo. 
Correspondingly, the antisense potentiated the growth-inhibitory effect of the 
vinblastine, decreasing the IC 50  value significantly (approx. 2-fold). This reversal of 
resistance by the antisense was slightly more effective than verapamil on its own, and 
when the antisense was combined with 1|jM of verapamil, the IC 50  value decreased 
approximately 4-fold.
Alahari et al. (1996) conducted an extensive study, analysing 32 different 
phosphorothioate oligonucleotides spanning almost every region of the mdr-1 mRNA 
including the 5’ Untranslated, AUG codon, Coding (splice junction), open reading
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frame (ORF), and stop codon, 3’ untranslated and 5’ Cap (Table 1.5.4). The cells used 
were mouse NIH3T3 fibroblasts, which had been transfected with an expression 
plasmid containing the human mdr-1 cDNA (pSKl MDR-1). The antisense oligos 
were used at a concentration of l|iM  in the presence of 20(j,g/ml of Lipofectin, and 
incubated with the cells for 24 h. One oligonucleotide which stood out from the others 
was one overlapping the AUG start codon (AS 5995), as it caused a substantial 
reduction in the mdr-1 message levels as measured by Northern blots. The other 
sequences tested were largely ineffective, including two other oligonucleotides that 
also overlapped the AUG codon. This result emphasises that slight alterations in the 
positioning of an antisense target can be of utmost importance in mediating antisense 
effects. Maximum specific reduction on mdr-1 mRNA was observed after 24h 
treatment of the cells with AS 5995, but reduction occurred only with the use of 
serum-free media and cationic liposomes. Multiple treatments with the AS 5995 did 
not cause any greater specific reduction in the mdr-1 messenger levels than a single 
treatment, whereas greater cytotoxicity was observed. The reduction in the mRNA 
expression was found to be readily reversible after the 24h exposure to AS 5995, with 
normal levels returning after 24 h if the cells were returned to complete culture 
medium. The treatment of the MDR 3T3 cells was concentration dependent with a 
slight reduction observable at lOOnM and maximum reduction (60%) at 1 |_iM. Higher 
concentrations of oligos (5-10|iiM) lead to greater non-specific effects with reduced 
control gene P-actin message levels and cytotoxicity observed. The PGP levels of the 
MDR 3T3 cells were also reduced, with the decrease being minimal after 24 h, readily 
detectable after 48 h and maximal after 72 h exposure to the antisense. By using a 2’- 
O-methyl analog of AS5995, Alahari et al. gave evidence for the role of RNase H in 
mediating antisense inhibition of PGP expression. 2’-O-methyl oligonucleotides do not 
illicit the action of RNase H, and, as expected, this analog did not cause any reduction 
in PGP levels of the MDR 3T3 cells when incubated under the same conditions as the 
AS 5995 oligo. Conjugation of oligonucleotides with lipophilic substituents had been 
reported to enhance oligonucleotide accumulation in cells and result in improved 
biological effects (Krieg et al., 1993). They therefore synthesised a 5’ cholesterol 
derivative of AS 5995. This analog used alone was shown to be as effective as the 
phosphorothioate molecule in combination with Lipofectin, causing a minimum
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decrease in PGP expression of 60%. In addition, the cholesterol oligonucleotides 
showed less experiment-to-experiment variation than the standard phosphorothioate 
oligos administered with cationic lipids. By conjugating these two oligonucleotides to 
FITC and using flow cytometry, the authors showed that over a 2 h incubation period, 
the cholesterol conjugated oligo was rapidly accumulated by cells, whereas both free 
AS 5995 and AS 5995 complexed with Lipofectin was accumulated to a far lesser 
degree. After an overnight incubation, free AS 5995 still showed considerably less 
accumulation than the cholesterol analog, while the Lipofectin complexed AS 5995 
displayed substantial but very heterogeneous cell uptake. Using confocal microscopy, 
these results were confirmed. In addition, while only a sub-population of the 
Lipofectin/antisense treated cells showed nuclear accumulation of oligo, cells treated 
with the cholesterol conjugate displayed uniformly extensive flourescence in both the 
cytoplasm and the nucleus. These results suggested that the cholesterol conjugation 
enhanced the rapidity, amount and uniformity of cellular uptake of the oligonucleotide. 
Therefore there appears to be significant advantages in using relatively low-molecular 
weight cholesterol oligonucleotides compared with extremely large 
oligonucleotide/cationic lipid complexes.
Cucco and Calabretta (1996) used just a single 18bp phosphorothioate antisense 
oligonucleotide along with sense and antisense controls (Table 1.5.4). The oligos were 
added to sensitive HL-60 human promyelohcytic cell line and a vincristine selected 
resistant variant, HL-60/Vinc, at a concentration of 200|ig/ml over 4 days (80 |Xg/ml 
on the first day, and 40 (xg/ml each subsequent day) or 360(ig/ml over 7 days. The 
oligos alone had no effect on cellular proliferation. Treatment with vincristine alone 
caused only a 48% inhibition at the highest concentration used (1 |ig/ml). Antisense 
oligo in combination with vincristine treatment caused significant inhibition, 58% with 
0.01|j,g/ml vincristine and 92% with 1 (J.g/ml vincristine: mdr-1 mRNA and protein 
levels were also reduced. There was no difference in any of these parameters with 
vincristine alone or vincristine with sense oligo or vincristine with scrambled oligo for 
sense or scrambled oligo treatment. In order to test the efficacy of this antisense 
oligonucleotide in vivo, Cucco and Calabretta, used SCID mice which were given 
injections of HL-60/Vinc leukaemia cells, and were subsequently treated by tail
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injection of antisense (lmg/mouse/day) for 10 days in combination with vincristine 
(20(j,g/mouse/day). Survival of the mice was not prolonged with vincristine alone, or 
when treated with sense or scrambled oligos either alone or with vincristine. Treatment 
with the antisense oligo alone was ineffective, with a median survival time of 57 days 
post leukaemia implant. However, the antisense and vincristine combination gave a 
median survival time of over 300 days. The mice were sacrificed at this time point and 
no trace of c-myb transcripts (a leukaemia cell load marker) was found by RT-PCR, 
indicating a lack of tumor cell presence. This evidence supports the specific mechanism 
of action of antisense to mdr-1 in vivo, leading to possibilities of future use in cancer 
patients.
Liu et al. designed two 17 bp phosphorothioate oligonucleotides complementary to 
ATG initiator codon region (bases -6 to + 10), AS-1, and a loop forming site within 
the coding region (bases +991 to +1007), AS-2 (Table 1.5.4) (Liu et a l, 1996) . They 
tested these two antisense molecules on the human leukaemic cell line K562 and its 
Adriamycin resistant subline K562/Adm, which was 155-fold and 74-fold more 
resistant than the parent to adriamycin and vincristine respectively. Both PGP and mdr- 
1 mRNA were shown to be overexpressed in the resistant subline as compared to the 
sensitive parent. In the presence of adriamycin, both AS-1 and AS-2 at 10fiM 
concentration caused significant inhibition of K562/Adm cell proliferation after 24, 48 
and 72 h incubation times. The inhibition was most prominent after 48 h, 66% for AS- 
1 and 72.8% for AS-2. The antisense oligos showed no inhibitory effects in the 
absence of adriamycin, indicating a sequence specific action of the antisense and a lack 
of unwanted toxicity. A control sense oligo showed no effect with or without 
adriamycin. Both AS-1 and AS-2, after a 48h incubation, caused a pronounced 
increase in daunorubicin accumulation from 18.2 % to 67.3% and 75.2% respectively, 
as measured by flow cytometry. The MDR modulator Verapamil caused an increase 
from 18.2% to just 27.2%, indicating the much greater efficacy of the antisense oligos. 
Correspondingly the number of PGP positively staining cells decreased from 71.62% 
for the control to 45.44% for a 10(iM concentration of AS-1 incubated for 48 h, while 
the ratio of mdr-1 mRNA to control P-actin expression decreased from 1,56 to 0.97.
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Sola and Colombani (1996) chose to target the initiation codon of mdr-1 using a 15bp 
phosphorothioate oligonucleotide (Table 1.5.4), with the corresponding sense as a 
control They also used the human erythroleukemic K562 cell line and a vincristine- 
selected resistant subline K562/VCRioo, which had a daunorubicin IC5o 40-fold higher 
than the parent and exhibited higher expression of PGP (95 .9% of cells) as compared 
to K562 cells (22.1%). The cells were incubated with lOjiM of the antisense or sense 
oligos for 48 h. The antisense, but not the sense, oligo enhanced daunorubicin toxicity 
and rhodamine uptake in the resistant line.
Hirtake el al. (1997) also used just a single phosphorothioate oligonucleotide, once 
again targeted to the initiation codon, but this time, of murine mdr-1 (Table 1.5.4). The 
oligo was tested on murine multidrug resistant P388/ADR lymphoid leukaemia cell line 
and the parental drug sensitive P388/p. The cells were cultured for 2 days in the 
presence of up to 500 |ig/ml (6.6 |iM ) of either the 20bp antisense oligo or the 
corresponding sense. This resulted in a dose-dependent decrease in PGP expression in 
the P3 88/ADR cell, which was reversed after a further 4 day incubation in the absence 
of antisense. Mdr-1 mRNA expression was also inhibited in a dose-dependent fashion. 
However, no internal housekeeping gene, such as P-actin, was used as a control for 
these experiments, with the authors relying an equal input of total RNA amounts for 
RT-PCR and an extraction of equal amounts of 18S rRNA from the AS treated cells. 
The adriamycin IC50 on the P388/ADR cells was reduced by approximately 2 log (100- 
fold), giving a similar effect to that obtained with the immnosuppressant FK506, used 
as a positive control. No change in resistance was observed after treatment with the 
sense oligo. In an effort to demonstrate the in vivo effect of the anti sense, they injected 
B6D2F1 mice with lx l 06 P388/ADR leukaemia cells which causes cancerous ascites 
and death within 2 weeks (mean survival time 13.4 days). These mice were then 
treated with the antisense or sense oligos via ip injection of 1, 3, 6 or 12 (im of oligo/g 
of body weight, followed by ip injection of ADR 48h later. With a single injection of 
12|j,m antisense oligo/g body weight the mean survival time of the mice increased to 
approximately 24 days. When the antisense was administered twice daily for three 
days, the survival increased further to a mean of over 35 days. No toxicity of the oligos 
was observed in the mice as measured by changes in behaviour, weight gain and
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peripheral blood count. Although none of the antisense treated mice were actually 
cured, the authors emphasise that the treatment duration was short during these 
studies. They state that since the responses observed were dose- and time- dependent, 
it was reasonable to assume that longer periods of infusions and larger amount of 
antisense oligo would be more effective in prolonging survival or leading to a cure. 
However, they did not actually recover any P388/ADR cells from the mice to check 
for decreases in PGP or mdr-1 mRNA levels, and stated simply that the results suggest 
that this was the case. They also said that although phosphorothioate oligonucleotides 
are reported to be nuclease resistant in vitro, some results indicate that injection of 
these type of oligonucleotide is followed by significant degradation (90% in 24 h) 
(Agrawal et a l, 1991).
Li and his co-workers designed three antisense phosphorothioate oligonucleotides to 
mdr-1 (Li et a l, 1991). One (1729) was just inside the coding region from bases +12 
to +36, another (474) was targeted to the last 20 bases of the 5’ untranslated region (- 
20 to -1), while the last oligo (1795) had the same sequence as 474 but with four 2’-0- 
methyl modified sugar linked bases at both ends (Table 1.5.4). The cells which were 
treated were a drug resistant subline (CEM60VCR) of CCRF-CEM leukaemia cells. 
The oligos were added to the cells at a concentration of lfiM combined with 2.5 jig/ml 
of Lipofectin, and incubated for four days, with the addition of 1ml of fresh medium 
containing oligonucleotide after three days. Each of the oligonucleotides decreased 
mdr-1 expression by 30 to 45% as measured by antibody staining and mean relative 
fluorescence, while the 1795 oligo, with the DNA-RNA hybrid backbone, being 
significantly more effective than the other two purely phosphorothioate oligos. 2’-0- 
methylribonucleotides at the 3’ and 5’ ends of the 474 antisense gives this oligo greater 
in vivo stability and allows for increased binding affinity at the ends of the sequence, 
while retaining the ability to activate RNase H in the middle segment. The persistence 
of PGP suppression was measured at 0, 3 and 6 days after the end of treatment. It 
ranged from 28-46% immediately after treatment, 20-34% 3 days after treatment and 
by 6 days, levels had returned to pretreatment levels. Rhodamine 123 retention was 
significantly increased by as little as 0.2(iM of antisense oligo, while being unaffected 
by control oligonucleotides. Sensitivity to vincristine was also greatly increased by
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antisense treatment. The LD50 in antisense-treated CEM60VCR cells was almost 3- 
fold less than in untreated cells. The induction of mdr-1 expression through 
daunorubicin exposure for 24 h was examined, and was shown to be inhibited by as 
much as 50% by pretreating the cells for antisense oligonucleotides for 4 days. 
Cyclosporin induction of PGP expression was abolished by similar pretreatment with 
antisense. These results show the potential of using chimeric oligonucleotide hybrids to 
increase the potency of antisense sequences, as opposed to using purely 
phosphorothioate or phosphodiester backbones. The authors also stated that, as the 
level of resistance in CEM60VCR cells was comparable to levels of drug resistance in 
clinical samples, the degree of sensitisation observed (almost 3-fold) might expect to 
be observed in the clinic. They postulated that this level of sensitisation would be 
sufficient to show an improvement of the therapeutic index, and proposed a use for the 
antisense oligonucleotides in the clinical setting both as sensitizing agents (alone or in 
combination with a functional PGP inhibitor) and as prophylactic agents during initial 
chemotherapy to prevent the emergence of mdr-1 expressing clones.
1.5.5 Use of Antisense Oligonucleotides to Inhibit MRP Expression
Due to the relatively recent discovery of the multidrug resistance protein (MRP) as a 
mediator of the MDR phenotype, only a limited amount of work on the antisense 
modulation of MRP gene expression has so far been carried out. The first report of the 
use of antisense oligonucleotides for the reduction of MRP expression came from 
Stewart et al. (1996). They designed sixteen oligonucleotides (15 phosphorothioate 
and one 2’-0-methyl derivative) complementary to different regions along the entire 
length of the MRP mRNA along with one sense control oligonucleotide (see Table
1.5.5). They tested these antisense sequences on a multidrug resistant MRP- 
overexpressing small cell lung cancer cell line, H69AR, and T5 (MRP cDNA 
transfected HeLa cells). Lipofectin was used to deliver the oligonucleotides to the cells 
at a concentration of 5 |ig/ml for HeLa/T5 cells and 10 p,g/ml for H69AR cells. 
Oligonucleotide concentrations were between 0.1 and 0.5 (j,M as higher concentrations 
were found to be mildly toxic in combination with Lipofectin. The cells were incubated
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Table 1.5.5 Types and target sites of antisense targeted to MRP mRNA.
Target site Oligo type Cells used Reference
-194 t o -176 
-106 t o -87 
-20 to -2 
+1 t o +16 
+19 t o + 38 
+106 to +125 
+1911 t o +1930 
+1911 t o +1930 
+1911 t o +1930 
+2307 to +2326 
+3328 to +3347 
+4526 to +4545 
+4579 to +4590 
+4616 to + 4635 
+4639 to + 4658 
+4742 to + 4761 
+4789 to + 4808
Phosphorothioate H69AR, HeLa/T5 Stewart et. al. (1996)
2 ’ -
2 ’ -
O-propyl/PS chimera 
O-Fluoro/PS chimera 
Phosphorothioate
HeLa/T5
H69AR, HeLa/T5
Canitrot et. al. (1996)
a
Stewart et. al. (1996)
with the Lipofectin/oligonucleotide for 4 h, then washed and incubated in fresh serum 
containing medium until harvested. In some cases they were retreated with the same 
concentrations of Lipofectin/oligonucleotide for another 4 h after a 48 h interval. After 
two 4 h treatments, MRP protein levels in the H69AR cells were found to vary 
considerably, depending on the antisense sequence used. Two oligonucleotides were 
found to be reproducibly the most effective. These were termed ISIS 7597 and 7598 
and were complementary to nucleotides +2107 to +2126 and +2503 to +2522 of MRP 
mRNA respectively. All the oligos were also screened for ability to reduce MRP 
mRNA levels, and after a single treatment only one was found to have no effect. This 
was the 2’-0-methyl oligoribonucleotide. The authors stated that as 2’-0-methyl 
oligonucleotides are not substrates for RNase H, a decrease in the MRP mRNA levels 
was not necessarily expected in the 4 h time frame of the experiment. All subsequent 
experiments focused on the ISIS 7597 oligonucleotide because of its efficacy in 
decreasing both MRP protein and mRNA levels. The other most efficacious oligo,
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ISIS 7598, was not chosen for further study because of its complementarity to a region 
highly conserved among the ABC transporter superfamily, and, as such, could 
potentially affect the expression of other proteins, making it less specific. Also, Stewart 
et al. decided to carry out all subsequent tests on the HeLa/T5 cells, as resistance in 
this cell line was known to be solely attributable to overexpression of MRP, while the 
resistance in H69AR was previously shown to be multifactorial (Cole, 1992, Almquist 
etal., 1995).
After a single treatment of T5 cells with ISIS 7597 a concentration dependent decrease 
in MRP mRNA was observed, with a significant decrease at 0.1 |iM and virtually 
complete elimination of detectable MRP mRNA with 0.3 and 0.5 |_iM of oligo. The 
corresponding sense had no effect at concentration up to 0.5 pM. This reduction in 
MRP mRNA was transient, with maximal inhibition reached at 4 h and maintained for 
24 h after treatment, but returning to 70 and 100% of those in untreated controls by 48 
and 72 h respectively. 0.5 |xM of ISIS 7597 decreased MRP protein levels transiently 
and maximally to 30% of control levels after 48 h. This is consistent with the 
previously determined half life of MRP protein and the kinetics with which MRP 
mRNA levels are depleted and restored. When a double treatment with 0.5 [iM of ISIS 
7597 was used, the levels of MRP mRNA 24 h after the second treatment were 
approximately 10% of those in control cells. 24 h later again, the mRNA levels had 
returned to 30% of the controls. A 0.3 (iM concentration of the oligonucleotide caused 
equal but more transient reduction. MRP protein levels were also decreased by 90% 24 
h after the second treatment, and this reduction was maintained for an additional 24 h. 
Thus, a double treatment of HeLa/T5 cells with ISIS 7597 was able to extend 
significantly the response at the mRNA level to at least 3 days and to decrease MRP 
protein levels by 90%. The authors also demonstrated the role of RNase H in the 
reduction of MRP mRNA levels. By using two DNA probes for Northern blots 
corresponding to regions in the 5’ and 3’ coding ends of the mRNA, they were able to 
detect the oligonucleotide induced cleavage fragments of MRP mRNA in whole cells.
Stewart et al. proposed that variations in secondary structure at different sites within 
the MRP mRNA may have been the cause of differences in efficacy of the various
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oligonucleotides tested. The AUG start site, as seen above, has been targeted in many 
studies because of the proposed accessibility of this sequence. However, this group 
found that oligos complementary to the coding region to be the most effective. These 
results indicate the importance of evaluating the activity of a number of 
oligonucleotides complementary to different regions of a given mRNA target rather 
than testing oligonucleotides directed against a single site. They also postulated that, 
variations in the doubling time of cells had an effect on the transiency of the antisense 
effect in these cells. They observed that, of the two cell lines they tested, inhibition was 
more prolonged in H69AR cells, which have a doubling time significantly longer than 
HeLa/T5 cells. They suggested that the rapidity with which MRP mRNA returns to 
normal levels is influenced by the decrease in intracellular concentration of 
oligodeoxynucleotide during cell division.
Many of the same group were involved in the second report of MRP directed antisense 
by Canitrot et al. (1996). The work presented was a continuation of that described 
above by Stewart et al. (1996). They used the same ISIS 7597 sequence with proven 
efficacy and made 2’-modifications in an attempt to improve this efficacy further. 
There were two oligonucleotides with different numbers of 2’-O-Propyl modified bases 
at both ends, while there were three oligos with 2’-0-F modification, either at both or 
just at single ends (Table 1.5.5). They were attempting to determine whether or not the 
2’-0-modified chimeric analogs containing various 2’-0-deoxy gaps were more 
effective at reducing MRP mRNA expression than the 2’-0-deoxyphosphorothioate 
ISIS 7597. The cells used in the assays were once again the HeLa/T5 cells derived by 
stable transfection of the MRP cDNA expression vector, pRc/CMV-MRPl. In the first 
set of experiments the effect of the modified chimeric oligos on viability of the cells 
was examined. The results indicated that the 2’-0-Fluoro/2’-0-deoxy oligos were 
considerably more toxic than the 2’-0-propyl/2’-0-deoxy oligos and the basic ISIS 
7597. The Fluoro modified oligos were toxic at concentrations greater than 0.1 |iM 
whereas the propyl modified oligos were not toxic up to 0.5 (iM. The T5 cells were 
then exposed to 0.5 (iM of the oligos for 4 h and RNA and protein samples were 
isolated at various times thereafter. All the modified oligos markedly but transiently 
reduced both the MRP protein and mRNA levels, by between 60 and 70% for both.
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There was complete restoration of the mRNA levels after 24 h. Once again, the role of 
RNase H in the decrease in MRP mRNA levels was demonstrated by using 3’ and 5’ 
Northern Blot probes to identify mRNA cleavage products. The bands obtained were 
of size 2.3 and 3.2 kb, which would be expected from the 5.5 kb MRP mRNA. Similar 
results were obtained for both fluoro and propyl modified oligos. To assess whether 
the reduction in MRP protein and mRNA levels was associated with enhanced 
chemosensitivity, cells were treated with 0.5 fiM of the 2’-O-propyl modified oligos 
for 4 h and then exposed to various concentrations of doxorubicin. The results 
indicated that, as with ISIS 7597, these oligos caused a significant but only partial 
reversal of MRP-mediated resistance. The 2’-0-fluoro modified oligos were not tested 
because of their inherent toxicity. So, in summary the 2’-0-modified chimeric 
oligonucleotides were equally, but not more, effective as the 2’-0- 
deoxyphosphorothioate oligonucleotides, with the Fluoro modification being 
increasingly cytotoxic.
1.5.6 Antisense approaches in the Study of MDR: Conclusion
The results from the various authors cited above, demonstrate clearly the potential 
usefulness of using antisense oligonucleotides, whether modified or chimeric, to 
effectively down-regulate the expression of MDR-related genes. It seems evident at 
this point that the use of liposomal carriers for the transfer of the antisense oligos into 
the cell can greatly enhance the efficacy and prolonged activity of the oligos, through 
efficient delivery to the intracytoplasmic and nuclear regions and affording protection 
from cellular nucleases. The conjugation of oligonucleotides to lipophilic substituents 
also appears to be a very effective means of delivering the antisense directly to the 
nucleus. However, it is also apparent that a large amount of work remains to be carried 
out in this area. In almost all of the studies carried out above, full reversion of multiple 
drug resistance was not achieved. In many cases, this is due to the MDR phenomenon 
being multifactorial, with a combination of proteins causing increased cytotoxic drug 
resistance, so that reducing the expression of any one individual gene will not eliminate 
the MDR phenotype.
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AIM  OF THESIS
There have many reports proposing LRP as a novel mechanism of multidrug 
resistance. However, the evidence presented is mainly inconclusive and presumptive. 
There has been no direct evidence which can conclusively link LRP to drug resistance. 
This thesis aims to use ribozyme and antisense technology to provide a clear picture of 
the function of LRP in relation to drug resistance. Ribozyme and antisense technology 
has been widely used in the study of oncogenes and other mediators of drug resistance. 
This previous work sets a precedent for the use of ribozymes and antisense in 
investigating LRP function. The ribozymes and antisense will allow an examination of 
the cytotoxic drug resistance of cells exhibiting reduced levels of LRP expression. The 
comparison of resistance levels in these reduced-LRP cells with untreated parental cells 
will allow a determination of whether LRP can mediate MDR. To this end, there are 
three main questions to answer:
a) is LRP expression clearly reduced at the mRNA and/or protein level in any of the 
cells;
b) is there a reduction in the resistance to cytotoxic drugs in these cells; and
c) can the levels of LRP expression be correlated with the levels of drug resistance.
By answering these questions, it is hoped to determine conclusively whether LRP plays 
any role in MDR.
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2. MATERIALS AND METHODS
2.1 Preparation for Cell Culture
2.1.1 Water
Water used in the preparation of media and solutions was purified by passing it through a 
Millipore milli-RO Plus system with an Elga Elgastat UHP. A pre-treatment step 
involving activated carbon, pre-filtration and anti-scaling, was carried out followed by a 
reverse osmosis step. Organic adsorption, ion exchange, ultra-microfiltration, photo­
oxidation and ultra-filtration completed the process. The quality of water was monitored 
on-line and a measure of 16MQ/cm at 25°C was considered acceptable.
2.1.2 Glassware
All glassware and bottle-caps used were soaked, for 1-2 hours in a 2%(v/v) solution of 
RBS (AGB Scientific; RBS-25) in warm water. The bottles were then scrubbed and both 
bottles and caps were rinsed in warm water and machine washed using Neodiser detergent, 
followed by rinsing twice in double-distilled water and once in ultra-pure water. The 
bottles were then prepared for autoclaving. Waste bottles containing spent medium from 
cells were autoclaved, rinsed in tap water and treated as above.
2.1.3 Sterilisation
Water, glassware and solutions containing thermostable compounds were sterilised by 
autoclaving at 120°C for 20min. at 15 p.s.i. pressure. Temperature labile compounds were 
filtered through a 0.22(xm sterile filter (Millipore; millex-gv).
2.1.4 Medium Preparation
Growth media for cell culture was prepared as indicated in Table 2.1.4.1. The pH was 
adjusted to 7.45 - 7.55 by the addition of sterile 1.5M NaOH, and the volume adjusted to 
5 litres and filtered through a sterile 0.22fim bell filter (Gelman; G.1423S) into sterile 
500ml bottles. Sterility checks were performed on each bottle by placing :
(a) 3ml in a sterile universal to check for turbidity
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(b) 1ml streaked onto a Columbia (Oxoid; CM331) blood agar plate
(c) 1ml in a 5ml sample of sterile Sabauraud (Oxoid; CM421) dextrose
(d) 1ml in a 5ml sample of sterile Thioglycollate (Oxoid; CM173) broth.
Sterility checks were incubated at 37°C and 4°C for 1 month and checked every 24hrs. 
Blood agar plates were kept for 7 days. The media bottles were labelled, dated and stored 
at 4°C until required. ATCC media was prepared by mixing equal volumes of DMEM and 
Hams F12.
Table 2.1.4.1 Preparation of Growth Media.
C o m p o n en ts D M EM
(Gibco;042-02501M)
Hams F12
(Gibco;074-01700N)
M EM
(Gibco;21430-
020)
lOXM edium 500m l Powder 500m l
Ultra-pure H 2O 4300m l 4700m l 4300m l
IM H epes (pH 7.5)* 100ml 100ml 100ml
7.5%  N a H C 0 3 45m l 45m l 100ml
* The w eight equivalent o f  1M N-(2-H ydroxyethyl)piperazine -N ’-(2-ethanesulfonic acid) (Hepes) was 
dissolved in an 80% volum e o f  ultra-pure water and autoclaved. The pH was then adjusted to 7 .5  with 5M  
NaO H .
2.2 Routine Management of Cells in Culture
All routine management of cells in culture, including cell feeding, sub-culturing, freezing 
and thawing, were performed aseptically in a down-flow re-circulating laminar flow 
cabinet (Holton or Gelman Cytoguard) which had been swabbed with 70% IMS (industrial 
methylated spirits). To maintain a sterile atmosphere inside of the laminar flow all articles 
entering the cabinet were also swabbed with 70% IMS. Gloves were worn at all times 
during these procedures.
2.2.1 Cell lines
All cell lines used throughout this thesis are outlined in Table 2.1.4.1. All cell lines are
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anchorage dependent. Cells were routinely grown in 25, 75 or 175cm2 flasks (Costar; 
3050, 3075: Nunc; 1-56502A, respectively). Cells were grown at 37°C and fed every 2-3 
days or when a medium pH change was observed (colour change in medium due to the 
presence of a phenol red indicator). Waste media was removed from the cells at this stage 
and replaced with fresh media, as indicated in Table 2.2.1 Separate waste and medium- 
containing bottles were kept exclusive to each cell line to prevent cross-contamination. 
When feeding more than one cell line a minimum of 15min should be left before 
introducing a new cell line in to the laminar flow to further ensure against cross­
contamination.
Table 2.2.7.1 Cell lines used throughout the course of this Thesis.
Cell Line Growth M edium Cell Type Source
SW 1573 A T C C 1 Non-sm all cell lung cancer Scheper2
SW 1573-2R 120 A T C C 1 Drug selected resistant variant o f  SW 1573 Scheper2
A 2780 A T C C 1 Ovarian carcinoma Scheper2
A 2780-A C 16 A T C C 1 Clone o f  A 2780 transfected with LRP cD N A Scheper2
DLK P-A A T C C 1 Adriam ycin-selected M DR variant o f  DLKP NCTCC
O AW 42 A T C C 1 Human serous adenocarcinoma o f  the ovaries ECACC3
O AW 42-S A T C C 1 Drug sensitive clone o f  O AW 42SR NCTCC
O AW 42-SR A T C C 1 Spontaneously resistant population o f  O AW 42 NCTCC
1 50:50 mixture of Hams F12 medium and Dulbecco’s Modified Eagle’s medium supplemented with 
5% foetal calf serum and 2mM L-Glutamine (Gibco; 25030-024) prior to use.
2 Rik Scheper, Dept. Pathology, Free University Hospital, De Boelelaan 1117, 1081 HV 
Amsterdam, the Netherlands.
3 European Culture Collection
2.2.2 Sub-Culture of Cell Lines
Monolayer cells grow attached to the bottom of flasks and upon reaching confluency (or 
when required for further studies) the cells were enzymatically detached from the flask 
base and sub-cultured. This involved removing waste medium from the flask of cells, 
rinsing the cells with 1ml of trypsin/EDTA (0.25% trypsin (Gibco; 043-05090), 0.01% 
EDTA (Sigma; EDS) solution in PBS (Oxoid; BR14a)) and then incubating with a further 
4ml of the trypsin/EDTA solution for 5-10min (or until a single cell suspension had been 
obtained) at 37°C. An equal volume of complete medium was then added to the flask and 
the total cell suspension was transferred to a 30ml sterile universal (Sterilin; 128a) and
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centrifuged at 120g. for 5min. The medium was poured off the cell pellet which was then 
resuspended in an appropriate volume of complete medium and re-seeded into fresh flasks 
at the cell density required (estimated by a cell count ; see section 2.2.3).
Suspension cells were sub-cultured simply by removing the cell suspension from the flask 
and pelleting the cells by centrifugation as above. Re-seeding and counting was carried out 
as for adherent cells.
2.2.3 Cell Counting
A sample of a single cell suspension was mixed in a ratio of 4:1 with trypan blue (Gibco; 
525) and incubated for 2min. after which lOjxl of the cell mixture was applied to a 
haemocytometer in the area under the cover-slip. Cells in the 16 squares of the four outer 
corner grids were counted, and the average of the four squares was multiplied by 104 and 
the initial dilution factor to determine the number of cells per ml of cell suspension. Cells 
that stained blue were considered non-viable while those unstained were accepted as viable 
cells.
2.2.4 Large-Scale Cell Culture
Cells required in large numbers were cultivated in roller bottles. Approximately 100ml of 
growth medium was allowed to equilibrate in a roller bottle at 37°C after which a single 
cell suspension of approximately 2xl07 cells was added. The roller bottle was incubated at 
0.25rpm overnight and then the rotor speed was increased to 0.50rpm. The cells were 
allowed to grow to 80% confluency and were fed when determined necessary.
2.2.5 Freezing Cells in Culture
Stocks of all cells used in this study were frozen to allow their long-term storage and 
adequate supply within a given passage number range.
A single-cell pellet suspension was prepared (Section 2.2.2) from a sub-confluent large- 
scale culture of cells (Section 2.2.4). The cell pellet was resuspended in foetal calf serum 
(FCS) and an equal volume of 10% (v/v) DMSO (Sigma; D5879) in FCS was added drop- 
wise, with constant agitation, to result in a final concentration of 107 (viable) cells/ml. 
1.5ml aliquots of the resulting cell suspension were placed in cryovials (Greiner; 122 278)
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(labelled with the cell line, passage number, date and operators initials) and stored in the 
vapour phase of liquid nitrogen for 2.5h. and then stored in the liquid phase until 
required. A vial of cells was thawed 2-5 days after freezing to determine the sterility and 
viability of the stock.
2.2.6 Cell Thawing
The required vial of cells was removed from its liquid nitrogen store and thawed in a 37°C 
water-bath. The thawed suspension was quickly transferred to a universal containing 5ml 
of medium and was centrifuged at 120g for 5min. The medium was poured off and the cell 
pellet was resuspended in 5ml of complete medium, transferred to a 25cm2 flask and 
incubated at 37°C. Following cell attachment, the cells were re-fed with fresh medium.
2.2.7 Mycoplasma Detection
All cell lines used in this study were routinely checked to ensure that Mycoplasma 
contamination had not occurred. These procedures were performed in isolation from the 
routine cell culture designated areas (by Dr. Mary Heenan and Mr. William Nugent) to 
avoid possible contamination of clean cell stocks. Two methods were used during analysis, 
namely the Hoechst 33258 indirect staining method and Mycoplasma culture methods.
The cell lines to be tested were grown in drug-free medium for a minimum of three 
passages following thawing. A 5ml aliquot of conditioned medium i.e. medium in which 
near-confluent cells had been grown for 2-3 days, was removed and analysed for the 
presence of Mycoplasma.
2.2.7.1 Hoechst 33258 Indirect Staining
Indicator cells (NRK) were grown (2xl03) overnight on sterile coverslips in 1ml DMEM 
medium supplemented with 5% FCS and 2mM L-Glutamine, in individual 35mm sterile 
petri-dishes. 1ml aliquots of the conditioned media (Section 2.2.7), from each cell line to 
be tested, were added to duplicate cover-slips of NRK cells and incubated for 5 days (to 
approximately 50% confluency). The cover-slips were then washed of media twice with 
PBS, once with a 1:1 solution of ice-cold PBS:Carnoy’s fixative (a freshly prepared 1:3 
solution of glacial acetic acid (Sigma; A0808) with methanol (BDH; 101584W) which had
63
been stored at -20°C for 30min prior to use), and fixed for lOmin in Carnoy’s fixative. 
The cover-slips were then allowed to air dry. 2ml of Hoechst 33258 stain (Sigma; B2883), 
at a concentration of 50ng/ml in PBS, was added to each cover-slip and incubated in 
darkness for lOmin. The coverslips were then washed in water and mounted on a glass 
slide using 50% glycerol (BDH; 101184K) in 0.1M citric acid (Sigma; C2916), 0.2M 
disodium phosphate (Sigma; S9390), pH 5.5 as the mounting solution. The slides were 
examined for Mycoplasma contamination under oil immersion using a mercury fluorescent 
lamp. Hoechst 33258 stains nucleic acids and therefore staining in the NRK cell nuclei 
was observed, any extra-nuclear staining was an indication of the presence of Mycoplasma 
contamination of the cell line under analysis. Both positive (a sample of medium known to 
be contaminated) and negative (medium not exposed to cells) controls were included in 
this procedure.
2.2.7.2 Mycoplasma Culture Method
The substrate used for the Mycoplasma culture method of detection consisted of 90ml of 
Mycoplasma agar (Oxoid; CM401) and Mycoplasma broth (Oxoid; CM403) bases, which 
were supplemented with 16.33% FCS, 0.002% DNA (BDH; 42026), 2fig/ml fungizone 
(Gibco; 05290), 2xl03 U penicillin (Sigma; Pen-3) and 10ml of a 25% (w/v) yeast extract 
solution (which had been boiled for lOmin. and filtered through a 0.2|xm filter). A 0.5ml 
aliquot of sample medium from the cell line being tested was incubated with 3ml of the 
broth for 48h. at 37°C in a 5% C02 environment. An aliquot of the broth was then 
streaked onto a 10ml agar plate, which was incubated for up to 3 weeks at 37°C in 5 % 
C02, and frequently monitored microscopically for colony formation. The presence of 
“fried egg”-type colonies was indicative of Mycoplasma contamination of the cell line.
2.2.8 Serum Batch Testing
One of the main problems associated with the use of FCS in cell culture is its batch to 
batch variation. In extreme cases this variation may result in a lack of cell growth, 
whereas in more moderate cases growth may be retarded. To avoid the effects of the 
above variation, a range of FCS batches were screened for growth of each cell line. A 
suitable FCS was then purchased in bulk for a block of work with each particular cell line
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in use. Screening involved growing cells in 96 well plates and growth was recorded as a 
percentage of growth of a serum with known acceptable growth rate.
Logarithmically growing cells were seeded into a 96 well plate (Costar; 3599) from a 
single cell suspension at a density of 103 cells/well in lOOul of medium without FCS. 
lOOfxl volumes of medium containing 10%, 20% or higher (if required by the particular 
cell line under analysis) (v/v) FCS was added to respective wells on the 96 well plate, 
resulting in final dilutions of the FCS to 5% and 10%, respectively. The first column of 
each plate was maintained as a control where FCS resulting in a known acceptable growth 
rate was used. Plates were placed at 37°C in 5% C02, for 5 days, after which growth was 
assessed by a crystal violet dye elution method or acid phosphatase (Martin and Clynes, 
1991). Crystal dye elution method involved removing the media from the wells and 
rinsing twice in PBS. The wells were then fixed in 10% formalin (Sigma; F1635) for 
lOmin, after which the formalin was removed and the plates allowed to dry. When the 
plates had dried 100^1 of 0.25% crystal violet dye (Sigma; C3886) was added to each well 
of the plate for lOmin; the dye was then removed and the plates were washed under 
running tap water 4 or 5 times and allowed to dry. The dye was eluted with a 33% 
solution of glacial acetic acid (Sigma; A6283) 100(xl/well. The plates were then read in a 
dual beam plate reader at 570nm (reference wavelength 620nm) (Titertek; Multiskan). 
When growth was assessed by the acid phosphatase method, the plates were washed twice 
in PBS and incubated with 100|xl of acid phosphatase buffer (consisting of lOmM p- 
nitrophenyl phosphate (Sigma; C104) in 0.1M Na-acetate, pH5.5 and 0.1% Triton X-100 
(Sigma; X-100) for 2 hours at 37°C. Following incubation, 50|il of 1.0M NaOH was 
added to the buffer and the plates read in a dual beam plate reader at 405nm (reference 
wavelength 620nm) (Titertek; Multiskan).
2.3 Miniaturised Toxicity Assay
Logarithmically growing cells were used in all miniaturised toxicity assays. The day prior 
to setting up the assay the cells were fed with fresh, complete medium. On the first day of 
the assay the cells were sub-cultured and a single cell suspension was obtained (as 
described in Section 2.2.2).
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2.3.1 Toxicity Assay - 96 well plate
Cells were seeded, from a single cell suspension, into a 96 well plate (Costar; 3599) at a 
cell density of lxl03cells/well in 100^1 medium; the first column of the plate was not 
seeded with cell suspension and was used as a control containing only medium. The cells 
were allowed to attach overnight at 37°C in a 5% C02environment. Drug concentrations 
used in each assay ranged from concentrations which would result in no kill (i.e. no drug) 
to approximately 100% kill. The required drug dilutions range was prepared (at twice the 
final concentration to be assayed) and lOOpl of each drug dilution was added to each well, 
in replicas of eight. The plates were covered in aluminium foil (most chemotherapeutic 
drugs are light sensitive) and incubated at 37°C in a 5 % C02 environment for a further 6 
days or until control wells (where no drug was added) reached 80-90% confluency. Drug 
toxicity was then determined by the acid phosphatase method (see Section 2.2.8).
2.3.2 Pulsing of cells with Drugs
Cells were seeded at a concentration of lxlO4 cells/ml into 25cm2 flasks, 24h prior to 
addition of drug, and incubated at 37°C. Cells were washed once with PBS. The required 
drug concentration was added to the flasks in a total volume of 2ml. The cells were 
incubated with the drug for 2 hours at 37°C. Cells were then washed twice with PBS. 
Finally fresh ATCC media, supplemented with 10% FCS, was added to the cells, and the 
flasks incubated for a further 7 days. Drug toxicity was assayed using the acid 
phosphatatse method (see Section 2.2.8). In this case, 2ml of the acid phosphatase buffer 
was added to the flasks and incubated for 2h. Then 1ml of 1M NaOH was added to the 
flasks to stop the reaction. 150 pL of each sample was placed in wells in a 96-well plate 
for reading in a dual beam plate reader (see Section 2.2.8).
2.3.3 Calculation of ICS0 values
The values from the dual beam plate reader for each drug concentration were calculated as 
a percentage of the control wells, which conatined no drug. This gave a percentage kill 
value for each drug concentration. The results were subsequently plotted on a graph of
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drug concentration versus percentage kill. The drug concentration which gave a 50% kill 
was read from the graph. This represented the IC50 value for the given drug. When a 
number of repeats of a given toxicity assay were carried out, the IC50 values were averaged 
and the standard deviation calculated.
2.4 Safe Handling of Drugs
There are many potential safety risks when using cytotoxic drugs and in order to minimise 
such dangers extreme care was exercised in handling and disposing of cytotoxic agents. 
All work with such drugs was performed in a Gelman “Cytoguard” laminar air flow 
cabinet (CG Series), face masks and double gloves were worn when dealing with 
concentrated stocks and all drug waste (pure or diluted in medium or in contaminated 
plastics) was disposed of as recommended by the manufacturers (outlined in Table 2.4.1).
Table 2.4.1 Storage and Disposal of Cytotoxic Drugs
Cytotoxic Agent
|pgjjy.r|  t £ I jj:i:
Stock concentration
ii J - Disposal
Adriam ycin1
(Doxoxrubicin)
2 m g/m l 4'’C in darkness Inactivate with 1 %hyperchlorite 
Autoclave
Vincristine2 1 m g/m l 4°C in darkness Autoclave 
D ispose with excess water
V P-163 (Etoposide) 20m g/m l R .T . in dark Incinerate
Carboplatin2 10m g/m l R .T . in dark Incinerate
M ethotrexate4 5m g/m l -20°C in dark Autoclave  
D ispose with excess water
5-FIuorouracil2 25m g/m l R.T . in dark Neutralise with 5M  NaOH  
Incinerate
Epiubicin' 5m g/m l 4 “C in darkness Incinerate
Daunorubicin 5m g/m l 4°C in darkness Incinerate
Taxotere 5 m g/m l 4°C in darkness Incinerate
Taxol3 6m g/m l 4°C in darkness Incinerate
M elphalan 5m g/m l 4°C in darkness Incinerate
Cytotoxic drugs used were supplied by 1 Farmatalia; 2David Bull Laboratories, Ltd.; 3Bristol Myers 
Pharmaceuticals; 4 Sigma-Aldrich;
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2.5 Dilution Cloning
To propagate a clonal population from a mixed parent population, individual cells were 
plated into wells of a 96 well plate and allowed to grow as an individual clonal sub­
population of the parental line. To achieve this a single cell suspension (see Section 2.2.2) 
was prepared at a density of approximately 1 cell per 300fxl of media. The cell suspension 
was then plated out by placing lOOfil into each well of a 96 well plate. The plates were 
then incubated at 37°C and 5 % C02 and monitored after 2 days for cell attachment; wells 
that were seen to have only one cell adhered after 2 days were chosen for expansion as 
clonal populations. When each individual well of the 96 well plate containing a clonal 
population had reached 80% confluency the cells were sub-cultured in to a well of a 24 
well plate (Greiner; 662160) and grown again to confluency after which time they were 
transferred to a 25cm2 flask. Frozen stocks of all clonal populations were made (Section
2.2.5) as soon as possible after propagation.
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2.6 Preparation for RNA Analysis
Due to the labile nature of RNA and the high abundance of RNase enzymes in the
environment a number of precautionary steps were followed when analysing RNA
throughout the course of these studies.
• General laboratory glassware and plasticware are often contaminated by RNases. To 
reduce this risk, glassware used in these studies was baked at 180°C (autoclaving at 
121°C does not destroy RNase enzymes) for at least 8h. Sterile, disposable 
plasticware is essentially free of RNases and was therefore used for the preparation 
and storage of RNA without pre-treatment. Polyallomer ultracentrifuge tubes, 
eppendorf tubes, pipette tips, etc. were all autoclaved prior to use. All spatulas 
which came in contact with any of the solution components were baked, chemicals 
were weighed out onto baked aluminium-foil and a stock of chemicals for “RNA 
analysis only” was kept separate from all other laboratory reagents.
• All solutions (which could be autoclaved) that came into contact with RNA were all 
prepared from sterile ultra-pure water and treated with 0.1% diethyl pyrocarbonate* 
(DEPC) (Sigma; D5758) before autoclaving (autoclaving inactivates DEPC), with 
the exception of Tris-containing solutions (DEPC reacts with amines and so is 
inactivated by Tris). The Tris-containing solutions were made with previously 
DEPC-treated ultra-pure water.
• Disposable gloves were worn at all times to protect both the operator and the 
experiment (hands are an abundant source of RNase enzymes). This prevented the 
introduction of RNases and foreign RNA/DNA into the reactions. Gloves were 
changed frequently.
• All procedures were carried out under sterile conditions when feasible.
• DEPC is a strong, but not absolute inhibitor of RNases. It is also a suspected carcinogen.
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2.7 Total RNA Isolation, Preparation and Analysis by RT-PCR
Total RNA was extracted from cultured cell lines and human tumour specimens 
throughout the course of these studies and analysed by the reverse transcriptase 
polymerase chain reaction.
2.7.1 Total RNA Extraction from Cultured Cell Lines
The following procedure was carried out in a laminar flow cabinet to maintain sterile 
conditions. Adherent cells were grown in 175cm2 tissue culture flasks until approximately 
80% confluent. The medium was removed and the cells in two replica flasks were rinsed 
twice with DEPC-treated PBS. Non-adherent cells were pelleted then resuspended and 
pelleted twice in DEPC-PBS. Cells prepared by either method were then lysed directly in 
a 4M guanidium thiocyanate (GnSCN) solution (Appendix K) (25ml per cell sample). The 
pooled cell lysate was centrifuged at 120g. for 5min and layered on 5.5ml of a 5.7M 
caesium chloride (Appendix K) cushion in a polyallomer ultracentrifuge tube. The mixture 
was spun at 100,000g. at 15°C for 21-24h in a swinging bucket centrifuge. This resulted 
in the separation of protein (at the top of the GnSCN layer) and DNA (at the GnSCN:CsCl 
interface) from the RNA pellet (at the bottom of the tube). Care was taken to prevent 
disturbing the RNA pellet or contaminating the RNA with DNA. The GnSCN solution and 
the “jelly-like” layer below the GnSCN:CsCl interface was removed by aspiration (using a 
pasteur pipette), until approximately 1ml of CsCl remained. The bottom of the tube 
(containing the RNA pellet and 1ml of CsCl) was cut from the rest of the tube using a 
heated scalpel blade. The tube bottom was inverted and the pellet rinsed with 95% ethanol 
at room temperature and resuspended in 200|il of DEPC-treated water by gently pipetting 
up and down whilst keeping on ice. The resuspended pellet was transferred to an 
eppendorf tube and the suspension remains were rinsed into the eppendorf with a further 
200fil of DEPC-treated water. The RNA was precipitated out of solution by the addition 
of 3M sodium acetate, pH 5.2, (to result in a final volume of 0.3M) and 2 volumes of ice- 
cold absolute ethanol, overnight at -20°C. The RNA was pelleted by spinning at 4°C, at 
maximum speed in a microfuge. The pellet was washed with 70% ethanol, the supernatant 
removed and the pellet was briefly air-dried*. The pellet was resuspended in lOOfxl of
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DEPC-treated water and stored at -80°C.
* The pellet was not allow ed to dry com pletely as this greatly decreases its solubility. The solubility o f  RN A  
can be improved by heating to 55-60°C with intermittent vortexing or by passing through a pipette tip.
Total RNA was also extracted as described in the technical bulletin for Tri Reagent 
(Sigma; T-9424). The DNA and protein fractions resulting from the total RNA isolation 
were discarded.
2.7.2 mRNA Extraction from Cultured Cell Lines
Adherent cells were grown in 175cm2 tissue culture flasks until approximately 80% 
confluent. The medium was removed and the cells in two replica flasks were trypsined and 
centrifuged at 120g. The pellet was washed once with 25mls of ice cold PBS and 
centrifuged again at 120g. The supernatant was poured off and the cell pellet stored on ice 
until ready to continue. The mRNA extraction procedure was carried out as described in 
the technical manual for the PolyAtract System 1000 from Promega. (Cat. # Z5400). The 
extracted mRNA was stored at -80° C.
2.7.3 RNA  Quantitation
RNA was quantified spectrophotometrically at 260nm and 280nm. An optical density of 1 
at 260nm is equivalent to 40mg/ml RNA. An A26o/A28o ratio of 2 is indicative of pure 
RNA. Partially solubilised RNA has a ratio of <1.6 (Ausubel et al., 1991). The yield of 
RNA from most lines of cultured cells is 100-200|ag/90mm plate (Sambrook et al., 1989). 
In these studies 200(xgRNA/175cm2 flask was retrieved.
2.7.3.1 RNA Quality
RNA quality was checked by running a quantity of RNA on a 1% 
formaldehyde/agarose gel. For a 100ml, 1% gel, lg  of agarose was combined with 
73.4ml sterile distilled water and dissolved by heating in microwave. In a fume hood 
10ml of 10X MOPS buffer (0.25M MOPS (Sigma; M8899), 0.05M Na-acetate,
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0.01M EDTA, pH 7.0) and 16.6ml formaldehyde (BDH; 15513) were added to the 
molten agarose. 2.5(j.l of ethidium bromide (Sigma; E8751) (lOmg/ml) was added and 
the gel was then poured. 1 .Ojal formaldehyde, 5.0|j,l formamide (BDH; 33272), 0.5(il 
loading buffer (50% glycerol (Sigma; G5576), lmg/ml xylene cyanol FF (BDH; 
44306), lmg/ml bromophenol blue (Sigma; B5525), ImM EDTA) was added to 
1.75(il of RNA, and incubated at 65°C for 15 minutes, placed on ice and then loaded 
onto the gel. The gel was run in IX MOPS buffer. Intact RNA is detected as two 
ribosomal (28S and 18S) RNA bands.
2.7.4 M icropipette Accuracy Tests
Accuracy and precision tests were carried out routinely on all micropipettes used in all 
steps of the RT-PCR reactions. The accuracy and precision of the pipettes was determined 
by standard methods involving repeatedly pipetting specific volumes of water and 
weighing them on an analytical balance. The specifications for these tests were supplied by 
Gilson
2.7.5 Reverse Transcription of RNA isolated from cell lines
The following components were used in the reverse transcriptase (RT) reaction for RNA 
isolated from cell lines, ljxl oligo (dT)i5 primers (lug/^1) (Eurogentec), ljil of total RNA 
(lng/[xl), and 3(xl of DEPC-H20  were mixed together and heated at 70°C for lOmin and 
then chilled on ice to remove any RNA secondary structure formation and allow the oligo 
(dT) primers to bind to the poly (A)+ tail on the mRNA. 4(il of a 5X buffer (consisting of 
250mM Tris-HCl, pH 8.3, 375mM KC1 and 15mM MgCl2), 2pl of DTT (lOOmM), l\d of 
RNasin (40U/|xl) (Promega: N2511), l|xl of dNTPs (lOmM each of dATP, dCTP, dGTP 
and dTTP), 6(il of water and lp.1 of Moloney murine leukaemia virus-reverse transcriptase 
(MMLV-RT) (40,000U/|il) (Promega: *) was then added to the heat-denatured RNA 
complex and the mixture was incubated at 37°C for lh to allow the MMLV-RT enzyme 
catalyse the formation of cDNA on the mRNA template. The enzyme was then inactivated
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and the RNA and cDNA strands separated by heating to 95°C for 2min. The cDNA was 
used immediately in the PCR reaction or stored at -20°C until required for analysis.
2.7.6 Polymerase Chain Reaction (PCR) Analysis of cDNA
The cDNA formed in the above reaction was used for subsequent analysis by PCR for the 
expression of specific mRNAs.
2.7.6.1 PCR Analysis of cDNA formed from mRNA isolated from cell lines
Typical PCR reactions were set up as 50(xl volumes using 2 to 5 jxl of cDNA formed 
during the RT reaction (see Section 2.7.5). cDNA was amplified for varying cycle 
numbers but where possible amplification was carried out in the exponential phase of 
amplification. The sequences of all primers used for PCR in this thesis are shown in 
Figure 2.7.6.1.
Each PCR reaction tube contained 5^1 lOXbuffer (lOOmM Tris-HCl, pH 9.0, 50mM KC1, 
1 % Triton X-100), 3 or 9 (J.1 25mM MgCl2*\ l(il of first strand target primer* (250rig/|nl), 
lfxl of second strand target primer* (250r|g/^.l), 0.5^1 of first strand endogenous control 
primer* (250rig/fil), 0.5fxl of second strand endogenous control primer* (250r|g/|il) and 
water to bring the volume to 35 to 38ja.l (depending on the volume of cDNA used). 2 to 
5fj,l of cDNA (pre-heated to 95°C for 3min. to separate strands and remove any secondary 
structure if the sample had been stored at -20°C) was added to the above and a drop of 
liquid paraffin (BDH; 29436) was added to each reaction tube. The mixture was heated to
94°C for 5min (reduces non-specific binding of primers to template). 1 or 2 jil of lOmM
dNTP” , 0.5(xl of Taq DNA Polymerase enzyme (Promega; N1862) and water to a total 
volume of lOfxl was then added to the above The cDNA was then amplified by PCR 
(Techne; PHC-3) using the following program:
• 94°C for 1.5min (denature double stranded DNA);
• 30-35 cycles 94°C for 1.5min (denature double stranded DNA);
55 or 65°C for lmin (anneal primers to cDNA);
72°C for 3min (extension);
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• 72°C for 7min (extension).
* All oligonucleotide primers used throughout the course of this thesis were made to order on an 
“Applied BioSystems 394 DNA/RNA Synthesiser” by Eurogentec Ltd., 4-10 The Quadrant, 
Barton Lane, Oxon, England. Sequences of primers used are shown in Table 3.1.1 and Appendix 
C
“All PCR reactions used 3(0.1 of MgCl2 and l(j.l of lOmM dNTP except for the amplification of LRP 
using the primers giving a 300 bp product. These reactions required 9^ 1 of 25mM MgCl2 and 2 fj.1 
of lOmM dNTP.
Figure 2.7.6.1 Sequences of primers used for PCR
Gene Primer
Length
Tm Amplified
length
Sequence
mdrl 20 58 157 GTT CAA ACT TCT GCT CCT GA
20 60 CCC ATC ATT GCA ATA GCA GG
MRP 21 58 203
21 62
ß-actin 29 84 383 GAA ATC GTG CGT GAC ATT AAG -
(large) GAG AAG CT
22 64 TCA GGA GGA GCA ATG ATC TTG A
ß-actin 23 70 142 TGG ACA TCC GCA AAG ACC TGT AC
(small) 22 64 TCA GGA GGA GCA ATG ATC TTG A
LRP 21 68 300 CAC AGG GTT GGC CAC TGT GCA
21 64 CCT CGA GAT CCA TTG TGC TGG
Ribozyme 19 60 118 AGC ACA GAG CCT CGC CTT T
Expression 17 54 TCT GGA TCC CTC GAA GC
Antisense 19 60 108 AGC ACA GAG CCT CGC CTT T
expression 17 54 TCT GGA TCC CTC GAA GC
Vector 19 60 96 AGC ACA GAG CCT CGC CTT T
expression 17 54 TCT GGA TCC CTC GAA GC
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All reaction tubes were then kept at 4°C until analysed by gel electrophoresis.
A 10^ -1 aliquot of tracking buffer, consisting of 0.25% bromophenol blue (Sigma; B5525) 
and 30% glycerol in water, was added to each tube of amplified cDNA products. 20^1 of 
cDNA products from each tube were then separated by electrophoresis at lOOmV through 
a 2% agarose (Promega; V3122) gel containing ethidium bromide (Sigma; E8751), using 
TBE (22.5mM Tris-HCl, 22.5mM boric acid (Sigma; B7901), 0.5mM EDTA) as running 
buffer. Molecular weight markers “(j)-X174” Hae III digest (Promega; G1761) were run, 
simultaneously, as size reference.
The resulting product bands were visualised as pink bands (due to the intercalation of the 
cDNA with the ethidium bromide) when the gels were placed on a transilluminator (UVP 
Transilluminator). The gels were photographed.
2.8 Detection of RNA expression by Northern Blotting
The RNA samples to be analysed were first separated by Formaldehyde-Agarose 
Electrophoresis
2.8.1 Formaldehyde-Agarose gel Electrophoresis
A 100ml 1% agarose gel was prepeared by dissolving lg of agarose in 73.4 ml of sterile 
distilled water (SDW). The gel was then cooled to around 60°C and 10ml of 10X MOPS 
buffer (0.25M MOPS, 0.05M Na acetate, 0.01 EDTA, pH 7.0) was added along with 16.6 ml 
formaldehyde and mixed well before pouring. The running buffer for the gel was IX MOPS 
containing 12.9 ml formaldehyde/300ml. 1 or 2\xg of mRNA was freeze dried overnight in a 
200)0.1 eppendorf and dissolved in 5(j.1 of SDW, to allow equal sample sizes. The RNA 
samples were mixed with RNA loading buffer (2.9p,l 10X MOPS, 5(0.1 formaldehyde, 14.3 fil 
formamide, 1.43(0,1 tracking buffer (Section 2.7.4.1)) and heated to 65°C for 15min, placed on 
ice and loaded onto the gel. The RNA samples were run on the gels at 75mV for 2 hours 
alongside RNA size markers (Promega). The gels were washed in 3 changes of SDW over 30 
minutes.
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2.8.2 Northern Blotting
A sheet of Hybond-N (Amersham) was cut to the same size as the RNA gel. A tray or glass 
dish was half filled with the transfer buffer (20X SSC (8.823 % (w/v) tri-sodium citrate, 
17.532 % (w/v) NaCl, pH 7-8)). A platform was made to stand in the tray above the level of 
the transfer buffer and a wick (3MM filter paper) was placed over the platform into the 
transfer buffer. The RNA gel was placed loading side down on the wick platform without 
trapping air bubbles. The Hybond-N was placed on top of the RNA gel and three sheets of 
3MM filter paper placed upon the Hybond-N. A stack of absorbent tissue paper over 5cm 
high was placcd on top of the filter paper and was covered with a glass plate. Finally a glass 
plate with a 75 Og weight were placed on top of the paper stack and the transfer was carries 
out overnight. After blotting, the transfer apparatus was dismantled and the gel loading tracks 
were marked on the Hybond-N to allow land identification. The nucleic acid was fixed to the 
membrane by baking at 80°C for 2 hours and stored until use between two sheets of dry filter 
paper.
After blotting, the gel was rehydrated in a 1 (Ag/ml EtBr solution. The gel was than viewed 
under a U.V. lamp. The efficiency of RNA transfer to the membrane could then be assessed 
by looking for remaining traces of 28 and 16S ribosomal bands. The lane on the gel conatining 
the RNA markers was removed from the gel before blotting and stained with EtBr alongside 
the blotted gel. The position of the RNA markers were photographed and used as a reference 
to size bands on the developed Northern Blots.
2.8.3 Slot-Blotting of RNA
Slot-Blots of mRNA samples was carried out using the Bio-Rad Bio-Dot SF cell slot blot. The 
protocol is as outlined in the accompanying manual. Briefly 1 fJ-g of Poly A+ RNA was 
diluting to 500 (xL in the denaturing blotting solution (0.5M NaOH). A piece of Hybond-N 
nylon membrane was cut to the same size as the blotter. Three pieces of thick filter paper were 
also cut to the same size as the blotter. The filter paper and the membrane were pre-wetted in 
20X SSC and put into place on the blotter and the vacuum attached. The wells not required 
were covered with masking tape to allow even suction on the wells. The wells were washed 
with the denaturing blotting solution using the vacuum. The diluted samples were added to the
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wells and transferred onto the membrane under vacuum. The wells were washed through 
under vacuum with a further 500 [iL of the denaturing blotting solution. The membrane was 
then baked at 80°C for 2 hours and stored dry until required.
2.8.4 Preparation of Hybridisation probe
The LRP probe was prepared from a LRP cDNA plasmid (LHN42) kindly donated by Rik 
Scheper. A 1 kb fragment of the LRP cDNA was restricted from the plasmid using two 
restriction enzymes. The fragment was electrophoresed on a 1% low-melting point agarose gel 
containaing ethidium bromide at 75mV for 1 to 2 hours along with the molecular weight size 
markers IX and III (Boehringer Mannheim: 558 552 and 1 449 460) to check for the correct 
fragment size. The gel was viewed under a U.V. illuminator and the fragement band cut out of 
the gel with a scalpel. The 1 kb fragment was then extracted from the agaraose using the 
Qiaex II Agarose Gel Extraction kit (Qiagen: 20021) according to the given protocol. 
Similarly a 1.3kb MRP and a 1.4kB mdr-1 fragment was restricted and purified from a MRP 
cDNA and a mdr-1 cDNA containing plasmid respectively.
2.8.5 Radioactive Labelling of Probes
All DNA probes were labelled with [a-32P]dCTP (Amersham) using the Prime-a-gene 
labelling kit (Promega : U1100) according to the supplied protocol. Riboprobes (RNA) were 
labelled with [a-32P]CTP (Amersham) using the Riboprobe In Vitro Transcription Systems 
kit (Promega: P1440) according to the supplied protocol. The T7 promoter and RNA 
polymerase were used in this labelling reaction. 20 to 40 ng of cDNA fragment and 5(0,1 of [a- 
32P]dCTP or [a-32P]CTP was used to make each probe.
To test the percentage incorporation of nucleotides into the DNA probes the following 
protocol was carried out. 1 jol out of the 50[ol reaction mix was diluted 1 inlOO with water. 
l(il of the diluted probe was then blotted onto four 1cm2 pieces of filter paper and air dried. 
Two of these pieces of filter paper were washed twice for 10 minutes in 10% Tri-chloro 
Acetic Acid (Riedel-del Haen: UN-No-1839), rinsed in 100% ethanol and air dried. Then the 
counts on the two washed and unwashed pieces of filter were measured using a scintillation 
counter. The filter paper was placed in scintillation counter tubes with 10ml of scintillation
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fluid (Ecolite : *) and the Counts per minute (CPM) read. The CPM of the washed pieces of 
filter paper as a percentage of the unwashed pieces of filter paper gave the percentage 
incorporation of oligonculeotides into the probe. Probes with less than 50% incorporation 
were purified using NAP 10 columns (Amersham ?) according to the manufacturuers 
protocol.
2.8.6 Hybridisation of labelled probes to RNA membranes
The baked Hybond-N membranes with the mRNA samples were prehybridised overnight at 
65°C in 10ml of hybridisation buffer (In 100ml : 43ml 1 M Sodium phosphate pH 7.2, 33 ml 
20% Sodium Dodecyl Sulphate (SDS), 20 ml 5% BSA, 4ml 0.5 M EDTA) per membrane. 
The hybridisation was carried out in glass hybridisation tubes in a hybridisation oven. The 
appropriate probe was heated to 94°C for 3 min before addition to 10ml of preheated (65°C) 
hybridisation buffer. Sufficient probe was used to give 1x106 CPM/ml hybridisation buffer. 
The pre-hybridisation buffer was discarded from the hybridisation tubes and replaced with the 
fresh hybridisation buffer with the probe. Hybridisation was carried out at 65°C overnight. 
The membranes were then washed at 65°C for 5 min in 2X SSC, followed by 2 x 15 min 
washes in 0.5X SSC, 0.1% SDS and 2 x 15 min washes in 0.1X SSC, 0.1% SDS. The 
membranes were wrapped in cling film and exposed to X-ray film at -80°C for the desired 
length of time (typically 24h to 5 days).
2.9 Protein Analysis
Protein analysis was carried out by Western blotting using whole cell extracts and 
immunocytochemistry using cytospins of whole cells.
2.9.1 Whole Cell Extract Preparation
Cells were grown in 175cm2 flasks until they reached 80-90% confluency. The cells were 
then trypsinised and centrifuged at 120g. for 5 min. The pellet was washed in PBS and re­
pelleted twice. 1ml of lysis buffer (PBS, 1% NP-40 (Sigma; N-3516), IX protease 
inhibitors and 0.2mg/ml PMSF(Sigma; P7626)) was added to the pellet and left on ice for
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20 min. A 100X stock solution of protease inhibitors consisted of 400mM DTT (Sigma; 
D5545), lmg/ml aprotonin (Sigma; A1153), lmg/ml leupeptin (Sigma; L2884), lmg/ml 
soybean trypsin inhibitor (Sigma; T9003), lmg/ml pepstatin A (Sigma; P6425) and 
lmg/ml benzamidine (Sigma; B6506). If cell lysis had not occurred after 20 min the cells 
were subjected to sonication. Whole cell extracts were aliquoted and stored at -80°C.
2.9.2 Quantification of Protein
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad; 500-0006) 
with a series of bovine serum albumin (BSA) (Sigma; A9543) as standards. The dye 
reagent was provided as 5-fold concentrate. The appropriate standards (0.02ml) and test 
samples (0.02ml) were placed in clean, dry test tubes. The diluted dye reagent (1ml) was 
added and the mixture vortexed. After a period of 5 min to lh, the OD595 was measured, 
against a reagent blank. From the plot of the OD595 of BSA standards versus their 
concentrations, the concentration of protein in the test samples was determined.
2.9.3 Gel electrophoresis
The protein present in the cell preparations were separated on a size basis using SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) :-
Table 2.13.4.1 SDS-PAGE Recipes for 2 x 0.75mm Thick Gels
Resolving Gel Stacking Gel
7.5% 12% 15% 5%
Acrylamide Stock* 3.8ml 5.25ml 7.5ml 0.8ml
Distilled H2O 8.0ml 6.45ml 4.3ml 3.6ml
1.875M Tris, pH 8.8 3.0ml 3.0ml 3.0ml
1.25M Tris, pH 6.8 0.5ml
10% SDS 150(4.1 150(0.1 150(0.1 50|ol
10% NH4-persurphate 60 (ol 50(ol 50 (ol 17(0.1
TEMED 9.0^1 10nl 7.5|ol 8jj.1
* Acrylamide stock solution consists of 29. lg acrylamide (Sigma; A8887) and 0.9g NN’-methylene 
bis-acrylamide (Sigma; 7256) dissolved in 60ml UHP water and made up to 100ml final volume. 
The solution was stored in the dark at 4°C for up to 1 month. All components were purchased from 
Sigma; SDS (L4509), NHj-persulphate (A1433) and TEMED, N,N,N’,N’- 
tetramethylethylenediamine (T8133).
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The resolving gel was immediately poured into two clean 10cm x 8cm gel cassettes 
comprising of a glass and aluminium plate separated by two 0.75cm spacers on either 
outer edge. The gel was overlayed with a 10% SDS solution and allowed to set. Once set, 
the SDS solution was poured off and the stacking gel layered on top of the resolving gel. 
A comb of appropriate thickness and well size was immediately inserted and the gel 
allowed to set. When the wells had formed, the gel combs were removed and the gels 
transferred to a mini-electrophoresis apparatus. The gels were flooded with running buffer 
(1.9M glycine (Sigma; G6761), 0.25M Tris, 0.1% SDS, pH 8.3 without adjustment). 
Protein samples were loaded into the wells, based on equal protein loading. The samples 
to be loaded were diluted 1:1 with loading buffer (50mM Tris-HCl, pH 6 .8; 0.1% SDS;
5% 2-mercaptoethanol (Sigma; M6350); 5% glycerol and 0.1% bromophenol blue) and
)
boiled for 2 min. They were then loaded onto the gel, as were the appropriate molecular 
weight markers (New England Biolabs; 77085). The gels were run for approximately 1.5 
hours with voltage set at 250V and current set at 45mA.
2.9.4 Western Blotting Procedure
Following electrophoresis, the acrylamide gels were equilibrated in transfer buffer (25mM 
Tris; 192mM glycine; pH 8.3 - 8.5 without adjustment). Nitrocellulose filter (Amersham; 
Hybond-ECL RPN2020D), which was cut to the same size as the gel, was soaked in 
transfer buffer for 5 min. If PVDF membrane (Boehringer Mannheim; 1 722 026) was 
used, the membrane, cut to the same size as the gel, was immersed in methanol for a few 
seconds, rinsed with water and then soaked in transfer buffer for 5 min. Six stacked sheets 
of gel-size Whatman 3mm filter paper were soaked in transfer buffer and placed on the 
cathode plate of a semi-dry blotting apparatus (BioRad). Excess air was removed from 
between the filters by sliding a pipette over and back on the filter paper. The 
nitrocellulose was placed over the filter paper, again ensuring no air bubbles became 
trapped. The acrylamide gel was placed on the nitrocellulose and the nitrocellulose was 
marked at the sites of the gel lanes and size markers. Six more sheets of pre-soaked filter 
paper was placed on top of the gel. The protein was transferred from the gel to the 
nitrocellulose at a current of 0.34mA/0.15V for 30 min. The nitrocellulose was then 
blocked in blocking buffer and exposed to specific antibodies. Negative blots were also 
performed whereby the primary antibody was replaced with antibody diluent.
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2.9.4.1 P-glycoprotein
Total protein was separated on a 7.5% SDS polyacrylamide gel. Following transfer of the 
protein to the nitrocellulose, the nitrocellulose was blocked for 2 hr at room temperature 
in TBS (500mM NaCl; 20mM Tris, pH 7.5) containing 0.5% non-fat dried milk 
(Cadbury; Marvel skimmed milk). The nitrocellulose was rinsed twice with TBS and was 
exposed to the primary antibody (1 in 200 dilution of mouse mdr-1 ascites MAb(BRI)) at 
4°C overnight. The nitrocellulose was washed three times in TBS containing 0.5% Tween- 
20 (Sigma; P1379). The nitrocellulose was exposed to the secondary antibody (horse 
radish peroxidase-conjugated (HRP)) (1:2000 dilution of goat anti-mouse-HRP (Dako; 
P0447) in TBS, 0.1% Tween-20) for 1.5 hours at room temperature. The nitrocellulose 
was again washed three times in TBS and was developed as outlined in Section 2.9.5.1.
2.9.4.2 MRP
The procedure was identical to that for P-Glycoprotein excpet for the primary and 
secondary antibodies used. The pimary antibody was 1/150 dilution of anti-human MRP 
Rat Mab (TCS; ZUMC-201). The secondary antibody was a 1/10,000 dilution of rabbit 
anti-rat-HRP immunoglobulin (Dako; P450). The membranes were washed 5 times in TBS 
(0.5% Tween). The membranes were developed using Pierce Super-Signal Ultra 
Chemiluminescence substarte as outlined in Section 2.8 .5.2
2.9.5 Development of Western Blots
2.9.5.1 Development of Western Blots with ECL
Western blots were developed by a chemiluminescence method. An equal volume of ECL 
solutions 1 and 2 (Amersham; RPN2209) was mixed together (3ml/blot). The 
nitrocellulose was placed, protein side up, on a piece of flat cling-film and covered with 
the detection reagent for 1 min at room temperature. Excess detection reagent was poured 
off and the membranes were wrapped in cling-film, ensuring no air-pockets were created. 
A sheet of autoradiography film was placed on top of the membranes and exposure time
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varied. Film was developed and fixed using standard methods.
2.9.5.2 Development of Western Blots with Super-Signal Ultra
An equal volume of Super-Signal Ultra Chemiluminescence substrate solutions 1 and 2 
(Pierce; 34075) were mixed together (3ml/blot). The nitrocellulose was placed, protein 
side up, on a piece of flat cling-film and covered with the detection reagent for 5 min at 
room temperature. Excess detection reagent was poured off and the membranes were 
wrapped in cling-film, ensuring no air-pockets were created. A sheet of autoradiography 
film was placed on top of the membranes and exposure time varied. Film was developed 
and fixed using standard methods.
2.9.6 Cellular Labelling and Immunoprécipitation of LRP
Adherent cells were grown to 80% confluency in 175 cm2 flasks. The medium was 
removed, the cells were trypsinised and centrifuged at 120g for 5 min. The supernatant 
was removed and the cell pellet was washed three times with PBS. The cell pellets were 
then stored at -80° C until required. The extraction and immunoprécipitation of the LRP 
protein from the cell pellets was carried out as detailed in the methods manual for the 
“Cellular Labelling and Immunoprecipitataion kit” (Boehringer Mannheim; 1 647 652). 
The antibody used for the immunoprécipitation was the LRP-56 monoclonal Antibody 
(TCS; ZIM 1001 and a gift from Rik Scheper). The samples containing the 
immunoprecipitated LRP protein were separated on a 7.5% SDS polyacrylamide gel by 
electrophoresis. After Western Blotting, the nitrocellulose or PVDF membrane was 
blocked for 2 h in 5% non-fat dried milk (Cadbury; Marvel skimmed milk). The 
membrane was rinsed twice with TBS (0.5% Tween). The membrane was then incubated 
with anti-biotin Antibody (HRP labelled; 1/3000 dilution) for 1 hr at room temperature. 
The membrane was rinsed again in TBS (0.5% Tween) for 10 min. The membranes were 
developed with ECL reagent as described in section 2.9.5.1.
2.9.7 Immunocytochemical analysis of protein expression
P-170 and LRP were detected on cytospins of the cells being tested using the ABC method
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2.9.7.1 Preparation of cytospins.
Cells to be tested were trypsinised (Section 2.2.2) to form a single cell suspension, and 
washed three-times with Phosphate Buffered Saline (PBS) and resuspended at a 
concentration not exceeding lxlO6 cells/ml. Cells were spun onto Poly-L-lysine coated 
slides and left to dry overnight at room temperature. Slides were then wrapped in tinfoil 
and stored at -20° C until required. Before use, slides were brought to room temperature 
for at least 15-20 min. For the detection of LRP and P-170 cells were fixed for 10 and 1 
minute respectively in ice-cold acetone. All slides were then air-dried for at least 15 min 
prior to immunostaining. Endogenous peroxidase activity was blocked by placing slides in 
0.6% (v/v) H20 2 in methanol for 5 min at room temperature. Slides were then washed for 
5 min with a washing buffer (lxTris Buffered Saline with 0.1% Tween). All cells were 
blocked with 20% normal rabbit serum (Dako; E0354) at room temperature. Primary 
antibodies were appropriately diluted (LRP-56 : 1/20, mdr MAb : 1/40) in washing buffer 
and applied overnight at 4° C. Biotinylated rabbit anti-mouse IgG secondary antibody 
(Dako), diluted in washing buffer (1/300), was applied for 30 min at room temperature. 
Finally, the StrepABC-complex/HRP was applied for 25min at room temperature. Slides 
were washed between each incubation in three changes of washing buffer within 15 min. 
The horseradish peroxidase substrate, DAB (3,3-diaminobenzidine tetrahydrochloride) 
containing 0.02% H20 2 was applied for 10 min at room temperature. Cells were then 
lightly counterstained with Cole’s haematoxylin for 50 seconds, differentiated in 1% acid 
alcohol and blued in Scott’s tap water. Negative controls on each slide were prepared 
using with either washing buffer alone or diluted control mouse ascites for LRP and P-170 
respectively.
The stained cytospins were viewed under a microscope and the level of intensity gauged 
on a scale of 0 to 3. Photographs were also taken.
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2.10 Transfection of Mammalian Cells with Exogenous DNA
Throughout the course of this thesis it was found necessary to introduce foreign DNA into 
host cells either to increase the level of expression of a particular gene (by transfecting 
with an expression plasmid) or decrease the level of expression of a particular gene (by 
transfecting with a plasmid containing a ribozyme or a antisense sequence or a free 
antisense oligonucleotide).
Sufficient plasmid was produced by transforming JM109 with the plasmid required, 
growing up a large stock of these cells and isolating the plasmid from them; this isolated 
plasmid was then transfected into the chosen cell line.
All the Phosphorothioate Antisense oligonucleotides used were made to order on an 
“Applied BioSystems 394 DNA/RNA Synthesiser” by Eurogentec Ltd., 4-10 The 
Quadrant, Barton Lane, Oxon, England. Sequences of antisense molecules used are shown 
in Table 3.4.1.
2.10.1 Plasmids and oligonucleotides used
The LRP ribozyme and the LRP antisense constructs were cloned into the pHp expression 
plasmid and were a generous gift from Dr. Kevin Scanlon. (The constructs are shown in 
Section 3.1). All antisense molecules used were phosphorothioate oligonucleotides and 
were manufactured by Eurogentec as for RT-PCR primers.
2.10.2 MgCl2 / CaCl2 Transformation of JM109 Cells
10ml of LB broth (Appendix K) was inoculated with a single colony of JM109 bacteria 
from an agar plate and incubated overnight at 37°C at 200r.p.m. The following day 500^1 
of this suspension was inoculated into 50ml of LB broth and grown to an OD6ooim of 0.3. 
The cells were then pelleted at 3000r.p.m. for lOmin, the supernatant removed and the 
pellet was resuspended in 10ml of lOOmM MgCl2, on ice for 15min. The cells were again 
precipitated at 3000r.p.m. for lOmin and the pellet was resuspended in 10ml of lOOmM 
CaCl2 on ice for a further 15min. The precipitation step was then repeated and the pellet 
was resuspended in l-2ml of lOOmM CaCl2 and left on ice for at least 15min. The cells
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were now competent and ready for transformation with the foreign DNA required.
100(xl of the competent cell suspension was mixed with 20ng DNA and placed on ice for 
40min after which the mixture was heat-shocked at 42°C for 90sec and then placed on ice 
for 3min. 1ml of LB broth was added to the competent cell suspension and incubated at 
37°C for 40min. 400p.l of this suspension was spread on a selecting agar plate 
(Ampicillin/AMP (Boehringer Mannheim; 835 269)) and incubated overnight at 37°C. 
Single colonies which grew on these selecting plates were further colonised on another 
selecting plate and allowed to grow overnight.
2.10.2.1 Isolation of Plasmid from JM109 cells
A single colony (from 2.14.2) was inoculated into 10ml of LB AMP 50(ig/ml and grown 
overnight; 2ml of this suspension was added to 200ml of TB AMP 50/ig/ml and left to 
grow overnight at 37°C for large scale isolation of plasmid from JM109 cells. The 
following day the cells were pelleted and pZ523 spin columns (5 Prime -» 3 Prime Inc.; 
5-523523) were used to isolate the plasmid according to the manufacturer’s instructions. 
This procedure involved lysing the pellet in 20ml of an ice-cold solution containing 50mM 
glucose, 25mM Tris-Cl, lOmM EDTA, pH8.0 and 5mg/ml lysozyme (Sigma; L6876) at 
room temperature for 10-15min. 40ml of a 0.2N NaOH and 1.0% SDS solution was 
gently mixed with the lysate until the suspension became clear and incubated on ice for 
lOmin. 30ml of 3M K-Acetate, pH5.2 was added to the above and mixed gently until a 
flocculent precipitate appeared at which stage the mixture was stored on ice for at least 
lOmin. The sample was centrifuged at 35,000g. for Ih at 4°C after which the supernatant 
was recovered and added to 0.6 volume of 100% Isopropanol, mixed gently and left at 
room temperature for 20-30min. The suspension was then centrifuged at 35,000g. for 
30min at 20°C after which the supernatant was discarded and the pellet washed in ice-cold 
70% ethanol and resuspended in 5ml of TE, pH8.0. To remove any contaminating RNA 
the plasmid solution was treated with RNase Plus (5 Prime -> 3 Prime Inc.; 5-461036) (to 
a final dilution of 1:250) for 30min at 37°C followed by phenol:chloroform:isoamyl 
alcohol extractions. 10M ammonium acetate was added to the aqueous phase to a final 
concentration of 2.0M and 0.6 volume of 100% Isopropanol was added to the sample, 
mixed and stored at room temperature for 20-30min. The sample was centrifuged at 
maximum speed in an epifuge and the DNA pellet was washed in 70% ethanol and
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resuspended in 3.6ml of lOmM Tris-Cl, ImM EDTA, and 1.0M NaCl, pH8.0. 1.8ml of 
this sample was loaded into one of two pZ523 columns (following the manufacturer’s 
instructions) and the column effluent was precipitated with 0.6 volume 100% Isopropanol, 
as described previously. The DNA was pelleted at maximum speed in an epifuge, washed 
in 70% ethanol and resuspended in TE. The DNA concentration was determined by 
measuring the OD260nm-
2.10.3 CaP04 Transfection of Mammalian Cells
On the day prior to transfection the cells to be transfected with plasmid DNA were plated 
from a single cell suspension (Section 2.2.2) and seeded into a 75cm2 flask at 5x10s cells 
per flask. The plasmid DNA was diluted to l|xg/^l in TE and 10(xg DNA was stored 
overnight in 410(11 H2O at 4°C.
On the day of the transfection the diluted DNA was incubated at 37°C for lh 60jj.1 2M 
CaCl2 was added dropwise to the DNA with continual mixing. Immediately the DNA- 
CaCl2 mixture was added dropwise into the 2XHBS (Appendix K) solution with continual 
mixing and left at room temperature for 30min to form a DNA-CaP04 mixture. The DNA- 
CaP04 mixture was added to the flask of cells (containing media) dropwise, swirling 
constantly to ensure even mixing. The cells were then incubated for 4h at 37°C after which 
time the cells were “shocked” with glycerol to aid the entry of the DNA into the cells. 
Glycerol-shocking was done by removing the media from the cells and adding 5ml of 10% 
glycerol in 1XHBS to the cells for 3min. The glycerol was then removed, the cells rinsed 
twice in 5ml serum-free media and then re-fed with 10ml fresh growth media and 
incubated for 2-3 days at 37°C.
2.10.3.1 Transfection of cells with Lipofection reagents
On the day prior to transfections, the cells to be transfected were plated from a single cell 
suspension (Section 2.2.2) and seeded into 25cm2 flasks at lxlO5 cells per flask. On the day of 
the transfection, the plasmid or oligonucleotides to be transfected were prepared along 
with the lipid transfection reagents according to the manufacturers protocols (DOTAP 
- Boehringer Mannheim; 1 202 375, Lipofectin - GibcoBRL ; 18292-011, Fugene6 - 
Boehringer Mannheim ; 1 814 443). The cells were either transfected for four hours in
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the absence of serum after which the media was replaced with serum containing 
media, or for 24h to 48 h in the presence of 10% FCS. For all transfections the cells 
were incubated at 37°C.
2.10.3.2 Selection and Isolation of Colonies
In order to study the true effect of transfection studies, single colonies of stably 
transfected cells were selected and isolated. The selection process was carried out by 
feeding the “transfected” cells with media containing geneticin (Sigma; G9516) - the 
plasmids used had a geneticin-resistant gene, therefore, only those cells containing the 
plasmid will survive treatment with geneticin. 2 days after transfection the flask of cells 
was fed with 200(xg/ml geneticin in complete media, when the cells grew readily in this 
concentration of selecting agent, the concentration was increased step-wise to a final 
concentration of 600|ig/ml. At this stage the cells were plated at clonal density (see 
Section 2.6) and clonal populations were propagated, as described previously. Transfected 
cells were periodically challenged with geneticin to establish stability of transfectants.
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3. RESULTS
3.1 Analysis of OAW42SR and OAW42s clones transfected with LRP-Ribozyme, 
LRP-Antisense or control plasmid pHp.
OAW42SR and OAW42S cells were transfected with either the pHp plasmid 
containing the anti-LRP ribozyme or the anti-LRP antisense constructs or the vector 
alone. The pHP plasmid construct is shown in Figure 3.1.1. The anti-LRP ribozyme 
and antisense constructs are shown in Figure 3.1.2. The cells were transfected and 
selected as described previously (section 2.10.3.1). After selection with a 
concentration of 400 |ag/ml of geneticin, cell stocks were frozen in liquid nitrogen. All 
clones were subsequently screened for decreased expression of LRP mRNA by RT- 
PCR and LRP protein by immunocytochemistry (Sections 2.7.5 and 2.9.7 
respectively). Cytotoxicity assays with Adriamycin and Vinblastine or Vincristine 
were also carried out (Section 2.3). The clones, which were initially isolated, are 
shown in Table 3.1.
3.1.1 LRP RT-PCR Analysis of Transfected clones
To determine if any of the selected clones displayed a reduction in LRP mRNA levels 
as compared to the parental or control clones, RT-PCR was carried out on total RNA 
extracted from each clone. The primers used amplified a 300 bp fragment of LRP 
corresponding to the 5’ end of the gene, and were designed as described previously 
(Section 2.7.6.1). Specific primers were used to produce a 142 bp band from (3-actin, 
which was used as an internal control. The RT-PCR reactions were carried out at least 
twice. The molecular weight marker (MWM) used for all PCRs in this thesis is 
“<J>-X174” Hae III digest (Promega: G1761). The results shown in Figure 3.1.1.1 for 
the OAW42SR clones, and in Figures 3.1.1.2 and 3.1.1.3 for the OAW42S clones, are 
representative of all the repeats. The results in Figures 3.1.1.2 and 3.1.1.3 were from 
the same PCR and so band intensities can be compared
From Figure 3.1.1.1 it can be seen that there were no observed decreases in LRP 
expression in any of the transfected OAW42SR clones. Figure 3.1.1.2 shows that 
there were LRP bands visible for all the OAW42S LRP-Ribozyme clones, except 
clone number 7. However, the P-actin control band was significantly reduced for this
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Figure 3.1.1 The pHpApr-l-neo (pH(3) plasmid vector
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Figure 3.1.2 Diagram of anti-LRP Ribozyme and Antisense RNA
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LRP mRNA 
LRP Ribozyme
LRP mRNA 
LRP Antisense
Table 3.1 Clones selected from transfection with LRP-Ribozyme, Antisense 
containing or control plasmid.
Plasmid Transfected OAW42SR parent OAW42S parent
pHß-LRP-Ribozyme SR-LRP-Rz 1 42S-LRP-Rz 2
SR-LRP-Rz 2 42S-LRP-Rz 3
SR-LRP-Rz 4 42S-LRP-Rz 4 
42S-LRP-RZ 7 
42S-LRP-Rz 8 
42S-LRP-Rz 10 
42S-LRP-Rz 15
pHß-LRP-Antisense SR-LRP-AS 1 42S-LRP-AS1
SR-LRP-AS 4 42S-LRP-AS 4
SR-LRP-AS 6 42S-LRP-AS 5
SR-LRP-AS 7 42S-LRP-AS 9
SR-LRP-AS 8 42S-LRP-AS 10 
42S-LRP-AS 13 
42S-LRP-AS 14
pHß control SR- pHß 1 42S-pHß 1
SR- pHß 3 42S-pHß 2
SR- pHß 6 42S-pHß 3
SR- pHß 7 42S-pHß 4 
42S-pHß 5
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Figure 3.1.1.3 RT-PCR Analysis of LRP expression in OAW42S LRP 
Antisense and Phß clones
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clone as compared to the rest. There appeared to be reduced expression in the LRP 
antisense transfected clones 42S-LRP-AS 10 and 14 (Figure 3.1.1.3). However, in 
other RT-PCRs, the decrease was not as dramatic (results not shown). Control 
plasmid transfectant 42S-pHp 1 also appeared to have a decrease in LRP expression 
as compared to the parental cell line OAW42S.
3.1.2 Analysis of Drug Toxicity Profiles of Transfected OAW42SR and OAW42S 
clones
Each of the selected clones was treated with a range of concentrations of Adriamycin 
and either Vinblastine (OAW42SR’s) or Vincristine (OAW42S’s) as described earlier 
(Section 2.3). Each toxicity assays was performed three times. The results for the 
OAW42SR clones for Adriamycin and Vinblastine are shown in Graphs 3.1.2.1 and
3.1.2.2 respectively. For OAW42SR clones, the IC50 values are only relative values, 
due to experimental variations, with the IC50 of the parental OAW42SRs given a 
value of 1. Graphs 3.1.2.3 and 3.1.2.4 show the IC50 values of Adriamycin and 
Vincristine respectively for the OAW42S clones. Averages of the IC50 values over 
three repeats were made and are shown in Graphs 3.1.2.5 and 3.1.2.6 for OAW42SR 
clones, and Graphs 3.1.2.7 and 3.1.2.8. for OAW42S clones.
Graphs 3.1.2.1 and 3.1.2.5 illustrate clearly that there were four OAW42SR clones 
(SR-LRP-Rz 2 and 4, SR-LRP-AS 1 and 4) that exhibited a marked reduction in 
resistance to Adriamycin as compared to the parental OAW42SR cell line. The clone 
SR-LRP-Rz 2 exhibited the largest change, with an average 10-fold reduction in 
resistance to Adriamycin. Some of the other antisense clones (SR-LRP-AS 7 and 8) 
also displayed decreases in resistance, but the changes were not as significant as those 
mentioned above, The clones SR-LRP-Rz 1 and SR-LRP-AS 2 and SR-LRP-AS 6 
displayed only very minor decreases in resistance to Adriamycin, possibly indicating 
that the transfected plasmids were not functioning in these clones.
Three of the control pHp plasmid transfectants (SR-pHf] 1, 6 and 7) showed increased 
sensitivity to Adriamycin, with only SR-pHp 3 showing no alteration. These
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Graph 3.1.2.1 Adriamycin toxicity assay on OAW42SR clones : Relative IC50
values
Graph 3.1.2.2 Vinblastine toxicity assay on OAW42SR clones : Relative IC50 
values
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Graph 3.1.2.3 Adriamycin toxicity assay for OAW42S clones: IC50 values (|ag/ml)
3 Repeats
Graph 3.1.2.4 Vincristine toxicity assay on OAW42S clone : IC50 values (jug/ml)
Graph 3.1.2.5 Adriamycin toxicity assay on OAW42SR clones : Average relative
IC50 values
G raph 3.1.2.6 Vinblastine toxicity assay on OAW42SR clones : Average relative 
IC50 values
98
Graph 3.1.2.7 Adriamycin toxicity assay on OAW42S clones : Average IC50
values (ng/ml)
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Graph 3.1.2.8 Vincristine toxicity assay on OAW42S clones : Average IC50 values 
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decreases in resistance to Adriamycin corresponded to the decreases in Vinblastine 
resistance (Graphs 3.1.2.2 and 3.1.2.6) with clones SR-LRP-Rz 2 and 4, SR-LRP-AS
1 and 4, showing the largest increases in sensitivity.
Similarly to the OAW42SR clones, there were a number of OAW42S transfectant 
which displayed varying levels of increased sensitivity to Adriamycin (Graphs 3.1.2.3 
and 3.1.2.7). However the magnitude of changes in resistance of these OAW42S 
clones (42S-LRP-Rz 2, 3, 4, 7 and 42S-LRP-AS 1, 4, 5, 10, 13 14) was not as great as 
for the OAW42SR clones with a maximum of around 5-fold decrease in IC50 values 
as compared to the parental cells. As with the OAW42SR clones, there were a number 
of control plasmid (pHp) transfectants (42S-pHP 3, 4) which also displayed reduced 
IC50 values. However, there were also a number of clones (42S-LRP-AS 9, 42S- pHp
2 and 5) which exhibited a greatly increased resistance to the cytotoxic effects of 
Adriamycin.
Once again, the results from the Vincristine toxicity assays on OAW42S clones 
(Graphs 3.1.2.4 and 3.1.2.8) strongly reflected those for Adriamycin.
3.1.3 Immunocytochemical staining of OAW42SR and OAW42S clones with 
LRP-56 MAb
In order to test if the observed reductions in cytotoxic drug resistance (Section 3.1.2.) 
and decreases in LRP mRNA level (Section 3.1.1) for the various clones 
corresponded with the level o f expression of LRP at the protein level, cytospins were 
prepared from the clones and were stained with the LRP-56 monoclonal antibody 
(MAb) (Sections 2.9.7). Each of the OAW42SR clones was examined while only a 
selection of OAW42S clones were analysed, due to the high number of these clones 
and time constraints. Which OAW42S clones to analyse by immunocytochemistry, 
was decided from the results of the LRP RT-PCRs and the toxicity assays (Sections
3.1.1 and 3.1.2). The clones chosen in Table 3.1.3.2 were thought to be interesting in 
terms of LRP protein down-regulation, as judged by decreased LRP mRNA levels and 
decreased resistance to adriamycin and vincristine.
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Cytospins from each clone were prepared on two separate occasions, and 
immunocytochemistry with the LRP-56 MAb repeated on each set of cytospins at 
least twice. The intensity of LRP staining for each OAW42SR clone is given in Table
3.1.3.1, while the corresponding photographs of the stained cytospins shown in Figure
3.1.3.1. The OAW42S clones were also tested for LRP expression on two occasions, 
with the levels of staining as shown in Table 3.1.3.2. and Figure 3.1.3.2. The values in 
Tables 3.1.3.1 and 3.1.3.2 are averaged from a number of cytospins and not just the 
ones shown in Figures 3.1.3.1 and 3.1.3.2.
From Table 3.1.3.1 and Figure 3.1.3.1, it is evident that a number of OAW42SR 
clones had reduced levels of LRP expression. Over the two repeats, SR-LRP-Rz 2 and 
SR-LRP-AS 1 displayed an almost total elimination of LRP expression. The clones 
SR-LRP-Rz 4, SR-LRP-AS 6, 7, SR- pHp 1 and 7 all showed significant reductions in 
LRP staining intensity as compared to the parental cells. The clones SR-LRP-Rz 1, 
SR-LRP-AS 2 and 4 and SR-pFip 3 and 6 exhibited very slight, if any, variations in 
the levels of LRP compared to parental OAW42SR cells.
A number of the OAW42S clones also showed reductions in the staining intensity 
compared to the parental cells (Table 3.1.3.2 and Figure 3.1.3.2). LRP expression 
appeared almost totally eliminated in 42S-LRP-Rz 2, 42S-LRP-AS 1 and 42S- pHP 1.
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Table 3.1.3.1 Immuncytochemical cytospin staining intensity with the LRP-56 
MAb on OAW42SR clones.
Clone 1st Repeat 2nd Repeat
OAW42SR +++ +++
SR-LRP-Rz 1 ++ +++
SR-LRP-Rz 2 0/+ 0
SR-LRP-Rz 4 ++ +/++
SR-LRP-AS 1 0 0/+
SR-LRP-AS 2 ++ ++
SR-LRP-AS 4 ++ ++
SR-LRP-AS 6 + 0/+
SR-LRP-AS 7 0/+ +/++
SR-LRP-AS 8 ++ +/++
SR- pHß 1 + ++
SR- pHß 3 ++ ++
SR- pHß 6 ++/+++ ++/+++
SR- pHß 7 ++ +/++
Intensity of staining was as follows: 0 - No cells staining; 0/+ - few cells lightly stained; + - significant 
number of cells lightly stained; ++ - most cells stained moderately; +++ - intense staining on almost all 
cells.
Table 3.1.3.2 Immuncytochemical cytospin staining of OAW42S clones
Clone 1st Repeat 2nd Repeat
OAW42S +/++ +++
42S-LRP-Rz 2 0/+ +
42S-LRP-Rz 4 +++ +++
42S-LRP-Rz 7 +++ +++
42S-LRP-AS 1 0/+ 0/+
42S-LRP-AS 10 +++ +++
42S-LRP-AS 13 +++ +++
42S-LRP-AS 14 +++ +++
42S-pHß 1 0 0
42S-pHß 4 +++ +++
Staining intensity as in legend for Table 3.1.3.1
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Figure 3.1.3.1 Immunocytochemical staining of OAW42SR clone cytospins
with LRP-56 MAb
(a)
(b)
(a) OAW42SR; (b) SR-LRP-Rz 1
1- Punctate cytoplasmic LRP staining; 2- Blue nucleus counter stain
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Figure 3.1.3.1 (cont’d) Immunocytochemical staining of OAW42SR clone
cytospins with LRP-56 MAb
(d)
(c) SR-LRP-Rz 2; (d) SR-LRP-Rz 2 negative control
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Figure 3.1.3.1 (cont’d) Immunocytochemical staining of OAW42SR clone
cytospins with LRP-56 MAb
(e)
(f)
(e) SR-LRP-Rz 4; (f) SR-LRP-AS 1
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Figure 3.1.3.1 (cont’d) Immunocytochemical staining of OAW42SR clone
cytospins with LRP-56 MAb
(g) SR-LRP -AS 2; (h) SR-LRP-AS 4
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Figure 3.1.3.1 (cont’d) Immunocytochemical staining of OAW42SR clone
cytospins with LRP-56 MAb
a)
(i) SR-LRP-AS 6; (j) SR-LRP-AS 7
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Figure 3.1.3.1 (cont’d) lmmunocytochemical staining of OAW42SR clone
cytospins with LRP-56 MAb
(k)
(1)
(k) SR-LRP-AS 8; (1) SR-pH|3 1
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Figure 3.1.3.1 (cont’d) Immunocytochemical staining of OAW42SR clone
cytospins with LRP-56 MAb
(m)
(n)
(m) SR-pHp 3; (n) SR-pH(3 6
Figure 3.1.3.1 (cont’d) Immunocytochemical staining of OAW42SR clone
cytospins with LRP-56 MAb
(o)
(o) SR-pHp 7
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Figure 3.1.3.2 Immunocytochemical staining of OAW42S clone
cytospins with LRP-56 MAb
(a) ( b )
(c) (d)
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(a) OAW42S; (b) 42S-LRP-Rz 2; (c) 42S-LRP-Rz 4; (d) 42S-LRP-RZ 7 
1- Punctate cytoplasmic LRP staining; 2- Blue nucleus counter stain
Figure 3.1.3.2 (cont’d) Immunocytochemical staining of OAW42S clone
cytospins with LRP-56 MAb
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(e) 42S-LRP-AS 1; (f) 42S-LRP-AS 10; (g) 42S-LRP-AS 13; (h) 42S-LRP-AS 14
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Figure 3.1.3.2 (cont’d) Inimunocytochemical staining of OAW42S clone
cytospins with LRP-56 MAb
Cl) 42S-3pHß 1; ß )  42S-pHß 4
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3.1.4 Assessment of results
The results up to this point illustrated that in a number of ribozyme and transfectant 
clones there was a significant reduction in LRP protein levels. This indicated that, in 
at least some of the clones, the ribozyme and antisense constructs were functioning 
effectively. However, a number of control vector (pHP) transfectants also displayed 
reductions in LRP expression. There, therefore, appears to be quite a high level of 
clonal variation arising out of the heterogeneous OAW42SR parental population. As a 
result, the reductions in LRP expression observed in the ribozyme and antisense 
transfectants may not be wholly attributed to the action of these constructs.
This clonal variation is also apparent at the level of drug resistance, where a number 
of control vector transfectants display a reduction in resistance to adriamycin and 
vinblastine/vincristine. The changes in IC50 values varied from a 10 to 20-fold 
reduction for SR-LRP-Rz 2 and SR-LRP-AS 1, to no change for the clones SR-LRP- 
Rz 1 and SR-pH(3 3. The magnitude of the changes was not as great in the OAW42S 
clones as for the OAW42SR clones. This may reflect the lower intrinsic resistance of 
the OAW42S cells.
For a number of the clones, there appears to be good correlation between the level of 
LRP expression and drug resistance. The clones SR-LRP-Rz 2 and SR-LRP-AS 1 
exhibit large reductions in LRP levels as well as IC50 values. SR-LRP-Rz 1 shows no 
reduction in LRP expression and no reduction in resistance as compared to the 
parental cells. However, some of the other clones display no obvious correlation. For 
instance, SR-LRP-Rz 4 and SR-LRP-AS 4 show large decreases in drug resistance, 
with relatively small decreases in LRP expression. SR-LRP-AS 6 exhibits no 
reduction in IC50 values, but has greatly reduced LRP expression. It is clear that there 
is a large degree of variability in these results, and that much more detailed work was 
required.
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3.1.5 Choice of OAW42SR and OAW42S clones for detailed analysis.
In order to feasibly carry out a detailed analysis of the OAW42SR and OAW42S 
transfection clones at the mRNA and protein level, it was necessary to limit the 
number of clones being investigated. Therefore a number of clones which exhibited 
varying levels o f LRP expression were chosen in order to allow the correlation of 
LRP expression and cytotoxic drug resistance. The clones chosen are shown in Table 
3.1.4.
A number of clones were chosen, as they appeared to display reduced LRP expression 
levels. From the OAW42SR clones, SR-LRP-Rz 2 and 4 and SR-LRP-AS 1, 
displayed decreased resistance to adriamycin and vinblastine and reduced levels of 
LRP expression as determined by immunocytochemical staining (Sections 3.1.2. and 
3.1.3). The clones SR-LRP-Rz 1 and SR-plip 3 were chosen as they showed an 
apparent lack of LRP down-regulation.
Similarly, 42S-LRP-Rz 2 and 42S-LRP-AS 1 were chosen from the OAW42S clones 
for their apparent decreases in LRP levels and cytotoxic drug resistance, while 42S- 
PH(3 4 was selected for its lack of LRP variation (Section 3.1.2 and 3.1.3). In addition 
to the above, the clones SR-pHP 1 and 42S-pH(3 1 were included in order to 
investigate their mechanism of LRP down-regulation and decreased drug resistance in 
the absence of an anti-LRP ribozyme or antisense molecules.
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Table 3.1.4 OAW 42SRand OAW42S clones chosen for detailed protein and 
mRNA analysis.
OAW42SR clones OAW42S clones
OAW42SR 
SR-LRP-Rz 1 
SR-LRP-Rz 2 
SR-LRP-Rz 4 
SR-LRP-AS 1 
SR-pHp 1 
SR-pHp 3
OAW42S 
42S-LRP-RZ 2 
42S-LRP-AS 1 
42S-pHP 1 
42S-pHp 4
116
3.2 Analysis of OAW42SR and OAW42S clones at the mRNA and protein level.
In order to clarify the role of LRP in multidrug resistance, it is important to show a 
clear and unambiguous decrease in the levels of LRP at the protein level, which may 
also, but not necessarily, be reflected at the mRNA level.
In this respect, LRP expression levels were determined at the mRNA level by further 
RT-PCR analysis and northern blots (Sections 2.7.5-2.7.6 and 2.8). At the protein 
level, LRP expression was examined by immunocytochemistry and 
immunoprécipitation (Sections 2.9.7 and 2.9.7). As a proposed functional assay, 
cytotoxic drug toxicity assays were carried out with a variety of classic MDR and 
non-MDR drugs (Section 2.3).
When attempting to ascertain a role for a certain protein in the functioning of a cell 
through its down-regulation, it is imperative to ensure that other proteins, which 
exhibit a similar function, are not also down-regulated. A decrease in the levels of 
related proteins could easily lead to a mis-interpretation of results. To avoid this, the 
levels o f expression of two classic MDR related genes, mdr-1 and MRP (Section 1.1), 
were examined in parallel to that of LRP. Elimination of a possible role for these 
proteins in the observed decreases in drug resistance would clarify the role of LRP in 
the observed MDR. Additionally, for the RT-PCR reactions and northern blotting, the 
levels o f gene expression were compared to those of internal controls, the house­
keeping genes P-actin and GAPDH, to ensure equal loading of samples.
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3.2.1 RT-PCR Analysis of mRNA expression levels in OAW42SR and OAW42S 
clones.
Total RNA was extracted from each clone by the method described earlier (Section
2.7.1). The primers used for detection of LRP, mdr-1, MRP, Ribozyme/Antisense and 
P-actin (short or long) expression by RT-PCR are as detailed earlier (Section 2.7.6.1).
3.2.1.1 Analysis of LRP mRNA expression by RT-PCR
The primers used to detect LRP mRNA expression yield a band of 300 bp (Section
2.7.6.1). The expression of the housekeeping gene (3-actin was used as a control, and 
the primers chosen (P-actin short 1 and 2) gave a band of 142 bp. Each RT-PCR 
reaction was repeated a minimum of three times on separate occasions with different 
RNA preparations. Total RNA extracted from SW1573-2R120 (2R120) cells was 
used as a positive control for LRP expression, as this cell line displays 
characteristically high levels of LRP mRNA (see Section 1.2). Water was used instead 
of cDNA as a negative control in the PCR reactions. The results shown in Figures
3.2.1.1.1 and 3.2.1.1.2, for OAW42SR and OAW42S clones respectively, are 
representative.
From Figure 3.2.1.1.1, it can be seen that the only SR-LRP-Rz 2 shows a significant n 
reduction in LRP mRNA expression. All the other clones displayed similar LRP 
levels to the parental OAW42SR cell line, while the positive and negative controls 
were as expected.
The OAW42S clones tested (Figure 3.2.1.1.2) failed to display decreases in LRP 
mRNA levels as determined by RT-PCR, while the positive (2R120) and negative 
(water) controls were as expected.
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Figure 3.2.1.1.1 RT-PCR Analysis of LRP expression in OAW42SR clones
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Figure 3.2.1.1.2 RT-PCR Analysis of LRP expression inOAW42S clones
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3.2.1.2 Analysis of mdr-1 mRNA expression by RT-PCR
The primers used to amplify a 157 bp fragment of mdr-1 cDNA were as described 
earlier (Section 2.7.6.1). The control gene used was P-actin, with the primers (long) 
amplifying a 383 bp fragment (Section 2.7.6.1). Once again, each RT-PCR reaction 
was repeated at least three times on separate occasions with different RNA samples 
from the OAW42SR and OAW42S clones, and the results shown in Figure 3.2.1.2.1 
and Figure 3.2.1.2.2 are representative.
The mdr-1 mRNA levels in the OAW42SR clones all appear to be equal to if not 
higher than those of the parent cells (Figure 3.2.1.2.1). The clone with the lowest 
observable levels o f mdr-1 mRNA expression, SR-LRP-Rz 2, has equal levels to that 
of the parent, indicating no significant down-regulation of mdr-1 in this clone. The 
mdr-1 negative control (2R120) shows equal p-actin expression to the OAW42SR 
clones, but no mdr-1 expression as expected.
Figure 3.2.1.2.2 shows the results of mdr-1 RT-PCR on total RNA extracted from the 
OAW42S clones. No completely satisfactory results were obtained for mdr-1 
expression in OAW42S cells. In the results shown, however, both 42S-LRP-Rz 2 and 
42S-LRP-AS 1 exhibit higher mdr-1 levels than the control vector transfectant 42S- 
pHP 1, indicating that mdr-1 expression was probably not reduced in these clones. 
Once again, the mdr-1 negative control (2R120) showed no observable mdr-1 
expression.
3.2.1.3 Analysis of MRP mRNA expression by RT-PCR
The primers designed to amplify a fragment of the MRP cDNA give a band of 203 bp 
(see section 2.7.6.1). The internal control gene is p-actin, with an amplified product of 
383 bp (long primers, see Section 2.7.6.1). Total RNA extracted from the MRP- 
positive cell line COR-L23R was used as a positive control for this RT-PCR. All 
reactions were repeated three times and the results shown (Figure 3.2.1.3.1 and 
3.2.1.3.2) are representative.
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Figure 3.2.1.2.1 RT-PCR Analysis of mdr-1 expression in OAW42SR clones
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Figure 3.2.1.2.2 RT-PCR Analysis of mdr-1 expression in OAW42S clones
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Figure 3.2.1.3.1 RT-PCR Analysis of MRP expression in OAW42SR clones
Figure 3.2.1.3.2 RT-PCR Analysis of MRP expression in OAW42S clones
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Figure 3.2.1.3.2 shows that there is no observable variation in MRP expression 
between the various OAW42SR clones and the parent cells. There is a strong band 
present for the COR-L23R sample, which is as expected. As with the OAW42SR 
clones, none of the OAW42S clones display reduced MRP levels as compared to the 
parental cells (Figure 3.2.1.3.2). The clones, in fact, all appear to have slightly higher 
levels o f MRP expression than the parental cell line.
3.2.1.4 Analysis of Ribozyme/Antisense expression by RT-PCR
The primers used to amplify fragments of the ribozyme or antisense expression 
plasmids yield bands of lengths 118 and 108 bp respectively (see Section 2.7.6.1).
No control gene was used in these PCRs due to the high cycle number and stringent 
reaction mixture formulation required to amplify the ribozyme/antisense bands. 
Figure 3.2.1.4.1 shows the results of amplification of total RNA samples from the 
OAW42SR clones. Expression of the ribozyme is clearly evident in the clones SR- 
LRP-Rz 1 and 2, while the band for SR-LRP-Rz 4 is somewhat fainter.
Expression of the antisense construct is evident in SR-LRP-AS 1, with the band being 
of smaller length than the ribozyme band as expected. The bands for the two control 
pHP plasmid transfectants confirm that the plasmid is present and functioning, while 
there is no amplification product for the untransfected OAW42SR parental cells, 
which acted as a negative control.
Figure 3.2.1.4.2 shows the ribozyme and antisense expression in the OAW42S clones. 
The ribozyme band in 42S-LRP-Rz 2 is clearly visible at 118bp. There is only a faint 
band visible for the antisense expression in 42S-LRP-AS 1. There are faint bands 
present for the control vector clones indicating plasmid presence. There appears to be 
an unexpected larger band present in the 42S-pHP 4 sample. It is not the right size to 
be a ribozyme or antisense expression band, or indeed a plasmid presence band, and 
may just be an artefact of the PCR, due to some contaminant particle. There are no 
bands present for OAW42SR or 2R120 cells,both of which acted as negative controls.
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Figure 3.2.1.4.1 RT-PCR Analysis of ribozyme/antisense expression in
OAW42SR clones
Figure 3.2.1.4.1 RT-PCR Analysis of ribozyme/antisense expression in 
OAW42SR clones
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3.2.2 Analysis of MDR-related gene expression by northern/slot blot.
Analysis of the levels of mRNA expression of LRP, mdr-1 and MRP was carried out 
by preparing either northern blots or slot blots of Poly A+ RNA isolated from each 
clone by the methods described earlier (Section 2.8). The probes used for 
hybridisation were isolated from the cDNA expression plasmids of the various genes. 
The LRP probe was a 1360 bp fragment isolated from the LHN42 plasmid. The mdr-1 
probe was a 1.38 kb fragment, while the MRP probe was 1 kb long. The probes were 
labelled with [a-32P]dCTP and hybridised overnight as described previously (Section 
2.8). An LRP Riboprobe, in which the probe is composed of [a-32P]-labelled RNA as 
opposed to DNA was also used to detect LRP. As RNA-RNA interactions are 
stronger than the corresponding RNA-DNA interactions, a higher signal strength 
would be expected. Hybridised filters were exposed with X-ray films for various time 
lengths, depending on the strength of signal. After exposure, filters were stripped of 
the probes and rehybridised with a probe for GAPDH as a housekeeping gene internal 
control. Densitometry was carried out on the bands obtained on the X-ray films in 
order to quantitatively compare the levels of mRNA expression present. The levels of 
LRP expression, as measured by densitometry, were normalised to the levels of 
GAPDH to give a comparison of the levels o f LRP mRNA expression between the 
parental cells line and the clones.
Figure 3.2.2.1 shows the results of northern blots of 1 |ig of mRNA from each clone, 
probed with LRP, (a) and GAPDH, (b). The DNA probe used for these blots afforded 
only a weak signal for LRP, even in the positive control sample from 2R120 cells. It 
is nonetheless evident that there is a virtual absence of an LRP band for the SR-LRP- 
Rz 2 clone (Figure 3.2.2.1 (a)). SR-pHp 1 also displayed a very weak signal. The 
levels o f LRP expression appeared similar for the other clones and the parent, while 
the band for the 2R120s was, as expected, the strongest.
The GAPDH control hybridisation on the same filter (Figure 3.2.2.1 (b)), shows that 
the loading of the RNA gels was uneven, probably due to inaccuracies in the 
measuring of RNA concentration. The very weak GAPDH band for SR-pHP 1, 
indicates that less RNA was loaded as compared to the other clones. This
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Figure 3.2.2.1 Northern Blot and Densitometry analysis of LRP expression
in OAW42SR clones
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Figure 3.2.2.1 (cont’d)Northern Blot and Densitometry analysis of LRP expression
in OAW42SR clones
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accounts for the lack of LRP signal for this clone. SR-LRP-Rz 1 also displays a weak 
band for GAPDH, once again indicating that a lower amount of RNA was loaded.
When the levels of LRP expression are normalised to those of GAPDH (Figure
3.2.2.1 (C)), it is evident that the clones SR-LRP-Rz 2 and SR- pH(3 1 have 
significantly reduced levels of LRP mRNA expression. SR-LRP-Rz 2 displays over a 
4-fold decrease in the levels of LRP rnRNA expression compared to the parental cells, 
and a 7-fold decrease as compared to the SR-LRP-Rz 1 clones. The clones SR-LRP- 
Rz 4 and SR-LRP-AS 1 also display reduced levels of LRP mRNA expression 
compared to the parental OAW42SR cells. However, the control plasmid transfectant 
SR-pH(3 3 also appears to have a decreased amount of LRP, while SR-LRP-Rz 1 
shows an increase in LRP levels as compared to the parent. As expected, the positive 
control, 2R120, as expected gave a strong signal for LRP expression.
The hybridisations of the probes to slot blots of 1 |ig of mRNA from the OAW42SR 
clones are shown in Figure 3.2.2.2. Once again, the signal from the DNA LRP probes 
is very weak, possibly indicating low expression levels or copy number of the mRNA 
(Figure 3.2.2.2. (a)). It is still possible to make out that the signals for most of the 
clones look fairly similar, being similar to the parent OAW42SR cells, with the 
exception of SR-LRP-Rz 2 and SR-pHp 1, which have slightly weaker signals, and 
SR-LRP-Rz 1, for which there is no visible signal. These results are in keeping with 
the previous findings, that SR-LRP-Rz 2 and SR-pHp 1 have the lowest levels of LRP 
mRNA (see above), except for that of SR-LRP-Rz 1. However, when the levels of 
LRP expression are compared with the control gene GAPDH (Figure 3.2.2.2 (C)) it is 
evident that there was far less SR-LRP-Rz 1 RNA loaded than the other clones. The 
signal for the LRP positive control SW1573-2R120 was clearly visible, being much 
stronger than the other signals even though the GAPDH signal for this sample was of 
similar strength to the OAW42SR clones.
Figure 3.2.2.2 (b) shows the results of the hybridisation of the slot blot with a mdr-1 
probe. The background over a number of the bands was quite strong, clouding 
somewhat the ability to judge the signal strength. However, the essential point is that 
none of the clones appear to exhibit lower mdr-1 expression levels than the
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OAW42SR parental cells. This is clearly evident for SR-LRP-Rz 2 , which displays 
mdr-1 levels equal to that of the other ribozyme clones and the control plasmid 
transfectant. This is especially important, as SR-LRP-Rz 2 displayed slightly 
decreased mdr-1 levels, as determined by mdr-1 RT-PCR (Section 3.2.1.2).
The same slot blot was used to examine MRP mRNA expression levels. However, the 
MRP signal strength was, as expected in OAW42SR cells, too weak to be visible by 
this method (result not shown).
Figure 3.2.2.3 (a) shows the results of probing lfj,g mRNA from the OAW42SR 
clones with a [a-32P] labelled RNA probe (Riboprobe) against LRP. The LRP band 
intensity varies between the clones, but is clearly much stronger as compared to the 
use of a DNA LRP probe (Figure 3.2.2.1 (a)). The weakest signals are present in the 
SR-LRP-Rz 2 and SR-pHp 1 samples. The band for OAW42SR was also relatively 
weak, while the signals for SR-LRP-Rz 1 and SR-pHfS 3 are very strong, even 
compared to that of the positive control sample, 2R120. These results are reflected in 
the densitometry values shown. However, probing with the internal control GAPDH 
(Figure 3.2.2.3 (b)) showed that there was unequal loading of samples. When the 
densitometry readings for the LRP bands were normalised to those for GAPDH 
(Figure 3.2.2.3 (c)), it can be seen that SR-LRP-Rz 2 exhibits a greatly reduced level 
of LRP expression as compared to the parental cells and the other clones. This points 
towards the effectiveness of the anti-LRP ribozyme in reducing cellular LRP mRNA 
levels in this clone. However, while the signals for SR-LRP-Rz 4 and SR-pH(3-l are 
also reduced compared to the OAW42SR cells, it is only a slight reduction. The signal 
for SR-LRP-AS 1 is actually slightly increased compared to the parental cells, as is 
SR-LRP-Rz 1.
Figure 3.2.2.4 (a) and (b) show the results of probing 1 \ig of mRNA from the 
OAW42S clones with a LRP riboprobe and a GAPDH probe respectively. As can be 
seen, there are no visible bands for either OAW42S or 42S-LRP-Rz 2 for either LRP 
or GAPDH. Therefore, no comparisons can be made with the rest of the clones. 
However, it can be seen from Figure 3.2.2.4 (a), that the LRP signal for 42S-LRP-AS
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Figure 3.2.2.3 Northern Blot and Densitometry analysis of LRP expression
in OAW42SR clones
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Figure 3.2.2.3 (cont’d) Northern Blot and Densitometry analysis of LRP 
expression in OAW42SR clones
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Figure 3.2.2.4 Northern Blot and Densitometry analysis of LRP expression
in OAW42S clones
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1 is much weaker than for 42S- pH^-l or 42S- pH(3-4. The signal for the positive 
control (2R120) is the strongest, as expected. This result is more significant when the 
levels of GAPDH are taken into account. Figure 3.2.2.4 (b) shows that 42S-LRP-AS 1 
has comparable amounts of GAPDH to 42S- pHP-1 and 4, indicating equal loading of 
mRNA samples.
3.2.2.1 Assessment of LRP mRNA expression
The above results show that a reduction in LRP mRNA is only evident in SR-LRP-Rz 
2, SR-LRP-Rz 4 and SR-pHp 1. The marked reduction in LRP expression in SR-LRP- 
Rz 2 demonstrates the ability of the ribozyme to inhibit LRP expression. The small 
reduction in LRP mRNA in SR-pHP 1 indicates that the clonal variation already 
observed (Section 3.1.4) is also exhibited at the transcriptional level, and is not due 
solely to post-transcriptional modifications. The absence of a reduction in LRP 
mRNA for the antisense transfectant, SR-LRP-AS 1, is not totally unexpected. 
Antisense RNA cannot elicit the action of RNase H when bound to the target RNA 
and acts predominantly through steric inhibition of the translation process (see 
Section 1.4). Therefore, reduced protein levels are not necessarily reflected by 
reduced RNA levels.
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3.2.3 Immunocytochemical Analysis of OAW42SR cytospins
Cytospins of the various clones were once again stained by immunocytochemistry 
with the LRP-56 MAb, to reconfirm the earlier findings for LRP protein expression 
levels (Section 3.1.3). Staining was repeated a minimum of three times on different 
cytospin preparations. The average level of LRP staining is indicated in Table 3.2.3. 
As can be seen, the pattern of staining is very similar to that found previously (Table
3.1.3.1). The clones exhibiting the lowest levels of LRP expression are once again 
SR-LRP-Rz 2, SR-LRP-AS 1 and SR-pHP-1. The clone SR-LRP-Rz 4 shows a slight 
reduction in staining intensity, while the other clones are all largely unchanged from 
the parental OAW42SR cells.
Cytospins of the OAW42SR clones were also stained with an mdr-1 monoclonal 
antibody isolated from mouse ascites (see section 2.9.7.1). The staining patterns are 
shown in Table 3.2.3. Photographs taken of the staining patterns for OAW42SR, SR- 
LRP-Rz 2 and SR-pHP-3 are shown in Figure 3.2.3.2 and are representative of the 
staining patterns observed. It can be seen from Table 3.2.3 and Figure 3.2.3.2 that the 
level of mdr-1 staining is similar in all of the clones and in the parental cells. 
Therefore it appears that the levels o f mdr-1 protein expression are unaltered in any of 
the clones. This reflects the findings in Section 3.2.2 of unchanged levels of mdr-1 
mRNA expression in the OAW42SR clones
Immunocytochemical staining of cytospins with a MRP antibody was not carried out 
due to the high background and associated ‘stickiness’ of the MRP antibody when 
used for immunocytochemistry.
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Table 3.2.3 Immunocytochemical Staining of OAW42SR clone cytospins
Clone LRP-56 MAb mdr-1 MAb
OAW42SR ++/+++ +++
SR-LRP-Rz 1 +++ +++
SR-LRP-Rz 2 + +++
SR-LRP-Rz 4 ++ +++
SR-LRP-AS 1 + +++
SR-pHß 1 + +++
SR-pHß 3 ++/+++ +++
SW1573-2R120 +++
136
Figure 3.2.3.2 Immunocytochemical staining of OAW42SR clone cytospins with
mdr-1 MAb
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Figure 3.2.3.2 (cont’d) Immunocytochemical staining of OAW42SR clone cytospins
with mdr-1 MAb
(c)
(C) SR-pHp 3
138
3.2.4 Analysis of LRP expression level by Immunoprécipitation and Western 
Blotting.
The LRP protein was immunoprecipitated from extracts of 107 cells from each clone 
on at least three separate occasions as described earlier (Section 2.9.6). The 
precipitates were subsequently electrophoresed on a 7.5% polyacrylamide gel, which 
was blotted onto PVDF membrane. This membrane was blocked with a bovine serum 
albumin (BSA) solution, probed with an anti-biotin antibody and developed with 
either ECL reagent or SuperSignal Ultra prior to exposure to X-ray film (see Sections 
2.9.3-2.9.5). 120kD protein size markers were run simultaneously during
electrophoresis as a size reference for the 11 OkD LRP band.
The results from two repeats of the entire procedure for both OAW42SR and 
OAW42S clones are shown in Figures 3.2.4.1 to 3.2.4.4. Densitometry analysis was 
carried out on the LRP bands to determine their intensity and allow comparison 
between expression levels. All the densitometry results are given in arbitrary values, 
and the value for each band was normalised against the background staining.
Figure 3.2.4.1 shows the results of the first repeat of the immunoprécipitation from 
OAW42SR clones. In Figure 3.2.4.1 (a), a large reduction in LRP protein expression 
can be clearly seen for both SR-LRP-Rz 2 and SR-LRP-AS 1, and to a lesser extent 
SR-LRP-Rz 4. This reduction is reflected in the densitometry analysis (Figure 3.2.4.1 
(b)), where SR-LRP-Rz 2 has a value of 36 units, while the parent OAW42SR has a 
value of 306 units, reflecting an almost 10-fold reduction in LRP protein expression 
levels. The clone SR-LRP-AS 1 exhibits an even larger reduction with a value of only 
12 units, while SR-LRP-Rz 4 is given a value of 121 units. The level of LRP 
expression appears only slightly reduced in SR-LRP-Rz 1 and largely unchanged in 
SR-pHP-1. However, SR-pHP-3 does exhibit a marked reduction in LRP expression. 
The lane containing the sample from SR-pHp-1 appears to be overloaded, judging by 
the strength of the background signal. No judgement should be passed, therefore, on 
this result alone.
139
Figure 3.2.4.1 Immunoprécipitation and Densitometry analysis of LRP expression
in OAW42SR clones : Repeat 1
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Figure 3.2.4.2 Immunoprécipitation and Densitometry analysis of LRP expression
in OAW42SR clones : Repeat 2
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Figure 3.2.4.3 Immunoprécipitation and Densitometry analysis of LRP expression
in OAW42S clones ; Repeat 1
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Figure 3.2.4.4 Immunoprécipitation and Densitometry analysis of LRP expression
in OAW42S clones : Repeat 2
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T h e  r e s u l t s  o f  a n o t h e r  r e p e a t  o f  t h e  p r o c e d u r e  a r e  s h o w n  i n  F i g u r e  3 .2 .4 .2 .  O n c e  a g a i n  
t h e r e  a r e  s i g n i f i c a n t  r e d u c t i o n s  i n  L R P  e x p r e s s i o n  l e v e l s  i n  S R - L R P - R z  2  a n d  S R -  
L R P - A S  1 a s  c o m p a r e d  t o  t h e  p a r e n t a l  c e l l s  a n d  t h e  o t h e r  c lo n e s .  H o w e v e r ,  t h e r e  a r e  
a  n u m b e r  o f  v a r i a t i o n s  f r o m  t h e  p r e v i o u s  r e s u lt .  S R - L R P - R z  1 ,  S R - L R P - R z  4  a n d  S R -  
p H P - 3  a l l  e x h i b i t  i n c r e a s e d  L R P  e x p r e s s io n  o v e r  t h e  p a r e n t a l  c e l l s ,  w h i l e  S R -  p H P - 1  
s h o w s  a  s i m i l a r  l e v e l  t o  t h e  O A W 4 2 S R s .
F i g u r e s  3 .2 .4 . 3  a n d  3 . 2 . 4 4  s h o w  t h e  r e s u l t s  f r o m  t w o  r e p e a t s  o f  t h e  
i m m u n o p r e c i p i t a t i o n / w e s t e r n  b l o t  p r o c e d u r e  o n  t h e  O A W 4 2 S  c l o n e s ,  a l o n g  w i t h  t h e  
d e n s i t o m e t r y  a n a l y s i s .  T h e  e x p e c t e d  d e c r e a s e  i n  L R P  e x p r e s s i o n  f o r  4 2 S - L R P - R z  2  
a n d  4 2 S - L R P - A S  1 ,  i s  n o t  e v id e n t .  I n  f a c t ,  t h e r e  a p p e a r s  t o  b e  a n  in c r e a s e  in  L R P  
e x p r e s s i o n  in  b o t h  o f  t h e s e  c l o n e s ,  d e s p i t e  t h e  l a c k  o f  L R P  e x p r e s s io n  a s  d e t e c t e d  b y  
i m m u n o c y t o c h e m i s t r y  ( s e c t i o n  3 . 1 . 3 ) .  T h e r e  i s  n o  b a n d  e v i d e n t  f o r  4 2 S -  p H P - 1 .  T h i s  
i s  r e f l e c t e d  i n  t h e  s e c o n d  r e p e a t  o f  t h is  p r o c e d u r e  ( F i g u r e  3 .2 .4 . 4 ) ,  w h e r e  t h e r e  i s  o n c e  
a g a i n  n o  b a n d  f o r  4 2 S -  p H P - 1 .  H o w e v e r ,  t h e  l e v e l s  o f  L R P  e x p r e s s io n  i n  t h e  o t h e r  
c l o n e s  a n d  t h e  p a r e n t  c e l l s  a l l  a p p e a r  s im i la r ,  p o s s i b l y  i n d i c a t i n g  u n e q u a l  p r o t e i n  
l o a d i n g  in  F i g u r e  3 .2 .4 .3 .
3.2.5 Analysis of MDR1 and MRP protein levels by Western Blotting
C e l l  e x t r a c t s  w e r e  m a d e  f r o m  e a c h  o f  t h e  O A W 4 2 S R  a n d  O A W 4 2 S  c l o n e s  a n d  
e le c t r o p h o r e s e d  o n  a  7 . 5 %  p o l y a c r y l a m i d e  g e l ,  w h i c h  w a s  b l o t t e d  o n t o  P V D F  
m e m b r a n e .  T h i s  m e m b r a n e  w a s  b l o c k e d  w i t h  a  5 %  m a r v e l  ( m i l k  p o w d e r )  s o lu t i o n  
a n d  p r o b e d  w i t h  a n  a n t i - m d r - 1  o r  a n t i - M R P  p r i m a r y  a n t ib o d y .  S u b s e q u e n t l y  t h e  
m e m b r a n e  w a s  e x p o s e d  t o  a  s e c o n d a r y  a n t i b o d y  a n d  d e v e l o p e d  w i t h  e i t h e r  E C L  
r e a g e n t  o r  S u p e r S i g n a l  U l t r a  p r i o r  t o  e x p o s u r e  t o  X - r a y  f i l m  ( s e e  S e c t i o n s  2 .9 . 3 -  
2 .9 . 5 ) .  P r o t e i n  s i z e  m a r k e r s  w e r e  r u n  s i m u l t a n e o u s ly  d u r i n g  e le c t r o p h o r e s i s  a s  a  s i z e  
r e f e r e n c e  f o r  t h e  m d r - 1  a n d  M R P  b a n d s .
F i g u r e s  3 . 2 . 5 . 1  a n d  3 . 2 . 5 . 2  s h o w  t h e  r e s u l t s  o f  r e p r e s e n t a t i v e  w e s t e r n  b l o t s  o f  
O A W 4 2 S R  a n d  O A W 4 2 S  c e l l  e x t r a c t s  r e s p e c t i v e l y ,  w i t h  t h e  m d r l  M A b .  A s  c a n  b e  
s e e n  f r o m  F i g u r e  3 . 2 . 5 . 1 ,  t h e r e  a r e  s o m e  v a r i a t i o n s  in  t h e  l e v e l s  o f  m d r - 1
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Figure 3.2.5.1 Western Blot and Densitometry analysis of mdr-1 expression
in OAW42SR clones
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Figure 3.2.5.2 Western Blot and Densitometry analysis of mdr-1 expression
in OAW42S clones
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Figure 3.2.6.1 Western Blot and Densitometry analysis of MRP expression
in OAW42SR clones
(a)
M R P
190kD
< Z JNT
%o
&
< N TT
C/5
fH
& £ £ S
j J - a
pi*
C O
di
C O
pis
0 3
05
G O
Pico
BU
in
X
N
io
u
(b) Densitometry
1 0 3
otU)
I
o
147
Figure 3.2.6.2 Western Blot and Densitometry analysis of MRP expression
in OAW42S clones
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e x p r e s s io n ,  a s  r e f l e c t e d  in  t h e  d e n s i t o m e t r y  v a l u e s .  H o w e v e r ,  o n l y  t h e  S R - L R P - R z  1 
a n d  S R - L R P - A S  1 c l o n e s  a p p e a r  t o  h a v e  d e c r e a s e d  M D R - 1  e x p r e s s i o n  a s  c o m p a r e d  
t o  p a r e n t a l  O A W 4 2 S R s .  T h e  c l o n e  S R - L R P - R z  2 , w h i c h  a p p e a r e d  t o  h a v e  s l i g h t l y  
r e d u c e d  l e v e l s  o f  m d r - 1  m R N A  a s  d e t e r m in e d  b y  R T - P C R  ( S e c t i o n  3 . 2 . 1 . 2 ) ,  a p p e a r s  
t o  h a v e  s l i g h t l y  g r e a t e r  M D R - 1  p r o t e i n  e x p r e s s i o n  t h a n  t h e  O A W 4 2 S R s .  T h e s e  r e s u l t s  
r e f l e c t  t h e  f i n d i n g s  f r o m  i m m u n o c y t o c h e m i s t r y  ( S e c t i o n  3 . 2 . 3 )  w h e r e  n o  s i g n i f i c a n t  
d e c r e a s e  i n  M D R - 1  p r o t e i n  l e v e l s  w e r e  o b s e r v e d  i n  t h e  c l o n e s  a s  c o m p a r e d  t o  t h e  
p a r e n t a l  c e l l s .  T h e  p o s i t i v e  c o n t r o l  c e l l  l i n e  D L K P - A  w h i c h  e x p r e s s e s  h i g h  l e v e l s  o f  
m d r - 1 ,  g a v e  a  v e r y  s t r o n g  s i g n a l  a s  e x p e c t e d .
S i m i l a r l y  f o r  t h e  O A W 4 2 S  c l o n e s  ( F i g u r e  3 .2 .5 .2 ) ,  t h e r e  a p p e a r s  t o  b e  n o  s i g n i f i c a n t  
d i f f e r e n c e s  i n  t h e  l e v e l s  o f  M D R 1  e x p r e s s i o n  b e t w e e n  t h e  c l o n e s  a n d  t h e  p a r e n t a l  
O A W 4 2 S  c e l ls .
T h e  r e s u l t s  f o r  t h e  w e s t e r n  b l o t  w i t h  t h e  M R P  M A b  f o r  O A W 4 2 S R  a n d  O A W 4 2 S  
c l o n e s  a r e  s h o w n  in  F i g u r e  3 . 2 . 5 . 5  a n d  3 . 2 . 5 . 6  r e s p e c t i v e l y .  F r o m  F i g u r e  3 . 2 .5 .5 ,  i t  
c a n  b e  s e e n  t h a t  t h e r e  a r e  o n l y  s l i g h t  d e c r e a s e s  i n  M R P  e x p r e s s i o n  l e v e l s  f o r  S R - L R P -  
A S  1 a n d  S R - p H P  3 , a s  c o m p a r e d  t o  t h e  p a r e n t a l  c e l l s ,  w h i l e  t h e r e  is  a  s l i g h t  in c r e a s e  
i n  t h e  c l o n e s  S R - L R P - R z  1 a n d  S R - p H P  1 . M R P  e x p r e s s io n  a p p e a r s  u n c h a n g e d  in  
S R - L R P - R z  2  a n d  4 . T h e  M R P - p o s i t i v e  c o n t r o l  c e l l  l i n e  C O R - L 2 3 R ,  g a v e  a n  i n t e n s e  
b a n d  a s  e x p e c t e d .
F i g u r e  3 . 2 . 5 . 6 ,  s h o w s  t h a t  a l l  o f  t h e  O A W 4 2 S  c l o n e s  h a v e  a  s l i g h t l y  h i g h e r  l e v e l  o f  
M R P  e x p r e s s i o n  c o m p a r e d  t o  t h e  u n t r a n s f e c t e d  p a r e n t s ,  w i t h  4 2 S - L R P - R z  2  
e x h i b i t i n g  t h e  h i g h e s t  l e v e l s .
3.2.6 Assessment of LRP, Pgp and M RP protein expression levels
T h e  a b o v e  r e s u l t s  c l e a r l y  d e m o n s t r a t e  t h a t  t h e  c lo n e s  S R - L R P - R z  2  a n d  S R - L R P - A S  
1 h a v e  d r a m a t i c a l l y  r e d u c e d  l e v e l s  o f  L R P  p r o t e in  e x p r e s s io n .  T h i s  h i g h l i g h t s  t h e  
e f f i c a c y  o f  t h e  r i b o z y m e  a n d  a n t i s e n s e  c o n s t r u c t s  in  i n h i b i t i n g  L R P  e x p r e s s io n .  I n  t h e  
f i r s t  r e p e a t  o f  t h e  i m m u n o p r é c i p i t a t i o n  p r o c e d u r e ,  t h e  c lo n e s  S R - L R P - R z  4  a n d  S R -
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p H P - 3  e x h i b i t e d  r e d u c t i o n s  i n  L R P  e x p r e s s io n ,  a s  c o m p a r e d  t o  t h e  p a r e n t a l  c e l l s .  I n  
t h e  s e c o n d  r e p e a t ,  h o w e v e r ,  n o  r e d u c t i o n  i s  e v i d e n t .  T h e  e x p r e s s i o n  l e v e l  o f  L R P  in  
t h e  O A W 4 2 S R  p a r e n t a l  c e l l s  a p p e a r s  t o  b e  r e d u c e d  i n  r e la t i o n  t o  m o s t  o f  t h e  c l o n e s  in  
t h i s  s e c o n d  r e p e a t .  I t  h a s  b e e n  n o t e d  t h a t  l o w  p a s s a g e  n u m b e r s  ( p a s s a g e  8 6 )  o f  
O A W 4 2 S R  c e l l s  c o n t a i n  l o w  l e v e l s  o f  L R P ,  a n d  t h a t  w i t h  i n c r e a s i n g  p a s s a g e  n u m b e r  
( o v e r  p a s s a g e  9 2 )  a n  i n c r e a s e  in  L R P  e x p r e s s i o n  l e v e l s  i s  p a r a l l e l e d  b y  a n  i n c r e a s e  
d r u g - r e s i s t a n c e  ( M o r a n  et al., 1997). I t  h a s  a l s o  b e e n  o b s e r v e d  in  t h i s  l a b o r a t o r y  ( d a t a  
n o t  s h o w n )  t h a t  w h e n  t h e  O A W 4 2 S R  p o p u l a t i o n  i s  p a s s a g e d  a  c e r t a i n  n u m b e r  o f  
t i m e s  ( 1 1 0 - 1 1 5 ) ,  t h e  L R P  e x p r e s s io n  l e v e l s  a p p e a r  t o  d e c r e a s e  g r a d u a l l y .  I t  m a y  b e  
t h a t ,  a b o v e  a  c e r t a i n  n u m b e r  o f  p a s s a g e s ,  t h e  c e l l s  a r e  o n c e  a g a i n  r e v e r t i n g  t o  t h e  
o r i g i n a l  l o w  l e v e l  o f  L R P  e x p r e s s io n .  T h e  O A W 4 2 S R  c e l l s  u s e d  i n  t h e  s e c o n d  r e p e a t  
o f  t h e  i m m u n o p r é c i p i t a t i o n  p r o c e d u r e  w e r e  a t  p a s s a g e  n u m b e r  1 1 2 ,  a n d  m a y  h a v e  
b e e n  e x h i b i t i n g  t h i s  l o w e r i n g  o f  L R P  l e v e l s .  T h i s  s h o u ld  b e  t a k e n  i n t o  a c c o u n t  w h e n  
c o m p a r i n g  t h e  s t r e n g t h  o f  L R P  e x p r e s s io n .  T h e  c l o n e  S R - L R P - R z  1 e x h i b i t e d  l i t t l e  
c h a n g e  in  L R P  e x p r e s s i o n  c o m p a r e d  t o  t h e  p a r e n t a l  c e l l s ,  a s  m e a s u r e d  b y  
i m m u n o c y t o c h e m i s t r y  a n d  t h e  f i r s t  r e p e a t  o f  t h e  im m u n o p r é c ip i t a t io n .  T h i s  c l o n e  
w a s ,  t h e r e f o r e ,  u s e d  a s  a  s t a n d a r d  a g a i n s t  w h i c h  t o  c o m p a r e  L R P  e x p r e s s i o n  i n  t h e  
s e c o n d  r e p e a t  o f  t h e  i m m u n o p r é c i p i t a t i o n .  I n  c o m p a r i s o n  t o  S R - L R P - R z  1 ,  b o t h  S R -  
L R P - R z  4  a n d  S R - p H P  3 m a i n t a i n  a  r e d u c t i o n  in  L R P  e x p r e s s io n .  S R - p H P  1 a ls o  
e x h i b i t s  a  r e d u c t i o n  in  L R P  l e v e l s  i n  c o m p a r i s o n  t o  S R - L R P - R z  1 . T h e r e  w a s  l i t t le  
v a r i a t i o n  i n  t h e  L R P  e x p r e s s i o n  i n  t h e  O A W 4 2 S  c lo n e s .
T h e  d e c r e a s e d  L R P  e x p r e s s i o n  i n  t h e  c o n t r o l  v e c t o r  c lo n e s ,  o n c e  a g a i n  i l l u s t r a t e s  t h e  
c l o n a l  v a r i a t i o n  t h a t  e x i s t s  w i t h i n  t h e  O A W 4 2 S R  p o p u la t io n .  I t  i s  t h e r e f o r e  p o s s i b l e  
t h a t  s o m e  o f  t h e  r e d u c t i o n s  i n  L R P  s e e n  f o r  S R - L R P - R z  2  a n d  S R - L R P - A S  1 ,  a n d  
i n d e e d  a l l  t h e  o t h e r  c l o n e s ,  a r e  i n h e r e n t  in  t h e  c e l l s  a n d  a r e  n o t  c a u s e d  b y  r i b o z y m e  o r  
a n t i s e n s e  e x p r e s s i o n .  A l t h o u g h  t h is  c l o n a l  v a r i a t i o n  m a s k s ,  s o m e w h a t ,  t h e  e f f i c a c y  o f  
t h e  r i b o z y m e  a n d  a n t i s e n s e ,  i t  n o n e t h e le s s  p r o v i d e s  a  n u m b e r  o f  c l o n e s  w i t h  v a r y i n g  
l e v e l s  o f  L R P  e x p r e s s i o n  w i t h  w h i c h  t o  c o r r e l a t e  d r u g  r e s i s t a n c e .  T h e  c l o n a l  v a r ia t i o n  
i s  a l s o  h i g h l i g h t e d  b y  t h e  s m a l l  v a r ia t i o n s  i n  P g p  a n d  M R P  e x p r e s s i o n  b e t w e e n  t h e  
c l o n e s .
T h e  l e v e l  o f  L R P  p r o t e i n  e x p r e s s i o n  in  t h e  O A W 4 2 S R  r i b o z y m e  t r a n s f e c t a n t s  a p p e a r s
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t o  c o r r e l a t e  q u i t e  w e l l  w i t h  t h e  l e v e l s  o f  L R P  m R N A  a s  m e a s u r e d  b y  n o r t h e r n  b l o t  
( S e c t i o n  3 .2 .2 ) .  S R - L R P - R z  1 e x h ib i t s  h i g h  L R P  m R N A  a n d  p r o t e i n  l e v e l s  w h i l e  S R -  
L R P - R z  2  e x h i b i t s  l o w  m R N A  a n d  p r o t e i n  e x p r e s s io n .  S R - L R P - R z  4  d i s p l a y e d  b o t h  
m R N A  a n d  p r o t e i n  l e v e l s  t h a t  w e r e  i n t e r m e d i a r y  b e t w e e n  t h e  a b o v e  t w o .  S R - p H p  3 
d i s p l a y s  s i m i l a r  L R P  m R N A  a n d  p r o t e i n  l e v e l s  t o  S R - L R P - R z  4 , w h i l e  S R - p H P  1 
e x h i b i t  s i m i l a r  p r o t e i n  b u t  s l i g h t l y  l o w e r  m R N A  l e v e l s .  T h e  o n l y  c l o n e  f o r  w h i c h  L R P  
m R N A  a n d  p r o t e i n  l e v e l s  d o  n o t  c o r r e l a t e  i s  S R - L R P - A S  1 . T h i s  c l o n e  e x h ib i t s  
m i n i m a l  r e d u c t i o n  i n  L R P  m R N A  b u t  a n  a l m o s t  t o t a l  e l i m in a t i o n  o f  p r o t e i n  
e x p r e s s i o n .  T h i s  i s  t h o u g h t  t o  b e  d u e  t o  t h e  f a c t  t h a t  a n t is e n s e  R N A  f u n c t i o n s  m a i n l y  
t h r o u g h  s t e r ic  i n h i b i t i o n  o f  t r a n s la t io n  r a t h e r  t h a n  c l e a v a g e  o f  t a r g e t  R N A .
3.2.7 Analysis of Drug toxicity profile of LRP protein.
3.2.7.1 Comparison of IC50 values for SR-LRP-Rz 1 and SR-LRP-Rz 2
I n  a n  a t t e m p t  t o  e s t a b l i s h  w h i c h ,  i f  a n y ,  c y t o t o x i c  d r u g s  h a v e  t h e i r  e f f i c a c y  a l t e r e d  b y  
L R P  e x p r e s s io n ,  a  r a n g e  o f  d r u g s  w a s  t e s t e d  o n  t h e  c l o n e s  S R - L R P - R z  1 a n d  S R -  
L R P - R z  2 . I t  a p p e a r s  f r o m  r e s u l t s  s h o w n  a b o v e  ( S e c t i o n s  3 . 2 . 1 - 3 . 2  5 )  t h a t  L R P  
e x p r e s s i o n  i s  d o w n - r e g u l a t e d  a t  b o t h  t h e  R N A  a n d  p r o t e i n  l e v e l  i n  S R - L R P - R z  2 , 
w h i l e  b e i n g  l a r g e l y  u n a l t e r e d  i n  S R - L R P - R z  1 . I n  a d d it io n ,  t h e  r e s u l t s  a l s o  
d e m o n s t r a t e  o n l y  s l i g h t  d i f f e r e n c e s  in  m d r - 1  a n d  M R P  e x p r e s s io n .  T h e s e  t w o  c l o n e s  
w e r e  t h e r e f o r e  d e e m e d  a p p r o p r ia t e  f o r  e x a m i n a t i o n  o f  a n y  r o l e  L R P  m i g h t  p l a y  in  
d r u g  r e s i s t a n c e .
T a b l e  3 . 2 . 7 . 1  s h o w s  t h e  I C 5 0  v a l u e s  o f  a  r a n g e  o f  d r u g s ,  a v e r a g e d  o v e r  t h r e e  r e p e a t s ,  
f o r  t h e  t w o  c l o n e s .  F r o m  t h is ,  i t  c a n  b e  s e e n  t h a t  t h e  d r u g s  t o  w h i c h  S R - L R P - R z  1 
d i s p l a y s  a  h i g h e r  l e v e l  o f  r e s i s t a n c e  t o  a r e :  a d r i a m y c i n ,  v i n c r i s t i n e ,  V P - 1 6 ,  t a x o t e r e ,  
d a u n o r u b i c i n ,  t a x o l  a n d  e p ir u b ic in .  T h e  f o l d  d i f f e r e n c e s  i n  r e s i s t a n c e  b e t w e e n  t h e  t w o  
c l o n e s  v a r y  f r o m  a  m a x i m u m  o f  3 7 - f o l d  f o r  V i n c r i s t i n e ,  t o  a  m i n im u m  o f  o v e r  3 - f o l d  
f o r  V P - 1 6 .  T h e r e  i s  n o  s i g n i f i c a n t  d i f f e r e n c e  in  t h e  I C 5 0  v a l u e s  o f  e i t h e r  c l o n e  f o r  5 -  
F l u o r o - U r a c i l ,  M e l p h a l a n  a n d  c a r b o p la t in .  I t  t h e r e f o r e  a p p e a r s  t h a t  5 - F l u o r o - U r a c i l ,  
M e l p h a l a n  a n d  c a r b o p l a t i n  a r e  l a r g e l y  u n a f f e c t e d  b y  t h e  e x p r e s s io n  o f  L R P .
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Table 3.2.7.1 Toxicity Assay drug IC50 values (|ig/ml) for SR-LRP-Rzl and SR- 
LRP-Rz2
DRUG SR-LRP-Rjz 1 SR-LRP-Rz 2 F O L D  C H A N G E  I N  
R E S I S T A N C E
A D R I A M Y C I N 0 .1 6 5  ± 0 . 0 0 7 0 .0 1 6 5  ± 0 . 0 0 0 7 1 0
V I N C R I S T I N E 0 . 1 6  ± 0 . 0 0 .0 0 4 2 5  ±  0 .0 0 0 0 7 3 7 . 6 9 7
V P - 1 6 0 .7 2 9  ± 0 . 2 3 8 0 .1 9 8  ± 0 . 0 5 5 3 .6 8 2
5 - F L U O R O - U R A C I L 1 . 6 4 7  ± 0 . 2 6 1 1 . 5 6  ± 0 . 2 9 7 1 .0 5 6
T A X O T E R E 0 .0 0 1 6 9  ± 0 .0 0 0 2 3 0 .0 0 0 0 6 5  ±  0 .0 2 6 .0 0 0
M E L P H A L A N 2 . 2 3 7  ±  0 .0 8 7 1 .8 6 5  ± 0 . 4 5 7 1 . 1 9 9
C A R B O P L A T I N 6 .0 6 7  ± 0 . 9 1 1 6 . 5 1 2  ± 2 . 1 5 7 0 .9 3 2
D A U N O R U B I C I N 0 .1 0 0  ± 0 . 0 1 2 0 .0 1 0 9 5  ± 0 . 0 0 1 8 4 9 . 1 3 2
T A X O L 0 .0 2 0 5  ± 0 . 0 0 5 2 0 .0 0 1 6 7  ±  0 .0 0 0 7 9 1 2 . 2 7 5
E P 1 R U B I C I N 0 . 1 1 1  ± 0 . 0 2 8 0 .0 0 7 6 8  ± 0 .0 0 0 3 1 1 4 . 4 3 5
Values are given in ng/ml and are averaged over three repeats.
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3.2.7.2 Drug Toxicity profiles for OAW42SR and OAW42S clones.
A s  a n  a d d i t i o n a l  s t u d y ,  a l l  t h e  O A W 4 2 S R  a n d  O A W 4 2 S  c l o n e s ,  w e r e  t r e a t e d  w i t h  a  
r a n g e  o f  d r u g s ,  t o  t e s t  i f  t h e  l e v e l  o f  d r u g  r e s i s t a n c e  c o r r e la t e d  w i t h  L R P  e x p r e s s i o n ,  
a n d  i f  t h e  p r o f i l e  o f  d r u g s  a f f e c t e d  b y  L R P  w a s  t h e  s a m e  a s  s h o w n  i n  T a b l e  3 . 2 . 7 . 1 .  
T a b l e s  3 . 2 . 7 . 2  ( a )  a n d  3 .2 .7 .3  ( a )  s h o w  t h e  I C 5 0  v a l u e s  a n d  o f  v a r i o u s  c l a s s i c a l  M D R  
a n d  n o n - M D R  d r u g s  f o r  t h e  O A W 4 2 S R  a n d  O A W 4 2 S  c l o n e s  r e s p e c t i v e l y .  T a b l e s  
22 .1 .2  ( b )  a n d  3 .2 . 7 . 3  ( b )  g i v e  t h e  f o l d  c h a n g e s  in  I C 5 0  v a l u e s  b e t w e e n  t h e  p a r e n t a l  
c e l l s ,  g i v e n  a  v a l u e  o f  1 , a n d  t h e  c l o n e s .  G r a p h s  3 . 2 . 7 . 1  t o  3 . 2 . 7 . 7  a ls o  i l l u s t r a t e  t h e s e  
r e s u l t s .
A s  c a n  b e  s e e n  f r o m  T a b l e s  3 . 2 . 7 . 2  ( a )  a n d  ( b )  a n d  G r a p h s  3 . 2 . 7 . 1  t o  3 . 2 . 7 . 7 ,  t h e  
p a t t e r n  o f  d r u g  r e s i s t a n c e  a m o n g  t h e  O A W 4 2 S R  c l o n e s  w a s  v e r y  s i m i la r  t o  t h e  o n e  
f o u n d  p r e v i o u s l y  f o r  a d r i a m y c i n  a n d  v in b l a s t i n e / v i n c r i s t i n e  a lo n e .  T h e  S R - L R P - R z  2 , 
S R - L R P - R z  4  a n d  S R - L R P - A S  1 a ll  s h o w e d  s i g n i f i c a n t  d e c r e a s e s  i n  I C 5 0  v a l u e s  
c o m p a r e d  t o  t h e  p a r e n t  c e l ls .  H o w e v e r ,  t h e  r e s i s t a n c e  o f  t h e  S R - p H P  3 c l o n e ,  w h i c h  
h a d  b e e n  i n c l u d e d  i n  t h e  a s s a y s  a s  a  c o n t r o l  c l o n e ,  w i t h  a p p a r e n t l y  u n a l t e r e d  l e v e l s  o f  
L R P  e x p r e s s i o n ,  d e c r e a s e d  d r a m a t i c a l l y ,  d o w n  t o  t h e  l e v e l  o f  t h e  S R - L R P - R z  2  a n d  
S R - L R P - A S  1 c l o n e s .  T h i s  is  a n  u n u s u a l  r e s u l t ,  a s  i t  p r e v i o u s l y  h a d  d i s p l a y e d  a  
r e s i s t a n c e  p r o f i l e  s i m i l a r  t o  t h a t  o f  t h e  p a r e n t a l  c e l l s  a n d  S R - L R P - R z  1 . T h e  o t h e r  
c l o n e s  w e r e  l a r g e l y  i n v a r i a n t  in  t h e i r  r e s i s t a n c e  t o  a d r i a m y c i n  a n d  v i n c r i s t i n e .
O n c e  a g a i n ,  t h e r e  a p p e a r s  t o  b e  v e r y  l i t t l e  d i f f e r e n c e  b e t w e e n  t h e  r e s i s t a n c e  o f  t h e  
c l o n e s  a n d  t h e  p a r e n t a l  c e l l s  t o  5 - f l u o r o - u r a c i l ,  c a r b o p l a t i n  a n d  m e l p h a l a n .  W h i l e  o n l y  
S R - L R P - R z  2  a n d  4  d i s p l a y  s l i g h t l y  r e d u c e d  l e v e l s  o f  r e s i s t a n c e  t o  V P  1 6  a s  c o m p a r e d  
t o  t h e  p a r e n t a l  c e l l s ,  ( T a b l e s  3 . 2 . 7 . 2 ( a )  a n d  ( b ) ) ,  a l l  o f  t h e  c lo n e s  d i s p l a y  a  r e d u c t i o n  in  
V P  1 6  r e s i s t a n c e  i n  r e l a t i o n  t o  t h a t  o f  S R - L R P - R z  1 .
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Table 3.2.1.2 (a) IC50 values (ng/ml) for several classical MDR and non-MDR 
drugs, averaged over three repeats, for the OAW42SR parent and clones.
DRUG OAW42SR SR-LRP-
Rzl
SR-LRP-
Rz2
SR-LRP-
Rz4
SR-LRP-
AS1
SR-pHpi SR-pH(33
ADRIAMYCIN 0.256 0.1496 0.0234 0.0247 0.0246 0.0305 0.028
±0.0 ± 0.0006 ± 0.0006 ±0,0012 ±0.0061 ±0.012 ± 0.004
VINCRISTINE 0.147 0.145 0.0021 0.0029 0.0033 0.0017 0.0043
±0.0 ± 0.006 ± 0.0002 ± 0.0004 ± 0.0009 ± 0.0004 ±0.0011
VP-16 0.128 0.303 0.103 0.083 0.159 0.141 0.107
± 0,02 ±0.168 ±0.055 ± 0.024 ± 0.087 ±0.093 ± 0.041
5-FLUORO- 1.464 1.220 1.609 1.524 1.756 0.954 1.146
URACIL ±0.0 ± 0.444 ±0.213 ±0.595 ± 0.308 ±0.144 ±0.689
MELPHALAN 0.51 1.731 1.245 0.565 0.836 0.476 0.586
± 0.038 ±0.0 ±0.65 ± 0.244 ±0.595 ± 0.433 ±0.384
TAXOL 0.064 0.062 0.00090 0.0010 0.00094 0.00129 0.00115
±0.0 ±0.0 ± 0.0001 ± 0.0003 ± 0.00007 ± 0.00061 ± 0.00005
CARBOPLATIN 2.88 4.165 4.66 4.692 4.877 2.284 3.44
±0.0 ± 0.997 ± 1.98 ± 1.041 ± 0.748 ± 1.097 ± 1.194
Table 3.2.1.2 (b) Fold changes in IC50 values between OAW42SR parental cells 
and clones.
DRUG OAW42SR SR-LRP-
Rzl
SR-LRP-
Rz2
SR-LRP-
Rz4
SR-LRP-
AS1
SR-pHpi SR-pHp3
ADRIAMYCIN 1 -1.71 -10.94 -10.36 -10.41 -8.39 -9.14
VINCRISTINE 1 -1.01 -70.00 -50.68 -44.55 -86.47 -34.18
VP-16 1 +2.37 -1.24 -1.54 +1.24 +1.10 -1.20
5-FLUORO-
IRAC1L
1 -1.20 +1.10 +1.04 +1.20 -1.53 -1.28
MELPHALAN 1 +3.39 +2.24 +1.11 +1.63 -1.07 +1.15
TAXOL 1 -1.03 -71.11 -64.00 -68.09 -49.61 -55.65
CARBOPLATIN 1 +1.45 +1.62 +1.63 +1.69 -1.26 +1.19
- indicates a fold decrease in IC50 value 
+ indicates a fold increase in IC50 value
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Table 3.2.7.3 (a) IC50 values (jig/ml) for several classical MDR and non-MDR 
drugs, averaged over three repeats, for the OAW42S parental cell line and 
clones.
DRUG OAW42S 42S-LRP-
Rz2
42S-LRP-
AS1
42S-pHpl 42S-pHp4
ADRIAMYCIN 0.0741 0.0657 0.02345 0.0198 0.175
±0.031 ±0.0289 ±0.0021 ±0.0001 ± 0.0082
VINCRISTINE 0.00583 0.00395 0.00304 0.00254 0.003475
+ 0.00181 ± 0.00085 ± 0.0003 ± 0.00068 ±0.00177
VP-16 0.363 0.207 0.158 0.213 0.147
±0.177 ±0.102 ±0.030 ±0.126 ±0.04
5-FLUORO- 1.866 1.03 1.921 1.424 0.559
URACIL ±0.605 ±0.587 ±0.347 ±0.748 ± 0.083
MELPHALAN 2.117 0.873 0.709 1.004 0.762
±0.270 ±0.449 ±0.250 ± 0.506 ±0.537
TAXOL 0.00279 0.00211 0.00168 0.00154 0.00215
±0.00121 ± 0.0003 ± 0.00055 ± 0.00096 ±0.00123
CARBOPLATIN 5.259 5.404 4.869 5.121 4.428
±2.77 ±2.39 ±3.554 ±2.818 ±3.482
Table 3.2.7.3 (b) Fold changes in IC50 values between OAW42S parental cells 
and clones.
DRUG OAW42S 42S-LRP-
Rz2
42S-LRP-
AS1
42S-pHpi 42S-pHp4
ADRIAMYCIN 1 -1.13 -3.15 -3.74 +2.36
VINCRISTINE 1 -1.48 -1.92 -2.30 -1.68
VP-16 1 -1.75 -2.30 -1.70 -2.47
5-FLUORO-
LRACIL
1 -1.81 +1.03 -1.31 -3.12
MELPHALAN 1 -2.42 -2.99 -2.11 -2.78
TAXOL 1 -1.32 -1.66 -1.81 -1.30
CARBOPLATIN 1 +1.03 -1.08 -1.03 -1.19
- indicates a fold decrease in IC50 value 
+ indicates a fold increase in IC50 value
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Graph 3.2.7.1 Adriamycin ICS0 values (jug/ml) for OAW42SR and OAW42S
clones
°F
G raph 3.2.7.2 Vincristine IC50 values (ng/ml) for OAW42SR and OAW42S 
clones
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Graph 3.2.7.3 VP-16 IC50 values (fj.g/ml) for OAW42SR and OAW42S clones
G raph 3,2.7.4 5-Fluoro-Uracil IC50 values (fxg/ml) for OAW42SR and OAW42S 
clones
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Graph 3.2.7.5 Melphalan IC50 values (|j,g/ml) for OAW42SR and OAW42S clones
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Graph 3.2.7.7 Carboplatin ICS0 values (ng/ml) for OAW42SR and OAW42S
clones
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F r o m  T a b l e s  3 . 2 .7 .3  ( a )  a n d  ( b ) ,  a n d  F i g u r e  3 . 2 . 7 . 1  t o  3 . 2 . 7 . 7 ,  i t  c a n  b e  s e e n  t h a t  t h e r e  
i s  v e r y  l i t t l e  v a r i a t i o n  i n  t h e  I C 5 0  v a l u e s  b e t w e e n  a n y  o f  t h e  c l o n e s  a n d  t h e  p a r e n t a l  
c e l l s .  4 2 S - L R P - A S 1  a n d  4 2 S - p H | 3  1 s h o w  a  3 - f o l d  r e d u c t i o n  in  t h e  r e s i s t a n c e  t o  
A d r i a m y c i n ,  b u t  o n l y  a  2 - f o l d  r e d u c t i o n  i n  t h e  r e s i s t a n c e  t o  V i n c r i s t i n e .  A l l  t h e  c l o n e s  
s h o w  g r e a t e r  t h a n  a  2 - f o l d  r e d u c t i o n  i n  t h e  r e s i s t a n c e  t o  M e l p h a l a n .
3.2.8 Assessment of drug toxicity assays
A l l  o f  t h e  O A W 4 2 S R  c l o n e s ,  w i t h  t h e  s o l e  e x c e p t i o n  o f  S R - L R P - R z  1 ,  e x h i b i t  a  
r e d u c t i o n  in  r e s i s t a n c e  t o  a d r i a m y c i n  a n d  v i n c r i s t i n e .  T h e  r e d u c t i o n s  i n  d r u g  
r e s i s t a n c e  a r e  n o t  c o n f i n e d  t o  t h e  r i b o z y m e  a n d  a n t i s e n s e  t r a n s f e c t e d  c e l l s ,  w i t h  t h e  
p H P  t r a n s f e c t a n t s  e x h i b i t i n g  s i m i l a r  I C 50 v a l u e s .  T h e  c l o n e  S R - p H p  3 e x h ib i t s  a  m u c h  
r e d u c e d  l e v e l  o f  d r u g  r e s i s t a n c e  a s  c o m p a r e d  w i t h  e a r l ie r  t o x i c i t y  a s s a y s  ( S e c t i o n  
3 . 1 . 2 ) .  T h e  d r u g s  t o  w h i c h  a  n u m b e r  o f  c l o n e s  s h o w  r e d u c e d  r e s i s t a n c e ,  f i t  t h e  c l a s s i c  
p r o f i l e  o f  d r u g s  t r a n s p o r t e d  b y  P g p .  T h e r e  i s  l i t t l e  v a r i a t i o n  in  t h e  I C 5 0  v a l u e s  
d i s p l a y e d  b y  t h e  O A W 4 2 S  c l o n e s ,  a s  c o m p a r e d  t o  t h e  p a r e n t a l  c e l l s .
3.2.9 Correlation between LRP expression and drug resistance
T h e  a b o v e  r e s u l t s  h a v e  s h o w n  a  la r g e  r e d u c t i o n  i n  L R P  m R N A  f o r  S R - L R P - R z  2 , 
w i t h  a  s m a l l e r  r e d u c t i o n  e v i d e n t  f o r  S R - L R P - R z  4  a n d  S R - p H P  1. H o w e v e r ,  a t  t h e  
p r o t e i n  l e v e l ,  S R - L R P - R z  2  a n d  S R - L R P - A S  1 b o t h  e x h i b i t  m a r k e d  r e d u c t i o n s  in  
L R P ,  w i t h  s m a l l e r  d e c r e a s e s  i n  S R - L R P - R z  4 , S R - p H p  1 a n d  S R - p H P  3 . H o w e v e r ,  a s  
r e g a r d s  a d r i a m y c i n  a n d  v i n c r i s t i n e  IC50 v a l u e s ,  S R - p H P  1 e x h ib i t s  a  g r e a t e r  r e d u c t i o n  
i n  a d r i a m y c i n  r e s i s t a n c e  t h a n  S R - L R P - R z  2  o r  S R - L R P - A S  1 . A d d i t i o n a l l y ,  S R - L R P -  
R z  4  e x h i b i t s  a n  e q u a l ,  o r  g r e a t e r ,  r e d u c t i o n  in  a d r i a m y c i n  a n d  v i n c r i s t i n e  r e s i s t a n c e  
a s  S R - L R P - A S  1 . C o n s e q u e n t l y ,  t h e r e  a p p e a r s  t o  b e  n o  c o r r e l a t i o n  b e t w e e n  L R P  
e x p r e s s i o n  a n d  d r u g  r e s i s t a n c e .
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3.3 Transfection of OAW42SR cells without cloning
T h e  O A W 4 2 S R  c e l l  l i n e  i s  a  h e t e r o g e n e o u s  p o p u la t i o n ,  h i g h l i g h t e d  b y  t h e  f a c t  t h a t  
f r o m  t h i s  p o p u l a t i o n  t h e  m o r e  s e n s i t iv e  c e l l  l i n e  O A W 4 2 S  w a s  o r i g i n a l l y  c lo n e d .  
T h u s ,  t h e r e  a r e  m a n y  i n d i v i d u a l  c e l l  p o p u l a t i o n s  w i t h i n  t h e  c e l l  l in e ,  w h i c h  w o u l d  
d i f f e r  p h e n o t y p i c a l l y  f r o m  e a c h  o t h e r  i f  c lo n e d .  T r a n s f e c t i n g  f o r e i g n  D N A  i n t o  c e l ls ,  
b y  i t s  v e r y  n a t u r e ,  p e r t u r b s  t h e  g e n e t i c  m a k e  u p  o f  t h e  c e l l s .  A s  t h e r e  i s  n o  c o n t r o l  
o v e r  t h e  s i t e  o f  in t e g r a t i o n  o f  t h e  f o r e i g n  D N A  i n t o  t h e  h o s t  g e n o m e ,  i t  i s  q u i t e  
p o s s i b l e  t h a t  t h e  t r a n s f e c t i o n  m a y  a l t e r  t h e  g e n e t i c  m a k e  u p  o f  t h e  c e l l s  in  s o m e  s m a l l  
w a y  o t h e r  t h a n  s i m p l y  t h e  i n t r o d u c t i o n  o f  t h e  f o r e i g n  D N A .  T h e r e f o r e  c l o n e s  w h i c h  
a r e  i s o l a t e d  a f t e r  t r a n s f e c t i o n  m a y  d i f f e r  f r o m  e a c h  o t h e r  a n d  f r o m  t h e  o r i g i n a l  
p o p u l a t i o n  in  s o m e  s m a ll ,  o f t e n  i m p e r c e p t i b l e ,  w a y .
D u e  t o  t h is  p o s s i b i l i t y  o f  c l o n a l  v a r ia t io n ,  a n d  d u e  t o  t h e  h i g h  d e g r e e  o f  v a r i a b i l i t y  
s e e n  in  t h e  c l o n e s  p r e v i o u s l y  i s o l a t e d  f r o m  t h e  O A W 4 2 S R  p o p u la t io n ,  t h e  O A W 4 2 S R  
c e l l  l i n e  w a s  o n c e  a g a i n  t r a n s f e c t e d  w i t h  t h e  a n t i - L R P  r i b o z y m e ,  a n t i - L R P  a n t is e n s e  
a n d  c o n t r o l  p H (3  p l a s m i d s  ( S e c t i o n  2 . 1 0 . 3 . 1 ) .  O n  t h is  o c c a s i o n ,  h o w e v e r ,  t h e  
t r a n s f e c t a n t s  w e r e  n o t  c l o n e d  i n t o  i n d i v i d u a l  c o l o n i e s  d u r in g  s e l e c t i o n  w i t h  G e n e t i c i n .  
R a t h e r  a l l  t h e  t r a n s f e c t a n t s  w e r e  p o o l e d  a n d  t h e  p o p u la t i o n  e x a m i n e d  i n  b u l k  in  a n  
e f f o r t  t o  e l i m in a t e  c l o n e  t o  c l o n e  v a r ia t i o n  t h a t  w a s  n o t  d u e  t o  d i f f e r e n t  l e v e l s  o f  L R P  
e x p r e s s io n .
A f t e r  t r a n s f e c t i o n  w i t h  t h e  p l a s m id s ,  t h e  c e l l s  w e r e  s e l e c t e d  w i t h  i n c r e a s i n g  
c o n c e n t r a t i o n s  o f  G e n e t i c i n .  A f t e r  f o u r  w e e k s ,  c e l l  s t o c k s  w e r e  m a d e  a n d  s t o r e d  in  
l i q u i d  N i t r o g e n .  S u b s e q u e n t l y ,  a d r i a m y c i n  a n d  v i n c r i s t i n e  t o x i c i t y  a s s a y s  w e r e  
p e r f o r m e d ,  a l o n g  w i t h  n o r t h e r n  b l o t s ,  I m m u n o p r e c i p i t a t i o n  a n d  R T - P C R ,  t o  s e e  i f  t h e  
r e d u c t i o n  o f  L R P  e x p r e s s i o n  in  t h e  b u l k  p o p u la t i o n  h a d  t h e  s a m e  e f f e c t  o n  d r u g  
r e s i s t a n c e  a s  i n d i v i d u a l  c l o n e s .  T h e  b u l k  p o p u la t i o n s  w e r e  s i m p l y  t e r m e d  S R - L R P -  
R z ,  S R - L R P - A S  a n d  S R - p H P  f o r  t h e  L R P - r i b o z y m e ,  L R P - a n t i s e n s e  a n d  c o n t r o l  
p l a s m i d  t r a n s f e c t a n t s  r e s p e c t i v e l y .
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T o x i c i t y  a s s a y s  w e r e  c a r r i e d  o u t  in  9 6 - w e l l  p l a t e s  w i t h  b o t h  a d r i a m y c i n  a n d  
v i n c r i s t i n e  a s  d e s c r i b e d  e a r l i e r  ( S e c t i o n  2 .3 ) .  T h e  a s s a y s  w e r e  r e p e a t e d  f o u r  t i m e s  f o r  
e a c h  o f  t h e  c l o n e s .  T h e  r e s u l t s  a r e  g i v e n  in  t e r m s  o f  I C 5 0  v a l u e s  a n d  a r e  s h o w n  in  
F i g u r e  3 . 3 . 1 . 1  a n d  F i g u r e  3 . 3 . 1 . 2  f o r  a d r i a m y c i n  a n d  v i n c r i s t i n e  r e s p e c t i v e l y .  T h e  
a v e r a g e s  o f  t h e  I C 5 0  v a l u e s  f o r  e a c h  c l o n e  a r e  d e p i c t e d  i n  F i g u r e s  3 . 3 . 1 . 3 .  a n d  3 . 3 . 1 . 4
F r o m  F i g u r e s  3 . 3 . 1 . 1  t o  3 . 3 . 1 . 4 ,  i t  c a n  b e  s e e n  t h a t  f o r  t h e  S R - L R P - R z  a n d  S R - L R P -  
A S  p o p u la t i o n s ,  t h e r e  w e r e  d e c r e a s e s  in  t h e  l e v e l s  o f  r e s i s t a n c e  t o  a d r i a m y c i n  a n d  
v i n c r i s t i n e  a s  c o m p a r e d  t o  t h e  p a r e n t a l  p o p u la t i o n .  T h e  m a g n i t u d e  o f  t h i s  d e c r e a s e  
w a s  o n l y  a p p r o x i m a t e l y  2 - f o l d  f o r  b o t h  d r u g s .  T h e  S R - p H P  p o p u la t io n ,  t r a n s f e c t e d  
w i t h  o n l y  t h e  c o n t r o l  p l a s m i d ,  h o w e v e r  s h o w e d  a  m a r g i n a l l y  g r e a t e r  i n c r e a s e  in  
s e n s i t i v i t y  t o  b o t h  d r u g s .  T h e r e  w a s  a  h i g h  d e g r e e  o f  s t a n d a r d  d e v i a t i o n  in  t h e  r e s u l t s  
f o r  t h e  p a r e n t a l  O A W 4 2 S R  p o p u la t io n ,  w h i c h  d e t r a c t s  f r o m  t h e  s i g n i f i c a n c e  o f  t h e s e  
r e s u l t s .
3.3.1 Adriamycin and Vincristine Toxicity assays on Uncloned OAW42SR
transfectants.
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Figure 3.3.1.1 Adriamycin toxicity assys on uncloned OAW42SR trasnfectants
IC50 values (fig/ml)
Adriamycin IC50 values
Figure 3.3.1.2 Vincristine toxicity assys on uncloned OAW42SR trasnfectants : 
IC50 values (^ig/ml)
V in cristin e  IC 50 v a lu es
□  OA W42SR
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Figure 3.3.1.3 Adriamycin toxicity assys on uncloned OAW42SR transfectants
Average IC50 values (|^g/ml)
Figure 3.3.1.4 Vincristine toxicity assys on uncloned OAW42SR transfectants : 
Average IC50 values (fig/ml)
1 6 4
N o r t h e r n  b l o t s  o f  2  | i g  o f  m R N A  i s o l a t e d  f r o m  e a c h  o f  t h e  t r a n s f e c t e d  p o p u la t i o n s  
w e r e  p r e p a r e d  a s  p r e v i o u s l y  d e s c r i b e d  ( S e c t i o n  2 .8 ) .  T h e  b l o t s  w e r e  h y b r i d i s e d  w i t h  
a n  L R P  r i b o p r o b e ,  s t r ip p e d  a n d  r e h y b r id i s e d  w i t h  a  G A P D H  p r o b e .  T h i s  p r o c e d u r e  
w a s  c a r r i e d  o u t  o n  t w o  s e p a r a t e  o c c a s i o n s ,  w i t h  d i f f e r e n t  p r e p a r a t io n s  o f  P o l y  A +  
R N A .  T h e  X - r a y s  d e v e l o p e d  f r o m  t h e  n o r t h e r n  b l o t s  a r e  s h o w n  in  F i g u r e  3 . 3 . 2 . 1  a n d  
F i g u r e  3 .3 .2 . 2 ,  a l o n g  w i t h  d e n s i t o m e t r y  a n a l y s i s  o f  t h e  s i g n a l  s t r e n g th .
F r o m  F i g u r e  3 . 3 . 2 . 1  ( a ) ,  i t  i s  c l e a r l y  e v i d e n t  t h a t  t h e r e  i s  a  r e d u c t i o n  in  t h e  L R P  b a n d  
in t e n s i t y  f o r  b o t h  S R - L R P - R z  a n d  S R -  p H |3 , w h i l e  t h e r e  a p p e a r s  t o  b e  a  s l i g h t  
i n c r e a s e  in  t h e  s i g n a l  s t r e n g t h  f o r  t h e  S R - L R P - A S  p o p u la t i o n ,  a s  c o m p a r e d  t o  t h e  
p a r e n t a l  O A W 4 2 S R  p o p u la t i o n .  H o w e v e r ,  t h e  G A P D H  b a n d s  ( F i g u r e  3 . 3 . 2 . 1  ( b ) )  
s h o w  t h a t  t h e  t h e r e  w a s  u n e q u a l  l o a d i n g  o f  m R N A  s a m p le s .  W h e n  t h e  v a l u e s  f o r  L R P  
s t r e n g t h  f r o m  d e n s i t o m e t r y  a r e  n o r m a l i s e d  t o  G A P D H  v a l u e s  ( F i g u r e  3 . 3 . 2 . 1  ( c ) ) ,  i t  
c a n  b e  s e e n  t h a t  t h e r e  i s  v e r y  l i t t l e  v a r i a t i o n  i n  L R P  e x p r e s s io n  b e t w e e n  S R - L R P - R z  
a n d  t h e  p a r e n t a l  c e l l s .  T h e  S R - L R P - R z  p o p u la t i o n  s h o w s  a  s l i g h t  d e c r e a s e  in  L R P  
e x p r e s s io n .  H o w e v e r  t h e  S R - L R P - A S  c e l l s  s h o w  a  s i g n i f i c a n t  i n c r e a s e  in  L R P  
m R N A  l e v e l s .  O n l y  t h e  S R -  pH (3 p o p u la t i o n  s h o w s  a  s u b s t a n t ia l  d e c r e a s e  i n  L R P  
e x p r e s s io n .
T h e  p a t t e r n  o f  s ig n a l  s t r e n g t h  in  t h e  r e p e a t  o f  t h is  p r o c e d u r e  ( F i g u r e  3 . 3 . 2 . 2 )  i s  v e r y  
s i m i l a r  t o  t h a t  a b o v e .  S R - L R P - R z  c e l l s  s h o w  a  s l i g h t  r e d u c t i o n  i n  L R P  m R N A  
e x p r e s s i o n .  T h e  S R - L R P - A S  p o p u la t i o n  s h o w s  a  s i g n i f i c a n t ,  i f  s o m e w h a t  s m a l le r  t h a n  
p r e v i o u s l y  f o u n d ,  i n c r e a s e  i n  L R P  s i g n a l  s t r e n g t h ,  w h i l e  S R -  pH (3 o n c e  a g a i n  e x h ib i t s  
a  m a r k e d  r e d u c t i o n  i n  L R P  m R N A  l e v e l s  c o m p a r e d  t o  t h e  p a r e n t a l  p o p u la t io n .
3.3.2 Northern blot analysis of LRP expression in uncloned OAW42SR
transfectants.
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Figure 3.3.2.1 Northern Blot and densitometry analysis of LRP expression in
uncloned OAW42SR transfectants : Repeat 1
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i
Figure 3.3.2.1 (cont’d)Northern Blot and densitometry analysis of LRP expression in
uncloned OAW42SR transfectants : Repeat 1
(C) LRP densitometry values normalised to GAPDH
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Figure 3.3.2.2 Northern Blot and densitometry analysis of LRP expression in
uncloned OAW42SR transfectants : Repeat 2
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Figure 3.3.2.2 (cont’d) Northern Blot and densitometry analysis of LRP expression
in uncloned OAW42SR transfectants: Repeat 2
(C) LRP densitometry values normalised to GAPDH
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R T - P C R  w a s  c a r r ie d  o u t  o n  t o t a l  R N A  s a m p le s  f r o m  e a c h  o f  t h e  t r a n s f e c t e d  
p o p u l a t i o n s  a s  p r e v i o u s l y  d e s c r i b e d  ( S e c t i o n s  2 . 7 . 5 - 2 . 7 . 6  a n d  3 . 2 . 1 ) .  T h e  r e s u l t s  o f  
R T - P C R  u s i n g  p r im e r s  f o r  r i b o z y m e / a n t i s e n s e  e x p r e s s io n ,  P - a c t in ,  M R P  a n d  m d r - 1  
a r e  s h o w n  i n  F i g u r e s  3 . 3 . 3 . 1 ,  3 .3 .3 . 2 ,  3 .3 .3 . 3  a n d  3 .3 . 3 . 4  r e s p e c t i v e l y .  D u p l i c a t e  
s a m p l e s  f r o m  e a c h  p o p u la t i o n  w e r e  a m p l i f i e d  i n  e a c h  r e a c t i o n .
F i g u r e  3 . 3 . 3 . 1  s h o w s  t h e  r e s u l t s  o f  R T - P C R  w i t h  t h e  r i b o z y m e  o r  a n t is e n s e  e x p r e s s i o n  
p r i m e r s .  I t  c a n  b e  c l e a r l y  s e e n  f r o m  t h is  t h a t  b o t h  t h e  r i b o z y m e  a n d  a n t i s e n s e  a r e  
b e i n g  e x p r e s s e d  in  t h e  a p p r o p r i a t e  t r a n s f e c t a n t s ,  a n d  t h e  p H p  p l a s m i d  i s  p r e s e n t  in  t h e  
S R -  p H P  p o p u la t io n .  T h e r e  a r e  n o  b a n d s  p r e s e n t  f o r  t h e  O A W 4 2 S R  p a r e n t a l  c e l l s ,  a s  
e x p e c t e d .  N o  p - a c t i n  c o n t r o l  p r im e r s  w e r e  i n c l u d e d  in  t h is  P C R ,  a s  t h e y  in t e r f e r e  w i t h  
t h e  a m p l i f i c a t i o n  o f  t h e  r i b o z y m e / a n t i s e n s e  e x p r e s s i o n  b a n d s .  H o w e v e r ,  P - a c t i n  R T -  
P C R  w a s  c a r r i e d  o u t  o n  d u p l i c a t e  s a m p le s  s i m u l t a n e o u s ly ,  a n d  t h e  r e s u l t  o f  t h is  is  
s h o w n  in  F i g u r e  3 . 3 .3 . 2 .  F r o m  t h i s  t h e r e  a p p e a r s  t o  b e  n o  v a r ia t i o n  in  t h e  P - a c t in  
b a n d s ,  a n d  t h u s  e q u a l  l o a d i n g  o f  R N A  s a m p le s  c a n  b e  a s s u m e d .
F i g u r e s  3 .3 .3 . 3  a n d  3 . 3 . 3 . 4  s h o w  t h e  r e s u l t  o f  R T - P C R  w i t h  p r im e r s  f o r  M R P  a n d  
m d r - 1  r e s p e c t i v e l y .  T h e s e  r e s u l t s  s h o w  t h a t  t h e r e  i s  n o  s i g n i f i c a n t  v a r i a t i o n  in  t h e  
l e v e l s  o f  M R P  o r  m d r - 1  e x p r e s s i o n  b e t w e e n  a n y  o f  t h e  p o p u la t i o n s .
3.3.3 RT-PCR analysis of mRNA expression levels in Uncloned OAW42SR
transfectants.
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Figure 3.3.3.1 RT-PCR analysis of ribozyme/antisense expression levels in uncloned
OAW42SR transfectants.
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Figure 3.3.3.2 RT-PCR analysis of p-actin expression levels in uncloned OAW42SR 
transfectants
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7igure 3.3.3.3 RT-PCR analysis of MRP expression levels in uncloned OAW42SR 
ransfectants
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Figure 3.3.3.4 RT-PCR analysis of mdr-1 expression levels in uncloned OAW42SR 
transfectants
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3.3.4 Correlation of LRP expression and drug resistance
T h e  a b o v e  r e s u l t s  d e m o n s t r a t e  a  r e d u c t i o n  i n  L R P  m R N A  e x p r e s s i o n  i n  t h e  r i b o z y m e  
a n d  p H p  t r a n s f e c t a n t s ,  w h i l e  n o  r e d u c t i o n  w a s  o b s e r v e d  i n  t h e  a n t i s e n s e  t r a n s f e c t a n t s .  
A s  t h e r e  w a s  n o  c o n c l u s i v e  i m m u n o p r e c i p i t a t i o n  d a t a ,  t h e  l e v e l s  o f  m R N A  a n d  
p r o t e i n  c a n n o t  b e  c o r r e la t e d .  N o  c o r r e l a t i o n  c a n  b e  d r a w n  f r o m  t h e  l e v e l s  o f  m R N A  
e x p r e s s i o n  a n d  d r u g  r e s i s t a n c e  i n  t h e s e  c e l l s .
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3.4 Antisense oligonucleotide treatm ent of OAW42SR and 2R120 cells
3.4.1 Antisense sequences
5 0  a n t i s e n s e  s e q u e n c e s ,  r a n g i n g  i n  s i z e  f r o m  1 6  t o  2 0 b p , w e r e  d e s i g n e d  f r o m  t h e  L R P  
c D N A  s e q u e n c e  u s i n g  t h e  c r i t e r i a  n o r m a l ly  a s s o c i a t e d  w i t h  p i c k i n g  P C R  p r im e r s ,  
w h i l e  a l s o  a v o i d i n g  s e q u e n c e s  k n o w n  t o  c a u s e  n o n - s e q u e n c e  s p e c i f i c  a n t i s e n s e  e f f e c t s  
( e .g .  G - q u a r t e t s  a n d  p a l i n d r o m e s ;  s e e  S e c t i o n  1 . 5 ) .  T h e s e  s e q u e n c e s  w e r e  t e s t e d  f o r  
c o m p a t i b i l i t y  t o  k n o w n  h u m a n  g e n e  s e q u e n c e s  o n  t h e  N a t i o n a l  C e n t r e  f o r  
B i o i n f o r m a t i c s  ( N C B I )  B l a s t  I n t e r n e t  s e r v e r .  6  s e q u e n c e s  ( L R P  A 1  t o  6 , s e e  T a b l e  
3 . 4 . 1 )  w e r e  t h e n  c h o s e n  o n  t h e  b a s i s  o f  l e a s t  c o m p a t i b i l i t y  t o  h u m a n  g e n e  s e q u e n c e s .  
I n  i n i t i a l  e x p e r i m e n t s ,  t h e  s e n s e  s e q u e n c e  c o r r e s p o n d i n g  t o  L R P  A S  5  ( L R P  S 5 )  w a s  
c h o s e n  a s  t h e  c o n t r o l .  I n  l a t e r  e x p e r im e n t s ,  t h e  c o r r e s p o n d in g  s e n s e  s e q u e n c e  t o  L R P  
A S  2  ( L R P  S 5 )  w a s  u s e d .  A  s c r a m b l e d  v e r s i o n  o f  L R P  A S  2  ( S C R  2 )  a n d  a  n o n s e n s e  
s e q u e n c e  ( N O N  1 )  w e r e  a l s o  i n c l u d e d  i n  l a t e r  e x p e r im e n t s .  T o  c h e c k  t h e  e f f e c t i v e n e s s  
o f  t h e  t r a n s f e c t i o n  p r o t o c o l  a n d  t h e  m e t h o d s  f o r  d e t e c t i n g  a n t i s e n s e  e f f i c a c y ,  a n t i s e n s e  
( m d r  A 1  a n d  A 2 )  a n d  s e n s e  ( m d r  S I  a n d  S 2 )  o l i g o n u c l e o t i d e s  a g a i n s t  t h e  m d r - 1  g e n e  
w e r e  a l s o  s y n t h e s is e d .
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Table 3.4.1 Sequences of anti-LRP Antisense, Sense and control oligonucleotides.
Name Sequence Position on cDNA*
L R P  A l C A A  C G T  C G A  T G G  A C G  T G A - 6 0  t o  - 4 2
L R P A 2 G A A  T C C  T C A  G T G  G T A  C C G - 1 2  t o +  6
L R P  A 3 C T C  A A G  T A G  T A G  G C G  T A G + 1 2  t o  +  3 0
L R P  A 4 T G G  T A G  T A G  T C C  G T C  T T G  G T +  4 9 5  t o +  5 1 4
L R P  A 5 C T C  T T C  C A G  A G T  G T G  G +  1 0 3 8  t o +  1 0 5 4
L R P  A 6 A A T  T A T  G T T  A C C  T T C  A A A  G A +  2 6 8 6  t o  +  2 7 0 6
m d r  A l C T C  C A C  C A C  T A C  C T C -9  t o  + 6
m d r  A 2 G T C  C C C  T T C  A A G  A T C  C A T + 1  t o + 1 8
L R P  S 2 C T T  A G G  A G T  C A C  C A T  G G C +  6  t o  - 1 2
L R P  S 5 G A G  A A G  G T C  T C A  C A C  C +  1 0 5 4  t o +  1 0 3 8
N O N A G C  G A T  C C A  G T A  T T A  G C G
S C R A C T  G C C  A T A  G G C  T C T  G C G
m d r  S I G A G  G T G  G T G  A T G  G A G + 6  t o  -9
m d r  S 2 A T G  G A T  C T C  G A A  G G G  G A C + 1 8  t o  + 1
* in all seq u en ces, +1 is  th e  p o s it io n  a ss ig n ed  to  th e  A  resid ue  in  th e  A T G  in itia tion  co d o n
Figure 3.4.1 Position of antisense sequences on LRP target
0 106 coding region 2840
Lrp S2 Lrp S5
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3.4.2 Treatm ent of OAW42SR and 2R120 cells with Antisense Oligonucleotides
T r e a t m e n t s  w e r e  c a r r ie d  o u t  in  e i t h e r  2 5  o r  7 5  c m 2 f l a s k s  o r  9 6  w e l l  p l a t e s .  2 4  h  p r io r  
t o  t r e a t m e n t  c e l l s  w e r e  s e e d e d  a t  a  d e n s i t y  o f  l x l 0 5/ m l f o r  t h e  2 5  c m 2 f l a s k s ,  1 o r  
2 x l 0 5/ m l f o r  t h e  7 5 c m 2 f l a s k s ,  a n d  l x l 0 4/ m l i n  t h e  9 6  w e l l  p l a t e s .  2 5  c m 2 f l a s k s  w e r e  
u s e d  f o r  t h e  i s o l a t i o n  o f  t o t a l  R N A  ( f o r  R T - P C R )  a n d  f o r  t r e a t in g  c e l l s  f o r  c y t o s p i n s .  
7 5 c m 2 f l a s k s  w e r e  u s e d  f o r  t r e a t i n g  c e l l s  f o r  i m m u n o p r é c i p i t a t i o n  a n d  i s o l a t i o n  o f  
P o l y  A +  R N A .  9 6 - w e l l  p l a t e s  w e r e  u s e d  f o r  t h e  t r e a t m e n t  o f  c e l l s  p r i o r  t o  t o x i c i t y  
a s s a y s .
C e l l s  w e r e  i n i t i a l l y  e x p o s e d  t o  t h e  a n t i s e n s e  f o r  2 4 h  a t  a  c o n c e n t r a t i o n  o f  l | i M  
c o m b i n e d  w i t h  L i p o f e c t i n  a t  a  c o n c e n t r a t i o n  o f  10 |_ iL /3 m ls m e d ia .  A f t e r  2 4 h , t h e  
m e d i a  c o n t a i n i n g  t h e  a n t i s e n s e  w a s  r e m o v e d  a n d  f r e s h  m e d i a  c o n t a i n i n g  f r e s h  
a n t i s e n s e  a n d  l i p o f e c t i n  a t  t h e  s a m e  c o n c e n t r a t i o n  w a s  a d d e d  t o  t h e  c e l l s .  A f t e r  a n  
a d d i t i o n a l  2 4  h  ( 4 8 h  t o t a l  t r e a t m e n t  t i m e )  c e l l s  w e r e  t a k e n  d o w n  f o r  e i t h e r  t o t a l  o r  
P o l y  A +  R N A  i s o l a t i o n .  A f t e r  7 2 h  c y t o s p i n s  w e r e  m a d e  f o r  i m m u n o c y t o c h e m i s t r y  o r  
c e l l  p e l l e t s  m a d e  f o r  i m m u n o p r é c ip i t a t i o n .  C e l l s  t r e a t e d  i n  9 6 - w e l l  p l a t e s  w e r e  
e x p o s e d  t o  c y t o t o x i c  d r u g s ,  i n  f r e s h  a n t i  s e n s e - f r e e  m e d ia ,  f o r  t h e  t o x i c i t y  a s s a y s  a f t e r  
7 2 h  a n d  l e f t  f o r  a  f u r t h e r  9 6  h .
3.4.3 Immunocytochemistry analysis of LRP expression
F o r  e a c h  a n t i s e n s e  t r e a t m e n t ,  f o u r  c y t o s p i n s  w e r e  m a d e  a s  d e s c r i b e d  e a r l i e r  ( 2 . 9 . 7 . 1 ) .  
T h e  i m m u n o c y t o c h e m i c a l  s t a i n i n g  w a s  c a r r ie d  o u t  o n  t h r e e  s e p a r a t e  o c c a s i o n s  f o r  
e a c h  s e t  o f  c y t o s p i n s .  T h e  r e s u l t s  a r e  s h o w n  i n  T a b l e s  3 . 4 . 3 . 1  t o  3 .4 .3 . 3  a n d  a r e  g i v e n  
i n  t e r m s  o f  s t a i n i n g  in t e n s i t y .  R e p r e s e n t a t iv e  s t a i n in g  p a t t e r n s  a r e  a l s o  s h o w n  in  
F i g u r e  3 . 4 . 3 . 1 .  T h e  s t a i n i n g  i n  t h e s e  p h o t o g r a p h s  r e la t e s  t o  t h o s e  i n  T a b l e  3 . 4 . 3 . 1 -  
t r e a t m e n t  1 ,  r e p e a t  1 .
T h e  f i r s t  t r e a t m e n t  ( T a b l e  3 . 4 . 3 . 1  a n d  F i g u r e  3 . 4 . 3 . 1 )  s h o w s  t h a t  a l l  o f  L R P  a n t i s e n s e  
s e q u e n c e s  a p p e a r e d  t o  d e c r e a s e  L R P  e x p r e s s io n  l e v e l s .  T r e a t m e n t  2  a p p e a r e d  n o t  t o  
b e  q u i t e  a s  e f f e c t i v e ,  o r  a s  c o n s is t e n t .  T h e  r e s u l t s  f o r  T r e a t m e n t  3 i n d i c a t e d  t h a t  L R P
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Table 3.4.3.1 Immunocytochemistry Staining intensity on OAW42SR cytospins
with LRP-56 MAb
Treatment 1 Treatment 2 Treatment 3
1 2 3 ill!! 2 3 1 2
•
3
LRP Al 0 0/+ ?• + + (?)
'
0 0/+ +
LRPA2 0/+ 0/+ 0/+ ++ 0/+ “ 0/+ 0/+ +/++
LRP A3 0/+ 0/+ + ++ 0/+ - + 0 +/++
LRPA4 0/+ 0/+ 0/+ + +/++ + + ++/++
+
LRPA5 0/+ + 0/+ ++ + (?) + ? ++/++
+
LRPA6 + (?) 0/+ + + + (?) *» + + +
LRP S
5/2*
++ +/++ ++ + ++ + + +++
Lipo +/++ 0/+ 0/+ ++ ++ - +/++ +/++ ++
Control ++ + ++ ++ +++ - ++ ++ +++
LRPA2
Imm
0 0/+ +/++
LRPA2
2^M
0/+ 0/+ +/++
LRPA2
5|^ M
0/+ 0/0/+ +
Staining intensity : 0 - No staining, + - low staining, ++ - medium level staining, +++ - very intense 
staining
/ - indicates a level of staining in between two of the above categories.
* - LRP S5 was used for treatment 1 only. LRP S2 was used for treatment 2 and 3.
? - Staining uncertain due to low cell number/ stickiness of the antibody
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Figure 3.4.3.X Immunocytochemical staining on LRP antisense treated
OAW42SRs with LRP-56 MAb
(a)
(b)
(a) LRP A1 treated; (b) LRP A2 treated
1- Punctate cytoplasmic LRP staining; 2- Blue nucleus counter stain
Figure 3.4.3.1 (cont’d) Immunocytochemical staining on LRP antisense treated
OAW42SRs with LRP-56 MAb
(C)
(d)
(C) LRP A3 treated; (d) LRP A4 treated
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Figure 3.4.3.1 (cont’d) Immunocytochemical staining on LRP antisense treated
OAW42SRs with LRP-56 MAb
(e)
(1)
(e) LRP A5 treated; (f) LRP A6 treated
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Figure 3.4.3.1 (cont’d) Immunocytochemical staining on LRP antisense treated
OAW42SRs with LRP-56 MAb
(g)
(h)
(g) LRP S2 treated; (h) Lipofectin treated
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Figure 3.4.3.1 (cont’d) Immunocytochemical staining on LRP antisense treated
OAW42SRs with LRP-56 MAb
(i)
(I) Untreated controls
A 1  a n d  A 2  w e r e  c o n s i s t e n t l y  t h e  m o s t  e f f e c t i v e  a t  d o w n  r e g u l a t i n g  L R P .  T h e  s e n s e  
o l i g o n u c l e o t i d e s ,  L R P  S 2  a n d  S 5 ,  a p p e a r e d  t o  h a v e  v a r y i n g  l e v e l s  o f  e f f e c t  o n  L R P  
e x p r e s s io n ,  b u t  w e r e  c o n s i s t e n t l y  l e s s  i n h i b i t o r y  t o  L R P  e x p r e s s i o n  t h a n  L R P  A 1  o r  
A 2 .  U s i n g  h i g h e r  c o n c e n t r a t i o n s  o f  L R P  A 2  ( 2  a n d  5 ( i M )  d id  n o t  h a v e  a  s i g n i f i c a n t l y  
g r e a t e r  i n h i b i t o r y  e f f e c t  o n  L R P  e x p r e s s io n  u n d e r  t h e s e  c o n d i t io n s .  T a b l e  3 . 4 . 3 . 2  ( s e e  
a l s o  F i g u r e  3 .4 . 3 . 2 )  s h o w s  t h a t  m d r - 1  A S  1 o r  2  h a v e  l i t t l e  e f f e c t  o n  t h e  e x p r e s s i o n  o f  
p - g l y c o p r o t e i n  c o m p a r e d  t o  t h e  s e n s e  o r  l i p o f e c t i n  t r e a t e d  o r  u n t r e a t e d  c e l ls .  T h e  c e l l s  
in  t h e s e  c y t o s p i n s  w e r e  c o n s i s t e n t l y  i n  b a d  c o n d i t i o n ,  p o s s i b l y  d u e  t o  t h e  h a r s h  
s t a i n i n g  p r o t o c o l ,  a n d  s o  a c c u r a t e  e v a l u a t i o n  w a s  d i f f i c u l t .
T a b l e  3 . 4 . 3 . 3 a  s h o w s  i m m u n o c y t o c h e m i s t r y  r e s u l t s  o f  t r e a t m e n t s  w i t h  j u s t  L R P  A 1  
a n d  A 2 ,  a l o n g  w i t h  L R P  S 2  a n d  n o n s e n s e  a n d  s c r a m b l e d  c o n t r o ls  ( N O N  a n d  S C R ) .  
2 R 1 2 0  c e l l s  w e r e  i n c l u d e d  in  t h i s  s e t  o f  t r e a t m e n t s  ( T a b l e  3 .4 .3 . 3 a ) .  T h e  r e s u l t s  s h o w  
t h a t  o n  t h i s  o c c a s i o n  o n l y  L R P  A 1  c o n s i s t e n t l y  d o w n - r e g u l a t e d  L R P  in  t h e  
O A W 4 2 S R s ,  w h i l e  i n  t h e  2 R 1 2 0  c e l ls ,  L R P  A 2  a p p e a r e d  t o  b e  m o r e  e f f e c t i v e .  T h e  
c o n t r o l  o l i g o n u c l e o t i d e s  a p p e a r e d  t o  h a v e  l i t t l e  e f f e c t  o n  L R P  e x p r e s s io n .  T h e  
d i f f e r e n c e  in  e f f e c t i v e n e s s  o f  L R P  A 1  a n d  A 2  i n  t h e  O A W 4 2 S R s  a n d  2 R 1 2 0 s ,  c o u l d  
i n d i c a t e  t h a t  t h e  s i t e  f o r  L R P  A 1  i s  m o r e  a c c e s s i b l e  i n  O A W 4 2 S R s  t h a n  2 R 1 2 0 s ,  a n d  
v i c e  v e r s a  f o r  L R P  A 2 .  T h i s  c o u l d  p o s s i b l y  b e  d u e  t o  d i f f e r e n t  p o s t - t r a n s c r ip t io n a l  
m o d i f i c a t i o n s  o f  t h e  L R P  m R N A  in  t h e  O A W 4 2 S R s  a n d  2 R 1 2 0 s .
T a b l e  3 . 4 . 3 . 3 b  a p p e a r s  t o  c o n t r a d ic t  t h i s  t r e n d  s i n c e  in  t h is  s e t  o f  t r e a t m e n t s ,  n e i t h e r  
a n t i s e n s e  o l i g o n u c l e o t i d e  a p p e a r s  t o  h a v e  a n y  e f f e c t  o n  L R P  l e v e l s  in  2 R 1 2 0  c e l ls .  
H o w e v e r ,  b o t h  L R P  A 1  a n d  A 2  a p p e a r  t o  h a v e  v a r y i n g  e f f e c t  o n  L R P  e x p r e s s i o n  in  
t h e  O A W 4 2 S R .  T h e  i m m u n o c y t o c h e m i c a l  s t a i n i n g  t e c h n i q u e  u s e d  t o  o b t a i n  t h e s e  
r e s u l t s  i s  k n o w n  t o  b e  s u s c e p t i b l e  t o  e x t r e m e s  o f  h e a t  o r  c o ld ,  o f t e n  r e s u l t i n g  i n  
i n a c c u r a t e  s t a in i n g  p a t t e r n s  w h e n  t h e  a m b i e n t  t e m p e r a t u r e  i s  a b o v e  n o r m a l .  T h i s  m a y  
g o  s o m e  w a y  t o  e x p l a i n  t h e  v a r i a t i o n s  o b s e r v e d .  O n c e  a g a in ,  t h o u g h ,  t h e  c o n t r o l  
o l i g o n u c l e o t i d e s  a p p e a r  t o  h a v e  l i t t l e ,  i f  a n y  e f f e c t  o n  L R P  e x p r e s s i o n  l e v e l s  
c o m p a r e d  t o  t h a t  o f  t h e  c o n t r o l  u n t r e a t e d  c e l ls .
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Table 3.4.3.2 Immunocytochemistry Staining intensity on OAW42SR cytospins
with mdr-1 MAb
■ •: i  ■ SrJ • •
1 2 3
mdr AS 1/2 * 0/+ +/++ +
mdrS 1/2 * + +/++ ++
Lipo ++ + +
Control ++ + +
Staining intensity : 0 - No staining, + - low staining, ++ - medium level staining, +++ - very intense 
staining
/ - indicates a level of staining in between two of the above categories.
* - rndr AS 1 and S1 were used in repeat 1, and mdr AS2 and S2 were used in repeats 2 and 3
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Figure 3.4.3.2 Immunocytochemical staining on mdr-1 antisense and sense
treated OAW42SRs with mouse ascites mdr-1 MAb
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OAW42SR 2R120
Table 3.4.3.3a Immunocytochemical staining on OAW42SR and 2R120 cytospins
with the LRP-56 MAb - treatm ent 1
.
1
•
. 2 -,
v
1
2
3
LRP Al + 0/+ + + 0/+ +++
LRP A2 ++ +/++ ++ + 0/+ * 0 *
LRP S2 ++ +/++ ++ ++ 0/+ * +++
NON ++/+++ +/++ ++ +++ +++ +++
SCR +++ +/++ +/++ ++ ++/+++ +++
Lipofectin +++ ++ ++ ++/+++ ++/+++ ++
Control +++ ++ ++ ++ +++ +++
Staining intensity : 0 - No staining, + - low staining, ++ - medium level staining, +++ - very intense 
staining
/ - indicates a level of staining in between two of the above categories.
* - indicates low cell numbers on cytospin, so staining intensity difficult to evaluate accuratcly.
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Table 3.4.3.3b Immunocytochemistry staining on OAW42SR and 2R120 cells
with the LRP-56 MAb - treatm ent 2
OAW42SR 2R120
■ F ■ 1 2 3 1 2 3
. . .
LRP A l ++ 0/+ +++ ++ ++ +++
LR PA 2 0/+ ++ +/++* +++ +++ +/++**
LR PS2 ++ ++/+++ +/++ ++/+++ ++/+++ ++/+++
NON ++/+++ ++ +++ +++ +++ +++
SCR ++ ++ ++ +++ +++ ++
Lipofectin ++ ++ +++ ++/+++ 0/+ ++
Control ++ ++ +++ ++ +++ +++
Staining intensity : 0 - No staining, + - low staining, ++ - medium level staining, +++ - very intense 
staining
/ - indicates a level of staining in between two of the above categories.
* - cells packed very tightly, accurate determination difficult 
** - cells dried up, accurate determination difficult
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3.4.4 LRP RT-PCR analysis
T o t a l  R N A  w a s  i s o l a t e d  f r o m  c e l l s  a f t e r  4 8 h  o f  t r e a t m e n t  w i t h  t h e  a n t is e n s e  
o l i g o n u c l e o t i d e s  a n d  R T - P C R  w a s  p e r f o r m e d  w i t h  p r i m e r s  f o r  L R P ,  g i v i n g  a  b a n d  
s i z e  o f  3 0 0 b p . 2  s e t s  o f  ( 3 - A c t in  p r im e r s ,  w h i c h  w e r e  u s e d  a s  in t e r n a l  c o n t r o ls ,  g a v e  
b a n d  s i z e s  o f  1 4 2  o r  3 5 3 b p .  M d r - 1  p r im e r s  w e r e  u s e d  f o r  R T - P C R  o n  R N A  e x t r a c t e d  
f r o m  m d r - 1  a n t i s e n s e  a n d  s e n s e  t r e a t e d  c e l l s ,  a n d  g a v e  a  b a n d  s i z e  o f  1 5 7 b p .  T h e  R T -  
P C R  p r o c e d u r e  i s  o u t l in e d  i n  S e c t i o n s  2 . 7 . 5  a n d  2 .7 .6 .
F i g u r e  3 . 4 . 4 . 1  s h o w s  r e p r e s e n t a t i v e  r e s u l t s  o f  R T - P C R  f r o m  t h e  f i r s t  t h r e e  s e t s  o f  
a n t i s e n s e  t r e a t m e n t s  o n  t h e  O A W 4 2 S R s .  T h e r e  w a s  n o  o b v i o u s  c o n s i s t e n t  r e d u c t i o n  
i n  t h e  L R P  b a n d s  f o r  a n y  o f  t h e  a n t i s e n s e  o l i g o n u c l e o t i d e s  a s  c o m p a r e d  t o  t h e  c o n t r o ls  
( L R P  S 5 ,  L i p o f e c t i n  a n d  u n t r e a t e d  C o n t r o l ) .  T h e  s a m p l e s  f r o m  L R P  A 5 ,  L R P  A 6 ,  
L R P  S 5 ,  L i p o f e c t i n  a n d  c o n t r o l  t r e a t e d  c e l l s  a c t u a l l y  a p p e a r  t o  h a v e  r e d u c e d  l e v e l s  o f  
L R P  e x p r e s s i o n  a s  c o m p a r e d  t o  t h e  o t h e r  a n t i s e n s e  t r e a t e d  c e l ls .  H o w e v e r ,  t h e  ( 3 - a c t in  
c o n t r o l  b a n d s  a r e  a l s o  r e d u c e d ,  i n d i c a t i n g  s i m p l y  r e d u c e d  l o a d i n g  o f  t h e s e  s a m p le s .  
F i g u r e  3 . 4 . 4 . 2  s h o w s  t h e  r e s u l t s  o f  m d r - 1  R T - P C R  o n  m d r - 1  a n t i s e n s e  a n d  s e n s e  
t r e a t e d  c e l l s .  A s  c a n  b e  s e e n ,  t h e  m d r - 1  b a n d  f o r  m d r  A 1  t r e a t e d  c e l l s  w a s  l e s s  t h a n  
f o r  m d r  S I  o r  l i p o f e c t i n  t r e a t e d  o r  c o n t r o l  c e l l s ,  w h i l e  t h e  P - a c t i n  b a n d s  a r e  a l l  o f  
e q u a l  i n t e n s i t y .  T h i s  i n d i c a t e d  t h a t  t h e  a n t is e n s e  t r a n s f e c t i o n  a n d  d e t e c t i o n  m e t h o d s  
w e r e  f u n c t i o n i n g  p r o p e r l y ,  a s  t h e  m d r - 1  a n t i s e n s e  a p p e a r e d  t o  b e  a b l e  t o  s p e c i f i c a l l y  
r e d u c e  t h e  l e v e l s  o f  m d r - 1  m R N A .
I n  a n  a t t e m p t  t o  s e e  i f  t h e  i n h i b i t i o n  o f  L R P  m R N A  l e v e l s  c o u l d  b e  o b s e r v e d  o v e r  
t i m e ,  c e l l s  w e r e  t r e a t e d  w i t h  L R P  A 2 ,  w i t h  t o t a l  R N A  s a m p l e s  i s o l a t e d  a t  0, 4 , 2 4  a n d  
4 8  h . T h i s  p r o c e d u r e  w a s  r e p e a t e d  t h r e e  t i m e s  a n d  t h e  r e s u l t s  a r e  s h o w n  i n  F i g u r e
3 .4 .4 . 3  ( a ) ,  ( b )  a n d  ( c ) .  F i g u r e  3 .4 .4 . 3 ( a ) ,  c l e a r l y  s h o w s  a  g r a d u a l  d e c r e a s e  in  L R P  
e x p r e s s i o n  l e v e l s  f r o m  0  t o  4 8  h . T h e r e  w a s  a  v e r y  s i g n i f i c a n t  r e d u c t i o n  i n  t h e  a m o u n t  
o f  L R P  p r e s e n t  a f t e r  4 h  a s  c o m p a r e d  t o  Oh, i n d i c a t i n g  t h a t  t h e  a n t i s e n s e  a c t s  r a p i d l y  t o  
r e d u c e  t h e  L R P  l e v e l s .  A  r e p e a t  o f  t h e  e x p e r im e n t ,  F i g u r e  3 .4 .4 . 3 ( b ) ,  a ls o  s h o w s  a  
g r e a t  r e d u c t i o n  i n  L R P  l e v e l s  b e t w e e n  0 a n d  4  h , w i t h  l e s s  c h a n g e  b e i n g  v i s i b l e  f o r  
t h e  a d d i t i o n a l  t i m e  p o in t s .  I t  a l s o  a p p e a r s  t h a t  t h e  l e v e l s  o f  L R P  m a y b e  i n c r e a s i n g  a t  
4 8 h , i n d i c a t i n g  t h a t  t h e  p h o s p h o r o t h i o a t e  o l i g o n u c l e o t i d e s  m a y  b e  b e i n g  d e g r a d e d  b y
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Figure 3.4.4.1 RT-PCR analysis of LRP mRNA expression in LRP antisense
treated OAW42SRs
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Figure 3.4.4.2 RT-PCR analysis of mdr-1 mRNA expression in mdr-1 antisense
treated OAW42SRs
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Figure 3.4.4.3 RT-PCR analysis of time scale of LRP down regulation in LRP
antisense treated OAW42SRs
(a) LRP A2 antisense treatment
Oh Oh 4h 4h 24h 48h 48h
(b) LRP A2 antisense treatment
Oh Oh 4h 4h 24h 24h 48h 48h
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Figure 3.4.4.3 (cont’d) RT-PCR analysis of time scale of LRP down regulation in
LRP antisense treated OAW42SRs
(C) LRP A2 antisense treatment
Oh Oh 4h 4h 24h 24h 48h 48h
LRP
p-actin
(d) LRP S2 sense treatment
Oh 4h 24h 48h 72h 96h
LRP
P-actin
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Figure 3.4.4.3 (cont’d) RT-PCR analysis of time scale of LRP down regulation in
LRP antisense treated OAW42SRs
(e) Control - no oligonucleotide
Oh 4h 24h 48h 72h 96h
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t h is  t i m e ,  a n d  l o s i n g  t h e i r  p o t e n c y .  A  t h ir d  r e p e a t  o f  t h is  p r o c e d u r e  y i e l d e d  a n  a l m o s t  
t o t a l  e l i m i n a t i o n  o f  L R P  R N A  b y  2 4 h  p o s t  i n i t i a t io n  o f  t r e a t m e n t ,  w h i c h  w a s  e v e n  
f u r t h e r  r e d u c e d  b y  4 8 h .
F i g u r e s  3 .4 .4 .3  ( d )  a n d  ( e )  s h o w  t h e  r e s u l t  R T - P C R  o n  R N A  e x t r a c t s  f r o m  a  t im e  
s c a l e  t r e a t m e n t  o f  O A W 4 2 S R  c e l l s  w i t h  t h e  s e n s e  o l i g o n u c l e o t i d e  c o r r e s p o n d in g  t o  
L R P  A 1  ( L R P  S I ) ,  a n d  u n t r e a t e d  c e l l s  a t  v a r i o u s  t im e  p o in t s .  T h e s e  f i g u r e s  c l e a r l y  
s h o w  n o  r e d u c t i o n  i n  L R P  l e v e l s  a t  a n y  t i m e  p o in t  c o m p a r e d  t o  t i m e  p o in t  O h, e v e n  u p  
t o  9 6 h ,  f o r  e i t h e r  u n t r e a t e d  o r  L R P  S 2  t r e a t e d  c e l ls .
T h i s  r e s u l t ,  w h i l e  n o t  b e i n g  q u a n t i t a t i v e ,  c l e a r l y  d e m o n s t r a t e s  t h e  e f f i c a c y  o f  t h e  L R P  
A 2  o l i g o  i n  r e d u c i n g  L R P  m R N A  l e v e l s .
F i g u r e  3 .4 .4 . 4  s h o w s  a  r e p r e s e n t a t i v e  r e s u l t  o f  L R P  R T - P C R  o n  O A W 4 2 S R s  t r e a t e d  
w i t h  L R P  A 1  a n d  A 2  a n d  a s  w e l l  a s  t h e  c o n t r o l  o l i g o n u c l e o t i d e s  L R P  S 2 ,  s c r a m b l e d  
( S C R )  a n d  n o n s e n s e  ( N O N ) .  A s  w i t h  p r e v i o u s  t r e a t m e n t s  ( F i g u r e  3 . 4 . 4 . 1 ) ,  t h e r e  w a s  
n o  o b v i o u s  d i f f e r e n c e s  b e t w e e n  t h e  d i f f e r e n t  t r e a t m e n t s ,  a l t h o u g h  o n  t h is  o c c a s i o n ,  a ll  
t r e a t m e n t s  a p p e a r e d  t o  h a v e  s l i g h t l y  l o w e r  l e v e l s  o f  L R P  c o m p a r e d  t o  t h e  u n t r e a t e d  
c o n t r o l .
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Figure 3.4.4.4 RT-PCR analysis of LRP mRNA expression in LRP antisense
and control oligonucleotide treated OAW42SRs
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3.4.5 Adriamycin Toxicity Assays on anti-LRP Antisense treated OAW42SRs
A f t e r  7 2 h  o f  t r e a t m e n t  w i t h  o l i g o n u c l e o t i d e s  i n  9 6  w e l l  p l a t e s ,  c e l l s  w e r e  t r e a t e d  w i t h  
v a r i o u s  c o n c e n t r a t i o n s  o f  A d r i a m y c i n  f o r  a  f u r t h e r  4  d a y s .  I n  a n  e f f o r t  t o  n e g a t e  t h e  
e f f e c t s  o f  t h e  e n d o g e n o u s  M R P  a n d  P G P  e x p r e s s i o n  in  O A W 4 2 S R s  o n  t h e  r e s i s t a n c e  
o f  t h e  c e l l s ,  i n d o m e t h a c i n  a n d  c y c l o s p o r i n  A ,  w h i c h  b l o c k  M R P  a n d  P G P  f u n c t i o n  
r e s p e c t i v e l y ,  w e r e  i n c l u d e d  in  s o m e  t r e a t m e n t s .  T h e  I C 5 0  v a l u e  f o r  e a c h  t r e a t m e n t  
w a s  c a l c u l a t e d  a n d  i s  s h o w n  b e l o w  ( T a b l e s  3 . 4 . 5 . 1  a n d  3 .4 .5 .2 ) .
T a b l e  3 . 4 . 5 . 1  s h o w s  t h e  r e s u l t s  f r o m  t h e  f i r s t  4  s e t s  o f  t r e a t m e n t s .  I t  c a n  b e  s e e n  t h a t  
in  t r e a t m e n t s  1 t o  3 , a l l  t h e  a n t is e n s e  o l i g o s  a p p e a r e d  t o  i n c r e a s e  t h e  s e n s i t i v i t y  o f  t h e  
c e l l s  t o  A d r i a m y c i n  a s  c o m p a r e d  t o  t h e  c o n t r o l  a n d  l i p o f e c t i n  o n l y  t r e a t e d  c e l ls .  T h e  
m a g n i t u d e  o f  t h i s  c h a n g e  w a s  g r e a t e r  w h e n  i n d o m e t h a c i n  a n d  c y c l o s p o r i n  A  w e r e  n o t  
i n c l u d e d  in  t h e  t r e a t m e n t s  ( T a b l e  3 . 4 . 5 . 1 ,  T r e a t m e n t  2 , n o r m a l  v s .  i n d o m e t h a c i n  +  
c y c l o s p o r i n  A ) .  H o w e v e r  t h e  s e n s e  o l i g o n u c l e o t i d e s  a l s o  h a d  a  c o n s i d e r a b l e  
s e n s i t i s i n g  e f f e c t ,  b e i n g  c o m p a r a b l e  t o  m a n y  o f  t h e  a n t i s e n s e  o l i g o n u c l e o t i d e s .
T h e  c e l l s  t r e a t e d  w i t h  m d r - 1  a n t i s e n s e  w e r e  g e n e r a l l y  m o r e  s e n s i t i v e  t h a n  t h o s e  
t r e a t e d  w i t h  m d r - 1  s e n s e .  H o w e v e r ,  t h e  m a r g i n  w a s  n e v e r  g r e a t e r  t h a n  t w o - f o l d ,  a n d  
b o t h  w e r e  s i g n i f i c a n t l y  m o r e  s e n s i t i v e  t h a n  t h e  c o n t r o l  o r  l i p o f e c t i n  o n l y  t r e a t e d  c e l ls .
I n c r e a s in g  t h e  c o n c e n t r a t i o n  o f  t h e  o l i g o n u c l e o t i d e s  a p p e a r e d  t o  h a v e  o n l y  a  m a r g i n a l ,  
i f  a n y ,  e f f e c t  o n  r e s i s t a n c e .  I n c r e a s i n g  t h e  c o n c e n t r a t i o n  o f  L R P  A 2  f r o m  1 t o  5 | j M  
o n l y  d e c r e a s e d  t h e  I C 5 0  v a l u e  f r o m  0 .0 2 0  t o  0 .0 1 5  |J.g/ml a n d  0 .0 3 2  t o  0 .0 1 8  [ ig / m l in  
t r e a t m e n t s  3  a n d  4  r e s p e c t i v e l y  w i t h  i n d o m e t h a c i n  a n d  c y c l o s p o r i n  A  in c lu d e d .  
H o w e v e r ,  w h e n  e x p o s e d  t o  A d r i a m y c i n  a lo n e ,  t h e  I C 5 0  a p p e a r e d  t o  i n c r e a s e  f r o m  
0 .3 0 2  t o  0 .8 7 8  ( ig / m l f o r  1 a n d  5  |j,M  L R P  A 2  r e s p e c t i v e l y .
T a b l e  3 . 4 . 5 . 2  s h o w s  t h e  I C 5 0  v a l u e s  f o r  O A W 4 2 S R  a n d  2 R 1 2 0  c e l l s  t r e a t e d  w i t h  L R P  
A l ,  A 2 ,  S 2  a n d  a d d i t i o n a l  c o n t r o l s ,  S C R  ( s c r a m b l e d )  a n d  N O N  ( n o n s e n s e ) ,  a s  w e l l  a s  
c o n t r o l  a n d  l i p o f e c t i n  o n l y  t r e a t e d  c e l l s .  T h e r e  w e r e  n o  s i g n i f i c a n t  r e d u c t i o n s  in  t h e  
d r u g  s e n s i t i v i t y  b e t w e e n  t h e  a n t i s e n s e  t r e a t e d ,  c o n t r o l  o l i g o n u c l e o t i d e  a n d  t h e  c o n t r o l  
c e l l s  f o r  t r e a t m e n t s  1 a n d  2 . I n d e e d ,  in  t r e a t m e n t  ¡ - ( I n d o m e t h a c i n  +  c y c l o s p o r i n  A )
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Table 3.4.5.1 Adriamycin IC50 values (ng/ml) for LRP and m dr Antisense oligo 
treated OAW42SR cells with or without the addition of cyclosporin and 
indomethacin (5ng/ml each)
Indomethacin + Cyclosporin A Normal
Treatment
::::
1
Treatment
2
Treatment
3
Treatment
;;F
Treatm ent
2
Treatment
4
LRP A1 0.108 0.037 0.026 0.037 0.313 0.849
LRP A2 0.064 0.019 0.020 0.032 0.154 0.302
LRP A3 0.200 0.025 0.018 0.011 0.502 0.531
LRP A4 0.127 0.056 0.034 0.026 1.482 0.544
LRP A5 0.077 0.034 0.018 0.019 0.630 0.299
LRP A6 0.060 0.022 0.029 0.026 0.455 0.314
LRP S5/2* 0.117 0.021 0.070 0.028 0.413 0.311
Lipofectin 0.382 0.101 0.169 0.029 5.000 0.950
Control 0.389 0.201 0.244 0.048 5.000 3.027
M dr AS
1/2 **
0.010 0.022 0.023 0.118 0.540
M dr S 1/2
**
0.020 0.028 0.018 0.145 0.940
LRPA2
ljim
0.020 0.032 0.302
LRPA2
2|_im
0.018 0.023 0.698
LRPA2
5|im
0.015 0.018 0.878
* - LRP S5 was used for repeats 1 and 2, while LRP S2 was used for repeats 3 and 4
** - mdr AS1 and SI were used for repeat 2, while mdr AS2 and S2 were used for repeats 3 and 4
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Table 3.4.5.2 Adriamycin IC50 values (pg/ml) for LRP antisense and control oligo 
treated OAW42SR and 2R120 cells
Indomethacin + Cyclosporin A Normal
T r e a t m e n t  1 T r e a t m e n t  2 T r e a t m e n t 3 * T r e a t m e n t  2 T r e a t m e n t s *
L R P  A l 2 .5 6 0 1 . 1 2 0 1 . 6 2 2 0 .5 4 1 0 .5 7 8
L R P  A 2 1 . 9 1 9 1 .2 8 0 1 . 7 6 1 0 .3 1 0 0 .4 0 8
L R P  S 2 1 . 5 3 0 0 .2 5 6 0 .4 7 2 0 .5 6 9 0 .5 2 3
N O N 1 . 7 2 4 0 .8 6 9 1 . 3 7 2 0 .3 3 0 0 .4 8 0
S C R 1 . 6 7 4 0 .8 7 6 0 .5 4 2 - 0 .6 9 1
L i p o f e c t i n 1 . 8 8 7 4 .2 5 0 5 .5 0 0 0 .2 7 5 0 . 5 1 4
C o n t r o l 1 . 9 2 4 1 . 6 5 6 5 .2 0 0 0 .2 7 2 0 .5 0 0
• - Cells in repeat 3 were incubated for 18h pre crug addition in antisense free media.
Table 3.4.5.3 Adriamycin IC50 values (Mg/ml) for LRP antisense pulse-treated 
OAW42SR cells in 25 cm2 flasks
R e p e a t  1 R e p e a t  2 R e p e a t  3 R e p e a t  4 A v e r a g e
L R P  A l .  * _ * .  * _ * -
L R P  A 2 3 .6 5 0 .6 3 .0 3 _ * 2 .4 3  ±  1 .6 1
L R P  S 2 -  * _ * 5 2 .5 3 . 7 5  ±  1 . 7 7
N O N S E N S E 1 3 .8 9 4 .8 2 2 .9 1 8 .5 1 1 2 . 5 3 ±  7 .8 6
C O N T R O L 5 . 1 8 5 .0 3 .8 5 2 .3 4 .0 8  ±  1 .3 3
* - Too few cells for accurate readings.
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a n d  t r e a t m e n t  2 - n o r m a l ,  L R P  A 1  t r e a t e d  c e l l s  a p p e a r  t o  h a v e  i n c r e a s e d  r e s i s t a n c e  t o  
A d r i a m y c i n .  O n l y  in  t r e a t m e n t  3 , w i t h  i n d o m e t h a c i n  a n d  c y c l o s p o r i n  A  a d d i t i o n ,  d o  
t h e  a n t i s e n s e  t r e a t e d  c e l l s  e x h i b i t  a  r e d u c t i o n  in  A d r i a m y c i n  r e s i s t a n c e  a s  c o m p a r e d  t o  
u n t r e a t e d  c e l l s .  H o w e v e r ,  i n  t h is  c a s e  a l l  o f  t h e  c o n t r o l  o l i g o n u c l e o t i d e s  c a u s e d  
g r e a t e r  s e n s i t i v i t y  t o  t h e  d r u g  t h a n  L R P  A 1  o r  A 2 .  T h is  i n d i c a t e s  t h a t  t h e  in i t i a l  
r e d u c t i o n s  o b s e r v e d  i n  d r u g  r e s i s t a n c e  ( T a b l e  3 . 4 . 5 . 1 )  m a y  b e  d u e  t o  p h o s p h o r o t h i o a t e  
o l i g o n u c l e o t i d e s  i n  g e n e r a l ,  p o s s i b l y  b e c a u s e  o f  s o m e  in h e r e n t  t o x i c i t y ,  a s  i t  d o e s  n o t  
a p p e a r  t o  b e  a n  a n t i s e n s e  s p e c i f i c  e f f e c t .
T o  e n s u r e  t h a t  t h e  a p p a r e n t  l a c k  o f  e f f e c t  o f  t h e  L R P  a n t i s e n s e  o l i g o n u c l e o t i d e s  in  
m o d u l a t i n g  r e s i s t a n c e  t o  A d r i a m y c i n  w a s  n o t  d u e  t o  t h e  t r e a t m e n t  c o n d i t i o n s ,  c e l l s  
w e r e  t r e a t e d  w i t h  a n t i s e n s e  i n  2 5  c m 2 f l a s k s  a s  o p p o s e d  t o  9 6 - w e l l  p l a t e s  u s e d  i n  t h e  
p r e v i o u s  e x p e r i m e n t s ,  p r i o r  t o  a d d i t i o n  o f  d r u g . A l l  t h e  c e l l s  t r e a t e d  f o r  t h e  a n a l y s i s  o f  
L R P  p r o t e i n  a n d  R N A  e x p r e s s i o n  w e r e  t r e a t e d  in  f l a s k s ,  w h i c h  c r e a t e s  a  s l i g h t l y  
d i f f e r e n t  c e l l u l a r  e n v i r o n m e n t  t h a n  in  9 6 - w e l l  p l a t e s .  I t  w a s  a l s o  d e c i d e d  t o  p u l s e  t h e  
c e l l s  a f t e r  a n t i s e n s e  t r e a t m e n t ,  f o r  j u s t  2  h o u r s  w i t h  a  h i g h e r  c o n c e n t r a t i o n  o f  d r u g . 
N o r m a l  t o x i c i t y  a s s a y  c o n d i t i o n s  r e q u ir e  t h a t  t h e  c e l l s  b e  e x p o s e d  t o  d r u g  
c o n t i n u o u s l y  o v e r  7  d a y s .  A n y  in i t i a l  e f f e c t  o f  t h e  a n t i s e n s e  m o l e c u l e s  o f  t h e  c e l l s  a t  
t h e  s t a r t  o f  t r e a t m e n t  w o u l d  h a v e  w o r n  o f f  b y  t h e  e n d  o f  t h e  d r u g  t r e a t m e n t .  
T h e r e f o r e ,  b y  p u l s i n g  t h e  c e l l s ,  i t  w a s  p o s t u l a t e d  t h a t  t h e  c e l l s  w o u l d  b e  “ h i t ”  w i t h  t h e  
d r u g  a t  a  t i m e  w h e n  t h e  a n t i s e n s e  w a s  a t  i t s  m o s t  p o t e n t .  A f t e r  p u ls i n g ,  c e l l s  w e r e  
i n c u b a t e d  f o r  a  f u r t h e r  7  d a y s  t o  a l l o w  a n y  d r u g  e f f e c t  t o  b e  e x p r e s s e d .
T a b l e  3 .4 .5 .3  s h o w s  t h e  r e s u l t  o f  f o u r  t r e a t m e n t s  w i t h  L R P  A l ,  L R P  A 2 ,  L R P  S 2 ,  
N o n s e n s e  a n d  u n t r e a t e d  c o n t r o l  a n d  t h e i r  s u b s e q u e n t  p u l s i n g  w i t h  A d r i a m y c i n .  N o  
r e s u l t s  w e r e  o b t a i n e d  f o r  t r e a t m e n t s  w i t h  L R P  A l ,  a s  t h i s  o l i g o n u c l e o t i d e ,  a l o n g  w i t h  
L R P  S 5  a p p e a r e d  t o  h a v e  t o x i c  n o n - s p e c i f i c  s i d e - e f f e c t s ,  p r e v e n t i n g  s u f f i c i e n t  c e l l s  t o  
g r o w  t o  e n a b le  a c c u r a t e  r e a d i n g s .  H o w e v e r ,  i t  c a n  b e  s e e n  t h a t  t h e  a v e r a g e  I C 5 0  v a l u e  
f o r  t r e a t m e n t  w i t h  L R P  A 2  i s  l o w e r  t h a n  f o r  L R P  S 2 ,  N o n s e n s e  t r e a t e d  a n d  u n t r e a t e d  
c e l l s .  H o w e v e r ,  t h is  r e d u c t i o n  i s  o n l y  o f  t h e  m a g n i t u d e  o f  1 . 7 .  G i v e n  t h e  l a r g e  
s t a n d a r d  d e v i a t i o n s ,  t h i s  r e s u l t  i s  p r o b a b l y  n o t  s i g n i f ic a n t .
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3.4.6 Immunoprécipitation analysis ofLRP expression
A f t e r  7 2  h  o f  t r e a t m e n t  w i t h  t h e  v a r i o u s  o l i g o n u c l e o t i d e s ,  c e l l s  w e r e  t r y p s i n i s e d ,  
w a s h e d  t h r e e  t im e s ,  p e l l e t e d  a n d  f r o z e n  a t  - 8 0 ° C  u n t i l  r e a d y  t o  u s e .  E a c h  p e l l e t  
c o n t a i n e d  l x l O 6 c e l ls .  P r o t e i n  w a s  p r e c i p i t a t e d  w i t h  t h e  L R P - 5 6  M A b  a n d  r u n  o n  a  
7 . 5 %  p o l y a c r y l a m i d e  g e l ,  a s  d e s c r i b e d  e a r l i e r  ( S e c t i o n  2 .9 4 - 2 .9 .6 ) .  B a n d  i n t e n s i t y  w a s  
m e a s u r e d  b y  d e n s i t o m e t r y  t o  g i v e  r e l a t i v e  l e v e l s  o f  p r o t e in  e x p r e s s io n .
F i g u r e  3 . 4 . 6 . 1  ( a )  s h o w s  t h e  r e s u l t s  o f  t h e  f i r s t  r e p e a t  o f  t h e  i m m u n o p r e c i p i t a t i o n  
p r o c e d u r e .  I t  c a n  b e  c l e a r l y  s e e n  t h a t  t h e  L R P  b a n d  f o r  L R P  A 1  t r e a t e d  O A W 4 2 S R s  i s  
v i r t u a l l y  e l i m in a t e d .  T h e  L R P  b a n d  f o r  S C R  t r e a t e d  c e l l s  i s  a l s o  s i g n i f i c a n t l y  r e d u c e d ,  
b u t  t h i s  i s  p r o b a b l y  d u e  t o  u n d e r  l o a d i n g  o f  t h a t  s a m p le ,  j u d g i n g  b y  t h e  l a c k  o f  a  
s e c o n d a r y  b a n d  ( I g G  b a n d )  o n  t h e  g e l .  L R P  A 2  d id  n o t  a p p e a r  t o  h a v e  a n y  a f f e c t  o n  
L R P  p r o t e i n  l e v e l s ,  n o r  d id  t h e  c o n t r o ls  L R P  S 2 ,  N O N  a n d  L i p o f e c t i n ,  a l l  b e i n g  
s i m i l a r  t o  t h e  c o n t r o l  c e l l  s a m p le s .  T h e  r e l a t i v e  q u a n t i t i e s  o f  p r o t e i n  p r e s e n t ,  a s  
m e a s u r e d  b y  d e n s i t o m e t r y ,  a r e  s h o w n  in  F i g u r e  3 . 4 . 6 . 1  (b ) .
T h e  r e s u l t s  f o r  t h e  s e c o n d  r e p e a t  o f  a n t i s e n s e  t r e a t m e n t  a n d  i m m u n o p r e c i p i t a t i o n  
p r o c e d u r e  a r e  s h o w n  i n  F i g u r e  3 .4 .6 . 2 .  F r o m  F i g u r e  3 .4 .6 . 2  ( a )  i t  c a n  b e  s e e n  t h a t  b o t h  
L R P  A 1  a n d  L R P  A 2  c a u s e d  a  s i g n i f i c a n t  d e c r e a s e  in  L R P  e x p r e s s i o n  l e v e l s  in  t h e  
O A W 4 2 S R  c e l l s ,  a s  c o m p a r e d  t o  t h e  c o n t r o ls .  T h i s  i s  a l s o  r e f l e c t e d  i n  t h e  
d e n s i t o m e t r y  m e a s u r e m e n t s  ( F i g u r e  3 .4 .6 . 2  ( b ) ) ,  w h i c h  s h o w  t h e  b a n d  i n t e n s i t y  f o r  
L R P  A 1  a n d  A 2  c l e a r l y  r e d u c e d .  T h e  d i s c r e p a n c y  b e t w e e n  b a n d s  f o r  L R P  A 2  in  
r e p e a t s  1 a n d  2  m a y  b e  d u e  t o  t h e  d e g r a d a t i o n  o f  t h e  o l i g o n u c l e o t i d e  u s e d  f o r  r e p e a t  1 . 
A  f r e s h  b a t c h  o f  a n t i s e n s e  w a s  u s e d  f o r  t h e  s e c o n d  r e p e a t ,  p o s s i b l y  e x p l a i n i n g  t h e  
g r e a t e r  e f f i c a c y .
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Figure 3.4.6.1 Immunoprécipitation and densitometry analysis of LRP antisense
and control oligo treated OAW42SR cells : Repeat 1
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(b) Densitometry results (arbitrary values)
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Figure 3.4.6.2 Immunoprécipitation and densitometry analysis of LRP antisense
and control oligo treated OAW42SR cells : Repeat 2
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(b) Densitometry results (arbitrary values)
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3.4.7 Northern blot analysis of LRP expression
P o l y  A +  R N A  w a s  i s o l a t e d  f r o m  a n t i s e n s e  a n d  c o n t r o l  o l i g o n u c l e o t i d e  t r e a t e d  
O A W 4 2 S R s ,  4 8 h  a f t e r  in i t i a t i o n  o f  t h e  t r e a t m e n t .  l ( i g  o f  P o l y  A +  R N A  f r o m  e a c h  
s a m p l e  w a s  r u n  o n  a  d e n a t u r in g  R N A  g e l  a n d  e l e c t r o b l o t t e d  o n t o  H y b o n d  n y l o n  
m e m b r a n e .  T h e  m e m b r a n e s  w e r e  t h e n  h y b r i d i s e d  w i t h  a n  L R P - R i b o p r o b e  a n d , a f t e r  
s t r ip p in g ,  a  G A P D H  p r o b e ,  b o t h  l a b e l l e d  w i t h  P 32. A f t e r  h y b r i d i s a t i o n  a n d  w a s h i n g  
t h e  m e m b r a n e s ,  X - r a y  f i l m  w a s  e x p o s e d  f o r  v a r y i n g  l e n g t h s  a n d  d e v e l o p e d .  F i g u r e
3 . 4 . 7  ( a )  a n d  ( b )  s h o w s  a  r e p r e s e n t a t i v e  r e s u l t  f r o m  h y b r i d i s i n g  w i t h  a n  L R P  a n d  a  
G A P D H  p r o b e  r e s p e c t i v e l y .  C o r r e s p o n d i n g  d e n s i t o m e t r y  r e a d i n g s  a r e  a l s o  g i v e n ,  a n d  
F i g u r e  3 . 4 . 7  ( c )  s h o w s  t h e  L R P  b a n d s  d e n s i t o m e t r y  v a l u e s  n o r m a l i s e d  t o  t h e  G A P D H  
b a n d s  d e n s i t o m e t r y  r e a d in g s .
F r o m  F i g u r e  3 . 4 . 7  ( a ) ,  i t  c a n  b e  s e e n  t h a t  t h e r e  a p p e a r e d  t o  b e  l i t t l e  d i f f e r e n c e  in  t h e  
l e v e l s  o f  L R P  e x p r e s s io n  b e t w e e n  t h e  a n t i s e n s e  t r e a t e d  o r  c o n t r o l  o l i g o n u c l e o t i d e  
t r e a t e d  c e l l s .  H o w e v e r ,  t h e  u n t r e a t e d  c o n t r o l  c e l l s  a p p e a r e d  t o  h a v e  r e d u c e d  l e v e l s  o f  
L R P  e x p r e s s io n .  A s  e x p e c t e d ,  t h e  2 R 1 2 0  c e l ls  g a v e  a  s t r o n g  p o s i t i v e  s i g n a l  f o r  L R P .
F i g u r e  3 . 4 . 7  ( b )  s h o w s  t h e  r e s u l t  o f  t h e  G A P D H  h y b r i d i s a t i o n  w i t h  t h e  s a m e  
m e m b r a n e  a s  a b o v e .  I t  is  c l e a r l y  e v i d e n t  t h a t  t h e  s a m p l e s  f r o m  L R P  A 1  a n d  L R P  A 2  
t r e a t e d  O A W 4 2 S R s  c o n t a i n  f a r  m o r e  P o l y  A +  R N A  t h a n  a n y  o f  t h e  o t h e r  s a m p le s .  
T h e  u n t r e a t e d  c o n t r o l  c e l l  s a m p l e  s h o w s  t h e  l e a s t  a m o u n t  o f  R N A  l o a d e d .
W h e n  t h e  v a l u e s  f o r  L R P  e x p r e s s i o n  a r e  n o r m a l i s e d  t o  t h e  G A P D H  v a l u e s  ( F i g u r e
3 . 4 . 7  ( c ) ) ,  t h e r e  is  c l e a r l y  a  s i g n i f i c a n t  r e d u c t i o n  in  t h e  l e v e l s  o f  L R P  m R N A  
e x p r e s s i o n  f o r  b o t h  t h e  L R P  A 1  a n d  t h e  L R P  A 2  t r e a t e d  O A W 4 2 S R  c e l ls .  L R P  A 1  
t r e a t e d  c e l l s  s h o w  o v e r  a  3 - f o l d  r e d u c t i o n  in  t h e  l e v e l s  o f  L R P  m R N A  e x p r e s s io n ,  a s  
c o m p a r e d  t o  t h e  u n t r e a t e d  c o n t r o l  c e l l s ,  w h i l e  L R P  A 2  t r e a t e d  c e l l s  e x h ib i t  a l m o s t  a  
2 - f o l d  d e c r e a s e .  U n u s u a l l y ,  t h e  N o n s e n s e  a n d  S c r a m b l e d  o l i g o n u c l e o t i d e  c o n t r o ls  
a p p e a r e d  t o  h a v e  i n c r e a s e d  t h e  l e v e l  o f  L R P  m R N A  e x p r e s s i o n  i n  t h i s  t r e a t m e n t .  T h e  
p o s i t i v e  c o n t r o l  c e l l  l in e ,  2 R 1 2 0 ,  h a s  t h e  h i g h e s t  l e v e l  o f  n o r m a l i s e d  L R P  e x p r e s s io n .
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Figure 3.4.7 Northen Blot and densitometry analysis of LRP expression in
LRP antisense treated OAW42SRs
(a) LRP Northern Blot
Densitometry
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Figure 3.4.7 (cont’d) Northen Blot and densitometry analysis of LRP expression in
LRP antisense treated OAW42SRs
(b) GAPDH Northern Blot
Densitometry
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Figure 3.4.7 (eont’d) Northen Blot and densitometry analysis of LRP expression in
LRP antisense treated OAW42SRs
(C) LRP Normalised to GAPDH
Densitometry
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3.4.8 Correlation of LRP expression and drug resistance
RT-PCR analysis demonstrated the ability of the antisense oligonucleotides to inhibit 
LRP mRNA expression maximally between 4 and 48h after initiation of treatment. 
Inhibition of LRP mRNA expression by LRP A1 and A2 was also clearly 
demonstrated by northern blot analysis. This inhibition of LRP mRNA expression was 
reflected by a marked reduction in the LRP protein levels in cells treated with these 
two antisense oligonucleotides. The control oligonucleotides had no obvious effect on 
LRP protein levels and little effect on mRNA levels. However, the adriamycin 
toxicity assays demonstrated no difference in drug resistance in cells treated with LRP 
A1 or A2 and the control oligonucleotides. This indicates that LRP does not directly 
mediate MDR in the OAW42SR cell line.
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4. DISCUSSION
4.1 Analysis of LRP-ribozyme and antisense RNA transfectants
4.1.1 Initial selection of clones
The OAW42SR and OAW42S cells were transfected with either the LRP-ribozyme or 
-antisense RNA plasmids, or the control vector pH(3. The ribozyme construct that was 
employed was designed using the recommendations in the literature to give optimum 
cleavage efficiency. The ribozyme targeting LRP was deigned to cleave a GUC triplet 
at base 1152 in the middle of the coding region of LRP. GUC triplets are the optimal 
cleavage sites (Perriman etal., 1992). The antisense flanking arms were 12 bases long 
in total, which represents the most efficient length for flanking sequences (Bertrand et 
a l, 1994). The ribozyme was inserted into the pHPApr-l-neo (pHp) expression 
vector, containing the P-actin promoter. This vector has previously been used for 
effective delivery of ribozyme constructs elsewhere (Kashani-Sabet and Scanlon, 
1995) and in our laboratory (Daly et al., 1996). Transfection was achieved with a 
liposomal transfection reagent, which has been shown to achieve high transfection 
efficiency. The antisense RNA expression plasmid targets exactly the same region in 
the LRP sequence, bases 1147 to 1160 as the LRP ribozyme.
The clones were selected with geneticin to a concentration of 400 (ig/ml. The 
geneticin IC50 value in the untransfected cells had been determined to be around 150 
lag /ml (data not shown). A large number of clones were selected, as can be seen from 
Table 3.1. These clones were screened for reductions in LRP expression at both the 
mRNA level, by RT-PCR, and the protein level, by immunocytochemistry. Both of 
these methods have been widely used by other researchers when examining mdr-1 
down-regulation (Holm et al., 1994; Kobayashi et al., 1994; Scanlon et al., 1994; 
Bertram et al., 1995; see also Section 1.5). In order to examine if any of the selected 
clones exhibited changes in resistance to cytotoxic drugs, miniaturised in vitro 
toxicity assays were performed on all clones.
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4.1.1.1 Analysis of LRP mRNA expression by RT-PCR
LRP expression levels were first measured at the mRNA level by RT-PCR. There 
were no significant decreases in LRP expression apparent in any of the OAW42SR 
clones as compared to the parental cells (Figure 3.1.1.1). There were some alterations 
in LRP expression evident in the OAW42S clones (Tables 3.1.1.2 and 3.1.1.3). There 
was an absence of an LRP band for the clone 42S-LRP-Rz 7. However, the internal 
control P-actin band for this clone was much weaker than for any of the other clones. 
The clones 42S-LRP-AS 1, 9 and 10, and 42S-pHP 2 exhibited reduced LRP mRNA 
levels, without a reduction in control p-actin levels. However, as this form of RT- 
PCR was not quantitative, these results acted only as an early indicator of LRP 
expression.
4.1.1.2 Analysis of Drug toxicity assay IC50 values
LRP over expressing cell lines have previously been shown to be cross-resistant to the 
drugs selected for use in these preliminary toxicity assays (Scheper et al., 1993; 
Moran et al., 1997; see also Section 1.2.1). The average adriamycin IC50 values from 
three repeats of toxicity assays (Figure 3.1.2.5) show that there were a number of 
OAW42SR clones which exhibited a marked reduction in resistance to this drug. (In 
Figures 3.1.2.5 and 3.1.2.6, the IC50 values presented are relative to that of the 
parental cells OAW42SR, which were given a value of 1). This was due to a high 
degree of variation between repeats of the toxicity assays on a day-to-day basis (all 
higher on some days, all lower on other days. Therefore normalisation was required). 
The resistance of the clones relative to the parental cells did not display such a large 
degree of variation, and was thought to give a better indication of the resistance of the 
clones. The clones SR-LRP-Rz 2, SR-LRP-Rz 4, SR-LRP-AS 1 and SR-LRP-AS 4 
exhibited between a 5 and 10-fold reduction in adriamycin IC50 values relative to the 
parental cells. The clones SR-LRP-AS 7, SR-LRP-AS 8, SR-pHp 1, SR-pHp 6, and 
SR-pHP 7, also displayed significant, if not as substantial, reductions in resistance
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relative to the parental cells. SR-LRP-Rz 1, SR-LRP-AS 2, SR-LRP-AS 6 and SR- 
pHp 3 showed little if any change in adriamycin resistance levels.
The reduction in resistance for 3 out of 4 of the control vector transfected clones was 
quite unexpected. The pHp plasmid contains no genetic element known to be capable 
of mediating a reduction in drug resistance and has had no effect on resistance when 
transfected into other cells in this laboratory. The only possible means of perturbation 
of the cellular machinery is the random integration of the plasmid into the cell’s 
genome. This could be expected to perhaps interfere with some drug resistance related 
gene, in a very small fraction of clones, but not in such a high proportion. The only 
logical explanation that one could envisage is the presence of a significant degree of 
clonal variation, inherent in individual cells within the heterogeneous OAW42SR 
population. It remained to be seen whether levels of LRP expression varied between 
the clones and the parental cells.
The vinblastine resistance levels followed the same trend for the OAW42SR clones 
(Figure 3.1.2.6) with one exception. The clone SR-LRP-AS 2 displayed minor 
(approx. 2-fold) reductions in resistance to vinblastine, whereas no changes in 
resistance to adriamycin was evident for these clones. The magnitude of reduction in 
IC50 values for all clones was greater for vinblastine than for adriamycin. For 
example, SR-LRP-Rz 2 showed around a 10-fold reduction in adriamycin resistance, 
but over a 20-fold reduction in vinblastine resistance. Therefore, any sensitisation to 
drugs appears to be amplified with the use of vinblastine. The appearance of reduced 
drug resistance in the clone SR-LRP-AS 2 in the vinblastine toxicity assay may be 
explained by this amplification effect.
The margin of sensitisation to adriamycin was not as great for clones of OAW42S 
(Figure 3.1.2.7) as for OAW42SR clones. However, the reductions in resistance were 
still quite significant for some clones. The clones 42S-LRP-Rz 2, 3, 4, 7 and 10 and 
42S-LRP-AS 1, 5, 10 and 13 all displayed a 2 to 3-fold reduction in IC50 values for 
adriamycin. Once again, however, some of the control vector transfectants, namely 
42S-pHP 3 and 4, also exhibited a lowering of resistance to adriamycin. This was 
especially unexpected, as the OAW42S is a cloned population, derived from a single
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cell. Cell to cell variation within a cloned population has, however, previously been 
observed (Hanchett etal., 1994; see also Section 1.4).
The reductions in vincristine IC50 values for the OAW42S clones (Figure 3.1.2.8) 
followed the same pattern as for adriamycin. In the case of these OAW42S clones, the 
proportion of pHp plasmid transfectants exhibiting reductions in resistance levels, is 
lower than for the OAW42SR clones, but it is still intriguingly high. It was deemed 
important, therefore, to examine if  any of these control clones exhibited a detectable 
down-regulation of any related MDR gene (Sections 3.2.1, 3.2.2, 3.2.3 and 3.2.5).
4.1.1.3 Analysis of LRP protein expression by immunocytochemistry with the 
LRP-56 MAb
Using the LRP-56 monoclonal antibody to stain cytospins of clones via 
immunocytochemistry, marked reductions in LRP expression levels were evident for 
a number of clones (Table 3.1.3.1 and Figure 3.1.3.1). The LRP-56 MAb was the 
antibody originally used to isolate LRP and the staining was punctate and cytoplasmic 
as has been observed in all LRP-overexpressing cell lines (Scheper et a l,  1993; 
Izquierdo et. al., 1995, Izquierdo et. al, 1996a, 1996b, Scheffer et. a l, 1995). The 
clones SR-LRP-Rz 2, SR-LRP-AS 1, 6 and 7 and SR-pHp 1 all exhibited little or no 
staining for LRP. The parental cells stained intensely, as did the clones SR-LRP-Rz 1, 
SR-pHP 6 and the SW1573-2R120 positive control cells (data not shown). Smaller 
reductions in LRP protein levels were evident for SR-LRP-Rz 4, SR-LRP-AS 2 and 4. 
The clones SR-pHP 3 and 7 also exhibited a marginal decrease in staining. It 
appeared, therefore, that the ribozyme and antisense constructs were effective in 
reducing LRP expression. However, the full extent of the inhibition of LRP 
expression is masked somewhat by the extent of clonal variation. The reduction in 
LRP expression in the pHp transfectants demonstrates that clonal variation was also 
evident in the levels of LRP.
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As regards the OAW42S clones, there were large decreases in LRP staining evident 
for 42S-LRP-Rz 2, 42S-LRP-AS 1 and 42S-pH(3 1. All the other clones expressed 
LRP at a similar level to the parental cells.
From these preliminary results, there appeared to be a number of clones where the 
extent of reduction in drug resistance corresponded with a decrease in LRP protein 
expression. The clones SR-LRP-Rz 2, SR-LRP-AS 1, 42S-LRP-Rz 2 and 42S-LRP- 
AS 1 all exhibited very low LRP expression and significant reductions in drug 
resistance. Some of the clones with a slightly higher level of LRP expression (i.e. SR- 
LRP-Rz 4, SR-LRP-AS 7 and 8) displayed a correspondingly higher level of 
resistance. Similarly, the clone SR-LRP-Rz 1, with expression levels of LRP similar 
to the parental cells, exhibited a matching drug resistance profile.
Likewise, however, there was a collection of clones for which no correlation between 
LRP expression and sensitivity to cytotoxic drugs could be found. The clones SR- 
LRP-AS 6 and 42S-pHP 1 displayed low LRP expression but high IC50 values. 
Conversely, SR-pHP 6 and 42S-LRP-Rz 4, exhibited high levels of LRP, yet low IC50 
values. In general, it seemed as if a greater number of clones supported a relationship 
between LRP expression and resistance, and it is possible that other factors are 
dominant in determining resistance in the clones where a correlation is not seen. 
Nevertheless, no definite conclusions could be drawn from these preliminary and 
contradictory results. It was, therefore, necessary to narrow down the number of 
clones being analysed, and employ more thorough assays for LRP mRNA and protein 
expression. Additionally, the expression levels of mdr-1 and MRP were examined, as 
alterations in these proteins could equally affect the levels of drug resistance 
observed.
The clones which were selected for further analysis were chosen to give a 
representative cross-section of the population of clones, reflecting low, medium and 
high levels of LRP expression and drug resistance. These clones are shown in Table 
3.1.4.
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4.1.2 Analysis of LRP, mdr-1 and MRP mRNA expression
4.1.2.1 mRNA analysis by RT-PCR
The only OAW42SR clone to exhibit a consistent reduction in LRP expression as 
measured by LRP RT-PCR (Figure 3.2.1.1.1) was SR-LRP-Rz 2. All the other clones 
maintained a level o f LRP similar to the parental cells. None of the OAW42S clones 
exhibited visible changes in LRP (Figure 3.2.1.1.2).
Mdr-1 RT-PCR showed that none of the OAW42SR clones displayed a lower level of 
mdr-1 expression than the parental cells (Figure 3.2.1.2.1). Indeed, all except SR- 
LRP-Rz 2 appeared to have slightly increased levels, compared to the parent 
OAW42SRs. Similarly, with MRP RT-PCR, no reductions in MRP expression for any 
of the OAW42SR or OAW42S clones was evident (Figures 3.2.1.3.1 and 3.2.1.3.2).
Ribozyme expression was detected for all the ribozyme clones (SR-LRP-Rz 1, 2 and 
4, 42S-LRP-Rz 2) (Figures 3.2.1.4.1 and 3.2.1.4.2). However, the level of expression 
for SR-LRP-Rz 4 was much weaker than any of the other ribozyme transfected 
clones. This lower level of expression may, however, be sufficient to cause a small 
reduction in LRP mRNA levels. The high level of ribozyme expression in SR-LRP- 
Rz 1 is unexpected, since no reductions in LRP mRNA or protein levels had been 
detected for this clone. For some unknown reason, the ribozyme appears not to be 
functioning in this clone.
As regards expression of the antisense construct, expression was detected for SR- 
LRP-AS 1, but not for the 42S-LRP-AS 1 clone. The bands that appeared in the lane 
for this clone in Figure 3.2.1.4.2, are primer dimers, which also appear in the lane for 
the negative control OAW42S cells. The pH{3 plasmid is present in the clones SR- 
pH(3 1, 3 and 42S-pH(3 1 and 4.
As valuable as RT-PCR is, it is not quantitative and gives only an approximate guide 
to mRNA expression levels.
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4.1.2.2 Northern and slot blot analysis of mRNA expression
Northern blotting of RNA samples and hybridising with a radioactive probe has been 
widely used to analyse the expression of both mdr-1 mRNA and other cancer related 
genes (Holm et a l,  1994; Kobayashi et a l,  1994; Scanlon et a l, 1994). However, 
there have been no previous reports of its use in detecting LRP mRNA expression. A 
probe to detect LRP was developed during the course of this thesis. Comparison of 
the size of the bands with standardised RNA size markers supported the hypothesis 
that the band detected was indeed LRP mRNA
The first LRP northern blot (Figure 3.2.2.1) shows that there was a significant 
reduction in LRP mRNA levels in the SR-LRP-Rz 2 clone, as well as the SR-pHP 1 
clone. Slight reductions were also visible for the SR-LRP-Rz 4, SR-LRP-AS 1 and 
SR-pHf3 3 clones. SR-LRP-Rz 1 appeared to show an increase in LRP expression over 
the parental cells. The procedure was repeated using a Riboprobe (Figure 3.2.2.3), 
which gives much stronger signals as RNA-RNA hybridisation is much stronger than 
RNA-DNA hybridisation. In this case SR-LRP-Rz 2 still exhibited a marked decrease 
in LRP mRNA The extent of LRP reduction was not as great for SR-pHP 1 in this 
repeat. SR-LRP-Rz 4 was the only other clone to demonstrate a reduction in LRP 
mRNA levels.
SR-LRP-Rz 2 appears to be the only one of the chosen clones, therefore, that 
consistently demonstrates a large reduction in LRP mRNA. SR-LRP-Rz 4 and SR- 
pHp 1 also demonstrate a consistent, if much smaller reduction. This decrease in LRP 
mRNA for SR-LRP-Rz 2 correlates with the RT-PCR results. The reductions 
observed for SR-LRP-Rz 4 and SR-pHP 1 may have been too minor to be observed 
by RT-PCR. It seems, also, that there was no reduction in LRP mRNA in the SR- 
LRP-AS 1 clone. This is not entirely unexpected, as antisense RNA cannot elicit 
RNase H activity (Branch, 1996), and may act through steric inhibition, translation 
arrest or inhibition of splicing molecules (Neckers et a l,  1992; Sharma and 
Narayanan, 1995; Crooke and Bennett, 1996). The reduction in LRP mRNA in SR- 
pHP 1 demonstrates that the clonal variation is displayed at the transcriptional level, 
and not just in levels of protein expression. This once again masks the degree of
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inhibition caused by the ribozyme, as it is unknown how much of the reduction is 
caused by the ribozyme, and how much is inherent in the cells.
Analysis of mdr-1 expression using Slot-blot preparation of membranes (Figure 
3.2.2.2) reveals no marked reductions in mdr-1 mRNA levels in any of the clones as 
compared to the parental OAW42SR cells. There may be a slight reduction in the SR- 
LRP-AS 1 clone, but it is difficult to discern, due to faintness of the signals. There 
was a high degree of background signal over a number of the bands, which gives the 
impression of stronger signals. MRP mRNA levels were also analysed using Slot- 
blots. However, no signals were observed for any of the clones or the parents. These 
low levels of mdr-1 and MRP expression in the OAW42SR cell line have been 
previously observed (Moran etal., 1997).
The analysis of mRNA expression levels in the OAW42S clones failed to yield any 
clear-cut results, despite numerous repeats. This was due mainly to high radioactive 
background on the northern blot membranes. This can occur through partial drying of 
the membrane during hybridisation. As a result, any bands present can become 
obscured. Figure 3.2.2.4, is an example of a northern blot with a probe for LRP. The 
bands for OAW42S and 42S-LRP-Rz2 are missing. There does appear to be a 
reduction in LRP mRNA in the 42S-LRP-AS 1, as compared to 42S-pHp 1 and 4. 
However, as the levels of LRP cannot be compared to the parental cells, no 
conclusions can be drawn from this result.
In summary, the analysis of mRNA expression shows that there are a number of 
clones with varying levels o f LRP mRNA expression. All of the observed reductions 
in expression cannot be attributed entirely to the expression of the ribozyme or 
antisense constructs. Nonetheless, these variations in LRP expression give a good 
basis to assess the expression of LRP in relation to drug resistance.
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4.1.3 Analysis of LRP protein expression
4.1.3.1 Immunocytochemical analysis of LRP expression with the LRP-56 MAb
The staining patterns on the OAW42SR clones with the LRP-56 MAb (Table 3.2.3) 
followed the same pattern as previous experiments (Table 3.1.3.1). Substantial 
reductions in LRP expression (approx. 70-80 %) were observed for the clones SR- 
LRP-Rz 2, SR-LRP-AS 1 and SR-pHP 1. A smaller decrease (approx. 40-50%) was 
once again observed for SR-LRP-Rz 4, while no significant changes were evident for 
SR-LRP-Rz 1 and SR-pHP 3, as compared to parental OAW42SR cells. LRP staining 
patterns of the OAW42S clones (data not shown) was also as previously observed 
(Table 3.1.3.2).
Staining with a mdr-1 monoclonal antibody (Table 3.2.3 and Figure 3.2.3.2) revealed 
no variations in Pgp expression between any of the clones. MRP expression was not 
analysed by this method due to the stickiness of the MAb to the OAW42 cells during 
the staining procedure. This makes accurate evaluation of staining intensity difficult.
4.1.3.2 Analysis of LRP expression by immunoprecipitation
The two repeats of the immunoprecipitation procedure (Figures 3.2.4.1 and 3.2.4.2) 
highlight a consistent and marked decrease in LRP expression in the clones SR-LRP- 
Rz 2 and SR-LRP-AS 1, as compared to OAW42SR cells. (The repeated presence of 
bands under the 110 kD LRP bands has been noted previously (Izquierdo et al., 
1996a). They are the result o f the precipitation of the immunoglobulins present in 
every sample). Indeed, there is an almost total elimination of LRP protein in these 
clones. These results correlate with the immunocytochemistry results, which also 
demonstrated a large reduction in LRP for both of these clones.
In Figure 3.2.4.1, reductions in LRP expression can be observed for the clones SR- 
LRP-Rz 4 and SR-pHP 3. However, upon repetition of the procedure (Figure 3.2.4.2),
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these reductions were no longer evident. The expression level of LRP in the 
OAW42SR parental cells appears to be reduced in relation to most of the clones in 
this second repeat. It has recently been observed in this laboratory that when the 
OAW42SR population is passaged a certain high number of times (110-115), the LRP 
expression levels appear to decrease gradually. It has been noted that low passage 
numbers (passage 86) of OAW42SR cells contain low levels of LRP, and that with 
increasing passage number (over passage 92) the LRP expression levels and drug- 
resistance increase (Moran et al., 1997). While these results are, at first sight, 
contradictory, it may be that above a certain number of passages, the cells are once 
again reverting to the original low level of LRP expression. The OAW42SR cells used 
in the second repeat of the immunoprécipitation procedure were at passage number 
112, and may have been exhibiting this lowering of LRP levels. This should be taken 
into account when comparing the strength of LRP expression. In comparison to SR- 
LRP-Rz 1, both SR-LRP-Rz 4 and SR-pH(3 3 maintain a reduction in LRP expression. 
This moderate reduction in LRP correlates with the immunocytochemistry results for 
SR-LRP-Rz 4, but not however for SR-pHP 3.
The clone SR-pHp 1 appears to display an over-expression of LRP in Figure 3.2.4.1, 
with a much lower level of expression in Figure 3.2.4.2. However, despite the fact 
that equal cell numbers of each clone are used for the preparation of samples, the SR- 
pHP 1 lane appears to be overloaded. This is highlighted by the strength of the 
secondary immunoglobulin band, which is much stronger for SR-pHP 1 than any 
other sample. In Figure 3.2.4.2, this clone appears to have a lower level of LRP 
expression than SR-LRP-Rz 1, SR-LRP-Rz 4 and SR-pHp 3. This is in line with the 
previous findings by immunocytochemistry, where SR-pHP 1 exhibited lower levels 
of LRP than these other three clones.
LRP expression levels appear to be similar for OAW42S, and the clones 42S-LRP-Rz 
2, 42S-LRP-AS 1 and 42S-pHp 4 (Figure 3.2.4.3 and 3.2.4.4). However, no LRP 
expression could be observed for the 42S-pHP 1 clone. This correlates with the 
immunocytochemistry results. However, the two sets of results do not correlate for the 
clones 42S-LRP-Rz 2 and 42S-LRP-AS 1, as they were found to have reduced LRP 
expression by immunocytochemistry.
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4.1.3.3 Analysis of Pgp and MRP expression by Western blotting
Figure 3.2.5.1 shows that both SR-LRP-Rz 1 and SR-LRP-AS 1 appear to have 
significant reductions in Pgp levels as compared to the OAW42SR parental cells. SR- 
LRP-Rz 4 and SR-pHf] 1 exhibited a smaller decrease in Pgp. These reductions 
contradict the earlier immunocytochemistry results, where no reduction in Pgp 
expression was observed in any clone. No significant differences were observed 
between the OAW42S clones and the parental cells.
Only SR-LRP-AS 1 and SR-pHP 3 appear to show a reduction (approx. 35% and 30% 
respectively) in MRP levels, as compared to OAW42SR cells (Figure 3.2.6.1). The 
variations observed are most likely due to the inherent variations in individual cells 
within the heterogeneous OAW42SR population. The OAW42S clones appear to have 
increased levels of MRP, when compared to the parental cells (Figure 3.2.6.2).
4.1.4 Correlation of LRP mRNA and protein expression levels
Table 4.1.4. shows the approximate levels of LRP expression at the mRNA and 
protein level of all the clones relative to their parental cells. This is to facilitate an 
understanding of all the above results and enable correlation’s to be drawn. The 
values shown are averaged from the results previously discussed, and are meant as 
only rough guides to the trends in expression levels.
For SR-LRP-Rz 1, there is a strong correlation between the mRNA and protein 
expression levels, both of which are largely unchanged from the parental cells. SR- 
LRP-Rz 2 shows a drop in LRP mRNA levels of around 50 to 70%, and this is 
reflected by a drop in LRP protein levels to between 5 and 20 % of the parental levels. 
SR-LRP-Rz 4 exhibits a smaller drop in LRP mRNA levels (~ 20%), and this is 
reflected in a smaller reduction in LRP protein levels of around 50%. The SR-LRP- 
AS 1 clone shows a very minimal, if any, reduction in LRP mRNA. However, there is 
a drop in protein expression in this clone to between 5 and 20% of the parental cell
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levels. This discrepancy between protein and RNA levels highlights the fact that 
cleavage of the target RNA is not strictly necessary in order to block translation of the 
target protein. As mentioned previously, antisense RNA is incapable of eliciting 
RNase H cleavage, and probably acts mainly through steric hindrance of the cellular 
translational machinery. (Branch, 1996).
The relatively high level (~45%) of downregulation of LRP at the mRNA level in SR- 
pHp 1, is reflected by approx. a 20% reduction as measured by 
immunocytochemistry, but only around a 50 % reduction at the protein level by 
immunoprécipitation. The two methods for assessing LRP protein expression in the 
SR-pHP 3 clone do not, however, correlate. While there is a moderate (~15%) 
reduction in LRP mRNA levels, no protein reduction was observed by 
immunocytochemistry. However, immunoprécipitation indicated over a 2-fold 
reduction in protein levels. The analysis by immunoprécipitation and 
immunocytochemistry was separated by a gap of several months. It may be that the 
SR-pHp 3, undergoes the same reversion in LRP levels with increasing passage 
number as has been by the OAW42SR parental cells. It has been shown that even 
within a clonal population, individual cells can maintain different expression levels of 
certain proteins (Hanchett et a l, 1994). A low LRP expressing sub-population may 
have dominated the growth in the SR-pH{3 3 cells, resulting in a reduction of observed 
LRP levels.
The immunocytochemistry and immunoprécipitation results for the clones of 
OAW42S also show a high degree of variation. However, since the only measure of 
LRP mRNA expression is the non-quantitative RT-PCR results, no conclusions can be 
made regarding a correlation of LRP mRNA and protein levels in these cells.
The results show that these clones represent a wide range of LRP expression levels, 
which allows an accurate analysis of LRPs role in drug resistance. The observed 
changes may not be strictly due to the action of the ribozyme or antisense, as 
highlighted by the reductions observed in pHP clones. However, the indications are 
that in SR-LRP-Rz 2 and SR-LRP-As 1 the ribozyme and antisense constructs
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respectively are functioning properly, as the margin of LRP reduction is much greater 
than for either pHp clone.
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Table 4.1.4 Expression levels of LRP mRNA and protein relative to the parental 
cells (Approximate values only)
RNA Protein
Clone RT-PCR Northern Blot Immnocyto-
chemistry
Immuno­
précipitation
OAW42SR 100 100 100 100
SR-LRP-Rz 1 100 135 100 135
SR-LRP-Rz 2 50 30 20 5
SR-LRP-Rz 4 100 80 50 50
SR-LRP-AS 1 100 95 20 5
SR-pHß 1 100 55 20 50*
SR-pHß 3 100 85 100 45
OAW42S 100 - 100 100
42S-LRP-Rz 2 100 - 30 140
42S-LRP-AS 1 100 - 20 195
42S-pHß 1 100 - 0 20
42S-pHß 4 100 - 100 120
Values are averages from at least two repeats, and are given as a rough percentage of the parental cell 
value (either OAW42SR or OAW42S).
* Estimated from only one repeat of immunocytochemistry through comparison with SR-LRP-Rz 1
222
4.1.5 Toxicity Assays and LRP drug profile
4.1.5.1 Toxicity Assays on SR-LRP-Rz 1 and SR-LRP-Rz 2
Extensive toxicity assays, using a wide range of cytotoxic drugs, were initially carried 
out on the clones SR-LRP-Rz 1 and SR-LRP-Rz 2. The reasoning behind this was to 
establish which drugs were affected by expression of the LRP protein. The two clones 
above were chosen, as one exhibits consistently high LRP expression levels, while the 
other exhibits almost total elimination of LRP protein expression. The drugs used in 
this assay were both classical MDR-related drugs and non-classical MDR drugs. 
There have been a number of reports in which both classical and non-classical MDR 
drugs appear to be modulated by the overexpression of LRP (Scheper et a l,  1993; 
Ikeda et a l, 1997; Komarov et a l, 1997; Moran et a l, 1997; Parker et a l,  1997). 
These drugs include adriamycin (doxorubicin), mitoxantrone, etoposide (VP 16), 
vincristine, cytarabine, methotrexate and cisplatin. These drugs fall into following 
categories: Anthracyclines (adriamycin); Epipodophyllotoxins (etoposide (VP-16)); 
Vinca alkaloids (vincristine); Antimetabolites (methotrexate and cytarabine); 
Covalent DNA-binding drugs (cisplatin); and Non-covalent DNA-binding drugs 
(mitoxantrone) (Pratt et al., 1994).
The drugs employed in this assay were selected from five of the aforementioned drug 
categories. From Table 3.2.6.1, it can be seen that SR-LRP-Rz 2 shows a decrease in 
resistance to anthracyclines (adriamycin, daunorubicin and epirubicin), 
epipodophyllotoxins (VP-16) and Vinca alkaloids (vincristine, taxol, and taxotere). 
This is in following with the previous reports mentioned above. However, there was 
no significant reduction in resistance between SR-LRP-Rz 1 and SR-LRP-Rz 2 for 
either 5-Fluoro-Uracil (antimetabolites), or the covalent DNA-binding drugs 
melphalan (alkylating agent) and carboplatin (platinum compound). This contradicts 
the reports in which cell lines overexpressing LRP have been found to be resistant to 
both these categories of drugs (Ikeda et a l, 1997; Komarov et a l, 1997; Parker et a l, 
1997).
This pattern, however, follows that of a typical mdr-1 overexpressing MDR cell line, 
which exhibit cross-resistance to anthracyclines, epipodophyllotoxins and Vinca
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alkaloids, but are unchanged in their resistance to antimetabolites, alkylating agents or 
platinum compounds (Clynes et al. 1993). Due to this striking similarity to an MDR 
drug-profile, and the fact that small differences in Pgp and MRP expression was 
observed between the clones SR-LRP-Rz 1 and SR-LRP-Rz 2, it was decided to 
extend this drug-profile assay, to all the OAW42SR and OAW42S clones. This was 
done to establish whether the same pattern of drug resistance was to be found between 
the parental cells and all of the clones.
4.1.5.2 LRP drug profile assay on all OAW42SR and OAW42S clones
Table 3.2.6.2 (a) and (b) shows that all the clones display the same pattern of drug 
resistance as seen between SR-LRP-Rz 1 and SR-LRP-Rz 2. However, there was only 
a minimal, if any, reduction in resistance to VP-16 in relation to the parental cells. 
The magnitude of resistance to VP-16 can be up to 100-fold smaller than for 
adriamycin and vincristine in MDR cell lines (Redmond, 1991; Heenan, 1991). It 
cannot be ruled out, therefore, that there is alteration in the resistance to 
epidophyllotoxins in these cells. Additionally, if the IC50 levels o f the clones are 
compared to that of SR-LRP-Rz 1, they all display a reduction in the resistance to 
VP 16. The SR-LRP-Rz 1 clone has been shown to be largely invariant in its 
expression levels of the various MDR-related genes and drug resistance, while the 
parental cells have displayed some fluctuations. These results, therefore, again 
appeared to represent a Pgp mediated MDR drug profile.
An interesting observation is that the clone SR-pHP 3 appears to have a significantly 
increased sensitivity to a number of drugs, whereas in previous experiments (Figures 
3.1.2.5 and 3.1.2.6) this clone displayed resistance levels on a par with the parental 
OAW42SR cells. This may possibly be a reflection of the reduction in LRP 
expression observed in this clone over time (see Section 4.1.3.2).
The changes in IC50 values between the OAW42S clones and the parental cells was 
very minimal for all the drugs (Table 3.2.6.3 (a) and (b)). The clone 42S-pHP 1, 
displays only a 3.7 and 2.4 fold increase in sensitivity to adriamycin and vincristine
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respectively, although no LRP expression could be observed for this clone by 
immunoprecipitation or immunocytochemistry (see Sections 3.1.3 and 3.1.4). This 
result correlates with the finding that for the OAW42S cells, an increase in 
adriamycin or vincristine resistance was not concomitant with the original increase in 
LRP expression (Moran et a l, 1997). It was postulated by Moran el al.7 that the form 
of LRP expressed in the OAW42S cells was non-functional. The results shown here 
seem to support this idea and the observed small changes in resistance could be due 
simply to clonal variation or changes induced by the selection process itself.
4.1.6 Correlation of LRP expression levels and drug resistance
It can be seen from Table 4.1.4 that, as regards LRP expression in the OAW42SR 
clones, SR-LRP-Rz 2 and SR-LRP-AS 1 have the lowest levels, with almost total 
elimination of protein expression. They are followed by SR-LRP-Rz 4, SR-pHP 1 and 
SR-pHP 3, all of which exhibit around a 50% reduction in LRP protein expression, as 
measured by immunoprecipitation. SR-LRP-Rz 1 displays a slight increase in LRP 
expression levels over the parental cells.
If LRP was directly linked to resistance to anthracyclines and Vinca alkaloids, then 
the magnitude of LRP downregulation should be reflected by a similar drop in the 
IC50 value for these drugs. It would follow, therefore, that SR-LRP-Rz 2 and SR-LRP- 
AS 2, would show a similar drop of resistance, which should be significantly greater 
than that for SR-LRP-Rz 4, SR-pHP 1 and SR-pHP 3. These clones, in turn, should 
display a much greater sensitivity than either SR-LRP-Rz 1 or the parental cells.
Table 4.1.6 represents a summary of the toxicity assay results discussed above for 
adriamycin, vincristine and VP 16. These three drugs represent the three classes of 
drugs (namely anthracyclines, Vinca alkaloids, and epipodophyllotoxins) to which the 
clones have displayed altered resistance. Results are given as a percentage value of 
the average IC50 value for the parental cells. This is to allow direct comparison with 
the levels of LRP mRNA and protein expression given in Table 4.1.4
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4.1.6 Adriamycin, Vincristine and VP16 toxicity assay IC50 values relative to the 
parental cells.
Adriamycin Vincristine VP16
OAW42SR 100 100 100
SR-LRP-Rz 1 58 99 240
SR-LRP-Rz 2 9 1.4 80
SR-LRP-Rz 4 10 2 65
SR-LRP-AS 1 10 2.2 124
SR-pHp 1 12 1.2 110
SR-pHP 3 11 3 84
OAW42S 100 100 100
42S-LRP-Rz 2 89 68 57
42S-LRP-AS 1 32 52 43
42S-pHp 1 27 44 59
42S-pHp 4 236 60 41
All IC50 values are given as a percentage of the average IC50 value for the parental cells.
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It can be seen from Table 4.1.6 that all of the OAW42SR clones, with the exception 
of SR-LRP-Rz 1, display almost identical levels of reduction in resistance to the drugs 
listed. This is in spite of the fact that SR-LRP-Rz 2 and SR-LRP-AS 1 have both 
exhibited almost total elimination of LRP protein expression, while SR-LRP-Rz 4 and 
SR-pHp 1 and 3 displayed only a 50 % reduction in LRP expression. Indeed, SR-pHP 
1 demonstrates a greater sensitivity to vincristine than any of the other clones. These 
results clearly indicate that no direct correlation can be drawn between LRP 
expression levels and resistance to these drugs. However, the fact that reductions in 
LRP expression, are almost always paralleled by some level of increased sensitivity to 
drugs, even if not directly correlateable points towards LRP being simply co­
expressed with another resistance mechanism. Although decreases in LRP expression 
are generally associated with some level of reduction in drug resistance for these 
chosen clones, the initial range of clones illustrated that this was not always the case. 
From Sections 3.1.2 and 3.1.3 it can be seen that the clones SR-LRP AS 6 and 42S- 
pHp 1 both exhibited low levels of LRP expression, yet high levels of resistance to 
adriamycin and vinblastine/vincristine. In addition low levels of drug resistance were 
observed in the clones SR-pHP 6 and 42S-LRP-Rz 4 in the absence of a decrease in 
LRP expression.
The observation that the drugs to which resistance is altered are the same as those for 
Pgp overexpressing cell lines, indicates that mdr-1 may be mediating resistance in 
these cells. The form of mdr-1 being expressed in the low-resistance clones may be 
somehow less active than in the parental cells or SR-LRP-Rz 1. These alterations may 
be a result of the clonal variation.
4.2 Analysis of Uncloned OAW42SR transfectants
As the variability of the results for the OAW42SR clones showed, the cloning of 
transfectants from a heterogeneous population can lead to complications in the 
analysis of protein expression and drug resistance. It is difficult to assess whether all 
the changes in LRP mRNA and protein expression which were observed, were 
actually due to targeting of the gene with the antisense and ribozyme constructs. The
227
high degree of variability seen in the control vector transfectants highlights the need 
for an alternative to the cloning out of individual cells from a population.
One method of circumventing this is to simply transfect the OAW42SR cell line with 
the same constructs and select with geneticin, but to analyse the heterogeneous 
transfectant population en mass. The levels of expression of the ribozyme and 
antisense constructs, and thus LRP mRNA and protein, may differ greatly from cell to 
cell. However, if the population as a whole exhibits a drop in LRP expression, it 
should be possible to assess whether drug resistance is affected, thus avoiding the 
additional problems of clonal variation.
In keeping with this proposal, the OAW42SR cell line was once again transfected 
with the anti-LRP ribozyme and antisense constructs, in addition to the control vector. 
The transfectants were selected for 4 weeks in increasing concentrations of geneticin. 
The populations were then analysed for LRP mRNA expression by northern blot, LRP 
protein expression by immunoprécipitation, and drug resistance by in vitro toxicity 
assays. The expression levels of mdr-1, MRP, ribozyme/antisense constructs and 
internal control gene P-actin were also assessed using RT-PCR.
4.2.1 Analysis of LRP mRNA expression by northern blot
The northern blot analysis o f LRP mRNA expression in the uncloned OAW42SR 
transfectants (Figures 3.3.2.1 and 3.3.2.2) show that the anti-LRP ribozyme caused 
only a very minor reduction in LRP expression. LRP expression in the antisense RNA 
transfectants appears to be increased as compared to the parental cells. In fact, only 
the control vector transfectants displayed a significant reduction in LRP mRNA 
levels, of between 40 and 60%. These results were contrary to expected findings.
Due to the substantial reduction in LRP mRNA for the pHp transfectants, it was 
important to establish that there was no mix up in plasmids prior to transfection, and 
that it was indeed the empty control vector pHP that had been transfected. RT-PCR
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analysis confirmed the presence of only the vector in these cells (Figure 3.3.3.1). The 
band seen for the pHp transfectants in the ribozyme/anti sense expression RT-PCR 
was slightly smaller than the antisense band, as expected. The ribozyme and antisense 
expression bands were present in the ribozyme and antisense transfectants samples 
respectively, confirming that the constructs were being expressed in these cells.
4.2.2 Analysis of LRP expression by immunoprécipitation
The immunoprécipitation procedure was repeated three times on different cell pellet 
samples, prepared at separate times, from the uncloned transfectants and the parental 
cells. However, absolutely no LRP expression could be observed in any of the 
samples on any occasion. Even, the positive control SW1573-2R120 cells failed to 
produce any hint of LRP expression. This failure of the immunoprécipitation 
procedure was perplexing. During earlier immunocytochemical analysis, batch 
variation in the LRP-56 MAb had been observed. On certain occasions, no LRP 
expression could be detected with certain batches of the antibody, in any of the 
OAW42SR or OAW42S clones. It may have been that the batch of antibody 
purchased for this immunoprécipitation analysis was not of adequate standard.
4.2.3 Adriamycin and Vincristine Toxicity assays
The results of the toxicity assays (Figures 3.3.1.1 to 3.3.1.4) revealed that all of the 
transfected cell populations displayed a reduction in resistance to both adriamycin and 
vincristine. For both drugs, the greatest decrease was observed for the pH(3 transfected 
cells. However, this decrease was only marginally greater than for the antisense or 
ribozyme transfected cells.
There appears to be no correlation between the levels of LRP mRNA in the 
transfected cells and the levels of resistance to adriamycin and vincristine. The 
antisense RNA expressing cells show a much greater level of LRP mRNA expression
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than the ribozyme expressing cells, while both exhibit similar drug resistance levels. 
However, as seen earlier, LRP mRNA levels in the antisense transfected cells cannot 
be correlated with LRP protein expression.
The levels of mRNA and protein expression were found to correlate for the ribozyme 
and control pHP vector clones described earlier. Therefore, between these two 
populations a weak correlation may be drawn between LRP expression and drug 
resistance. However, there is some discrepancy between the magnitude of reduction in 
LRP mRNA and the magnitude of reduction in IC50 values. The pHp-transfected 
population exhibits a 2-fold lower level of LRP mRNA expression, and yet exhibits 
only a 1.3-fold drop in adriamycin and vincristine IC50 values.
There is, once again, little evidence to support a direct role for LRP in multidrug 
resistance
4.2.4 RT-PCR analysis of mdr-1 and MRP expression
RT-PCR analysis revealed a lack of reduction in either mdr-1 or MRP expression for 
any of the transfected populations (Figures 3.3.3.3 and 3.3.3.4). These two MDR 
related proteins appear, therefore, to have no role in the observed reductions in drug 
resistance, although variations in protein level and activity cannot be ruled out. It may 
be that the transfection of cells with an expression vector interferes with some other 
mediator of drug resistance, whose analysis has not been included in this work. 
Whether this postulated mediator of drug resistance was a known protein, or some, as 
yet, undiscovered mechanism would require much time and effort.
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4.3 Use of antisense oligonucleotides to downregulate LRP expression
Another method of modulating LRP expression without the associated problems of 
selection of clones and clonal variation is to use antisense oligonucleotides. The use 
of antisense oligonucleotides is more widespread than the use of ribozymes or 
antisense RNA to downregulate the expression of a target gene. There are therefore 
an extensive number of reports and guidelines governing their use, as discussed 
earlier (Stein, 1994; Branch, 1996; Byrne et al., In press; see also Section 1.5).
Out o f 50 potential sequences, only 6 were found to be sufficiently unique in terms of 
compatibility to the human genome. These 6 sequences spanned the entire LRP gene 
sequence (see Figure 3.4.1): LRP Al was targeted to the 5’ untranslated region; LRP 
A2 targeted the initiation codon region; LRP A3 was directed to a site just 3 ’ of the 
initiation codon; LRP A4 and A5 were targeted to coding region; and LRP A6 was 
directed against the 3’ untranslated region. All of these sites have been successfully 
targeted by other researchers targeting different genes (see Section 1.5.4 and Table
1.5.4). The sequence targeted by LRP A5 was the same as that targeted by the anti- 
LRP ribozyme and antisense RNA constructs. The sense sequences corresponding to 
LRP A2 and A5 (LRP S2 and LRP S5 respectively) were used as controls. In later 
experiments, a scrambled version of LRP A2 and a nonsense oligonucleotide were 
used as additional controls. Cells treated with only lipofectin and untreated controls 
were also used. All the oligonucleotides were phosphorothioates, the most widely 
used form of antisense (see Section 1.5.3). The oligonucleotides ranged in size from 
16 to 20 bp, and thus, were sufficiently long to be unique relative to the entire genome 
(Branch, 1996). All oligonucleotides were delivered using lipofectin, a liposome 
based transfection reagent. They were delivered, unless otherwise stated, at a 
concentration of 1 |iM. Cells were treated with a double dose of antisense, separated 
by 24h.
The total length of treatment was 48h prior to RNA isolation, and 72h before protein 
analysis and toxicity assays. Work on the downregulation of Pgp expression using 
antisense oligonucleotides, (Bertram et al., 1995; Li et al., 1997) has demonstrated 
that treatment length must be sufficient to allow for the full antisense effect on protein
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expression to be observed. The length of treatment required depends on the half-life 
of the target protein. The half-life of the LRP protein is, as yet, unknown. It was 
thought that 72 h of treatment should allow for downregulation of the protein to be 
evident. Stewart et al., (1996), demonstrated the increased efficacy of antisense 
oligonucleotides when employed in a two-hit or double-dose regime, as was 
employed in this thesis.
In order to test the transfection procedure, and the methods used to detect target gene 
mRNA and protein expression levels, anti-mdr-1 antisense oligonucleotides were 
employed (Table 3.4.1). The two antisense sequences used had previously been 
shown to cause downregulation of mdr-1 mRNA and Pgp expression (see Table
1.5.4). The corresponding sense sequences were used as controls. If the down­
regulation of mdr-1 and Pgp could be demonstrated through the use of these antisense 
oligos, then it could reasonably assumed that the same methods of transfection and 
detection would work for LRP antisense sequences.
4.3.1 Immunocytochemical staining with LRP-56 MAb on antisense treated 
OAW42SR cells
Initial immunocytochemical analysis with the LRP-56 MAb (Table 3.4.3.1) showed 
that all 6 antisense oligonucleotides caused a reduction in LRP expression in relation 
to sense oligonucleotide treated, lipofectin treated and untreated control cells. There 
was a degree of variation in staining intensity present, even on different cytospins 
from the same antisense treatment. It has been noted in this laboratory that the 
staining can be affected by ambient conditions, leading to day-to-day variations in 
staining patterns and intensity. It was thought unusual that all of the antisense 
sequences appeared capable of downregulating LRP. Many researchers have 
employed only one or two antisense oligonucleotides in their experiments, and based 
all their work upon these (Vasanthakumar and Ahmed, 1989; Rivoltini et a l,  1990; 
Clynes et al., 1992; Efferth and Volm, 1993; Thierry et al., 1993; Cucco and 
Calabretta, 1996; Hirtake et al., 1997; Liu et al., 1997; Sola and Colombani, 1997). 
However, any work which has employed a number of oligonucleotides and a 
screening process to find the most effective sequence, has found that only a small
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fraction of sequences tested will actually exhibit antisense effects (Jaroszewski et al., 
1990; Bertram et a l, 1995; Alahari et al., 1996; Stewart et al., 1996). The fact that all 
of the antisense sequences were effective, could indicate that the LRP mRNA has a 
fairly open structure with low levels of intramolecular bonding and secondary 
structure formation.
To see if the concentration of oligonucleotide being used (1 pM) was the optimal 
concentration, the effects of three different concentrations (1 ,2  and 5 fxM) of LRP A2 
on LRP expression were compared. The concentration of antisense oligonucleotide to 
be used in an experiment appears to vary greatly between authors, with no general 
consensus being evident. Vasanthakumar and Ahmed, (1989), used a 30 pM 
concentration of oligo. Efferth and Volm, (1993), found that in their experiments 10 
pM was more effective than 1 or 5 pM. Bertram et a l,  (1995), observed that a 
concentration of 2 |iM gave better results than either 0.2 or 5 [iM. When targeting 
MRP expression, Stewart and colleagues used an oligonucleotide of 0.5 pM, as higher 
concentrations were found to be slightly toxic to cells. It can be seen from these 
examples that there are no strict guidelines as to which concentration to employ. It 
appears to vary between the choice of oligonucleotide and cell line. One definite 
observation is that increased oligonucleotide concentration does not always lead to 
increased antisense effects, as the use of too high a concentration of oligonucleotides 
could be toxic to the cells. In the work presented here (Table 3.4.3.1), only very 
minimal variations were observed, with all three concentrations causing a marked 
drop in LRP expression. It was therefore decided that the original concentration of 1 
|iM was sufficient for the purposes of these experiments.
The treatment of the OAW42SR cells with the anti-mdr-1 antisense and sense 
oligonucleotides had variable effects (Table 3.4.3.2). In 2 out of 3 repeats, the mdr-1 
antisense induced a greater reduction in Pgp levels than the corresponding sense 
sequence. However, in only 1 out of 3 repeats did mdr-1 antisense treated cells show a 
reduction in Pgp as compared to lipofectin-only treated or untreated cells.
The use of sense control oligonucleotides alone is not deemed sufficient for proof of 
antisense effect (Stein, 1994; Wagner, 1994; Branch, 1996). Therefore, the scrambled
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control (SCR) and a nonsense oligonucleotide (NON) were employed in further 
imrnunocytochemical analysis in addition to the LRP A1 and A2 antisense sequences, 
and the LRP S2 sense oligonucleotide. 2R120 cells were also treated with these 
oligonucleotides, to examine if cells with higher expression levels of LRP could also 
be targeted effectively with the antisense sequences.
In the first set of treatments (Table 3.4.3.3 (a)), the LRP A1 antisense appeared to 
have a greater impact than the LRP A2 sequences in downregulating LRP expression 
in the OAW42SR cells. However, in the 2R120 cells, this efficacy was reversed, with 
LRP A2 being more effective than LRP Al. The results for the second set of 
treatments (Table 3.4.3.3 (b)) shows a highly variable pattern of staining for both 
antisense sequences. Both antisense sequences appeared to be largely ineffective in 
2R120 cells. Both LRP A l and A2 had varying success in reducing LRP levels in the 
OAW42SR cells. LRP A2 caused a decrease in LRP in OAW42SR cells in repeats 1 
and 3 of the staining, while LRP Al reduced LRP levels in repeat 2, All the other 
oligonucleotides had no visible effect on LRP expression, in comparison to the 
untreated control cells.
This variability in staining patterns meant that these results in isolation were of no real 
value in determining whether the downregulation of LRP with the antisense 
sequences, was a true sequence-specific antisense effect.
4.3.2 Immunoprécipitation analysis of LRP expression in antisense treated 
OAW42SR cells
All samples for immunoprécipitation analysis were taken 72h post-initiation of 
treatment. The first repeat of the immunoprécipitation procedure (Figure 3.4.6.1) 
demonstrated an almost total elimination of LRP expression in the LRP Al antisense 
treated OAW42SRs. All the other oligonucleotides appeared ineffective at reducing 
LRP expression. The reduced LRP band observed for cells treated with the scrambled 
control (SCR), is probably not that significant. The lack of the immunoglobulin 
secondary band indicates unequal loading of this sample. However, from this result,
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LRP A2 appeared to have no effect on LRP expression, contrary to the findings by 
immunocytochemistry.
In a second repeat of this procedure (Figure 3.4.6.2), however, both LRP Al and LRP 
A2 caused a significant reduction in the level of LRP expression, as compared to 
control oligonucleotide treated and untreated cells. A possible explanation for the 
failure of LRP A2 to reduce LRP expression during the first treatment, is the 
degradation of the oligonucleotide through repeated thawing and freezing of the stock 
sample, although there have been no such reports in the literature. A freshly 
manufactured batch of antisense oligonucleotides was used for the second repeat of 
the immunoprécipitation procedure. From that point onwards, the oligonucleotides 
were aliquoted upon delivery, to avoid repeated thawing/freezing.
These more unambiguous immunoprécipitation results, in addition to the 
immunocytochemistry results, clearly indicate the ability of the antisense 
oligonucleotide to reduce LRP expression at the protein level. This reduction appears 
to be a sequence-specific antisense effect, as none of the control oligonucleotides 
caused a similar decrease in LRP expression.
4.3.3 RT-PCR analysis of LRP mRNA expression in antisense treated OAW42SR 
cells
Initial RT-PCR analysis of total RNA samples extracted from OAW42SR cells after 
48h treatment with all 6 antisense oligonucleotides (Figure 3.4.4.1), failed to show up 
any reduction in LRP levels. It may have been that the level of LRP downregulation 
by the antisense was not discernible by RT-PCR. As seen with anti-LRP ribozyme 
transfected OAW42SR cells (see Section 4 .4), the magnitude of LRP down-regulation 
was much greater at the protein level than the mRNA level. It seems that small 
reductions in the mRNA are being amplified to large reductions at the protein level.
RT-PCR on mdr-1 antisense and sense treated cells revealed a visible drop in mRNA 
levels for the antisense treated over sense treated or untreated cells (Figure 3.4.4.2).
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This demonstrated the efficacy of the mdr-1 antisense, and validated the protocols 
used for transfection of the antisense.
In an attempt to demonstrate antisense inhibition of LRP over a period of time, total 
RNA samples were taken from OAW42SR cells treated with LRP A2, at times 0, 4, 
24 and 48h post initiation of treatment. As with all treatments, a second dose of 
antisense was added at 24h to prolong the antisense effect. The first repeat of this 
experiment showed that at 4h post-initiation of treatment, the level o f LRP mRNA is 
already significantly reduced (Figure 3.4.4.3 (a)). At 24h, the LRP levels appear to 
have reduced further, with this level of inhibition being maintained until at least 48h. 
However, the bands for the internal control (3-actin gene, are slightly fainter for these 
last two time points, indicating that maximal inhibition may indeed be reached by 4h. 
This is borne out by two further repeats of this assay (Figure 3.4.4.3 (b) and (c)), in 
which LRP reaches its lowest level after just 4h of treatment, and this level is 
maintained for at least 44h. The actual maximal level of inhibition reached appears to 
vary from repeat to repeat, possibly reflecting batch variation in the oligonucleotides. 
Cells treated with sense (LRP S2) oligonucleotides, or untreated cells display no 
reduction in LRP levels over time (Figure 3.4.4.3 (d) and (e)).
When treatment of the OAW42SR cells with LRP A1 and A2 was compared to 
treatment with the full range of control oligonucleotides, no differences in LRP 
expression were discernible (Figure 3.4.4.4). This is despite the fact that changes in 
LRP expression were clearly visible by RT-PCR for the treatment with LRP A2 over 
time (Figure 3.4.4.3). This indicates the intrinsic variability of the RT-PCR procedure.
4.3.4 N orthern blot analysis of LRP mRNA expression in antisense treated 
OAW42SR cells
Northern blots, using probes for LRP and GAPDH, confirmed the ability of both LRP 
A1 and A2 to inhibit LRP expression at the mRNA level. Figure 3.4.7 (c) illustrates 
the three fold reduction in LRP mRNA seen after treatment with LRP Al, and the 
almost 2-fold drop after treatment with LRP A2, as compared to untreated cells. Sense
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and lipofectin only treated cells, exhibited similar LRP expression levels as the 
untreated controls, while nonsense (NON) and scrambled (SCR) oligonucleotide 
treated cells, appeared to show an actual increase in LRP expression. Similar 
increases in target mRNA expression have been seen even after antisense treatment in 
some cell systems (Probst and Skutella, 1996).
4.3.5 Adriamycin toxicity assays on antisense treated OAW42SR cells
The above results have clearly demonstrated the potential o f the anti-LRP antisense 
sequences to inhibit LRP expression at both the mRNA and protein level. Adriamycin 
toxicity assays were used to see if this reduction in LRP was correlated to a decrease 
in drug resistance. In order to eliminate any possible complication of toxicity assay 
results through the expression of Pgp and MRP, inhibitors of these proteins were 
employed in the toxicity assays. Indomethacin and cyclosporin A were used to inhibit 
MRP and Pgp respectively, and were used at the maximum non-toxic dose. This dose 
was calculated from toxicity assays using these compounds (data not shown). Toxicity 
assays were also performed in the absence of these inhibitors.
Table 3.4.5.1 illustrates that all of the antisense oligonucleotides caused a decrease in 
adriamycin IC50 in the OAW42SR cells, as compared to lipofectin only treated or 
untreated cells. Increasing the concentration of LRP A2 causing only a minor increase 
in sensitivity. This correlates with the minimal reduction in LRP protein expression 
seen when oligonucleotide concentration was increased from 1 to 5 (J.M (Table 
3.4.3.1).
However, sense treated cells also displayed a significant, if somewhat smaller, 
decrease in adriamycin IC50 value as compared to the untreated controls. Mdr-1 
antisense treated cells were shown to be more sensitive than the untreated cells. 
However, once again, the sense treated cells also displayed a significant reduction in 
IC50 value. All these effects were seen in either the presence or absence of 
indomethacin and cyclosporin A. This appeared to indicate that the effects seen were 
due to alterations in LRP alone.
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It was not clear, at this point, whether the observed reductions in IC50 value after 
treatment with sense oligonucleotides were isolated phenomena, or whether all 
oligonucleotides would cause a similar effect. This would indicate that the antisense 
was acting non-specifically to induce reductions in adriamycin IC50 value.
When the action of LRP A1 and A2 was examined in parallel with the sense, 
nonsense and scrambled control oligonucleotides (Figure 3.4.5.2), it was found that 
there was no difference in IC5o value between anti sense treated or control oligo 
treated cells. It has been clearly demonstrated that both LRP A1 and LRP A2 do 
reduce LRP expression levels, while the control oligos have no apparent effect. The 
absence of decreases in IC50 values for the antisense treated cells over control oligo 
treated cells, obviously points towards LRP having no role in drug resistance.
There were a number of considerations, however, before fmal judgement on LRP’s 
role in drug resistance in antisense treated cells could be made. The toxicity assays, 
described above, were performed in 96-well plates. The cells, which were used for 
analysis of mRNA and protein expression, were grown in 25 and 75 cm2 flasks. 
Flasks and 96-well plates cultivate different cellular environments. For instance, the 
IC50 value for a given drug would be different for cells grown in flasks and cells 
grown in 96-well plates. In addition, a number of the oligonucleotides displayed toxic 
effects on cells grown in 96-well plates, while no effects were generally visible in 
cells grown in flasks (results not shown). This may be due only to the difference in 
culture times between cells grown for mRNA/protein analysis (2/3 days) and toxicity 
assays (8 days), but this was not proven. It was decided, therefore, to perform a 
number of toxicity assays on cells grown in 25cm2 flasks.
Another consideration was that during conventional drug toxicity assays, the cells are 
incubated with drug present for 7 days. Obviously, during the last few days of the 
assay, any antisense effect would have worn off, with the oligonucleotides being 
degraded. Therefore, the results seen may not truly reflect the effect of the antisense 
on protein expression. To overcome this problem, pulsed drug addition was used. 
After 72 h of antisense treatment, cells were pulsed with adriamycin for 2 hours. The 
cells were then incubated for a further 4 days in antisense- and drug-free media, to 
allow any toxic effect of the drug on cellular metabolism to be expressed. It has been
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s h o w n  ( F i g u r e  3 . 4 . 6 . 1  a n d  3 .4 .6 . 2 )  t h a t  L R P  p r o t e in  e x p r e s s i o n  is  s i g n i f i c a n t l y  
r e d u c e d  a t  7 2 h .  I t  w a s  p o s t u la t e d ,  t h e r e f o r e ,  t h a t  t h is  m e t h o d  o f  p u l s i n g  c e l l s  w i t h  
d r u g ,  w h e n  t h e r e  w a s  a  s i g n i f i c a n t  r e d u c t i o n  o f  L R P  e x p r e s s io n  in  a n t i s e n s e  t r e a t e d  
c e l l s ,  s h o u ld  c l e a r l y  i n d i c a t e  w h e t h e r  o r  n o t  L R P  p l a y e d  a  r o l e  i n  d r u g  r e s i s t a n c e .
T a b l e  3 .4 .5 .3  s h o w s  t h a t  L R P  A 2  t r e a t e d  c e l l s  d o  s h o w  s l i g h t l y  r e d u c e d  a d r i a m y c i n  
I C 5 0  v a l u e s ,  a s  c o m p a r e d  t o  s e n s e  t r e a t e d  a n d  u n t r e a t e d  c e l ls .  N o n s e n s e  t r e a t e d  c e l ls ,  
a p p e a r  t o  s h o w  a  s i g n i f i c a n t  i n c r e a s e  i n  r e s i s t a n c e  t o  a d r ia m y c in .  T h e  f a c t  t h a t  L R P  
A 2  t r e a t e d  c e l l s  d i s p l a y e d  n o t  e v e n  a  2 - f o l d  r e d u c t i o n  in  r e s i s t a n c e  t o  a d r i a m y c i n  a s  
c o m p a r e d  t o  u n t r e a t e d  c e l l s ,  w h i l e  L R P  e x p r e s s i o n  l e v e l s  i n  a n t i s e n s e  t r e a t e d  c e l l s  
h a v e  b e e n  s h o w n  t o  b e  d r a m a t i c a l l y  r e d u c e d ,  in d i c a t e s  a  l a c k  o f  a n y  s i g n i f i c a n t  r o l e  
f o r  L R P  i n  d r u g  r e s i s t a n c e .  T h i s  i s  s u p p o r t e d  b y  t h e  f a c t  t h a t  a d r i a m y c i n  r e s i s t a n c e  
w a s  m a r k e d l y  e l e v a t e d  i n  n o n s e n s e  t r e a t e d  c e l l s ,  w h i l e  n o  in c r e a s e  in  p r o t e i n  
e x p r e s s i o n  w a s  o b s e r v e d  i n  t h e s e  c e l ls .  H o w e v e r ,  t h e  t o x i c i t y  a s s a y s  d i s p l a y e d  a  h i g h  
d e g r e e  o f  v a r i a t i o n  a n d  t h e  m a r g i n s  o f  e r r o r  f o r  t h e s e  r e s u l t s  a r e  q u i t e  la r g e .  I n  s p i t e  o f  
t h is ,  t h e r e  a p p e a r s  t o  b e  n o  e v i d e n c e  f r o m  t h e  a b o v e  a n t i s e n s e  e x p e r im e n t s ,  t o  s u p p o r t  
a  d i r e c t  r o l e  f o r  L R P  i n  d r u g  r e s i s t a n c e .
4.4 LRP plays no m ajor role in MDR in OAW42SR cell line
A l l  o f  t h e s e  r e s u l t s  p r e s e n t e d  a b o v e  c o n t r a d ic t  t h e  t h e o r y  t h a t  L R P  i s  i n v o l v e d  i n  d r u g  
r e s i s t a n c e .  T h e  e v i d e n c e  t h a t  h a d  b e e n  p r e s e n t e d  t o  d a t e , p o s t u l a t i n g  t h a t  L R P  
m e d i a t e d  a  n o v e l  f o r m  o f  m u l t i d r u g  r e s i s t a n c e ,  i s  m a i n l y  c i r c u m s t a n t i a l .  L R P  w a s  
d i s c o v e r e d  t h r o u g h  t h e  s e l e c t i o n  o f  S W 1 5 7 3  l u n g  c a r c i n o m a  c e l l  l i n e  t o  i n c r e a s i n g  
c o n c e n t r a t i o n s  o f  a d r i a m y c i n  ( S c h e p e r  et. al., 1 9 9 3 ) .  T h e s e  c e l l s  w e r e  f o u n d  t o  b e  P g p  
n e g a t i v e ,  b u t  e x h ib i t e d  a n  e n e r g y  d e p e n d e n t  r e d u c t i o n  o f  d r u g  a c c u m u la t i o n .  T h e y  
a l s o  d i s p l a y e d  m o d e r a t e  c r o s s - r e s i s t a n c e  t o  v i n c r i s t i n e ,  g r a m i c i d i n  D  a n d  e t o p o s id e .  A  
r e v e r t a n t  c e l l  l i n e ,  w h i c h  w a s  c u l t u r e d  f o r  9  m o n t h s  w i t h o u t  d r u g ,  e x h i b i t e d  a  
r e d u c t i o n  i n  L R P  e x p r e s s i o n  b a c k  t o  p a r e n t a l  l e v e l s ,  a n d  a  c o n c o m i t a n t  r e v e r s a l  o f  
d r u g  r e s i s t a n c e .
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L R P  w a s  f o u n d  t o  b e  t h e  m a j o r  v a u l t  p r o t e i n  ( M V P )  ( S c h e f f e r  et a l, 1 9 9 5 ) .  T h e  
e v o l u t i o n a r y  c o n s e r v a t i o n  o f  t h e  M V P  s e q u e n c e ,  a n d  i t s  a b u n d a n t  e x p r e s s io n ,  i m p l i e d  
i t s  i m p o r t a n c e  i n  c e l l  f u n c t i o n  ( R o m e  et a l,  1 9 9 1 ) .  S t r u c t u r a l  s im i l a r i t ie s  s u g g e s t e d  
t h a t  v a u l t s  c o m p r i s e  t h e  c e n t r a l  p l u g  o f  t h e  N P C  a n d  m a y  m e d i a t e  b i d i r e c t i o n a l  
t r a n s p o r t  o f  s u b s t r a t e s  b e t w e e n  t h e  n u c l e u s  a n d  c y t o p l a s m  ( R o m e  et al., 1 9 9 1 ;  
C h u g a n i  et al., 1 9 9 3 ) .
W i d e s p r e a d  o v e r e x p r e s s i o n  o f  L R P  w a s  f o u n d  in  b o t h  d r u g - s e l e c t e d  a n d  d r u g -  
u n s e l e c t e d  d r u g  r e s i s t a n t  c a n c e r  c e l l  l i n e s  o f  v a r i o u s  o r i g i n s  ( S c h e p e r  et al., 1 9 9 3 ;  
V e r o v s k i  et al., 1 9 9 6 ;  M o r a n  et al., 1 9 9 7 ;  s e e  a l s o  S e c t i o n  1 .2 .3 ) .  L R P  is  
o v e r e x p r e s s e d  in  c e l l  l i n e s  s e l e c t e d  w i t h  a  w i d e  r a n g e  o f  c l a s s i c a l  ( i .e .  a n t h r a c y c l i n e s ,  
Vinca a l k a l o i d s  a n d  e p i p o d o p h y l l o t o x i n s )  a n d  n o n - c l a s s i c a l  ( i .e .  a n t im e t a b o l i t e s ,  
c o v a l e n t  D N A - b i n d i n g  d r u g s  a n d  n o n - c o v a l e n t  D N A - b i n d i n g  d r u g s )  M D R  d r u g s  
( S c h e p e r  et al., 1 9 9 3 ;  I k e d a  et a l, 1 9 9 7 ;  K o m a r o v  et al., 1 9 9 7 ) .
L R P  h a s  b e e n  f o u n d  t o  b e  a  v e r y  u s e f u l  p r o g n o s t i c  i n d i c a t o r  in  t h e  t r e a t m e n t  o f  
c a n c e r s .  L R P  i s  h i g h l y  e x p r e s s e d  i n  c a n c e r s  t h a t  a r e  r e f r a c t o r y  t o  c h e m o t h e r a p y ,  w h i l e  
c h e m o s e n s i t i v e  t u m o r s  e x p r e s s  L R P  i n  o n l y  a  m i n o r i t y  o f  c a s e s  ( I z q u i e r d o  et a l, 
1 9 9 6 a ) .  L R P  is  m o r e  l i k e l y  t o  b e  e x p r e s s e d  i n  m a l i g n a n t  m e l a n o m a s  a n d  l u n g  c a n c e r s  
t h a t  h a v e  p r e v i o u s l y  b e e n  e x p o s e d  t o  c h e m o t h e r a p e u t i c  d r u g s  t h a n  u n t r e a t e d  c a n c e r s  
( S c h a d e n d o r f  et a l, 1 9 9 5 ;  D i n g e m a n s  et al., 1 9 9 6 ) .  T h i s  s u g g e s t s  a n  a s s o c i a t i o n  
b e t w e e n  e x p o s u r e  t o  a n t i c a n c e r  d r u g s  a n d  i n d u c t i o n  o f  L R P .  A d d i t i o n a l l y ,  L R P  is  
k n o w n  t o  b e  a  g o o d  i n d i c a t o r  o f  p o o r  r e s p o n s e  t o  c h e m o t h e r a p y  i n  a d u l t  a c u t e  
l e u k a e m i a  ( K l u m p e r  et al., 1 9 9 5 ) .  I t  h a s  a l s o  b e e n  d e m o n s t r a t e d  t h a t  L R P  
o v e r e x p r e s s i n g  c e l l  l i n e s  r e d is t r ib u t e  d a u n o r u b ic i n  i n t o  a  p u n c t a t e  c y t o p l a s m i c  
p a t t e r n .  L R P  n e g a t i v e  p a r e n t a l  c e l l s  l o c a l i s e  d a u n o r u b ic in  in  a  d i f f u s e  n u c l e a r  a n d  
c y t o p l a s m i c  p a t t e r n  ( D i e t e l  et al., 1 9 9 0 ) .
H o w e v e r ,  n o n e  o f  t h e s e  f i n d i n g s  p r o v i d e d  d i r e c t  e v i d e n c e  o f  L R P  m e d i a t e d  d r u g  
r e s i s t a n c e .  T h e r e  h a v e  a l s o  b e e n  r e p o r t s  t h a t  a p p e a r  t o  c o n t r a d ic t  t h is  t h e o r y .  I n  t h e  
o v a r i a n  c a r c i n o m a  c e l l  l i n e  O A W 4 2 S ,  i t  w a s  f o u n d  t h a t  w i t h  i n c r e a s i n g  p a s s a g e s  o f  
t h e  c e l l s ,  t h e  l e v e l  o f  L R P  e x p r e s s i o n  i n c r e a s e d  s i g n i f i c a n t l y  ( M o r a n  et a l,  1 9 9 7 ) .  
H o w e v e r ,  t h e r e  w a s  n o  c o n c o m i t a n t  i n c r e a s e  in  t h e  c e l l s  r e s i s t a n c e  t o  
c h e m o t h e r a p e u t i c  d r u g s .  T h e  a u t h o r s  p o s t u l a t e d  t h a t  a  n o n - f u n c t i o n a l  f o r m  o f  L R P
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m i g h t  b e  p r e s e n t  in  t h e s e  c e i l s .  H o w e v e r ,  i t  c o u l d  e q u a l l y  b e  t h a t  L R P  is  n o r m a l l y  c o ­
e x p r e s s e d  w i t h  s o m e  u n k n o w n  r e s i s t a n c e  m e c h a n i s m ,  t h a t  i s  a b s e n t  in  t h e s e  O A W 4 2 S  
c e l ls .
T r a n s f e c t i o n  a n d  e x p r e s s i o n  o f  t h e  f u l l - l e n g t h  L R P  c D N A  c o n s t r u c t  in t o  m o u s e  3 T 3  
f i b r o b l a s t s  f a i l e d  t o  c o n f e r  a  M D R  p h e n o t y p e  ( S c h e f f e r  et a l , 1 9 9 5 ) .  I t  h a s  a l s o  b e e n  
r e p o r t e d  b y  t h e  s a m e  a u t h o r s ,  t h a t  in d u c t i o n  o f  L R P  e x p r e s s i o n  i n  d r u g  s e l e c t e d  c e l l  
l i n e s  c a u s e d  a  1 5 - f o l d  i n c r e a s e  in  v a u l t  s y n t h e s is  ( K i c k h o e f e r  et al., 1 9 9 8 ) .  I t  i s  
t h o u g h t  t h a t  L R P  i s  t h e  l i m i t i n g  f a c t o r  in  v a u l t  s y n t h e s is .  I f  t h is  i s  t h e  c a s e ,  t h e  l a c k  o f  
e v e n  a  m i n i m a l  in c r e a s e  i n  d r u g  r e s i s t a n c e  f o l l o w i n g  m a s s i v e  o v e r e x p r e s s i o n  o f  t h e  
L R P  c D N A ,  i n d i c a t e s  a  m i n o r  r o l e  i f  a n y  f o r  L R P  in  d r u g  r e s i s t a n c e .
S i n c e  t h e  d i s c o v e r y  o f  L R P  in  1 9 9 3 ,  t h e r e  h a s  b e e n  n o  e v i d e n c e  d i r e c t l y  l i n k i n g  L R P  
t o  d r u g  r e s i s t a n c e .  I n  n o  c a s e  h a s  L R P  e x p r e s s i o n  b e e n  e l i m in a t e d  t h r o u g h  t h e  u s e  o f  
g e n e t i c  m a n i p u l a t io n ,  t h u s  a l l o w i n g  c l e a r  a s s e s s m e n t  o f  i t s  r o l e  i n  d r u g  r e s i s t a n c e .  
T h e  w o r k  p r e s e n t e d  in  t h i s  t h e s i s  p r o v i d e s  t h i s  e v i d e n c e .  T h e  c l o n a l  v a r ia t i o n s  
o b s e r v e d  in  t h e  O A W 4 2 S R  a n d  O A W 4 2 S  t r a n s f e c t i o n  c l o n e s  m a s k e d  s o m e w h a t  t h e  
f u l l  e f f e c t  o f  t h e  r i b o z y m e s  a n d  a n t is e n s e .  Y e t ,  i t  w a s  t h is  v e r y  v a r i a t i o n  t h a t  p r o v i d e d  
a  w i d e  b a s e  o f  c l o n a l  p o p u l a t i o n s  w i t h  v a r y i n g  l e v e l s  o f  L R P  e x p r e s s i o n  w h i c h  a l l o w  
a  t h o r o u g h  c o m p a r i s o n  o f  L R P  e x p r e s s i o n  w i t h  d r u g  r e s i s t a n c e .  I t  w a s  s h o w n  t h a t ,  in  
t h e  O A W 4 2 S R  c e l l  l i n e  a t  l e a s t ,  L R P  p l a y e d  n o  d i r e c t  r o l e  i n  m e d i a t i n g  m u l t i d r u g  
r e s i s t a n c e .
I t  m a y  b e  t h a t  in  o t h e r  c e l l  l i n e s  L R P  i s  i n v o l v e d  i n  M D R ,  a n d  u n t i l  t h e s e  t y p e s  o f  
e x p e r i m e n t s  a r e  r e p e a t e d  i n  d i f f e r e n t  c e l l  l in e s ,  i t  c a n n o t  b e  r u l e d  o u t  t o t a l l y  t h a t  L R P  
i s  i n v o l v e d  i n  M D R .  H o w e v e r ,  t h e  e v i d e n c e  p r e s e n t e d  in  t h i s  t h e s i s  f o r  t h e  
O A W 4 2 S R  c e l l  l i n e  a p p e a r s  f a i r l y  c o n c l u s i v e .  I t  m a y  b e  t h a t  L R P  i s  c o - e x p r e s s e d  
w i t h  o t h e r  r e s i s t a n c e  m e c h a n i s m s .  K i c k h o e f e r  et a l ,  ( 1 9 9 8 ) ,  p o s t u la t e d  t h a t  L R P  m a y  
i n t e r a c t  w i t h  p r o t e i n s  o r  R N A  t h a t  a c t i v e l y  b in d  d r u g s .  T h e  f a c t  t h a t  L R P  w a s  f o u n d  
t o  b e  d o w n r e g u l a t e d  t o  s o m e  e x t e n t  i n  m a n y  c e l l s  ( s e e  S e c t i o n  4 . 1 . 6 ) ,  w h i c h  e x h ib i t e d  
l o w  d r u g  r e s i s t a n c e ,  l e n d s  s u p p o r t  t o  t h is  t h e o r y .
241
5. SUMMARY AND CONLCUSIONS
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5.1 Analysis of ribozyme and antisense RNA inhibition of LRP expression
A n a l y s i s  o f  t h e  a n t i - L R P  r i b o z y m e  a n d  a n t i s e n s e  t r a n s f e c t a n t  c l o n e s  d e m o n s t r a t e d  
t h a t  t h e r e  w a s  a  h i g h  d e g r e e  o f  v a r i a t i o n  i n  t h e  l e v e l s  o f  L R P  e x p r e s s io n  a n d  d r u g
r e s i s t a n c e  b e t w e e n  t h e  c l o n e s .  T h e  m a in  r e s u l t s  w e r e :
•  T h e r e  w a s  u p  t o  a  1 0 - f o l d  a n d  2 0 - f o ld  d e c r e a s e  i n  a d r i a m y c i n  a n d  v i n b l a s t i n e  IC50 
v a l u e s  r e s p e c t i v e l y ,  f o r  a  n u m b e r  o f  r i b o z y m e  a n d  a n t i s e n s e  R N A  t r a n s f e c t e d  
O A W 4 2 S R  c e l l s  ( F i g u r e s  3 . 1 . 2 . 5  a n d  3 . 1 . 2 . 6 ) .  H o w e v e r ,  s o m e  r i b o z y m e  a n d  
a n t i s e n s e  R N A  t r a n s f e c t a n t s  d i s p l a y e d  n o  r e d u c t i o n  in  r e s i s t a n c e .  A d d i t i o n a l l y ,  
w h i l e  s o m e  c o n t r o l  v e c t o r  ( p H f i)  t r a n s f e c t a n t s  w e r e  u n c h a n g e d  in  t h e ir  r e s i s t a n c e
l e v e l s ,  o t h e r s  s h o w e d  a  m a r k e d  r e d u c t i o n  in  r e s i s t a n c e .  T h i s  w a s  t h e  f i r s t
i n d i c a t i o n  o f  t h e  h i g h  d e g r e e  o f  c l o n a l  v a r i a t i o n  in h e r e n t  w i t h i n  t h e  h e t e r o g e n e o u s  
O A W 4 2 S R  p o p u la t io n .
•  T h e  r e d u c t i o n s  i n  I C 50 v a l u e s  f o r  r i b o z y m e  a n d  a n t i s e n s e  R N A  t r a n s f e c t e d  
O A W 4 2 S  ( F i g u r e s  3 . 1 . 2 . 7  a n d  3 . 1 . 2 . 8 )  c e l l s  w e r e  n o t  a s  d r a m a t ic  a s  f o r  t h e  
O A W 4 2 S R  c l o n e s .  T h i s  m a y  b e  d u e  t o  t h e  l o w e r  in t r i n s i c  r e s i s t a n c e  o f  t h e  
p a r e n t a l  O A W 4 2 S  c e l ls .  A  n u m b e r  o f  t h e  p H |3  t r a n s f e c t a n t s  d e m o n s t r a t e d  a  
r e d u c t i o n  i n  r e s i s t a n c e  t o  a d r i a m y c i n  a n d  v i n c r i s t i n e ,  s i m i l a r l y  t o  t h e  O A W 4 2 S R  
c l o n e s .  H o w e v e r ,  a s  t h e  O A W 4 2 S  c e l l  l i n e  is  a  h o m o g e n e o u s  c l o n e d  p o p u la t i o n ,  it  
h a d  b e e n  e x p e c t e d  t h a t  t h e  e x p r e s s io n  l e v e l s  in  t h e  c o n t r o l  c l o n e s  s h o u ld  b e  l e s s  
v a r i a b l e .  T h e r e  h a v e  b e e n  r e p o r t s  i n d i c a t i n g  t h a t  t h e  e x p r e s s i o n  l e v e l  o f  a  g i v e n  
g e n e  c a n  v a r y  e v e n  w i t h i n  a  c l o n e d  p o p u la t io n ,  d e r i v e d  e n t i r e l y  f r o m  o n e  c e l l  
( H a n c h e t t  et al. , 1 9 9 4 ) .
•  L R P  p r o t e i n  e x p r e s s i o n  w a s  s h o w n  t o  v a r y  g r e a t l y  b e t w e e n  b o t h  t h e  O A W 4 2 S R  
a n d  O A W 4 2 S  c l o n e s  a n d  t h e i r  r e s p e c t i v e  p a r e n t a l  c e l l s  ( S e c t i o n  3 . 1 . 3 ) .  I n  a  
n u m b e r  o f  c l o n e s  ( e .g .  S R - L R P - R z  2  a n d  S R - L R P - A S  1 )  L R P  e x p r e s s io n  w a s  
v i r t u a l l y  e l i m in a t e d ,  w h i l e  in  o t h e r s  ( e .g .  S R - L R P - R z  1 a n d  4 2 S - L R P - A S  1 0 )  n o  
c h a n g e  w a s  e v i d e n t .  T h e  d i f f e r e n c e s  in  L R P  e x p r e s s i o n  s e e n  f o r  t h e  d i f f e r e n t  p H 0  
c l o n e s  h i g h l i g h t s  t h e  e x t e n t  o f  t h e  c l o n a l  v a r ia t io n .
•  F r o m  t h i s  e a r l y  a n a l y s i s  o f  L R P  e x p r e s s i o n  a n d  d r u g  r e s i s t a n c e ,  t h e r e  a p p e a r e d  t o  
b e  l i t t l e  e v i d e n c e  c o r r e l a t i n g  L R P  w i t h  a  d i r e c t  r o l e  i n  m u l t i d r u g  r e s i s t a n c e .  S o m e  
c l o n e s  ( e .g .  S R - L R P - R z  2  a n d  S R - L R P - A S  1 )  a p p e a r e d  t o  h a v e  l o w  l e v e l s  o f  L R P
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a n d  c o r r e s p o n d in g  l o w  r e s i s t a n c e  l e v e l s .  I n  c o n t r a s t ,  t h e  c l o n e s  S R - L R P - A S  6  a n d  
4 2 S - p H P  1 d i s p l a y e d  l o w  L R P  e x p r e s s io n ,  b u t  h i g h  d r u g  I C 50 v a l u e s .  C o n v e r s e l y ,  
S R - p H f3  6  a n d  4 2 S - L R P - R z  4  e x h ib i t e d  h i g h  l e v e l s  o f  L R P ,  y e t  l o w  d r u g  
r e s i s t a n c e .  I n  s u m m a r y ,  t h e r e  w a s  a n  e q u a l  n u m b e r  o f  O A W 4 2 S R  c l o n e s  t h a t  
s u p p o r t e d  a  c o r r e l a t i o n  o f  L R P  e x p r e s s i o n  w i t h  d r u g  r e s i s t a n c e ,  a s  t h e r e  w a s  
c l o n e s  t h a t  f a i l e d  t o  s h o w  a n y  c o r r e l a t i o n .  A s  r e g a r d s  t h e  O A W 4 2 S  c l o n e s ,  t h e r e  
w e r e  a  g r e a t e r  n u m b e r  o f  c l o n e s  t h a t  d is c o u n t e d  a  r o l e  f o r  L R P  in  d r u g  r e s i s t a n c e  
t h a n  s u p p o r t e d  it .
N o  c o r r e l a t i o n  b e t w e e n  L R P  a n d  M D R  c o u l d  b e  c o n c l u d e d  f r o m  t h e  in i t i a l  a n a l y s i s  o f
O A W 4 2 S R  a n d  O A W 4 2 S  c l o n e s .  T h e r e f o r e ,  f u r t h e r ,  d e t a i l e d  a n a l y s i s  w a s  p e r f o r m e d
o n  a  s e l e c t e d  n u m b e r  o f  c l o n e s .
•  O n l y  t h e  c l o n e  S R - L R P - R z  2  d e m o n s t r a t e d  a  r e d u c t i o n  in  L R P  m R N A ,  a s  
m e a s u r e d  b y  R T - P C R  ( F i g u r e  3 . 2 . 1 . 1 . 1 ) .  N o r t h e r n  b l o t  a n a l y s i s  ( S e c t i o n  3 .2 .2 )  
a l s o  d e m o n s t r a t e d  a  s i g n i f i c a n t  r e d u c t io n  in  L R P  m R N A  in  S R - L R P - R z 2 ,  w i t h  
s m a l l e r  r e d u c t i o n s  b e i n g  e v i d e n t  in  S R - L R P - R z  4  a n d  S R - p H p  1 .  A l l  t h e  o t h e r  
c l o n e s ,  a l o n g  w i t h  t h e  p a r e n t a l  c e l l s ,  a p p e a r e d  i n v a r i a n t  i n  t h e i r  l e v e l s  o f  L R P  
e x p r e s s i o n .
•  T h e  l e v e l s  o f  L R P  m R N A  e x p r e s s io n  g e n e r a l l y  c o r r e l a t e d  w e l l  w i t h  p r o t e i n  
e x p r e s s i o n ,  a s  m e a s u r e d  b y  i m m u n o c y t o c h e m i s t r y  ( S e c t i o n  3 . 2 . 3 )  a n d  
i m m u n o p r é c i p i t a t i o n  ( S e c t i o n  3 .2 .4 ) .  T h e  o n l y  e x c e p t i o n  w a s  S R - L R P - A S  1 , 
w h i c h  d i s p l a y e d  o n l y  a  m i n o r  r e d u c t i o n  in  L R P  m R N A  l e v e l s ,  w i t h  a  v i r t u a l  
e l i m i n a t io n  a t  t h e  p r o t e i n  l e v e l .  T h i s  s u g g e s t e d  t h a t  a n t is e n s e  R N A  c a n  e f f e c t i v e l y  
i n h i b i t  p r o t e i n  p r o d u c t i o n  w i t h o u t  c l e a v i n g  t h e  p r e c u r s o r  m R N A .
•  N o  c o r r e l a t i o n  w a s  o b s e r v e d  b e t w e e n  L R P  m R N A  a n d  p r o t e i n  l e v e l s  i n  t h e  
O A W 4 2 S  c l o n e s .  H o w e v e r ,  m R N A  l e v e l s  w e r e  m e a s u r e d  o n l y  b y  R T - P C R  a n d , 
t h u s ,  w e r e  n o t  q u a n t i t a t iv e .
•  R T - P C R ,  i m m u n o c y t o c h e m i s t r y  a n d  W e s t e r n  b l o t  a n a l y s i s  d e m o n s t r a t e d  t h a t  
t h e r e  w a s  l i t t l e  v a r i a t i o n  i n  t h e  l e v e l s  o f  m d r - 1  a n d  M R P  e x p r e s s i o n  b e t w e e n  t h e  
c l o n e s  a n d  t h e  p a r e n t a l  c e l l s  ( S e c t i o n s  3 . 2 . 1 ,  3 .2 .5 ,  a n d  3 .2 .6 ) .
•  A n a l y s i s  o f  L R P  e x p r e s s i o n  i n  t h e  O A W 4 2 S R  c l o n e s  s u g g e s t s  t h a t  t h e  r i b o z y m e  
a n d  a n t i s e n s e  c o n s t r u c t s  w e r e  f u n c t i o n i n g ,  b u t  t h a t  t h e  e f f e c t s  o f  c l o n a l  v a r ia t i o n  
r e n d e r e d  a n a l y s i s  o f  t h e  e f f e c t  o f  L R P  m R N A  d o w n r e g u l a t i o n  o n  d r u g  r e s i s t a n c e
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d i f f i c u l t .  R T - P C R  a n a l y s i s  s h o w s  t h a t  t h e  r i b o z y m e  a n d  a n t i s e n s e  c o n s t r u c t s  w e r e  
b e i n g  e x p r e s s e d  i n  t h e  r e s p e c t i v e  c l o n e s .  B u t  a s  t h e r e  w a s  l a r g e  v a r ia t i o n s  i n  L R P  
e x p r e s s i o n  i n  t h e  p H p  c l o n e s ,  i t  c a n n o t  b e  a s s u m e d  t h a t  t h e  r e d u c t i o n s  i n  L R P  
e x p r e s s i o n  s e e n  i n  t h e  o t h e r  c l o n e s  a r e  d u e  e n t i r e ly  t o  t h e  e x p r e s s i o n  o f  t h e  
r i b o z y m e  a n d  a n t i s e n s e  c o n s t r u c t s .
•  I n  s p i t e  o f  t h is  u n c e r t a i n t y  r e l a t i n g  t o  r i b o z y m e / a n t i s e n s e  e f f i c a c y ,  t h e  w i d e  
s p e c t r u m  o f  L R P  e x p r e s s i o n  l e v e l s  in  t h e  d i f f e r e n t  c l o n e s  p r o v i d e s  a  g o o d  b a s is  
f o r  a s s e s s m e n t  o f  L R P ’ s  r o l e  in  d r u g  r e s i s t a n c e .
T o x i c i t y  a s s a y s  w e r e  p e r f o r m e d  w i t h  a  w i d e  r a n g e  o f  c l a s s i c a l  a n d  n o n - c l a s s i c a l  M D R  
d r u g s .  T h i s  w a s  d o n e  t o  i n d i c a t e  w h i c h  d r u g s  h a d  a  r e d u c e d  e f f i c a c y  i n  t h e  t r a n s f e c t e d  
c e l l s .
•  I t  a p p e a r s  t h a t  i n  s e l e c t e d  c l o n e s  e x p r e s s i n g  t h e  a n t i - L R P  r i b o z y m e  a n d  a n t i s e n s e  
c o n s t r u c t s  t h e r e  w a s  a  r e d u c t i o n  o f  r e s i s t a n c e  t o  a n t h r a c y c l i n e s  a n d  Vinca 
a l k a l o i d s ,  a n d  p o s s i b l y  t o  a  l e s s e r  e x t e n t  e p i p o d o p h y l l o t o x i n s  ( S e c t i o n  3 .2 .7 ) .  T h e  
r e s i s t a n c e  o f  t h e  c l o n e s  t o  a n t im e t a b o l i t e s ,  c o v a l e n t  D N A - b i n d i n g  a n d  n o n -  
c o v a l e n t  D N A - b i n d i n g  d r u g s  w a s  u n a f f e c t e d .
•  N o  d i r e c t  c o r r e la t i o n  c o u l d  b e  m a d e  b e t w e e n  t h e  l e v e l s  o f  L R P  p r o t e in  e x p r e s s io n  
a n d  l e v e l s  o f  r e s i s t a n c e  t o  e i t h e r  a d r i a m y c i n  o r  v i n c r i s t i n e .  A  n u m b e r  o f  d i f f e r e n t  
c l o n e s ,  w i t h  v a r y i n g  l e v e l s  o f  L R P  e x p r e s s io n ,  e x p r e s s e d  t h e  s a m e  l e v e l s  o f  
r e s i s t a n c e  t o  t h e  d r u g s  t e s t e d .
•  T h e  s i m i l a r i t y  o f  t h e  d r u g  p r o f i l e  d e s c r i b e d  a b o v e  t o  t h a t  o f  P g p ,  a ls o  r a is e s  
d o u b t s  a s  t o  w h e t h e r  t h e  o b s e r v e d  r e d u c t i o n s  in  d r u g  r e s i s t a n c e  a r e  m e d ia t e d  b y  
L R P  a s  o p p o s e d  t o  m d r - 1 .  E v e n  t h o u g h  t h e r e  w e r e  o n l y  s m a l l  a l t e r a t i o n s  i n  m d r - 1  
e x p r e s s io n ,  a l t e r e d  a c t i v i t y  o f  P - g l y c o p r o t e i n  b y  a l t e r e d  p h o s p h o r y l a t i o n  i s  a  
p o s s i b i l i t y .  N e v e r t h e l e s s ,  t h e  r e s u l t s  f o r  V P  1 6  m a y  n o t  b e  e n t i r e l y  c o n c o m i t a n t  
w i t h  a  P - 1 7 0 - m e d i a t e d  m e c h a n is m .
T h e  h i g h  d e g r e e  o f  c l o n a l  v a r i a t i o n  o b s e r v e d  in  t h is  w o r k  p r e v e n t e d  a  c l e a r  
e x a m i n a t i o n  o f  t h e  e f f i c a c y  o f  r i b o z y m e s  a n d  a n t i s e n s e  R N A  in  m o d u l a t i n g  L R P  
e x p r e s s io n .  H o w e v e r ,  i t  d id  p r o v i d e  a  n u m b e r  o f  c l o n e s  w i t h  v a r y i n g  l e v e l s  o f  L R P  
r e d u c t i o n ,  w h e t h e r  i t  w a s  in h e r e n t  o r  i n d u c e d .  T h e s e  c l o n e s  p r o v i d e d  a  c l e a r  b a s i s  
w i t h  w h i c h  t o  e x a m i n e  t h e  e f f e c t  o f  L R P  e x p r e s s io n  o n  t h e  d r u g  r e s i s t a n c e  o f  t h e
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c e l ls .  T h e  a b o v e  r e s u l t s  c l e a r l y  i n d i c a t e  t h a t  L R P  is  n o t  i n v o l v e d  in  t h e  m u l t i d r u g  
r e s i s t a n c e  i n  t h e  O A W 4 2 S R  c e l l s ,  o r  a t  l e a s t  is  n o t  t h e  r a t e - l i m i t i n g  s t e p  in  d r u g  
r e s i s t a n c e .  T h e  s i m i l a r i t y  o f  t h e  d r u g  p r o f i l e s  o f  t h e  c l o n e s  w i t h  t h a t  o f  P - g l y c o p r o t e i n  
o v e r e x p r e s s i n g  c e l l s  i n d i c a t e s  t h a t  m d r - 1  o v e r e x p r e s s i o n  m a y  b e  t h e  p r e d o m in a n t  
m e c h a n i s m  o f  r e s i s t a n c e  f o r  t h e s e  c e l l s .  N e v e r t h e l e s s ,  t h e  S R - L R P - R z  1 c l o n e ,  w h i c h  
e x h i b i t e d  h i g h  l e v e l s  o f  a d r i a m y c i n ,  v i n c r i s t i n e  a n d  V P - 1 6  r e s i s t a n c e ,  d id  n o t  a p p e a r  
t o  b e  o v e r e x p r e s s i n g  m d r - 1 .  H o w e v e r ,  t h e r e  m a y  h a v e  b e e n  s o m e  p o s t - t r a n s la t io n a l  
m o d i f i c a t i o n s  in  t h i s  c l o n e ,  w h i c h  i n d u c e d  t h e  P g p  p r e s e n t  t o  b e c o m e  a c t i v e .
5.2 Analysis of uncloned ribozyme and antisense RNA transfected OAW42SRs
T h e  t r a n s f e c t i o n  a n d  s e l e c t i o n  o f  O A W 4 2 S R  c e l ls ,  w i t h o u t  t h e  c l o n i n g  o u t  o f
i n d i v i d u a l  c e l l s ,  w a s  u s e d  a s  a n  a t t e m p t  t o  o v e r c o m e  t h e  p r o b l e m s  o f  c l o n a l  v a r ia t io n .
T h e  t r a n s f e c t e d  p o p u la t i o n s  w e r e  a n a l y s e d  a s  a  w h o l e  a n d  t h e r e f o r e  i n d i v i d u a l  c e l l  t o
c e l l  v a r i a t i o n s  s h o u ld  h a v e  b e e n  a v e r a g e d  o u t .  T h e  m a in  f i n d i n g s  w e r e :
•  T h e  l e v e l s  o f  L R P  m R N A  e x p r e s s i o n  w e r e  f o u n d  t o  b e  o n l y  m i n i m a l l y  d e c r e a s e d  
in  t h e  r i b o z y m e  t r a n s f e c t e d  c e l l s  ( S e c t i o n  3 .3 .2 ) .  T h i s  m a y  i n d i c a t e  t h a t  t h e  
e f f i c i e n c y  o f  r i b o z y m e  t r a n s f e c t i o n  w a s  n o t  s u f f i c i e n t  t h r o u g h o u t  t h e  p o p u la t i o n  t o  
r e s u l t  in  a  s i g n i f i c a n t  r e d u c t i o n  i n  L R P  e x p r e s s io n .  I n d i v i d u a l  c e l l s  m a y  h a v e  
e x h i b i t e d  h i g h  e x p r e s s i o n  o f  t h e  r i b o z y m e  a n d  t o t a l  e l i m in a t i o n  o f  L R P ,  b u t  t h e  
a p p a r e n t  h i g h  L R P  e x p r e s s i o n  in  t h e  m a j o r i t y  o f  c e l l s  w o u l d  h a v e  n e g a t e d  t h is  
e f f e c t .
•  T h e  a n t i s e n s e  R N A  t r a n s f e c t e d  O A W 4 2 S R  c e l l s  e x h ib i t e d  a n  i n c r e a s e  i n  L R P  
m R N A  l e v e l s ,  a s  c o m p a r e d  t o  t h e  p a r e n t a l  c e l l s  ( S e c t i o n  3 .3 .2 ) .  T h is  m a y  n o t  
n e c e s s a r i l y  i n d i c a t e  t h a t  t h e  a n t i s e n s e  c o n s t r u c t  w a s  n o t  f u n c t i o n i n g .  I t  h a s  b e e n  
s e e n  e a r l i e r  t h a t  a  c l o n e d  a n t i s e n s e  R N A  O A W 4 2 S R  t r a n s f e c t a n t  e x h ib i t e d  h i g h  
L R P  m R N A  l e v e l s ,  b u t  a lm o s t  t o t a l  e l im in a t io n  o f  p r o t e i n  l e v e l s .  C l e a v a g e  o f  t h e  
t a r g e t  R N A  is  n o t  n e c e s s a r y  f o r  i n h i b i t i o n  o f  p r o t e i n  p r o d u c t io n .
•  T h e  c o n t r o l  v e c t o r  p H 0  t r a n s f e c t e d  c e l l s  e x h ib i t e d  a  s i g n i f i c a n t  r e d u c t i o n  in  L R P  
m R N A  e x p r e s s i o n ,  u p  t o  2 - f o ld  in  c o m p a r i s o n  t o  t h e  p a r e n t a l  c e l l s  ( S e c t i o n  3 .3 .2 ) .
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T h i s  o n c e  a g a i n  h i g h l i g h t s  t h e  p r o b l e m s  a s s o c i a t e d  w i t h  t h e  t r a n s f e c t i o n  a n d  
s e l e c t i o n  o f  c e l l s .  S i n c e  t h e  p H P  p l a s m i d  c o n t a in s  n o  c o n s t r u c t s  c a p a b l e  o f  
c l e a v i n g  L R P ,  o r  ( a s  f a r  a s  k n o w n )  a n y  o t h e r ,  m R N A ,  t h i s  r e d u c t i o n  in  L R P  
e x p r e s s i o n  i s  a  m y s t e r y .  I t  r e f l e c t s  t h e  r e d u c t i o n s  in  L R P  m R N A  s e e n  e a r l ie r  f o r  
c l o n e d  p H P  t r a n s f e c t a n t s .
•  N o  c h a n g e s  i n  m d r - 1  o r  M R P  e x p r e s s io n  c o u l d  b e  o b s e r v e d  b y  R T - P C R  a n a ly s i s  
in  a n y  o f  t h e  p o p u la t i o n s  ( S e c t i o n  3 .3 .3 ) .
•  In vitro  t o x i c i t y  a s s a y s  s h o w e d  t h a t  t h e  a d r i a m y c i n  a n d  v i n c r i s t i n e  IC50 v a l u e s  f o r  
a l l  t h e  t r a n s f e c t e d  p o p u la t i o n s  w e r e  l o w e r  t h a n  t h e  p a r e n t a l  v a l u e s  ( S e c t i o n  3 . 3 . 1 ) .  
T h e  r i b o z y m e  a n d  a n t i s e n s e  R N A  e x p r e s s i n g  p o p u la t i o n s  e x h ib i t e d  a  2 - f o ld  
r e d u c t i o n  in  r e s i s t a n c e  t o  b o t h  a d r i a m y c i n  a n d  v i n c r i s t i n e .  T h e  c o n t r o l  p H P  v e c t o r  
t r a n s f e c t e d  c e l l s ,  h o w e v e r ,  e x h ib i t e d  a lm o s t  a  3 - f o l d  r e d u c t i o n  i n  IC50 v a l u e s  f o r  
b o t h  d r u g s .
•  R e p e a t e d  i m m u n o p r é c i p i t a t i o n  s t u d ie s  f a i l e d  t o  p r o d u c e  u s e f u l  r e s u lt s .
•  T h e r e  a p p e a r s  t o  b e  n o  c o r r e la t i o n  b e t w e e n  t h e  l e v e l s  o f  L R P  m R N A  i n  t h e
t r a n s f e c t e d  c e l l s  a n d  t h e  l e v e l s  o f  r e s i s t a n c e  t o  a d r i a m y c i n  a n d  v i n c r i s t i n e .  T h e
a n t is e n s e  R N A  e x p r e s s i n g  c e l l s  s h o w  a  m u c h  g r e a t e r  l e v e l  o f  L R P  m R N A  
e x p r e s s i o n  t h a n  t h e  r i b o z y m e  e x p r e s s i n g  c e l l s ,  w h i l e  b o t h  e x h ib i t  s i m i la r  d r u g  
r e s i s t a n c e  l e v e l s .  H o w e v e r ,  a s  s e e n  e a r l i e r ,  L R P  m R N A  l e v e l s  in  t h e  a n t i s e n s e  
t r a n s f e c t e d  c e l l s  c a n n o t  b e  c o r r e l a t e d  w i t h  L R P  p r o t e in  e x p r e s s io n .
•  T h e  l e v e l s  o f  m R N A  a n d  p r o t e i n  e x p r e s s io n  w e r e  f o u n d  t o  c o r r e l a t e  f o r  t h e
r i b o z y m e  a n d  c o n t r o l  p H P  v e c t o r  c lo n e s  d e s c r ib e d  e a r l i e r .  T h e r e f o r e ,  b e t w e e n
t h e s e  t w o  p o p u la t i o n s  a  w e a k  c o r r e l a t i o n  m a y  b e  d r a w n  b e t w e e n  L R P  e x p r e s s io n  
a n d  d r u g  r e s i s t a n c e .  H o w e v e r ,  t h e r e  i s  s o m e  d i s c r e p a n c y  b e t w e e n  t h e  m a g n i t u d e  
o f  r e d u c t i o n  in  L R P  m R N A  a n d  t h e  m a g n i t u d e  o f  r e d u c t i o n  in  IC50 v a l u e s .  T h e  
p H P - t r a n s f e c t e d  p o p u la t i o n  e x h i b i t s  a  2 - f o l d  l o w e r  l e v e l  o f  L R P  m R N A  
e x p r e s s i o n  t h a n  t h e  r i b o z y m e - t r a n s f e c t e d  p o p u la t io n ,  a n d  y e t  e x h ib i t s  o n l y  a  1 . 3 -  
f o l d  d r o p  in  a d r i a m y c i n  a n d  v i n c r i s t i n e  IC50 v a l u e s .
O n c e  a g a i n ,  t h e r e  is  v e r y  l i t t l e  e v i d e n c e  t o  s u p p o r t  t h e  h y p o t h e s i s e d  r o l e  o f  L R P  in
M D R .
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T h e  u s e  o f  a n t i s e n s e  o l i g o n u c l e o t i d e s  t o  m o d u l a t e  g e n e  e x p r e s s i o n  i s  m o r e  
w i d e s p r e a d  t h a n  t h e  u s e  o f  r i b o z y m e  a n d  a n t i s e n s e  e x p r e s s i o n  v e c t o r s .  U s i n g  
a n t i s e n s e  o l i g o n u c l e o t i d e s  a v o i d s  t h e  p r o b l e m s  a s s o c i a t e d  w i t h  t h e  s t a b l e  t r a n s f e c t i o n  
o f  c e l l s  a n d  t h e  s e l e c t i o n  o f  c l o n e s ,  w h i c h  m a y  e x h i b i t  in h e r e n t  v a r ia t i o n .  T h e  
p r i n c i p a l  r e s u l t s  w e r e  a s  f o l l o w s :
•  6  a n t i s e n s e  o l i g o n u c l e o t i d e s  w e r e  t a r g e t e d  t o  t h e  5 ’ U T R  t h e  in i t i a t i o n  c o d o n ,  t h e  
c o d i n g  r e g i o n  a n d  t h e  3 ’ U T R  o f  t h e  L R P  g e n e  ( S e c t i o n  3 . 4 . 1 ) .  S e n s e ,  n o n s e n s e  
a n d  s c r a m b l e d  o l i g o n u c l e o t i d e  c o n t r o l s  w e r e  u s e d ,  a l o n g  w i t h  l i p o f e c t i n - o n l y  
t r e a t e d  a n d  u n - t r e a t e d  c e l ls .
•  A l l  o f  t h e  a n t i s e n s e  o l i g o n u c l e o t i d e s  t e s t e d ,  a t  a  c o n c e n t r a t io n  o f  1 ( iM , a p p e a r e d  
t o  r e d u c e  L R P  e x p r e s s io n ,  a s  m e a s u r e d  b y  i m m u n o c y t o c h e m i s t r y  ( S e c t i o n  3 .4 .3 ) .  
L R P  e x p r e s s i o n  w a s  u n a f f e c t e d  b y  c o n t r o l  s e n s e  o l i g o n u c l e o t i d e s .  N o  c h a n g e s  in  
L R P  l e v e l s  w e r e  o b s e r v e d  in  l i p o f e c t i n - o n l y  t r e a t e d  o r  u n t r e a t e d  c e l l s .
•  I n c r e a s i n g  t h e  c o n c e n t r a t i o n  o f  o n e  a n t i s e n s e  o l i g o n u c l e o t i d e  ( L R P  A 2 ) ,  t a r g e t e d  
t o  t h e  i n i t i a t i o n  c o d o n  o f  t h e  L R P  g e n e ,  f r o m  1 t o  5  |x M  h a d  m i n i m a l  e f f e c t  o n  
L R P  e x p r e s s i o n  l e v e l s .  T h e r e f o r e ,  a l l  r e m a i n i n g  e x p e r i m e n t s  w e r e  c a r r ie d  o u t  
u s i n g  o l i g o n u c l e o t i d e  c o n c e n t r a t io n s  o f  1 ( iM .
•  F u r t h e r  i m m u n o c y t o c h e m i c a l  a n a l y s i s  o f  t w o  o f  t h e  a n t i s e n s e  o l i g o n u c l e o t i d e s  
( L R P  A 1  a n d  A 2 ) ,  t a r g e t e d  t o  t h e  5 ’ U T R  a n d  i n i t i a t i o n  c o d o n ,  d e m o n s t r a t e d  t h e ir  
a b i l i t y  t o  r e d u c e  L R P  e x p r e s s io n ,  a lb e i t  w i t h  v a r y i n g  s u c c e s s  ( S e c t i o n  3 .4 .3 ) .  
W h i l e  t h e  c o n t r o l  o l i g o n u c l e o t i d e s  ( s e n s e ,  n o n s e n s e  a n d  s c r a m b le d )  c o n t i n u a l l y  
h a d  n o  e f f e c t  o n  L R P  e x p r e s s i o n ,  t h e  v a r ia t i o n s  in  s t a in i n g  i n t e n s i t y  f o r  t h e  t w o  
a n t i s e n s e  o l i g o s  h i g h l i g h t e d  t h e  n e e d  f o r  a  m o r e  a c c u r a t e  m e a s u r e  o f  L R P  
e x p r e s s i o n  a t  t h e  p r o t e i n  l e v e l .
•  R e p e a t e d  i m m u n o p r é c i p i t a t i o n  a n a l y s i s  o f  t h e  a n t i s e n s e  a n d  c o n t r o l  
o l i g o n u c l e o t i d e  t r e a t e d  c e l ls ,  c l e a r l y  d e m o n s t r a t e d  t h e  a b i l i t y  o f  t h e  L R P  A 1  a n d  
A 2  a n t i s e n s e  o l i g o n u c l e o t i d e s  t o  in h ib i t  L R P  e x p r e s s io n  ( S e c t i o n  3 .4 .6 ) .  T h e  
c o n t r o l  o l i g o n u c l e o t i d e  t r e a t e d ,  l i p o f e c t i n - o n l y  t r e a t e d  o r  u n t r e a t e d  c e l l s  a l l  
m a i n t a i n e d  h i g h  l e v e l s  o f  L R P  e x p r e s s io n .  A l l  s a m p le s  f o r  im m u n o p r é c i p i t a t i o n  
a n a l y s i s  w e r e  t a k e n  7 2 h  p o s t - i n i t i a t i o n  o f  t r e a t m e n t .
5.3 Analysis of antisense oligonucleotide mediated inhibition of LRP expression
in OAW42SR cells
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•  R T - P C R  a n a l y s i s  d e m o n s t r a t e d  t h a t  L R P  m R N A  e x p r e s s io n  i n  L R P  A 2  t r e a t e d  
O A W 4 2 S R  c e l l s  w a s  g r e a t l y  r e d u c e d  b y  4 h  o f  t r e a t m e n t ,  a n d  t h is  r e d u c t i o n  w a s  
m a i n t a i n e d  f o r  a t  l e a s t  4 8 h  p o s t  i n i t i a t i o n  o f  t r e a t m e n t  ( S e c t i o n  3 .4 .4 ) .  C e l l s  
t r e a t e d  w i t h  a  s e n s e  o l i g o n u c l e o t i d e ,  o r  u n t r e a t e d  c e l ls ,  d e m o n s t r a t e d  n o  c h a n g e s  
in  L R P  m R N A  e x p r e s s io n  o v e r  t im e .
•  N o r t h e r n  b l o t  a n a l y s i s  a l s o  d e m o n s t r a t e d  t h e  a b i l i t y  o f  L R P  A 1  a n d  A 2  t o  
s i g n i f i c a n t l y  r e d u c e  L R P  m R N A  e x p r e s s i o n  a f t e r  4 8 h  o f  t r e a t m e n t  ( S e c t i o n  3 .4 .7 ) .  
T h e  s e n s e ,  n o n s e n s e  a n d  s c r a m b l e d  o l i g o n u c l e o t i d e  t r e a t e d  c e l l s  e x h ib i t e d  n o  
r e d u c t i o n s  i n  L R P  m R N A  l e v e l s  a s  c o m p a r e d  t o  u n t r e a t e d  c e l ls .
•  In vitro  t o x i c i t y  a s s a y s  s h o w e d  t h a t  a l l  o f  a n t i s e n s e  o l i g o n u c l e o t i d e s  t e s t e d  
r e d u c e d  a d r i a m y c i n  IC50 v a l u e s  i n  O A W 4 2 S R  c e l l s  ( S e c t i o n  3 .4 .5 ) .  H o w e v e r ,  t h e  
s e n s e  o l i g o n u c l e o t i d e  t r e a t e d  O A W 4 2 S R  c e l l s  a l s o  e x h i b i t e d  r e d u c t i o n s  in  
a d r i a m y c i n  IC50 a s  c o m p a r e d  t o  u n t r e a t e d  c e l ls .
•  F u r t h e r  t o x i c i t y  a s s a y s  r e v e a l e d  n o  d i f f e r e n c e  i n  t h e  a b i l i t y  o f  t h e  a n t i s e n s e  o r  
c o n t r o l  o l i g o n u c l e o t i d e s  t o  m o d u l a t e  a d r i a m y c i n  r e s i s t a n c e  ( S e c t i o n  3 .4 .5 ) .  I t  d id  
a p p e a r ,  h o w e v e r ,  t h a t  a l l  o l i g o n u c l e o t i d e s  e x h ib i t e d  a  s i g n i f i c a n t  l e v e l  o f  t o x i c i t y ,  
w h i c h  r e s u l t e d  i n  r e d u c e d  a d r i a m y c i n  r e s i s t a n c e  a s  c o m p a r e d  t o  l i p o f e c t i n - o n l y  
t r e a t e d  o r  u n t r e a t e d  c e l ls .
•  P u l s e  t o x i c i t y  a s s a y s  i n  c e l l  c u l t u r e  f l a s k s  w e r e  u s e d  a s  a  m e a n s  t o  m o r e  
a c c u r a t e l y  r e f l e c t  t h e  c o n d i t i o n  o f  c e l l s  u s e d  f o r  p r o t e in  a n d  m R N A  a n a ly s i s .  
T h e s e  t o x i c i t y  a s s a y s  r e v e a l e d  a  v e r y  m a r g i n a l  d e c r e a s e  in  a d r i a m y c i n  I C 50  v a l u e  
f o r  L R P  A 2  t r e a t e d  c e l l s  a s  c o m p a r e d  t o  s e n s e  o l i g o n u c l e o t i d e  o r  u n t r e a t e d  c e l ls .  
I t  is  f e l t  h o w e v e r ,  t h a t  t h e  m a r g i n  o f  t h e  r e d u c t i o n  in  a d r i a m y c i n  r e s i s t a n c e  d id  n o t  
r e f l e c t  t h e  l a r g e  r e d u c t i o n s  in  L R P  m R N A  a n d  p r o t e i n  e x p r e s s i o n  i n  c e l l s  t r e a t e d  
w i t h  L R P  A 2 .
T h e  t r e a t m e n t  o f  O A W 4 2 S R  w i t h  a n t i - L R P  a n t i s e n s e  a n d  c o n t r o l  o l i g o n u c l e o t i d e s  
a p p e a r s ,  o n c e  a g a in ,  t o  d i s c o u n t  L R P ’ s r o l e  in  M D R .  T h e r e  w a s  c o n c l u s i v e  e v i d e n c e  
o f  t h e  a b i l i t y  o f  t h e  a n t i s e n s e  o l i g o n u c l e o t i d e s  t o  in h ib i t  t h e  e x p r e s s io n  o f  L R P  a t  b o t h  
t h e  p r o t e i n  a n d  m R N A  l e v e l .  T h e r e  w a s  s o m e  d e g r e e  o f  v a r i a b i l i t y  in  t h e  e f f i c a c y  o f  
t h e  o l i g o n u c l e o t i d e s ,  a n d  e v i d e n c e  o f  o l i g o n u c l e o t i d e  t o x i c i t y ,  p o s s i b l y  d u e  t o  t h e ir  
p r e p a r a t i o n  a n d  p u r i f i c a t i o n .  H o w e v e r ,  t h e  r e s u l t s  f a i l e d  t o  s h o w  a n y  l i n k  b e t w e e n  a n y  
L R P  e x p r e s s i o n  l e v e l s  a n d  r e s i s t a n c e  t o  a d r i a m y c i n .
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5.4 Conclusions
A l l  t h e  r e s u l t s  p r e s e n t e d  i n  t h is  t h e s i s  a g r e e  in  o n e  r e s p e c t :  t h e  l a c k  o f  s u b s t a n t ia l  
e v i d e n c e  t o  s u p p o r t  a  d i r e c t  r o l e  f o r  L R P  i n  d r u g  r e s i s t a n c e  in  t h e  O A W 4 2 S R  o r  
O A W 4 2 S  c e l l  l in e .  T h e  e v i d e n c e  c i t e d  in  t h e  l i t e r a t u r e ,  w h i c h  s u p p o r t s  a  r o l e  f o r  L R P  
in  M D R ,  i s  p u r e l y  c i r c u m s t a n t ia l .  T h e r e  w a s  e q u a l l y ,  a l t h o u g h  s o m e w h a t  l e s s  p r o l i f i c ,  
e v i d e n c e  w h i c h  s u g g e s t e d  t h a t  L R P  m a y  o n l y  b e  l i n k e d  t o  d r u g  r e s i s t a n c e ,  a n d  n o t  
d i r e c t l y  i n v o l v e d .  R e d u c e d  r e s i s t a n c e  i s  s e e n  i n  c l o n e s  t h a t  e x h ib i t  r e d u c e d  L R P  
e x p r e s s io n .  H o w e v e r  t h e  l e v e l s  o f  L R P  e x p r e s s i o n  a n d  r e s i s t a n c e  d o  n o t  c o r r e l a t e .  I t  
m a y  b e  t h a t  L R P  is  c o - e x p r e s s e d  w i t h  s o m e  o t h e r  r e s i s t a n c e  m e c h a n i s m .  T h e  r e s u l t s  
f o r  t h e  r i b o z y m e  a n d  a n t i s e n s e  R N A  t r a n s f e c t i o n s  o f  O A W 4 2 S R  c e l l s  i n d i c a t e s  t h a t  
v a r i a t i o n  in  P - g l y c o p r o t e i n  a c t i v i t y ,  p o s s i b l y  b y  p o s t - t r a n s la t i o n a l  m o d i f i c a t i o n s ,  m a y  
b e  s o l e l y  r e s p o n s i b l e  f o r  t h e  r e s i s t a n c e  m e c h a n i s m s  o f  t h e s e  c e l l s ,  a l t h o u g h  t h e  r e s u l t s  
f o r  V P - 1 6  m a y  n o t  e n t i r e l y  s u p p o r t  th is .
H o w e v e r ,  a n  a l t e r n a t i v e  e x p l a n a t i o n  is  t h a t  L R P  m a y  n o t  b e  a  r e l e v a n t  m e c h a n i s m  o f  
d r u g  r e s i s t a n c e  in  t h e  O A W 4 2 S R  c e l l  l i n e ,  d u e  t o  o t h e r  r e s i s t a n c e  m e c h a n i s m s  b e i n g  
d o m in a n t .  T h i s  h a s  a l r e a d y  b e e n  p o s t u l a t e d  f o r  t h e  O A W 4 2 S  c e l l  l in e .  I t  h a s  
p r e v i o u s l y  b e e n  o b s e r v e d  t h a t  d e c r e a s i n g  t h e  l e v e l s  o f  m d r - 1  i n  a  h u m a n  n o n - s m a l l  
c e l l  l u n g  c a n c e r  c e l l  l i n e  ( S W 1 5 7 3 )  d id  n o t  a f f e c t  i t s  r e s i s t a n c e ,  a s  m d r - 1  e x p r e s s io n  
w a s  s e c o n d a r y  t o  M R P  i n  m e d i a t i n g  r e s i s t a n c e  in  t h e s e  c e l l s  ( E i j d e m s  et al., 1 9 9 5 a ) .  
T h e r e f o r e ,  f u r t h e r  r i b o z y m e  a n d  a n t i s e n s e  w o r k  n e e d s  t o  b e  c a r r ie d  o u t  in  a n  
a l t e r n a t i v e  L R P - e x p r e s s i n g  c e l l  l in e ,  b e f o r e  L R P  c a n  b e  c o n c l u s i v e l y  r u l e d  o u t  o f  
d r u g  r e s i s t a n c e .  I n  c o n c l u s i o n ,  i t  a p p e a r s  u n l i k e l y  t h a t  L R P  p l a y s  a  s i g n i f i c a n t  r o l e  in  
t h e  r e s i s t a n c e  m e c h a n i s m s  o f  O A W 4 2 S R  c e l ls .
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5.5 Future W ork
•  F u t u r e  w o r k  a r i s i n g  f r o m  t h is  t h e s is  s h o u l d  i n c l u d e  t r a n s f e c t i o n  o f  a l t e r n a t i v e  L R P  
o v e r e x p r e s s i n g  c e l l  l i n e s  w i t h  t h e  a n t i  L R P - r i b o z y m e  a n d  - a n t i s e n s e  p l a s m i d s ,  
a l o n g  w i t h  t h e  c o n t r o l  p H (3  v e c t o r .  T h e  c e l l  l i n e s  c h o s e n  s h o u l d  b e  h o m o g e n o u s  s o  
a s  t o  m i n i m i s e  c l o n a l  v a r ia t io n .  T h e  t r a n s f e c t a n t s  s h o u ld  b e  a n a l y s e d  in  a  s i m i la r  
m a n n e r  t o  t h a t  c a r r ie d  o u t  i n  t h is  t h e s is .  T h i s  w o r k  s h o u ld  i n d i c a t e  w h e t h e r  t h e  
l a c k  o f  a  r o l e  i n  d r u g  r e s i s t a n c e  f o r  L R P  is  c o n f i n e d  t o  t h e  O A W 4 2 S R  c e l l  l in e ,  o r  
i f  i t  i s  a  w i d e s p r e a d  p h e n o m e n o n .
•  T h e  in vitro c l e a v a g e  a c t i v i t y  o f  t h e  r i b o z y m e  c o n s t r u c t s  s h o u ld  b e  a s s e s s e d .  T h i s  
w o u l d  c o n f i r m  t h a t  t h e  r i b o z y m e  c o n s t r u c t  c a n  f u n c t i o n  p r o p e r l y ,  a t  l e a s t  in  a n  
e x t r a - c e l l u l a r  e n v i r o n m e n t .
•  D i f f e r e n t  r i b o z y m e  a n d  a n t i s e n s e  c o n s t r u c t s  s h o u ld  b e  e m p l o y e d  t o  s e e  i f  a  m o r e  
e f f i c i e n t  t a r g e t  s i t e  o n  t h e  L R P  c D N A  c a n  b e  f o u n d .  O t h e r  s i t e s  in  t h e  L R P  
s e q u e n c e  m a y  b e  m o r e  a c c e s s i b l e  t o  c l e a v a g e ,  s u c h  a s  o p e n  s i t e s  a t  t h e  e n d  o f  
s t e m  l o o p s .  A  m o r e  e f f i c i e n t  r i b o z y m e  o r  a n t is e n s e  c o n s t r u c t  c a p a b l e  o f  t o t a l  
e l i m i n a t i o n  o f  L R P  e x p r e s s i o n  w o u l d  g i v e  a  c l e a r e r  p i c t u r e  o f  L R P ’ s r o l e  i n  d r u g  
r e s i s t a n c e .  C o n s t r u c t i n g  c o m p u t e r  m o d e l s  o f  t h e  L R P  R N A  s e c o n d a r y  s t r u c t u r e  
w o u l d  f a c i l i t a t e  t h e  d e s i g n  o f  t h e s e  r i b o z y m e s  a n d  a n t is e n s e  c o n s t r u c t s .
•  U s i n g  a l t e r n a t i v e  b a c k b o n e  m o d i f i c a t i o n s  in  t h e  a n t i s e n s e  o l i g o n u c l e o t i d e s  m a y  
c r e a t e  l e s s  n o n - a n t i s e n s e  s p e c i f i c  t o x i c  s id e  e f f e c t s  t h a t  w e r e  e v i d e n t  w i t h  a l l  th e  
o l i g o n u c l e o t i d e s .  P h o s p h o r o t h i o a t e  o l i g o n u c l e o t i d e s  a r e  k n o w n  t o  b e  s o m e w h a t  
t o x i c  t o  c e l l s .  B y  s u b s t i t u t i n g  s o m e  o r  a l l  o f  t h e  p h o s p h o r o t h i o a t e  n u c l e o t i d e s  f o r  
a l t e r n a t i v e  l e s s  t o x i c  a n a l o g u e s ,  t h is  t o x i c i t y  p r o b l e m  m a y  b e  e l im in a t e d .  T h e  
t o x i c i t y  p r o b l e m  m a y  a l s o  h a v e  b e e n  d u e  t o  t h e  p r e p a r a t io n  o f  t h e  
o l i g o n u c l e o t i d e s ,  a n d  c o u l d  t h e r e f o r e  p o s s i b l y  b e  e l i m in a t e d  b y  f u r t h e r  
p u r i f i c a t i o n
•  T h e  R T - P C R  t i m e - s c a l e  a n a l y s i s  o f  L R P  m R N A  d o w n r e g u l a t i o n  u s i n g  a n t i s e n s e  
o l i g o n u c l e o t i d e s  s h o u ld  b e  e x t e n d e d  f o r  a  n u m b e r  o f  d a y s .  T h i s  w o u l d  a l l o w  a  
d e t e r m in a t i o n  o f  t h e  l o n g e v i t y  o f  t h e  a n t i s e n s e  m e d i a t e d  i n h i b i t i o n  o f  L R P  
e x p r e s s io n .  T h e  t i m e - s c a l e  a n a l y s i s  c o u l d  a l s o  b e  c a r r ie d  o u t  a t  t h e  p r o t e i n  l e v e l  
u s i n g  i m m u n o p r é c i p i t a t i o n .
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•  A  d o s e - r e s p o n s e  c u r v e  a s s a y  w i t h  t h e  a n t i s e n s e  o l i g o n u c l e o t i d e s  s h o u l d  b e  c a r r i e d  
o u t  t o  f u r t h e r  p r o v e  t h a t  t h e  i n h i b i t o r y  e f f e c t s  s e e n  a r e  o f  a  t r u e  a n t is e n s e  n a t u r e .  
I n c r e a s i n g  t h e  o l i g o n u c l e o t i d e  c o n c e n t r a t i o n  f r o m  1 t o  5  (J.M d id  n o t  s i g n i f i c a n t l y  
i n c r e a s e  t h e  a n t i s e n s e  e f f e c t .  T h e r e  i s  p r o b a b l y  a  s a t u r a t io n  p o in t  o f  a n t i s e n s e  
c o n c e n t r a t i o n ,  a b o v e  w h i c h  n o  f u r t h e r  i n h i b i t i o n  i s  a c h i e v e d .  T h e r e f o r e ,  
d e c r e a s i n g  c o n c e n t r a t i o n s  o f  a n t i s e n s e  s h o u l d  b e  e m p l o y e d  i n  t h e  d o s e - r e s p o n s e  
c u r v e .
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